

Risk Factors Comparison 2024-03-28 to 2023-03-30 Form: 10-K

Legend: **New Text** ~~Removed Text~~ Unchanged Text **Moved Text** Section

• Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, **if approved**. • If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection. • We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. **Risks Related to Our Securities** • The market price of our common stock may be significantly volatile. • Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. • Future sales of our common stock in the public market could cause our stock price to fall. • Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants. • Our ability to use net operating losses to offset future taxable income are subject to certain limitations. • We have never paid cash dividends on our common stock and do not anticipate paying dividends in the foreseeable future. **RISKS RELATED TO OUR BUSINESS AND OPERATIONS** We have a history of significant losses from operations and expect to continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. Since our inception, our expenses have substantially exceeded our revenue, resulting in continuing losses and an accumulated deficit of \$ ~~369-388~~ million at December 31, ~~2022-2023~~. For the years ended December 31, ~~2022 and 2021~~, we incurred net losses of \$ ~~19.5 million and \$ 35.9 million and \$ 20.8 million~~, respectively. We currently have no product revenue and do not expect to generate any product revenue for the foreseeable future. Because we are committed to continuing our product research, development, clinical trial and commercialization programs, we will continue to incur significant operating losses unless and until we complete the development of ~~GEN-1MNN-1-001~~ and other new drug candidates and these drug candidates have been clinically tested, approved by the ~~U.S.~~-FDA and successfully marketed. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, the following, which we cannot guarantee: us or our collaborators successfully developing drug candidates, obtaining regulatory approvals to market and commercialize drug candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third- party alternatives for any approved product, generating sufficient sales revenue from our drug candidates, and raising sufficient funds to finance business activities. **We might not be able to continue as a going concern, which could cause our stockholders to lose most or all of their investment. Our audited financial statements for the year ended December 31, 2023 were prepared under the assumption that we would continue as a going concern. However, we have concluded that there is substantial doubt about our ability to continue as a going concern, therefore our independent registered public accounting firm included a “ going concern ” explanatory paragraph in its report on our financial statements for the year ended December 31, 2023, indicating that, without additional sources of funding, our cash at December 31, 2023 is not sufficient for us to operate as a going concern for a period of at least one year from the date that the financial statements included in this Annual Report on Form 10- K are issued. Management’s plans concerning these matters, including our need to raise additional capital, are described in Note 2 of our financial statements included within this Annual Report on Form 10- K, however, management cannot assure you that its plans will be successful. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.** We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates. We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, ~~2022-2023~~, we incurred a net loss of \$ ~~35-19.9-5~~ million. We have incurred approximately \$ ~~369-388~~ million of cumulative net losses. As of December 31, ~~2022-2023~~, we had cash and cash equivalents, short- term investments, interest receivable, ~~and~~ net proceeds on the sale of net operating losses ~~and restricted money market investments~~ of \$ ~~38-17.9-0~~ million. We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages. We are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialize approved products, if any. We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. If we do not obtain or maintain FDA and foreign regulatory approvals for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, we will be unable to sell those products and our business, results of operations and financial condition will be negatively affected. To obtain regulatory approvals from the FDA and foreign regulatory agencies, we must conduct clinical trials demonstrating that our drug candidates are safe and effective. We may need to amend ongoing trials, or the FDA and / or foreign regulatory agencies may require us to perform additional trials beyond those we planned. The testing and approval process requires substantial time, effort and resources, and generally takes a number of years to complete. The time to obtain approvals is also uncertain, and the FDA and foreign regulatory agencies have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical studies or other testing, delay or withhold approval, and mandate product withdrawals, including recalls. In addition, our drug candidates may have undesirable side effects or other unexpected characteristics that could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. Even if we receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. The failure to obtain timely regulatory approval of drug candidates, the imposition of marketing limitations, or a product withdrawal would negatively impact our business. Even if we receive approval, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our drug candidates, when and if approved. Finally, even if we obtain FDA approval of any of our drug candidates, we may never obtain approval or commercialize such products outside of the U. S., given that we may be subject to additional regulatory burdens in other markets. This could limit our ability to realize their full market potential. Drug development is an inherently uncertain process with a high risk of failure at every stage of development. Securing FDA or comparable foreign regulatory approval requires the submission of extensive preclinical and clinical data and supporting information for each therapeutic indication to establish the drug candidate’s safety and efficacy for its intended use. It takes years to complete the testing of a new drug or biological product and development delays and / or failure can occur at any stage of testing. Any of our present and future clinical trials may be delayed, halted, not authorized, or approval of any of our products may be delayed or may not be obtained due to any of the following: • factors related to **the ongoing effects of** the COVID- 19 pandemic, including regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; • any preclinical test or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or comparable foreign regulatory authorities; • preclinical and clinical data can be interpreted in different ways, which could delay, limit, or prevent marketing approval; • negative or inconclusive results from a preclinical test or clinical trial or adverse events during a clinical trial could cause a preclinical study or clinical trial to be repeated or a development program to be terminated, even if other studies relating to the development program are ongoing or have been completed and were successful; • the FDA or comparable foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that subjects enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury; • the facilities that we utilize, or the processes or facilities of third- party vendors, including without limitation the contract manufacturers who will be manufacturing drug substance and drug product for us or any potential collaborators, may not satisfactorily complete inspections by the FDA or comparable foreign regulatory authorities; and • we may encounter delays or rejections based on changes in FDA policies or the policies of comparable foreign regulatory authorities during the period in which we develop a drug candidate, or the period required for review of any final marketing approval before we are able to market any drug candidate. In addition, information generated during the clinical trial process is susceptible to varying interpretations that could delay, limit, or prevent marketing approval. Moreover, early positive preclinical or clinical trial results may not be replicated in later clinical trials. As more drug candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Failure to demonstrate

adequately the quality, safety, and efficacy of any of our drug candidates would delay or prevent marketing approval. We cannot assure you that if clinical trials are completed, either we or our potential collaborators will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in a timely manner, if at all. ~~The outbreak, duration and severity of the novel coronavirus disease, COVID-19 pandemic, or other similar health crises could adversely impact our business, including our preclinical studies and clinical trials. The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the ongoing COVID-19 pandemic. As a result of the COVID-19 pandemic, or similar pandemics, we may experience disruptions that could severely affect our business, including our preclinical studies, the clinical trials process and enrollment of patients. This may delay commercialization efforts. The Company is currently monitoring its operating activities in light of these events and it is reasonably possible that the virus could have a negative effect on the Company's financial condition and results of operations. The specific impact is not readily determinable as of the date of this report. The extent to which COVID-19 will continue to impact our business will depend on future developments, which are highly uncertain and its implications cannot be predicted with confidence. While, as of the date of this report, we have not experienced any material disruptions to the execution of the clinical trials and the research and development activities that we currently have underway, if we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial condition.~~ New gene- based products for therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other countries. The precise regulatory requirements with which we will have to comply, now and in the future, are uncertain due to the novelty of the gene- based products we are developing. The regulatory approval process for novel drug candidates such as ours can be significantly more expensive and take longer than for other, better known or more extensively studied drug candidates. Limited data exist regarding the safety and efficacy of DNA- based therapeutics compared with conventional therapeutics, and government regulation of DNA- based therapeutics is evolving. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of **Therapeutic Products Cellular, Tissue and Gene Therapies** within CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our drug candidates in either the U. S. or the European Union or how long it will take to commercialize our drug candidates. Adverse events or the perception of adverse events in the field of gene therapy generally, or with respect to our drug candidates specifically, may have a particularly negative impact on public perception of gene therapy and result in greater governmental regulation, including future bans or stricter standards imposed on gene- based therapy clinical trials, stricter labeling requirements and other regulatory delays in the testing or approval of our potential products. For example, if we were to engage an NIH- funded institution to conduct a clinical trial **involving recombinant or nucleic acid molecules**, we may be subject to review by **an IBC and, in some cases,** the NIH ~~Office of Biotechnology Activities' Recombinant DNA Advisory Committee (the RAC). Such review if undertaken, RAC can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND application on a clinical hold even if the RAC IBC or the NIH has provided a favorable review or an exemption from in- depth, public review.~~ Such ~~committee and advisory group~~ reviews and any new guidelines ~~they promulgate~~ may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our drug candidates or lead to significant post- approval limitations or restrictions. Any increased scrutiny could delay or increase the costs of our product development efforts or clinical trials. Even if our products receive regulatory approval, they may still face future development and regulatory difficulties. Government regulators may impose ongoing requirements for potentially costly post- approval studies. This governmental oversight may be particularly strict with respect to gene- based therapies. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including: ● the patient eligibility and exclusion criteria defined in the protocol; ● the size of the patient population required for analysis of the trial' s primary endpoints and the process for identifying patients; ● delays in our research programs resulting from factors related to the COVID- 19 pandemic; ● the willingness or availability of patients to participate in our trials; ● the proximity of patients to trial sites; ● the design of the trial; ● our ability to recruit clinical trial investigators with the appropriate competencies and experience; ● clinicians' and patients' perceptions as to the potential advantages and risks of the drug candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; ● the availability of competing commercially available therapies and other competing drug candidates' clinical trials; ● our ability to obtain and maintain patient informed consents; and ● the risk that patients enrolled in clinical trials will drop out of the trials before completion. Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, delay or halt the development of and approval processes for our drug candidates and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. Enrollment delays may also delay or jeopardize our ability to commence sales and generate revenues from our drug candidates. Any of the foregoing could cause the value of our company to decline and limit our ability to obtain additional financing, if needed. We rely on third parties to conduct all of our clinical trials. If these third parties are unable to carry out their contractual duties in a manner that is consistent with our expectations, comply with budgets and other financial obligations or meet expected deadlines, we may not receive certain development milestone payments or be able to obtain regulatory approval for or commercialize our drug candidates in a timely or cost- effective manner. We do not independently conduct clinical trials for our drug candidates. We rely, and expect to continue to rely, on third- party clinical investigators, ~~clinical research organizations ("CROs"),~~ clinical data management organizations and consultants to design, conduct, supervise and monitor our clinical trials. Because we do not conduct our own clinical trials, we must rely on the efforts of others and have reduced control over aspects of these activities, including ~~the~~ timing of such trials, the costs associated with such trials and the procedures that are followed for such trials. We do not expect to significantly increase our personnel in the foreseeable future and may continue to rely on third parties to conduct all of our future clinical trials. If we cannot contract with acceptable third parties on commercially reasonable terms or at all, if these third parties are unable to carry out their contractual duties or obligations in a manner that is consistent with our expectations or meet expected deadlines, if they do not carry out the trials in accordance with budgeted amounts, if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, or if they fail to maintain compliance with applicable government regulations and standards, our clinical trials may be extended, delayed or terminated or may become significantly more expensive, we may not receive development milestone payments when expected or at all, and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. Despite our reliance on third parties to conduct our clinical trials, we are ultimately responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires clinical trials to be conducted in accordance with good clinical practices for conducting, recording and reporting the results of clinical trials and that the rights, integrity and confidentiality of clinical trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government- sponsored database, ClinicalTrials. gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or a third party we rely on fails to meet these requirements, we may not be able to obtain, or may be delayed in obtaining, marketing authorizations for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. This could have a material adverse effect on our business, financial condition, results of operations and prospects. Because we rely on third ~~party~~ manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. We rely on third ~~party~~ supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials. There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials will not be limited, interrupted, ~~or~~ restricted in certain geographic regions or **will be** of satisfactory quality or **will** continue to be available at acceptable prices. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by FDA and foreign regulatory authorities in order to comply with regulatory standards, such as current cGMP. If we or any of our third- party manufacturers or testing contractors fail to maintain regulatory compliance, this could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our drug candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or

interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. The regulatory authorities also may, at any time following approval of a product for sale, **audit/inspect** the manufacturing facilities of our third-party manufacturers. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and / or time-consuming for us or our third-party manufacturers to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a manufacturing facility. Any such remedial measures imposed upon third parties with whom we contract could materially harm our business. If we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate development or increase our expenditures. To the extent **was we** are able to enter into strategic transactions, we will be exposed to risks related to those collaborations and alliances. An important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances with pharmaceutical companies, research institutions or other industry participants to advance our programs and enable us to maintain our financial and operational capacity. We face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all. In addition, these alliances may be unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our drug development or research programs. If we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms. We may not successfully engage in future strategic transactions, which could adversely affect our ability to develop and commercialize drug candidates, impact our cash position, increase our expenses and present significant distractions to our management. In the future, we may consider strategic alternatives intended to further the development of our business, which may include acquiring businesses, technologies, or products, out- or in-licensing drug candidates or technologies or entering into a business combination with another company. Any strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management's time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and have a negative impact on the competitiveness of any drug candidate that reaches market. We have obtained Orphan Drug Designation for IMNN-001 and may seek Orphan Drug Designation for other drug candidates, but we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity. IMNN-001 has been granted orphan drug designation for ovarian cancer in both the U.S. and Europe. Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if the disease or condition for which the drug is intended affects fewer than 200,000 individuals **annually** in the U.S., or, if the drug is intended for a disease or condition affecting 200,000 or more people in the U.S., there is no reasonable expectation that the cost of **research and developing and making available in the U.S.** the drug or biologic for the **indication can disease or condition will** be recovered **by from** sales of the drug in the U.S. Even though we have obtained Orphan Drug Designation for IMNN-001 and may obtain such designation for other drug candidates in specific indications, we may not be the first to obtain marketing approval of these drug candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same **condition/indication**. Even after an orphan product is approved, the FDA can subsequently approve **a different sponsor's application for** the same drug **with for** the same **indication active moiety for the same condition** if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Fast Track designation may not actually lead to a faster development or regulatory review or approval process. IMNN-001 has received U.S. FDA Fast Track **Designation/designation** in 2021. However, we may not experience a faster development process, review, or approval compared to **conventional FDA procedures a product that lacks Fast Track designation**. The FDA may withdraw our Fast Track designation if the FDA believes that the designation is no longer supported by data from our clinical or pivotal development program. Our Fast Track designation does not guarantee that we will qualify for or be able to take advantage of the FDA's expedited review procedures or that any application that we may submit to the FDA for regulatory approval will be accepted for filing or ultimately approved. Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable false claims act, anti-kickback, transparency, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, administrative burdens, reputational harm and diminished profits and future earnings. Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute biopharmaceutical products. In particular, the research of our drug candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission (s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of biopharmaceutical products. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company's attention from the business. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management's attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. Ongoing legislative and regulatory changes affecting the healthcare industry could have a material adverse effect on our business. Political, economic and regulatory influences are subjecting the healthcare industry to potential fundamental changes that could substantially affect our results of operations by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products, **if approved**, or (iv) additional record-keeping requirements. We cannot predict what healthcare reform initiatives may be adopted in the future. Further, federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues **for** any drug candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates. We may fail to comply with evolving European and other privacy laws. We are subject to varying degrees of **governmental privacy**

regulation in the countries in which we operate operations, and the general trend is toward increasingly stringent regulation and enforcement. We are, for example, subject to costly and complex U. S. and foreign laws governing the collection, use, disclosure, and cross-border transfer of information about patients and other individuals that may materially adversely affect our financial condition and business operations. Since we **have conducted and may** conduct clinical trials in the European Economic Area (“ EEA ”), we are subject to additional data protection and clinical trial laws in the European Union. The General Data Protection Regulation, (EU) 2016 / 679 (“ GDPR ”), for example, governs the processing of personal data, and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing notices to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, alerting data subjects and authorities about data breaches, and taking specific measures when engaging third- party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the U. S., and confers on data subjects the right to lodge complaints with supervisory authorities, and seek certain judicial review for violations of the GDPR. In addition, the GDPR includes restrictions on cross- border data transfers. Under the GDPR, competent regulatory authorities have the power to impose fines up to EUR 20 million or 4 % of the global annual turnover (whichever is higher), depending on the nature of the violation (see Art. 83, GDPR). Further consequences of non- compliance could be cease and desist claims by certain organizations / competitors, damage claims and reputational damage. Further, Regulation (EU) No 536 / 2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001 / 20 / EC governs how we conduct clinical trials in the European Union together with Good Clinical Practices. As a result of Brexit, moreover, we also have independent obligations, similar to those already imposed on us by GDPR, under the United Kingdom’ s Data Protection Act, 2018 . **Additionally, there are** ~~as amended and replaced from time to time, as well as~~ other local ~~Member State~~ data protection laws, industry- specific requirements, regulations, or applicable codes of conduct **which may impact our operations** . We have ~~established~~ **taken steps to implement** privacy compliance programs and controls, but ~~as with many technology and data- driven initiatives being prioritized across throughout our~~ **business remains subject to operations and involving multiple vendors and third parties, there are** potential risks of controls imposed on cross border data flows, unauthorized access, and loss of personal data through internal and external threats that could impact our business operations and research activities. The success of our products , **if approved,** may be harmed if the government, private health insurers and other third- party payors do not provide sufficient coverage or reimbursement. Our ability to commercialize our new cancer treatment systems successfully will depend in part on the extent to which reimbursement for the costs of such products , **if approved,** and related treatments will be available from third- party payors, which include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Patients who are provided medical treatment for their conditions generally rely on third- party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our drug candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our drug candidates. Our products , **if approved,** may not achieve sufficient acceptance by the medical community to sustain our business. The commercial success of our products , **if approved,** will depend upon their acceptance by the medical community and third- party payors as clinically useful, cost effective and safe. Any of our drug candidates or similar drug candidates being investigated by our competitors may prove not to be effective in trial or in practice, cause adverse events or other undesirable side effects. Our testing and clinical practice may not confirm the safety and efficacy of our drug candidates or even if further testing and clinical practice produce positive results, the medical community may view these new forms of treatment as effective and desirable or our efforts to market our new products , **if approved,** may fail. Market acceptance depends upon physicians and hospitals obtaining adequate reimbursement rates from third- party payors to make our products , **if approved,** commercially viable. Any of these factors could have an adverse effect on our business, financial condition and results of operations. We have no internal sales or marketing capability. If we are unable to create sales, marketing and distribution capabilities or enter into alliances with others possessing such capabilities to perform these functions, we will not be able to commercialize our products , **if approved,** successfully. We currently have no sales, marketing, or distribution capabilities. We intend to market our products, if and when such products are approved for commercialization by the FDA and foreign regulatory agencies, either directly or through other strategic alliances and distribution arrangements with third parties. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration, and compliance capabilities, including providing adequate training on such topics. If we rely on third parties with such capabilities to market our products, we will need to establish and maintain partnership arrangements, and there can be no assurance that we will be able to enter into third- party marketing or distribution arrangements on acceptable terms or at all. To the extent that we do enter into such arrangements, we will be dependent on our marketing and distribution partners. In entering into third- party marketing or distribution arrangements, we expect to incur significant additional expenses and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for our products and services. Our success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth effectively. Our business strategy contemplates growth and diversification. Our ability to manage growth effectively will require that we continue to expend funds to improve our operational, financial and management controls, reporting systems and procedures. In addition, we must effectively expand, train and manage our employees. We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner. There can be no assurance that we will be able to manage our growth and a failure to do so could have a material adverse effect on our business. We face intense competition and the failure to compete effectively could adversely affect our ability to develop and market our products, if approved. There are many companies and other institutions engaged in research and development of various technologies for cancer treatment products that seek treatment outcomes similar to those that we are pursuing. We believe that the level of interest by others in investigating the potential of possible competitive treatments and alternative technologies will continue and may increase. Potential competitors engaged in all areas of cancer treatment research in the U. S. and other countries include, among others, major pharmaceutical, specialized technology companies, and universities and other research institutions. Most of our current and potential competitors have substantially greater financial, technical, human and other resources, and may also have far greater experience than do we, both in pre- clinical testing and human clinical trials of new products and in obtaining FDA and other regulatory approvals. One or more of these companies or institutions could succeed in developing products or other technologies that are more effective than the products and technologies that we have been or are developing, or which would render our technology and products obsolete and non- competitive. Furthermore, if we are permitted to commence commercial sales of any of our products, we will also be competing, with respect to manufacturing efficiency and marketing, with companies having substantially greater resources and experience in these areas. We may be subject to significant product liability claims and litigation. Our business exposes us to potential product liability risks inherent in the testing, manufacturing and marketing of human therapeutic products. We presently have product liability insurance limited to \$ 10 million per incident and \$ 10 million annually. If we were to be subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim with our own limited resources, which could have a severe adverse effect on our business. Whether or not we are ultimately successful in any product liability litigation, such litigation would harm the business by diverting the attention and resources of our management, consuming substantial amounts of our financial resources and by damaging our reputation. Additionally, we may not be able to maintain our product liability insurance at an acceptable cost, if at all. Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses and malicious software that could attack our networks and data centers or those of our service providers; unauthorized parties may attempt to gain access to our systems, networks, or facilities, or those of third parties with whom we do business, through fraud, trickery, or other forms of deceiving our employees or contractors, direct social engineering, phishing, credential stuffing, ransomware, denial or degradation of service attacks and similar types of attacks against any or all of us, our patients and our services providers; inadvertent security breaches or theft, misuse, unauthorized access or other improper actions by our employees, patients, service providers and other business partners; natural disasters, terrorism, war and telecommunication and electrical failures. - These extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of our systems and networks, and the confidentiality, integrity, and availability of our sensitive data. We continually assess these threats and ~~makes~~ **make** investments to increase internal protection, detection, and response capabilities, as well as ensure that our third- party providers have required capabilities and controls, to address those risks. Even so, such events could cause significant interruptions of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our drug candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any disruption or privacy or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be subject to reputational harm, monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and other forms of liability and the development of our drug candidates could be delayed. In addition, such interruptions and cyber security incidents and faults can cause reputational damage. Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non- compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. We are exposed to the risk that

our employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and / or negligent conduct or disclosure of unauthorized activities to us that violates: (1) FDA regulations or similar regulations of comparable non- U. S. regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non- U. S. regulatory authorities, and (4) laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self- dealing, bribery and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or collaborator misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. While we have a code of conduct and business ethics, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and / or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, **if approved**. Our success will depend, in a substantial part, on our ability to maintain our rights under license agreements granting us rights to use patented technologies. For instance, we are party to license agreements with Duke University, under which we have exclusive rights to commercialize medical treatment products and procedures based on Duke’ s thermo- sensitive liposome technology. The Duke University license agreement contains a license fee, royalty and / or research support provisions, testing and regulatory milestones, and other performance requirements that we must meet by certain deadlines. If we breach any provisions of the license and research agreements, we may lose our ability to use the subject technology, as well as compensation for our efforts in developing or exploiting the technology. Any such loss of rights and access to technology could have a material adverse effect on our business. Further, we cannot guarantee that any patent or other technology rights licensed to us by others will not be challenged or circumvented successfully by third parties, or that the rights granted will provide adequate protection. We may be required to alter any of our potential products or processes or enter into a license and pay licensing fees to a third party or cease certain activities. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology. If a license is not available on commercially reasonable terms or at all, our business, results of operations, and financial condition could be significantly harmed, and we may be prevented from developing and commercializing the product. Litigation, which could result in substantial costs, may also be necessary to enforce any patents issued to or licensed by us or to determine the scope and validity of another’ s claimed proprietary rights. If any of our pending patent applications **do are not issue-issued**, or are deemed invalid following issuance, we may lose valuable intellectual property protection. The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own various U. S. and international patents and have pending U. S. and international patent applications that cover various aspects of our technologies. There can be no assurance that patents that have **been** issued will be held valid and enforceable in a court of law through the entire patent term. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time-consuming and costly. Additionally, issued patents can be subject to opposition, interferences or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage). Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products, **if approved**, encompassed by our patents. We may have to participate in interference proceedings declared by the U. S. Patent and Trademark Office, which could result in a loss of the patent and / or substantial cost to us. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our technologies and our proprietary drug candidates. There can be no assurance that the patent applications for which we apply would actually issue as patents or do so with commercially relevant or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued. The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications. In addition, there is no guarantee that we will be the first to file a patent application directed to an invention. An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute. In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products. We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. We rely on trade secrets and confidential information that we seek to protect, in part, by confidentiality agreements with our corporate partners, collaborators, employees and consultants. We cannot assure you that these agreements are adequate to protect our trade secrets and confidential information or will not be breached or, if breached, we will have adequate remedies. Furthermore, others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition. We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. Our commercial success depends on our ability to operate without infringing the patents and other proprietary rights of third parties. Although we currently are not involved in any material litigation involving patents, a third- party patent holder may assert a claim of patent infringement against us in the future. Alternatively, we may initiate litigation against the third- party patent holder to request that a court declare that we are not infringing the third party’ s patent and / or that the third party’ s patent is invalid or unenforceable. Any infringement action asserted against us, even if we are ultimately successful in defending against such action, would likely delay the regulatory approval process of our products, harm our competitive position, be expensive and require the time and attention of our key management and technical personnel. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions.

RISKS RELATED TO OUR SECURITIES The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation. The trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading in our stock, regardless of our financial condition, results of operations, business or prospects. In addition to the factors discussed in this “ Risk Factors ” section and elsewhere in this **annual-Annual report-Report**, these factors include: • disclosure of actual or potential clinical results with respect to drug candidates we are developing; • regulatory developments in both the United States and abroad; • developments concerning proprietary rights, including patents and litigation matters; • public concern about the safety or efficacy of our drug candidates or technology, or related technology, or new technologies generally; • concern about the safety or efficacy of our drug candidates or technology, or related technology, or new technologies generally; • public announcements by our competitors or others; and • general market conditions and comments by securities analysts and investors. Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. Our common stock is currently traded on The Nasdaq Capital Market under the symbol “ IMNN. ” If we fail to comply with Nasdaq’ s continued listing standards, we may be delisted and our common stock will trade, if at all, only on the over- the- counter market, such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker- dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Further, delisting of our common stock would likely result in our common stock becoming a “ penny stock ” under the Exchange Act. **On December 26, 2023, we received a notice from the staff of the Nasdaq Stock Market LLC (the “ Staff ”) notifying us that, based upon the closing bid price of our common stock, for the 30 consecutive business days prior to the notice, we no longer met the requirement to maintain a minimum closing bid price of \$ 1. 00 per share, as set forth in Nasdaq Listing Rule 5550 (a) (2). In accordance with Nasdaq Listing Rule 5810 (c) (3) (A), we were granted 180 calendar days, or until June 24, 2024, to regain compliance with the minimum bid price rule. To regain compliance, the**

closing bid price of our common stock must be \$ 1.00 per share or more for a minimum of 10 consecutive business days at any time before June 24, 2024. If we do not regain compliance with Rule 5550 (a) (2) by June 24, 2024, we may be eligible for an additional 180 calendar day compliance period. To qualify, we will be required to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and would need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If it appears to the Staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq would notify us that our securities will be subject to delisting. In the event of such notification, we may appeal the Staff's determination to delist our securities, but there can be no assurance the Staff would grant our request for continued listing. If our common stock is delisted by Nasdaq, it may be eligible for quotation on an over-the-counter quotation system or on the pink sheets. Upon any such delisting, our common stock would become subject to the regulations of the SEC relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a market price of less than \$ 5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for our common stock and could limit the ability of stockholders to sell securities in the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market value of our common stock, and there can be no assurance that our common stock will be eligible for trading or quotation on any alternative exchanges or markets. Delisting from Nasdaq could adversely affect our ability to raise additional financing through public or private sales of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. Future sales of our common stock in the public market could cause our stock price to fall. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of March 28-26, 2023-2024, we had 9,089,399, 789 shares of common stock outstanding, all of which, other than shares held by our directors and certain officers, were eligible for sale in the public market, subject in some cases to compliance with the requirements of Rule 144, including the volume limitations and manner of sale requirements. In addition, all of the shares of common stock issuable upon exercise of warrants will be freely tradable without restriction or further registration upon issuance. Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants. In order to raise additional capital or pursue strategic transactions, we may in the future offer, issue or sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock, including the issuance of common stock in relation to the achievement, if any, of milestones triggering our payment of earn-out consideration in connection with the EGEN acquisition. Our stockholders may experience significant dilution as a result of future equity offerings or issuances. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. As of March 28-December 31, 2023, we have had the following number of securities convertible into, or allowing the purchase of, our common stock, including 168-160, 519-060 shares of common stock issuable upon exercise of warrants outstanding, 820-1, 507-095, 582 options to purchase shares of our common stock and restricted stock awards outstanding, and 388-1, 932-206, 342 shares of common stock reserved for future issuance under our stock incentive plan. Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and share price. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the current-ongoing conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including with respect to global supply chain and energy concerns. Additionally, disruptions to the U.S. banking system may adversely affect our ability to access additional capital when needed on acceptable terms. For example, on March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. Although the Department of the Treasury, the Federal Reserve and the FDIC stated all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, or any other financial institution that is placed into receivership by the FDIC may be impacted by other disruptions to the U.S. banking system caused by the recent developments involving SVB, including potential delays in the ability to transfer funds and in the short-term potential delays in making payments to vendors while new banking relationships are established. Any such volatility may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Our ability to use net operating losses to offset future taxable income are subject to certain limitations. On December 22, 2017, the then President of the U.S. signed into law the Tax Reform Act. The Tax Reform Act significantly changes-changed U.S. tax law by, among other things, lowering corporate income tax rates, implementing a quasi-territorial tax system, providing a one-time transition toll charge on foreign earnings, creating a new limitation on the deductibility of interest expenses and modifying the limitation on officer compensation. The Tax Reform Act permanently reduces-reduced the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. We currently have significant net operating losses ("NOLs") that may be used to offset future taxable income. In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. During 2022, 2021 and years prior, we performed analyses to determine if there were changes in ownership, as defined by Section 382 of the Internal Revenue Code, that would limit our ability to utilize certain net operating loss and tax credit carry forwards. We determined we experienced ownership changes, as defined by Section 382, in connection with certain common stock offerings in 2011, 2013, 2015, 2017, 2018, 2020 and 2021. As a result, the utilization of our federal tax net operating loss carry-forwards generated prior to the ownership changes is limited. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code, which would significantly limit our ability to utilize NOLs to offset future taxable income. Future changes in tax laws could also impair our corporate tax rate and / or our ability to utilize our NOLs. We have never paid cash dividends on our common stock in the past and do not anticipate paying cash dividends on our common stock in the foreseeable future. We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future for holders of our common stock. Anti-takeover provisions in our charter documents and Delaware law could prevent or delay a change in control. Our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that a stockholder may consider favorable by authorizing the issuance of "blank check" preferred stock. This preferred stock may be issued by our Board of Directors on such terms as it determines, without further stockholder approval. Therefore, our Board of Directors may issue such preferred stock on terms unfavorable to a potential bidder in the event that our Board of Directors opposes a merger or acquisition. In addition, our staggered Board of Directors may discourage such transactions by increasing the amount of time necessary to obtain majority representation on our Board of Directors. Certain other provisions of our bylaws and of Delaware law may also discourage, delay or prevent a third party from acquiring or merging with us, even if such action were beneficial to some, or even a majority, of our stockholders. ITEM 1B. UNRESOLVED STAFF COMMENTS None. ITEM 1C. CYBERSECURITY We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology ("IT") function and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, and routine review of our policies and procedures to identify risks and refine our practices. We engage certain external parties, including a full service managed IT service provider, to enhance our cybersecurity oversight. Our Audit Committee of the Board of Directors (the "Audit Committee") is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding any significant new cybersecurity threats or incidents. We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. Management is responsible for the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks. In an effort to deter and detect cyber threats, we annually provide all employees with cybersecurity and prevention training, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. ITEM 2. PROPERTIES We own no real property and have no plans to acquire any real property in the future. Lawrenceville, NJ Lease In July 2011-August 2023, we entered into a the Company renewed its Lawrenceville office lease with Brandywine Operating Partnership, L.P., a Delaware limited partnership for a 24-month agreement for 10,870 square foot premises located in Lawrenceville;

New Jersey in connection with the relocation of our offices from Columbia, Maryland. On February 1, 2019, we amended the current terms of the lease to increase the size of the premises by 2,285 square feet to 9,850 square feet **with monthly rent payments of approximately \$ 22** and also extended the lease term by one year to September 1, 2023 **983 and \$ 23,394**. Huntsville, AL Lease In connection with the Asset Purchase Agreement with EGEN in June 2014, we assumed the existing lease with another landlord for an 11,500 square foot premises located in Huntsville, Alabama. In January 2018, we entered into a 60-month lease agreement for 9,049 square feet with rent payments of approximately \$ 18,100 per month. On June 9, 2021, the Company and the Huntsville landlord entered into a 22-month lease, as amended on July 2021, for an additional 2,197 square foot premises with rent payments of approximately \$ 5,500 per month. In January 2023, we **the Company** renewed **its** Huntsville **facility lease** for a 60-month lease agreement for 11,420 square feet with **monthly** rent payments of approximately \$ 28,550 **to \$ 30,903**. We believe our existing facilities are suitable and adequate to conduct our business. Following is a table of future payments and maturity of our operating lease liabilities as of December 31, 2022-2023: For the year ending December 31, 2023-2024 **238 \$ 626**, 609 323 2025 543, 009 2026 362, 976 2027 370, 236 2028 and thereafter **-30,903** Subtotal future lease payments **238-1, 609-933, 447** Less imputed interest (**7-308, 860-733**) Total lease liabilities **\$ 230-1, 749 624, 714** Weighted average remaining life **0-3, 61-5** years Weighted average discount rate **9.98 %** **For 2023, operating lease expense was \$ 646, 633 and cash paid for operating leases included in operating cash flows was \$ 644, 593.** For 2022, operating lease expense was \$ 587, 744 and cash paid for operating leases included in operating cash flows was \$ 601, 495. For 2021, operating lease expense was \$ 560, 513 and cash paid for operating leases included in operating cash flows was \$ 568, 269. **ITEM 3. LEGAL PROCEEDINGS-PROCEEDINGS** On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the "Spar Individual Defendants") in the U. S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff **alleges-alleged** that the Company and Spar Individual Defendants made false and misleading statements regarding one of the Company's drug candidates, ThermoDox®, and **brings-brought** claims for damages under Section 10 (b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all **Defendants-defendants**, and under Section 20 (a) of the Exchange Act of 1934 against the Spar Individual Defendants. **The Company believes that the case is without merit and intends to defend it vigorously. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined.** On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted **the Plaintiff-plaintiff** leave to file an amended complaint within 30 days. **The Plaintiff plaintiff** did not file an amended complaint within the 30-day deadline. **In September 2023, the U. S. District Court issued an Order for Dismissal without prejudice.** In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U. S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al., Case No. 3:21-cv-02662. The plaintiff **alleges** breach of fiduciary duty and other claims arising out of alleged statements made by certain of the Company's directors and / or officers regarding ThermoDox®. The Company believes it has meritorious defenses to these claims and intends to vigorously contest this suit. At this stage of the case **neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined.** On March 10, 2023, the U. S. District Court for the District of New Jersey issued an order that the action is administratively terminated pending the submission, by March 17, 2023, of a joint letter advising as to how the parties wish to proceed in the matter. In August 2021, a complaint regarding a corporate books and records demand was filed against the Company in the Court of Chancery of the State of Delaware, captioned Pacheco v. Celsion Corporation, Case No. 2021-0705. The plaintiff alleges he is entitled to inspect the Company's books and records concerning the OPTIMA Study and other materials. The Company believes that the scope of the demand is without merit and intends to defend it vigorously. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. In October 2021, an arbitration was commenced against the Company before the CPR Institute for Conflict Prevention & Resolution, captioned Curia New Mexico, LLC v. Celsion Corp., Case No. G-22-85-S. The plaintiff alleges that the Company failed to pay invoices for the manufacture of ThermoDox®. The Company believes it has a meritorious defense to these claims and is vigorously contesting this allegation. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. **ITEM 4. MINE SAFETY DISCLOSURES** Not Applicable. **PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES** Market for Our Common Stock Our common stock trades on The Nasdaq Capital Market under the symbol "IMNN." Record Holders As of March 30-28, 2023-2024, there were approximately 28,000 stockholders of record of our common stock. The actual number of stockholders may be greater than this number of record stockholders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of stockholders of record also does not include stockholders whose shares may be held in trust by other entities. Dividend Policy We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain all of our future earnings for use in the operation of our business and to fund future growth and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject to applicable law, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our Board of Directors may deem relevant. **Performance Graph Not required.** Unregistered Sales of Equity Securities **On December 7, 2023, we granted (i) an option to purchase 80,000 shares of the Company's common stock with an exercise price of \$ 0.88 per share and (ii) a restricted stock award of 20,000 restricted shares to Dr. Sébastien Hazard, our Executive Vice President and Chief Medical Officer, as an "inducement" grant pursuant to Rule 5635 (c) (4) of the Nasdaq Listing Rules. The grant of the option was exempt from registration under the Securities Act, pursuant to Section 4 (a) (2) thereof as a transaction by an issuer not involving a public offering.** Issuer Purchases of Equity Securities **ITEM 6. RESERVED SELECTED FINANCIAL DATA** Not required. **ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** The following discussions should be read in conjunction with the **Financial-financial Statements-statements** and related notes thereto included in this Annual Report. The following discussion contains forward-looking statements made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements are based on the Company's beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results. Factors that could cause or contribute to such differences include those described under "Part I, Item 1A- Risk Factors" appearing in this Annual Report and factors described in other cautionary statements, cautionary language and risk factors set forth in other documents that the Company files with the **SEC Securities and Exchange Commission**. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. Overview On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock continues to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN," effective as of the opening of trading on September 21, 2022. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name-Imunon, Inc.-("Imunon" and the "Company") is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms **with the aim** to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon **has two platform is developing its non-viral DNA technologies-technology** **Our across four modalities. The first modality, TheraPlas®, is being developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is being developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid-vaccines for-in** infectious diseases and. The third modality, FixPlas®, concerns the application of Imunon's DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neopeptide cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-IL-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting **IND-enabling preclinical proof-of-concept studies on-for the development of a nucleic acid-COVID-19 booster vaccine (IMNN candidate targeting SARS-CoV-2-101) and a treatment for the Lassa virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine** in order to validate its PLACCINE platform melanoma (IMNN-201). Imunon's platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms **modalities** and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. **Business Plan and Going Concern Risk As IMMUNO-ONCOLOGY Program** On June 20, 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., a privately held corporation located in Huntsville, Alabama. Pursuant to the Asset Purchase Agreement, CLSN Laboratories acquired all of EGEN's right, title and interest in substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. A key asset acquired from

EGEN was the TheraPlas technology platform. The first drug candidate developed from this technology platform is IMNN-001, a **stage biopharmaceutical company** TheraPlas Technology Platform TheraPlas is a technology platform for the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA. There are two components of the TheraPlas system, a plasmid-DNA or **our business** mRNA payload encoding a therapeutic protein, and **our** a delivery system. The delivery system is designed to protect the DNA / mRNA from degradation and promote trafficking into cells and through intracellular compartments. We designed the delivery system of TheraPlas by chemically modifying the low molecular weight polymer to improve its gene transfer activity without increasing toxicity. We believe that TheraPlas may be a viable alternative to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to potentially improve activity and safety. The design of the TheraPlas delivery system is based on molecular functionalization of polyethyleneimine ("PEI"), a cationic delivery polymer with a distinct ability to **execute our strategy** escape from the endosomes due to **achieve our corporate goals are subject** heavy protonation. The transfection activity and toxicity of PEI is tightly coupled to its molecular weight; therefore **numerous risks and uncertainties. Material risks and uncertainties relating to our business and our industry are described in " Part I , the clinical application of PEI is limited Item 1A. Risk Factors " in this Annual Report on Form 10- K .** We have used molecular functionalization strategies **not generated and do not expect** to **generate any revenue** improve the activity of low molecular weight PEIs without augmenting their cytotoxicity. In one instance, chemical conjugation of a low molecular weight branched BPEI800 with cholesterol and polyethylene glycol ("PEG") to form **from product sales** PEG-PEI-Cholesterol ("PPC") dramatically improved the transfection activity of BPEI800 following in vivo delivery. Together, the **next several years, if** cholesterol and PEG modifications produced approximately 20-fold enhancement in transfection activity. Biodistribution studies following intraperitoneal or subcutaneous administration of DNA / PPC nanocomplexes showed DNA delivery localized primarily at the injection site with only a small **all** amount escaping into the systemic circulation. **An element** PPC is the delivery component of our **business strategy** lead TheraPlas product, IMNN-001, which is in clinical development for the treatment of ovarian cancer. The PPC manufacturing process has been scaled up to pursue, as resources permit, the research and development of a range of drug candidates for a **variety of indications. We may also evaluate licensing products** from third parties bench scale (1-2 g) to **expand our** 0.6Kg, and several current Good Manufacturing Practice ("cGMP") lots have been produced **product pipeline** with reproducible quality. **This is intended** We believe that TheraPlas has emerged as a viable alternative to **allow us** current approaches due to **diversify** several distinguishing characteristics such as strong molecular versatility that may allow for complex modifications to potentially improve activity and safety with little difficulty. The biocompatibility of these **the** polymers reduces the risk **risks associated** of adverse immune response, thus allowing for repeated administration. Compared to naked DNA or cationic lipids, TheraPlas is generally safer, more efficient, and cost effective. We believe that these advantages place Immunon in a position to capitalize on this technology platform. IMNN-001 (formerly GEN-1) Immunotherapy IMNN-001 is a DNA-based immunotherapeutic drug candidate for the localized treatment of ovarian cancer by intraperitoneally administering an Interleukin-12 ("IL-12") plasmid formulated with our **research** proprietary TheraPlas delivery system. In this DNA-based approach, the immunotherapy is combined with a standard chemotherapy drug, which can potentially achieve better clinical outcomes than with chemotherapy alone. We believe that increases in IL-12 concentrations at tumor sites for several days after a single administration could create a potent immune environment against tumor activity and **development** **expenditures. To** that a direct killing of the **extent we are** tumor with concomitant use of cytotoxic chemotherapy could result in a more robust and durable **unable** antitumor response than chemotherapy alone. We believe the rationale for local therapy with IMNN-001 is based on the following: • Local regional production of the potent cytokine IL-12 avoids toxicities and poor pharmacokinetics associated with systemic delivery of recombinant IL-12; • Persistent local delivery of IL-12 lasts up to **maintain** one week and dosing can be repeated; and • Local therapy is ideal for long-term maintenance therapy. OVATION I Study. In February 2015, we announced that the FDA accepted, without objection, the OVATION I Study. On September 30, 2015, we announced enrollment of the first patient in the OVATION I Study. The OVATION I Study was designed to: (i) identify a safe, tolerable and therapeutically active dose of IMNN-001 by recruiting and maximizing an immune response; (ii) enroll three to six patients per dose level and evaluate safety and efficacy; and (iii) attempt to define an optimal dose for a follow-on Phase II study. In addition, the OVATION I Study established a unique opportunity to assess how cytokine-based compounds such as IMNN-001, directly affect ovarian cancer cells and the tumor microenvironment in newly diagnosed ovarian cancer patients. The study was designed to characterize the nature of the immune response triggered by IMNN-001 at various levels of the patients' immune system, including: • Infiltration of cancer-fighting T-cell lymphocytes into primary tumor and tumor microenvironment including peritoneal cavity, which is the primary site of metastasis of ovarian cancer; • Changes in local and systemic levels of immuno-stimulatory and immuno-suppressive cytokines associated with tumor suppression and growth, respectively; and • Expression profile of a comprehensive panel of immune related genes in pre-treatment and IMNN-001-treated tumor tissue. We initiated the OVATION I Study at four clinical sites at the University of Alabama at Birmingham, Oklahoma University Medical Center, Washington University in St. Louis, and the Medical College of Wisconsin. During 2016 and 2017, we announced data from the first fourteen patients in the OVATION I Study. On October 3, 2017, we announced final translational research and clinical data from the OVATION I Study. Key translational research findings from all evaluable patients are consistent with the earlier reports from partial analysis of the data and are summarized below: • The intraperitoneal treatment of IMNN-001 in conjunction with NACT resulted in dose dependent increases in IL-12 and Interferon-gamma (IFN- γ) levels that were predominantly in the peritoneal fluid compartment with little to no changes observed in the patients' systemic circulation. These and other post-treatment changes including decreases in VEGF levels in peritoneal fluid are consistent with an IL-12 based immune mechanism; • Consistent with the previous partial reports, the effects observed in the IHC analysis were pronounced decreases in the density of immunosuppressive T-cell signals (Foxp3, PD-1, PDL-1, IDO-1) and increases in CD8 cells in the tumor microenvironment; • The ratio of CD8 cells to immunosuppressive cells was increased in approximately 75% of patients suggesting an overall shift in the tumor microenvironment from immunosuppressive to pro-immune stimulatory following treatment with IMNN-001. An increase in CD8 to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved OS; and • Analysis of peritoneal fluid by cell sorting, not reported before, shows a treatment-related decrease in the percentage of immunosuppressive T-cell (Foxp3), which is consistent with the reduction of Foxp3 T-cells in the primary tumor tissue, and a shift in tumor naive CD8 cell population to more efficient tumor-killing memory effector CD8 cells. The Company also reported encouraging clinical data from the first fourteen patients who completed treatment in the OVATION I Study. IMNN-001 plus standard chemotherapy produced no dose-limiting toxicities and positive dose dependent efficacy signals which correlate well with positive surgical outcomes as summarized below: • Of the fourteen patients treated in the entire study, two patients demonstrated a complete response, ten patients demonstrated a partial response and two patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate and an 86% objective response rate ("ORR"). Of the five patients treated in the highest dose cohort, there was a 100% ORR with one complete response and four partial responses; • Fourteen patients had successful resections of their tumors, with nine patients (64%) having a complete tumor resection ("R0"), which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Seven out of eight (88%) patients in the highest two dose cohorts experienced a R0 surgical resection. All five patients treated at the highest dose cohort experienced a R0 surgical resection; and • All patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells. On March 26, 2020, the Company announced with Medidata, a Dassault Systèmes company, that examining matched patient data provided by Medidata in a synthetic control arm ("SCA") with results from the Company's completed Phase Ib dose-escalating OVATION I Study showed positive results in progression-free survival ("PFS"). The hazard ratio ("HR") was 0.53 in the ITT group, showing strong signals of efficacy. The Company believes these data may warrant consideration of strategies to accelerate the clinical development program for IMNN-001 in newly diagnosed, advanced ovarian cancer patients by the FDA. In its March 2019 discussion with the Company, the FDA noted that preliminary findings from the Phase Ib OVATION I Study were exciting but lacked a control group to evaluate IMNN-001's independent impact on impressive tumor response, surgical results and PFS. The FDA encouraged the Company to continue its IMNN-001 development program and consult with FDA with new findings that may have a bearing on designations such as Fast Track and Breakthrough Therapy. SCAs have the potential to revolutionize clinical trials in certain oncology indications and some other diseases where a randomized control is not ethical or practical. SCAs are formed by carefully selecting control patients from historical clinical trials to match the demographic and disease characteristics of the patients treated with the new investigational product. SCAs have been shown to mimic the results of traditional randomized controls so that the treatment effects of an investigational product can be visible by comparison to the SCA. SCAs can help advance the scientific validity of single arm trials, and in certain indications, reduce time and cost, and expose fewer patients to placebos or existing standard-of-care treatments that might not be effective for them. On July 29, 2021, the Company announced final progression free survival ("PFS") results from the OVATION I Study published in the Journal of Clinical Cancer Research. Median PFS in patients treated per protocol (n=14) was 21 months and was 18.4 months for the intent-to-treat ("ITT") population (n=18) for all dose cohorts, including three patients who dropped out of the study after 13 days or less, and two patients who did not receive full NAC and IMNN-001 cycles. Under the current standard of care, in women with Stage III/IV ovarian cancer undergoing NAC, their disease progresses within about 12 months on average. The results from the OVATION I Study support continued evaluation of IMNN-001 based on promising tumor response, as reported in the PFS data, and the ability for surgeons to completely remove visible tumor at interval debulking surgery. IMNN-001

was well tolerated, and no dose-limiting toxicities were detected. Intraperitoneal administration of IMNN-001 was feasible with broad patient acceptance. OVATION 2 Study. The Company held an Advisory Board Meeting on September 27, 2017 with the clinical investigators and scientific experts including those from Roswell Park Cancer Institute, Vanderbilt University Medical School, and M. D. Anderson Cancer Center to review and finalize clinical, translational research and safety data from the OVATION 1 Study in order to determine the next steps forward for our IMNN-001 immunotherapy program. On November 13, 2017, the Company filed its Phase I/II clinical trial protocol with the FDA for IMNN-001 for the localized treatment of ovarian cancer. The protocol is designed with a single dose escalation phase to 100 mg/m² to identify a safe and tolerable dose of IMNN-001 while maximizing an immune response. The Phase I portion of the study will be followed by a continuation at the selected dose in approximately 110 patients randomized Phase II study. In the OVATION 2 Study, patients in the IMNN-001 treatment arm will receive IMNN-001 plus chemotherapy pre- and post-interval debulking surgery ("IDS"). The OVATION 2 Study will include up to 110 patients with Stage III/IV ovarian cancer, with 12 to 15 patients in the Phase I portion and up to 95 patients in Phase II. The study is powered to show a 33% improvement in the primary endpoint, PFS, when comparing IMNN-001 with neoadjuvant adjuvant chemotherapy versus neoadjuvant adjuvant chemotherapy alone. The PFS primary analysis will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later. In March 2020, the Company announced encouraging initial clinical data from the first 15 patients enrolled in the Phase I portion of the OVATION 2 Study for patients newly diagnosed with Stage III and IV ovarian cancer. The OVATION 2 Study combines IMNN-001, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy ("NACT"). Following NACT, patients undergo interval debulking surgery (IDS), followed by three additional cycles of chemotherapy. IMNN-001 plus standard NACT produced positive dose-dependent efficacy results, with no dose-limiting toxicities, which correlates well with successful surgical outcomes as summarized below: ● Of the fifteen patients treated in the Phase I portion of the OVATION 2 Study, nine patients were treated with IMNN-001 at a dose of 100 mg/m² plus NACT and six patients were treated with NACT only. All fifteen patients had successful resections of their tumors, with eight out of nine patients (88%) in the IMNN-001 treatment arm having an R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed. Only three out of six patients (50%) in the NACT only treatment arm had a R0 resection. ● When combining these results with the surgical resection rates observed in the Company's prior Phase Ib dose-escalation trial (the "OVATION 1 Study"), a population of patients with inclusion criteria identical to the OVATION 2 Study, the data reflect the strong dose-dependent efficacy of adding IMNN-001 to the current standard of care NACT: % of Patients R0 Resections 0, 36, 47 mg/m² of IMNN-001 plus NACT N=12 42% 61, 79, 100 mg/m² of IMNN-001 plus NACT N=17 82% ● The ORR as measured by Response Evaluation Criteria in Solid Tumors ("RECIST") criteria for the 0, 36, 47 mg/m² dose IMNN-001 patients were comparable, as expected, to the higher (61, 79, 100 mg/m²) dose IMNN-001 patients, with both groups demonstrating an approximate 80% ORR. On March 23, 2020, the Company announced that the European Medicines Agency (the "EMA") Committee for Orphan Medicinal Products ("COMP") has recommended that IMNN-001 be designated as an orphan medicinal product for the treatment of ovarian cancer. IMNN-001 is an IL-12 DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. IMNN-001 previously received orphan designation from the FDA. In February 2021, the Company announced that it has received Fast Track designation from the FDA for IMNN-001, its DNA-mediated IL-12 immunotherapy currently in Phase II development for the treatment of advanced ovarian cancer and also provided an update on the OVATION 2 Study. The Company reported that approximately one-third, or 34 patients, of the anticipated 110 patients had been enrolled into the OVATION 2 Study, of which 20 are in the treatment arm and 14 are in the control. Of the 34 patients enrolled in the trial, 27 patients have had their interval debulking surgery with the following results: ● 80% of patients treated with IMNN-001 had a R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed. ● 58% of patients in the control arm had an R0 resection. ● This interim data represents a 38% improvement in R0 resection rates for IMNN-001 patients compared with control arm patients and is consistent with the reported improvement in resection scores noted in the encouraging Phase I OVATION 1 Study, the manuscript of which has been submitted for peer review publication. In June 2022, the Company announced that following a pre-planned interim safety review of 87 as treated patients (46 patients in the experimental arm and 41 patients in the control arm) randomized in the OVATION 2 Study, the Data Safety Monitoring Board ("DSMB") unanimously recommended that the OVATION 2 Study continue treating patients with the dose of 100 mg/m². The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that patients tolerate IMNN-001 during a course of treatment that lasts up to six months. No dose-limiting toxicities were reported. Interim clinical data from patients who have undergone interval debulking surgery showed that the IMNN-001 treatment arm is continuing to show improvement in R0 surgical resection rates and CRS 3 chemotherapy response scores over the control arm. A complete tumor resection (R0) is a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. The chemotherapy response score is a three-tier standardized scoring system for histological tumor regression into complete/near complete (CRS 3), partial (CRS 2) and no/minimal (CRS 1) response based on omental examination. In September 2022, the Company announced that its Phase I/II OVATION 2 Study with IMNN-001 in advanced ovarian cancer has completed enrollment with 110 patients. Topline results are expected in the first half of 2024. IMNN-001 in Combination with Avastin. In February 2023, the Company and Break Through Cancer, a public foundation dedicated to supporting translational research in the most difficult-to-treat cancers that partners with top cancer research centers, announce the commencement of patient enrollment in a collaboration to evaluate IMNN-001 in combination with Avastin® (bevacizumab) in patients with advanced ovarian cancer in the frontline, neoadjuvant clinical setting. This Phase I/2 study, titled "Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies," is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer and is being led by principal investigator Amir Jazaeri, M. D., Vice Chair for Clinical Research and Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson. Dana-Farber Cancer Institute, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Memorial Sloan Kettering Cancer Center will also be participating in the trial. In addition, The Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) will provide artificial intelligence services including biomarker and genomic analysis. Patients will be randomized 1:1 in a two-arm trial. The primary endpoint is second look laparoscopy (SLL) and the secondary endpoint is progression-free survival (PFS). Initial SLL data are expected within one year from the completion of enrollment and final PFS data are expected approximately three years from the completion of enrollment. PLACCINE DNA VACCINE TECHNOLOGY PLATFORM In January 2021, the Company announced the filing of a provisional U. S. patent application for a novel DNA-based, investigational vaccine for preventing or treating infections from a broad range of infectious agents including **drug candidates, our dependence on the success of one or** coronavirus disease using its PLACCINE DNA vaccine technology platform ("PLACCINE"). The provisional patent covers a **few drug candidates would increase** family of novel composition of multi-estronic vectors and polymeric nanoparticles that comprise the PLACCINE DNA vaccine platform technology for preventing or treating infectious agents that have the potential for global pandemics, including the SARS-CoV-2 virus and its variations, using the Company's TheraPlas platform technology. Imunon's PLACCINE DNA vaccine technology platform is characterized by a single multi-estronic DNA plasmid vector expressing multiple pathogen antigens delivered with a synthetic delivery system. We believe it is adaptable to creating vaccines for a multitude of pathogens, including emerging pathogens leading to pandemics as well as infectious diseases that have yet to be effectively addressed with current vaccine technologies. This flexible vaccine platform is well supported by an **and would** established supply chain to produce any plasmid vector and its assembly into a respective vaccine formulation. The need for new vaccine technologies is urgent. Since 1980 more than 80 pathogenic viruses have been discovered, yet fewer than 4% have a commercially available prophylactic vaccine **more significant impact on our financial prospects, financial condition, and market value**. We have engaged with the Biomedical Advanced **may also consider and evaluate strategic alternatives, including investment in, or acquisition of, complementary businesses, technologies, or products.** Drug Research **research** and Development **development** Authority (BARDA), a division of the U. S. Department of Health and Human Services, to pursue certain pathogens BARDA has identified as the most urgent and the most important. PLACCINE is an extension of **inherently uncertain process and the there is** Company's synthetic, non-viral TheraPlas delivery technology currently in a **high risk** Phase II trial for the treatment of late-**failure at every** stage ovarian cancer with IMNN-001. Imunon's proprietary multifunctional DNA vaccine technology concept is built on the flexible PLACCINE technology platform that is amenable to rapidly responding to the SARS-CoV-2 virus, as well as possible future mutations of SARS-CoV-2, other future pandemics, emerging bioterrorism threats, and novel infectious diseases. Imunon's extensive experience with TheraPlas suggests that the PLACCINE-based nanoparticles are stable at storage temperatures of 4oC to 25oC, making vaccines developed on this platform easily suitable for broad world-wide distribution. Imunon's vaccine approach is designed to optimize the quality of the immune response dictating the efficiency of pathogen clearance and patient recovery. Imunon has taken a multivalent approach in an effort to generate an even more robust immune response that not only results in a strong neutralizing antibody response, but also a more robust and durable T-cell response. Delivered with Imunon's synthetic polymeric system, the proprietary DNA plasmid is protected from degradation and its cellular uptake is facilitated. COVID-19 Vaccine Overview Emerging data from the recent literature indicates that the quality of the immune response as opposed to its absolute magnitude is what dictates SARS-CoV-2 viral clearance and recovery and that an ineffective or non-neutralizing enhanced antibody response might actually exacerbate disease. The first-generation COVID-19 vaccines were developed for rapid production and deployment and were not optimized for generating cellular responses that result in effective viral clearance. Though early data has indicated some of these vaccines to be over 95% effective, these first-generation vaccines were primarily designed to generate a strong

antibody response, and while they have been shown to provide prophylactic protection against disease, the durability of this protection is currently unclear. Most of these vaccines have been specifically developed to target the SARS-CoV-2 Spike (S) protein (antigen), though it is known that restricting a vaccine to a sole viral antigen creates selection pressure that can serve to facilitate the emergence of viral resistance. Indeed, even prior to full vaccine rollout approval, the timing and the outcome of clinical results are extremely difficult to predict. The success or failure of any preclinical development and clinical trial can have a disproportionately positive or negative impact on our results of operations, it has been observed financial condition, prospects, and market value. Our current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development and commercialization of our drug candidates. In the event that third parties are contracted to manage the clinical trial process S protein is a locus for one rapid evolutionary and functional change as evidenced by the D614G, Y453F, 501Y-V2, and VUI-202012/01 mutations/deletions. This propensity for or mutation more of our drug candidates, the S protein leads estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future risk of efficacy reduction over time as these mutations accumulate collaborative arrangements, in whole or in part, and how such arrangements would affect our development plan or capital requirements. We may also apply for subsidies, grants or government or agency Our Next Generation Vaccine Initiative Imunon's vaccine candidate comprises a single plasmid vector containing the DNA sequence encoding multiple SARS-CoV-2 antigens sponsored studies that could reduce our development costs. Delivery However, we cannot forecast with any degree of certainty whether we will be evaluated intramuscularly selected to receive any subsidy grant intradermally, or governmental subcutaneously with a non-viral synthetic DNA delivery carrier that facilitates vector delivery into the cells of the injected tissue and has potential immune adjuvant properties. Unique designs and formulations of Imunon vaccine candidates may offer several potential key advantages. The synthetic polymeric DNA carrier is an important component of the vaccine composition as it has the potential to facilitate the vaccine immunogenicity by improving vector delivery and, due to potential adjuvant properties, attract professional immune cells to the site of vaccine delivery. Future vaccine technology will need to address viral mutations and the challenges of efficient manufacturing, distribution, and storage. We believe an adaptation of our TheraPlas technology, PLACCINE, has the potential to meet these challenges. Our approach is described in our provisional patent filing and is summarized as a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:

- Viral Mutations: PLACCINE may offer broad-spectrum and mutational resistance (variants) by targeting multiple antigens on a single plasmid vector.
- Durable Efficacy: PLACCINE delivers a DNA plasmid-based antigen that could result in durable antigen exposure and a robust vaccine response to viral antigens.
- Storage & Distribution: PLACCINE allows for stability that is compatible with manageable vaccine storage and distribution.
- Simple Dosing & Administration: PLACCINE is a synthetic delivery system that should require a simple injection that does not require viruses or special equipment to deliver its payload. We are conducting preliminary research associated with our recently announced proprietary DNA vaccine platform provisional patent filing. At the same time, we are redoubling our efforts and R & D resources in our immuno-oncology and next generation vaccine program. On September 2, 2021, the Company announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 when immunizing BALB/c mice with the Company's next-generation PLACCINE DNA vaccine platform. Moreover, the antibodies to SARS-CoV-2 spike antigen prevented the infection of cultured cells in a viral neutralization assay. The production of antibodies predicts the ability of PLACCINE to protect against SARS-CoV-2 exposure, and the elicitation of cytotoxic T-cell response shows the vaccine's potential to eradicate cells infected with SARS-CoV-2. These findings funding demonstrate the potential immunogenicity of Imunon's PLACCINE DNA vaccine, which is intended to provide broad-spectrum protection and resistance against variants by incorporating multiple viral antigens, to improve vaccine stability at storage temperatures of 4°C and above, and to facilitate cheaper and easier manufacturing. On January 31, 2022, the Company announced it had engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Imunon's DNA-based approach for a SARS-CoV-2 vaccine. The NHP pilot study follows the generation of encouraging mouse data and will evaluate the Company's lead vaccine formulations for safety, immunogenicity and protection against SARS-CoV-2. In completed preclinical studies, Imunon demonstrated safe and efficient immune responses including IgG response, neutralizing antibodies and T-cell responses that parallel the activity of commercial vaccines following intramuscular (IM) administration of novel vaccine compositions expressing a single viral antigen. In addition, vector development has shown promise of neutralizing activity against a range of SARS-CoV-2 variants. Imunon's novel DNA-based vaccines have been based on a simple intramuscular injection that does not require viral encapsulation or special equipment for administration. In April 2022, the Company presented its PLACCINE platform technology at the 2022 World Vaccine Congress. In an oral presentation during a Session on Cancer and Immunotherapy, Dr. Khurshed Anwer, the Company's Chief Science Officer, highlighted the Company's technology platform in his presentation entitled: "Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines." PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine. There is a clear public health need for vaccines today that address more than one strain of viruses, like COVID-19, which have fast evolving variant capability to offer the widest possible protection. Murine model data has thus far been encouraging and suggests that the Company's approach provides not only flexibility, but also the potential for efficacy comparable to benchmark COVID-19 commercial vaccines with durability to protect for more than 6 months. In September 2022, the Company provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. The Company reported evidence of IgG, neutralizing antibody, and T-cell responses to its SARS-CoV-2 PLACCINE vaccines in normal mice. In this murine model, the Company's multivalent PLACCINE vaccine targeted against two different variants showed to be immunogenic as determined by the levels of IgG, neutralizing antibodies, and T-cell responses. Additionally, our multivalent vaccine was equally effective against two different variants of the COVID-19 virus while the commercial mRNA vaccine appeared to have lost some activity against the newer variant. Final data from its now completed proof-of-concept mouse challenge study confirmed that a PLACCINE DNA-based vaccine can produce robust levels of IgG, neutralizing antibodies, and T-cell responses. The data demonstrates the ability of the Company's PLACCINE vaccine to protect a SARS-CoV-2 mouse model in a live viral challenge. In the study, mice were vaccinated with a PLACCINE vaccine expressing the SARS-CoV-2 spike antigen from the D614G variant or the Delta variant, or a combination vaccine expressing both the D614G and Delta spike variants. The vaccination was administered by intramuscular injection on Day 0 and Day 14, followed by challenge with live SARS-CoV-2 virus on Day 42. All three vaccines, including the single and dual antigen vaccines, were found to be safe and elicited IgG responses and inhibited the viral load by 90-95%. The dual antigen vaccine was equally effective against both variants of the SARS-CoV-2 virus. In October 2022, the Company reported partial results from an ongoing non-human primate study designed to examine the immunogenicity of its proprietary PLACCINE vaccine which supports PLACCINE as a viable alternative to mRNA vaccines. The study examined a single plasmid DNA vector containing the SARS-CoV-2 Alpha variant spike antigen formulated with a synthetic DNA delivery system and administered by intramuscular injection. In the study, Cynomolgus monkeys were vaccinated with the PLACCINE vaccine or a commercial mRNA vaccine on Day 1, 28 and 84. Analysis of blood samples for IgG and neutralizing antibodies showed evidence of immunogenicity both in PLACCINE and mRNA vaccinated subjects. Analysis of bronchoalveolar lavage for viral load by quantitative PCR showed viral clearance by >90% of the non-vaccinated controls. Viral clearance from nasal swab followed a similar pattern in a majority of vaccinated animals and a similar clearance profile was observed when viral load was analyzed by the tissue culture infectious dose method. In March 2023, the Company announced final results from the non-human primate study involving three vaccine-treated non-human primates. The final data are consistent with the earlier data, and show excellent immunological response and viral clearance. More specifically, in this NHP study, we examined PLACCINE activity against a more advanced SARS-CoV-2 variants and at a DNA dose that was not previously tested in NHP and demonstrated robust IgG responses, neutralizing antibody responses and complete clearance of virus following the challenge as seen in the previous study. In a recent mouse study, a single dose of PLACCINE vaccine without a booster dose produced longer duration of IgG responses and higher T-cell activation than an mRNA vaccine. A 12-month PLACCINE stability study has now completed 9 months demonstrating continued drug stability at 4°C (standard refrigerated temperature). During 2023, the Company intends to choose the next pathogen target for our PLACCINE modality and to hold a pre-Investigational New Drug (pre-IND) meeting with the U. S. Food and Drug Administration in advance of beginning human testing of a SARS-CoV-2 seasonal booster vaccine. Of note, the design of that trial will also inform the path for the next pathogen we will study, perhaps in early 2024. Incremental investments to generate novel vaccine designs with optimized antigens will allow Imunon to quickly generate early clinical data against additional pathogen targets that position the company to partner with large vaccine companies who will fund remaining clinical development. THERMODOX®-DIRECTED CHEMOTHERAPY Liposomes are manufactured submicroscopic vesicles consisting of a discrete aqueous central compartment surrounded by a membrane bilayer composed of naturally occurring lipids. Conventional liposomes have been designed and manufactured to carry drugs and increase residence time, thus allowing the drugs to remain in the bloodstream for extended periods of time before they are removed from the body. However, the current existing liposomal formulations of cancer drugs and liposomal cancer drugs under development do not provide for the immediate release of the drug and the direct targeting of organ specific tumors, two important characteristics that are required for improving the efficacy of cancer drugs such as doxorubicin. A team of research scientists at Duke University developed a heat-sensitive liposome that rapidly changes its structure when heated to a threshold minimum temperature of 39.

5° to 42° Celsius. Heating creates channels in the liposome bilayer that allow an encapsulated drug to rapidly disperse into the surrounding tissue. This novel, heat-activated liposomal technology is differentiated from other liposomes through its unique low heat-activated release of encapsulated chemotherapeutic agents. We are able to use several available focused heat technologies, such as radiofrequency ablation ("RFA"), microwave energy and high intensity focused ultrasound ("HIFU"), to activate the release of drugs from our novel heat-sensitive liposomes. OPTIMA Study The OPTIMA Study represents an evaluation of ThermoDox® in combination with a first line therapy, RFA, for newly diagnosed, intermediate stage HCC patients. The OPTIMA Study was designed to enroll up to 550 patients globally at approximately 65 clinical sites in the U. S., Canada, European Union ("EU"), China and other countries in the Asia-Pacific region and will evaluate ThermoDox® in combination with standardized RFA, which will require a minimum of 45 minutes across all investigators and clinical sites for treating lesions three to seven centimeters, versus standardized RFA alone. The primary endpoint for the OPTIMA Study is OS, and the secondary endpoints are progression free survival and safety. The statistical plan calls for two interim efficacy analyses by an independent Data Monitoring Committee ("DMC"). In August 2018, the Company announced that the OPTIMA Study was fully enrolled. On August 5, 2019, the Company announced that the prescribed number of OS events had been reached for the first prespecified interim analysis of the OPTIMA Phase III Study. Following preparation of the data, the first interim analysis was conducted by the DMC. The DMC's pre-planned interim efficacy review followed 128 patient events, or deaths, which occurred in August 2019. On November 4, 2019, the Company announced that the DMC unanimously recommended the OPTIMA Study continue according to protocol. The recommendation was based on a review of blinded safety and data integrity from 556 patients enrolled in the OPTIMA Study. Data presented demonstrated that PFS and OS data appeared to be tracking with patient data observed at a similar point in the Company's subgroup of patients followed prospectively in the earlier Phase III HEAT Study, upon which the OPTIMA Study was based. On April 15, 2020, the Company announced that the prescribed minimum number of events of 158 patient deaths had been reached for the second pre-specified interim analysis of the OPTIMA Phase III Study. The hazard ratio for success at 158 deaths is 0.70, which represents a 30% reduction in the risk of death compared with RFA alone. On July 13, 2020, the Company announced that it has received a recommendation from the DMC to consider stopping the global OPTIMA Study. The recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. However, the 2-sided p-value of 0.524 for this analysis provides uncertainty; subsequently, the DMC left the final decision of whether or not to stop the OPTIMA Study to the Company. There were no safety concerns noted during the interim analysis. The Company followed the advice of the DMC considered its options either to stop the study or continue to follow patients after a thorough review of the data, and an evaluation of our probability of success. On August 4, 2020, the Company issued a press release announcing it would continue following patients for OS, noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020, may be associated with a data maturity issue. On October 12, 2020, the Company provided an update on the ongoing data analysis from its Phase III OPTIMA Study with ThermoDox® as well as growing interest among clinical investigators in conducting studies with ThermoDox® as a monotherapy or in combination with other therapies. On February 11, 2021, the Company provided a final update on the Phase III OPTIMA Study and the decision to stop following patients in the Study. Independent analyses conducted by a global biometrics contract research organization and the NIH, did not find any evidence of significance or factors that would justify continuing to follow patients for OS. Therefore, the Company notified all clinical sites to discontinue following patients. The OPTIMA Study database of 556 patients is now frozen at 185 patient deaths. While the analyses did identify certain patient subgroups that appear to have had a clinical benefit, the Company concluded that it would not be in its best interest to pursue these retrospective findings as the regulatory hurdles supporting further discussion will be significant. Investigator-Sponsored Studies with ThermoDox® The Company continues working closely and supporting investigations by others to evaluate the use of ThermoDox® for the treatment of various cancers. Following inquiries from the NIH, we renewed our Cooperative Research and Development Agreement ("CRADA") with the Institute at a nominal cost, one goal of which is to pursue their interest in a study of ThermoDox® to treat patients with bladder cancer. Importantly, the Company is developing a business model to support these investigator-sponsored studies in a manner that will not interfere with its current focus on our IMNN-001 program and vaccine development initiative. Business Plan Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the FDA, U.S. Food and Drug Administration. The Company has not generated significant revenue and has incurred significant net losses in each year since our inception. As of December 31, 2022-2023, the Company has incurred approximately \$ 369-388 million of cumulative net losses and had approximately \$ 38-15, 9-7 million in cash and cash equivalents, short-term investments, and interest receivable, and restricted cash to fund its operations. The Company also has a \$ 1.3 million receivable from the sale of the Company's State of New Jersey net operating losses. We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its drug candidates and technologies. The Company expects its primary sources of cash have been proceeds from the issuance and sale of its operating losses common stock via its ATM program and other potential funding transactions. There can be no assurance that the Company will be able to continue for do so in the foreseeable future on a timely basis on terms acceptable to the Company, or at all. The Company as has it continues not yet commercialized any of its product development efforts candidates. Even if the Company commercializes one or more of its product candidates, and when it undertakes marketing and sales activities may not become profitable in the near term. The Company's ability to achieve profitability is dependent depends upon several factors, including its ability to obtain governmental regulatory approvals approval for, manufacture, and market and sell its new product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. Given our development plans, we anticipate cash resources will be sufficient to fund our operations into the fourth quarter of 2024. The Company has no committed sources of additional capital. As a result of the risks and uncertainties discussed in this Annual Report on Form 10-K, among others, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialized approved products, if any. We do There can be no not know whether we assurance that the Company will be able to commercialize access additional capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2023 includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern. Management's plan includes raising funds from outside investors via its technology successfully ATM program and other potential funding sources as mentioned. However, as mentioned above, there is no assurance such funding will be available to the Company or that profitability it will ever be achieved obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The operating results of the Company have fluctuated significantly in the past. In January 2020, the World Health Organization declared an outbreak of coronavirus, COVID-19, to be a "Public Health Emergency of International Concern," and the U.S. Department of Health and Human Services declared a public health emergency to aid the U.S. healthcare community in responding to COVID-19. This virus continues to evolve and may have an adverse effect on our operations and drug candidate development timelines. Uncertainty with respect to the economic impacts of the pandemic introduced significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of operations during 2021 or 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company's future results will depend on future developments, financial statements do not include any adjustments relating to the pandemic recoverability and associated economic impacts could result in classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern material impact to the Company's future financial condition, results of operations and cash flows. The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the ongoing effects of the COVID-19 pandemic and the Russian invasion of Ukraine. These disruptions may also disrupt the clinical trials process and enrollment of patients. This may delay commercialization efforts. The Company continues to monitor its operating activities in light of these events, and it is reasonably possible that the virus could have a negative effect on the Company's financial condition and results of operations. The specific impact, if any, is not readily determinable as of the date of the Financial financial Statements statements included in this Annual Report. Financing Overview Equity The actual amount of funds the Company will need to operate is subject to many factors. Debt some of which are beyond the Company..... 0.900 was crossed with an and actual value of 0.903. The Company followed the Other advice Forms of Financing the DMC and

considered its options to either stop the study or continue to follow patients after a thorough review of the data, and an evaluation of the probability of success. On February 11, 2021, the Company issued a letter to shareholders stating that the Company was notifying all clinical sites to discontinue following patients in the OPTIMA Study. Since 2018, the Company has annually submitted applications to sell a portion of the Company's State of New Jersey net operating losses ("NOLs") as part of the Technology Business Tax Certificate Program (the "NOL Program") sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. In 2018 and 2019, the Company sold cumulative NOLs from 2011 to 2018 totaling \$13.15 million and received net proceeds of \$14.2 million. As part of the NOL Program, the Company sold \$1.6 million and \$1.5 million of its New Jersey NOLs in 2022 and 2021, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$1.3 million in 2023 and \$1.6 million in 2022 and \$1.4 million in 2021. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$15 million to \$20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$10.8 million in net operating losses under this maximum lifetime benefit. In June 2018, the Company entered into a Credit Agreement with Horizon Technology Finance Corporation ("Horizon") that provided \$10 million in capital (the "Horizon Credit Agreement"). The obligations under the Horizon Credit Agreement are secured by a first-priority security interest in substantially all assets of Imunon other than intellectual property assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus 7.625%) for the first 24 months through July 2020, followed by a 21-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity date on April 1, 2023. On August 28, 2020, in connection with an Amendment to the Horizon Credit Agreement, Imunon repaid \$5 million of the \$10 million loan and \$0.2 million in related end of term charges, and the remaining \$5 million in obligations were restructured. As more fully discussed in Note 8 to the our Financial Statements, in June 2021, the Company entered into a \$10 million loan facility (the "SVB Loan Facility") with Silicon Valley Bank ("SVB"). The Company immediately used \$6 million from this facility to retire all outstanding indebtedness with Horizon. The funding is in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 7.75%). Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. Financing Overview Equity, Debt and Other Forms of Financing Since 2018, the Company has annually submitted applications to sell a portion of the Company's State of New Jersey net operating losses as part of the NOL Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. In 2018, 2019 and 2020, the Company sold cumulative NOLs from 2011 to 2019 totaling \$15 million and received net proceeds of \$14 million. As part of the NOL Program, the Company sold \$1.6 million and \$1.5 million of its New Jersey NOLs in 2022 and 2021, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$1.6 million in 2022 and \$1.4 million in 2021. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$15 million to \$20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$1.9 million in net operating losses under this maximum lifetime benefit. As more fully discussed in Note 10 to the Financial Statements, during 2021, the Company raised approximately \$6.9 million in gross proceeds from the use of its JonesTrading Capital on Demand FM financing facility, \$35 million from a registered direct financing completed in January 2021, \$15 million from a registered direct financing completed on April 5, 2021, and \$1.5 million from warrant exercises. With \$38.9 million in cash and cash equivalents, short-term investments, interest receivable, net proceeds on the sale of NOLs and restricted cash, the Company believes it has sufficient capital resources to fund its operations into 2025. The Company entered into a Credit Agreement with Horizon Technology Finance Corporation ("Horizon") that provided \$10 million in capital (the "Horizon Credit Agreement") in June 2018. The obligations under the Horizon Credit Agreement are secured by a first-priority security interest in substantially all assets of Imunon other than intellectual property assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus 7.625%) for the first 24 months through July 2020, followed by a 21-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity date on April 1, 2023. On August 28, 2020, in connection with an Amendment to the Horizon Credit Agreement, Imunon repaid \$5 million of the \$10 million loan and \$0.2 million in related end of term charges, and the remaining \$5 million in obligations were restructured. As more fully discussed in Note 8 to the Financial Statements included in this Annual Report, in June 2021, the Company entered into a \$10 million loan facility with Silicon Valley Bank (the "SVB Loan Facility"). The Company immediately used \$6 million from this facility to retire all outstanding indebtedness with Horizon Technology Finance Corporation. The funding is in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 7.75%). The SVB Loan Facility was repaid in full during the quarter ended June 30, 2023. Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. On March 10, 2023, the Federal Deposit Insurance Corporation was appointed as receiver for SVB and created the National Bank of Santa Clara to hold the deposits of SVB after SVB was unable to continue their operations. While the National Bank of Santa Clara has publicly assured holders of credit facilities that they intend to honor those facilities, our credit agreement may not be available in all or in part in the near future depending on the resolution of SVB. On March 19, 2021, the Company filed with the SEC a new \$400 million shelf registration statement on Form S-3 (the "2021 Registration Statement") that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock in an amount up to \$100 million. This shelf registration statement was declared effective on March 30, 2021. The 2021 Registration Statement was intended to provide us with flexibility to raise capital in the future for general corporate purposes. However, as of the date of this filing and so long as our public float remains below \$75 million, we are subject to limitations with respect to the use of the 2021 Registration Statement and any other shelf registration statement that we file with the SEC pursuant to General Instruction I. B. 6 of Form S-3 (the "Baby Shelf Limitation"), which limits the amount we can offer to up to one-third of our public float during any trailing 12-month period. We would be no longer subject to the Baby Shelf Limitation if our public float exceeds \$75 million. During 2021 and 2022, we issued a total of 43.75 million shares of common stock as discussed below for an aggregate \$64.45 million in gross proceeds. ● On December 4, 2018, the Company entered into the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through JonesTrading shares of Common Stock having an aggregate offering price of up to \$16.0 million. During 2021, the Company has sold 0.5 million shares under the Capital on Demand Agreement, receiving approximately \$6.9 million in gross proceeds under the Capital on Demand Agreement. The Capital on Demand Agreement with JonesTrading was terminated in the first quarter of 2021. ● On January 22, 2021, the Company entered into a Securities Purchase Agreement (the "January 2021 Purchase Agreement") with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "January 2021 Offering"), an aggregate of 1,728,395 shares of the Company's common stock at an offering price of \$20.25 per share for gross proceeds of approximately \$35 million before the deduction of the January 2021 Placement Agents (as defined below) fee and offering expenses. The closing of the January 2021 Offering occurred on January 26, 2021. In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners ("AGP") and together with Brookline Capital Markets, the "January 2021 Placement Agents" pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed \$82,500. ● On March 31, 2021, the Company entered into a Securities Purchase Agreement (the "March 2021 Purchase Agreement") with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "March 2021 Offering"), an aggregate of 769,230 shares of the Company's common stock, at an offering price of \$19.50 per share for gross proceeds of approximately \$15 million before the deduction of the placement agents fee and offering expenses. The shares were offered by the Company pursuant to the 2021 Registration Statement. The closing of the offering occurred on April 5, 2021. In connection with the March 2021 Offering, the Company entered into a placement agent agreement with AGP, as lead placement agent (together with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Areadia Securities, LLC, serving as co-placement agents, the "March 2021 Placement Agents"), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed \$82,500. ● On January 10, 2022, the Company entered into the Preferred Stock Purchase Agreement with several institutional investors, pursuant to which the Company agreed to issue and sell, in the Preferred Offerings, (i) 50,000 shares of Series A Preferred Stock and (ii) 50,000 shares of Series B Preferred Stock, in each case at an offering price of \$285 per share, representing a 5% original issue discount to the stated value of \$300 per share, for gross proceeds of from each Preferred Offering offering of \$14.25 million, or approximately \$28.50 million in the aggregate for the Preferred Offerings, before the deduction of the Placement Agent's (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$300 per share and are convertible, at a conversion price of \$13.65 per share, into 1,098,901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$300 per share and are convertible, at a conversion price of \$15.00 per share, into 1,000,000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. The On February 28, 2022, the Company held effected a 15-for-1 special meeting of stockholders to consider an amendment (the

Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of its the outstanding shares of common stock (“Common Stock”) by a ratio to be determined by the Board of Directors of the Company (the “Reverse Stock Split”), which was made effective ranging from 7 to 1 to, 10 to 1, 12 to 1 or for 15 to 1 trading purposes as of the commencement of trading on March 31, 2022. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the “Placement Agent Agreement”) with AGP, as placement agent pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1,000,000 and reimburse AGP for certain of their expenses in an amount not to exceed \$ 110,000. On March 3, 2022, the Company redeemed for cash at a price equal to 105 % of the \$ 300 stated value per share of all of its 50,000 outstanding shares of Series A Preferred Stock and its 50,000 outstanding Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Immunon’s only class of outstanding stock is its common stock. • On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “April 2022 Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “April 2022 Offering”), an aggregate of 1,328,274 shares of the Company’s common stock at an offering price of \$ 5.27 per share for gross proceeds of \$ 7.0 million before the deduction of the April 2022 Placement Agent (as defined below) fees and offering expenses. The closing of the April 2022 Offering occurred on April 8, 2022. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5 % of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. • On May 25, 2022, the Company entered into an At the Market Offering Agreement (the “Agreement”) with H. C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to \$ 7,500,000. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. The Company did not sell any shares under the Agreement with Wainwright in the first nine months of 2022. From October 1, 2022 through the date of December 31, 2022, the Company sold 336,075 shares of common stock for net proceeds of \$ 503,798. In During the year ended December 31, 2023, the Company has sold 1,653,878, 392,488 shares of common stock for net proceeds of \$ 2.8 million; 465,656. Please refer to Note 2 to our Financial financial Statements statements included in this Annual Report. Also refer to Part I, Item 1A, Risk Factors, in this Annual Report, including, but not limited to, “ We will need to raise substantial additional capital to fund our planned future operations, and we may be unable to secure such capital without dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates.” Critical Accounting Policies and Estimates Our financial statements included in, which appear at Part II, Item 8: Financial Statements and Supplementary Data of this Annual Report have been prepared in accordance with accounting principles generally accepted in the U. S. (“GAAP”), which require that we make certain assumptions and estimates and, in connection therewith, adopt certain accounting policies. Our significant accounting policies are set forth in Note 1 to our Financial financial Statements statements included in this Annual Report. Of those policies, we believe that the policies discussed below may involve a higher degree of judgment and may be more critical to an accurate reflection of our financial condition and results of operations. In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6 to our Financial financial Statements statements included in this Annual Report, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. As further discussed in Note 6 to our financial statements included in this Annual Report, during the year ended December 31, 2022, the Company recorded a \$ 13.4 million IPR & D impairment charge. We review our financial reporting and disclosure practices and accounting policies on an ongoing basis to ensure that our financial reporting and disclosure system provides accurate and transparent information relative to the current economic and business environment. As part of the process, the Company reviews the selection, application and communication of critical accounting policies and financial disclosures. The preparation of our Financial financial Statements statements in conformity with GAAP accounting principles generally accepted in the U. S. requires that our management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial financial Statements statements and the reported amounts of revenues and expenses during the reporting period. We review our estimates and the methods by which they are determined on an ongoing basis. However, actual results could differ from our estimates. Results of Operations Comparison of Fiscal Year Ended December 31, 2022-2023 and Fiscal Year Ended December 31, 2021-2022. For the year ended December 31, 2022-2023, our net loss was \$ 35-19.9-5 million compared to a net loss of \$ 20-35.8-9 million for the year ended December 31, 2021-2022. The Company recognized \$ 1.6-3 million and \$ 1.4-6 million in tax benefits from the sale of its New Jersey NOLs net operating losses under the NOL Program in each of the fourth quarters of 2023 and 2022 and 2021, respectively. With As of December 31, 2023, the Company had \$ 38-15.9-7 million in cash and cash equivalents, short-term investments, and interest receivable, net proceeds on the sale of net operating losses and restricted cash, the Company believes it has sufficient capital resources to fund its operations into. The Company also has a \$ 1.3 million receivable from the sale of the Company’s State of New Jersey NOLs. The Company’s primary sources of cash have been proceeds from the issuance and sale of its common stock via its ATM program and other funding transactions. There can be no assurance that the Company will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. The Company has not yet commercialized any of its product candidates. Even if the Company commercializes one or more of its product candidates, it may not become profitable in the near term. The Company’s ability to achieve profitability depends on several factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2025-2023 includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern. Technology Management’s plan includes raising funds from the issuance and sale of its common stock via its ATM program and other funding transactions. However, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The Company’s financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern. For the year ended December 31, (In thousands) Change Increase (Decrease) 2023 2022 Licensing Revenue: \$- \$ 500 \$ (500) (100.0) % Operating Expenses: Clinical Research OVATION 1, 197 1, 536 (339) (22.1) % OPTIMA- 950 (950) (100.0) % Other Clinical and regulatory 1, 793 1, 906 (113) (5.9) % Subtotal 2, 990 4, 392 (1, 402) (31.9) % Non- Clinical R & D and CMC OVATION 1, 504 3, 659 (2, 155) (58.9) % PlacCine Vaccine 4, 511 2, 439 2, 072 85.0 % Manufacturing (CMC) 2, 283 1, 244 1, 039 83.5 % Subtotal 8, 298 7, 342 956 13.0 % Research and Development development expenses 11, 288 11, 733 (446) (3.8) % General and administrative expenses 9, 742 13, 688 (3, 946) (28.8) % Total operating expenses 21, 030 25, 422 (4, 392) (17.3) % Loss from operations \$ (21, 030) \$ (24, 922) \$ (3, 892) (15.6) % Licensing Revenue In January 2013, we entered into a technology development contract with Zhejiang Hisun Pharmaceutical Co. Ltd. (“ Hisun ”), pursuant to which Hisun paid us a non-refundable technology transfer fee of \$ 5.0 million to support our development of ThermoDox ® in the China territory. The \$ 5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and was amortized over the ten-year term of the agreement; therefore, we recognized revenue of \$ 500,000 in each of the years year 2022 and 2021-. As of December 31, 2022, this contract has been fully amortized and recognized as revenue. Research and Development Expenses Research and development (“ R & D ”) expenses increased-decreased \$ +0. +4 million from to \$ 10-11. 6-3 million in 2021-2023 to from \$ 11.7 million in 2022. Costs associated with the OVATION 2 Study were \$ 1.5-2 and \$ 1.3-5 million in 2023 and 2022 and 2021-, respectively. Costs associated with the OPTIMA Study were insignificant decreased to \$ 0.5 million in 2022-2023 compared to \$ 1.0 million in 2021-2022. Other clinical and regulatory costs were \$ 2-1. 3-8 million in 2023 compared to \$ 1.9 million in 2022 compared to \$ 2.6 million in 2021-. R & D costs associated with the development of IMNN-001 to support the OVATION 2 Study as well as were \$ 1.5 million in 2023, a decrease from \$ 3.7 million in same period of 2022. The development of the PLACCINE DNA vaccine technology platform increased to \$ 6-4. +5 million in 2023 compared to \$ 2.4 million in 2022 compared, CMC costs increased to \$ 4-2. 3-2 million in the same period of 2021-2023 compared, CMC costs decreased to \$ 1.2 million in 2022 compared to \$ 1.5 million in the same period of 2021 due to the discontinuation of the ThermoDox ® clinical development program in primary liver cancer. General and Administrative Expenses General and administrative expenses increased-decreased to \$ 9.7 million in 2023 compared to \$ 13.7 million in 2022 compared to \$ 10.9 million in 2021-. This increase-decrease is primarily attributable to lower non-cash stock compensation expenses higher professional fees (primarily legal fees) of \$ 1.3 million, employee related costs of \$ 0.8 million and an increase in staffing, legal expenses of \$ 1.0 million, insurance costs of \$ 0.6 million, which were partially public company expenses of \$ 0.2 million offset by lower stock compensation costs higher consulting fees of \$ 0.2 million. Change in Earn-out Milestone Liability The total aggregate purchase price for the acquisition of assets from EGEN included potential future earn-out payments contingent upon achievement of certain milestones. The difference between the aggregate \$ 30.4 million in future earn-

out payments and the \$ 13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. The milestone liability is fair valued at the end of each quarter and any change in the value is recognized in our **Financial financial Statements statements**. On March 28, 2019, the Company and EGWU, Inc. entered into an amendment to the Asset Purchase Agreement discussed in Note 13 to our **Financial financial Statements statements included in this Annual Report**. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of \$ 12.4 million has been modified. The Company has the option to make the payment as follows: ● \$ 7.0 million in cash within 10 business days of achieving the milestone; or ● \$ 12.4 million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. At December 31, 2022, the Company wrote off the earn-out milestone liability as a result of the requirements not being achieved and recognized a non-cash gain of \$ 5.4 million during 2022 as a result of the change in the fair value of the earn-out milestone liability. ~~The At December 31, 2021, the Company fair valued value of the earn-out milestone liability at \$ 5.4 million and recognized a non-cash gain of \$ 1.6 million during 2021 as was zero a result of the change in the fair value of the earn-out milestone liability of \$ 7.0 million at December 31, 2020 2023.~~ In assessing the fair value of the earnout milestone liability at December 31, 2021, the Company considered each of the settlement provisions per the Amended Asset Purchase Agreement and equally weighted the probability of a cash or cash and common stock payment. Impairment of Goodwill and IPR & D IPR & D and Goodwill are reviewed for impairment at least annually by assessing if any events or changes in circumstances have occurred which indicate that the carrying value of the assets might not be recoverable. As of December 31, 2022, the Company assessed whether there were indicators of impairment for the Company's IPR & D and determined that the IPR & D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2022 and 2021 and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company's IPR & D assets, the Company concluded the IPR & D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the \$ 13.4 million carrying value of this asset, thereby recognizing a non-cash charge of \$ 13.4 million in the fourth quarter of 2022. The Company fair value conducted a valuation analysis of its the IPR & D for the ovarian cancer indication as was of zero at December 31, 2021 2023. Based on this valuation analysis, the Company has concluded that it is not more likely than not that the asset is impaired as of December 31, 2021. As such, no impairment charges for IPR & D related to the ovarian cancer indication were recorded during 2021. Due to the continuing deterioration of public capital markets in the biotech industry in 2021 and its impact on market capitalization rates in this sector, Goodwill was reviewed for impairment as of December 31, 2021. Based on this assessment, the Company concluded that Goodwill was impaired during the fourth quarter of 2021. As of December 31, 2021, the Company wrote off the \$ 2.0 million carrying value of this asset, thereby recognizing a non-cash charge of \$ 2.0 million in the fourth quarter of 2021. Investment income and interest expense The Company recognized interest expense of \$ 0.2 million in 2023 compared to \$ 5.0 million in 2022 compared to \$ 0.6 million in 2021. As more fully discussed in Note 9 to the our **Financial financial Statements statements included in this Annual Report**, in June 2021, the Company entered into a \$ 10 million loan facility with Silicon Valley Bank. The Company immediately used \$ 6 million from this facility to retire all outstanding indebtedness with Horizon Technology Finance Corporation. ● In connection with the SVB and Horizon loan Loan facilities Facility, the Company incurred \$ 0.52 million in interest expense in 2022-2023 compared to \$ 0.65 million in 2021-2022. In connection with the termination of the Horizon SVB loan Loan facility Facility in the second quarter of 2021-2023, the Company paid early termination and end of term charges to Horizon SVB and recognized \$ 0.23 million as a loss on debt extinguishment. ● As more fully discussed in Note 10 to the our **Financial financial Statements statements included in this Annual Report**, in the first quarter of 2022, the Company incurred interest expense totaling \$ 4.6 million attributed to the Series A and Series B Convertible Redeemable Preferred Stock Offering Offerings. Investment income from the Company's short-term investments was \$ 1.2 million in 2023 compared to \$ 0.5 million in 2022. Investment income was insignificant in 2021. Income Tax Benefit Annually, the State of New Jersey enables approved technology and biotechnology businesses with New Jersey NOLs net operating tax losses the opportunity to sell these losses through the NOL Program, thereby providing cash to companies to help fund their research and development and business operations. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years. After the cumulative NOL net operating loss sales through 2022-2023, the Company has approximately \$ 10.94 million remaining under the NOL Program. The Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2023 for \$ 1.3 million. At December 31, 2023, the Company evaluated the valuation reserve for its NOLs associated with its New Jersey NOLs and reduced the valuation reserve and recognized \$ 1.3 million as a deferred tax asset and an income tax benefit. The Company completed the sale of these NOLs in March of 2024. During the fourth quarter of 2022, the Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2022 for \$ 1.6 million. At December 31, 2022, the Company evaluated the valuation reserve for its tax net operating losses associated with its New Jersey NOLs and reduced the valuation reserve and recognized \$ 1.6 million as a deferred tax asset and an income tax benefit. The Company completed the sale of these NOLs net operating losses in January of 2023. During the fourth quarter of 2021, the Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2021 for \$ 1.4 million. At December 31, 2021, the Company evaluated the valuation reserve for its tax net operating losses associated with its New Jersey NOLs and reduced the valuation reserve and recognized \$ 1.4 million as a deferred tax asset and an income tax benefit. The Company completed the sale of these net operating losses in February of 2022. During the first quarter of 2021, the Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2020 for approximately \$ 1.9 million. At December 31, 2020, the Company evaluated the valuation reserve for its tax net operating losses associated with its New Jersey NOLs and reduced the valuation reserve and recognized approximately \$ 1.9 million as a deferred income tax asset and an income tax benefit. The Company completed the sale of these net operating losses in May of 2021. Financial Condition, Liquidity and Capital Resources Since inception, we have incurred significant losses and negative cash flows from operations. We have financed our operations primarily through the net proceeds from the sales of equity, credit facilities and amounts received under our product licensing agreement with Yakult and our technology development agreement with Hisun. The process of developing ThermoDox®, IMNN-001 and other drug candidates and technologies requires significant research and development work and clinical trial studies, as well as significant manufacturing and process development efforts. We expect these activities, together with our general and administrative expenses to result in significant operating losses for the foreseeable future. Our expenses have significantly and regularly exceeded our revenue, and we had an accumulated deficit of \$ 369.388 million at December 31, 2022-2023. At December 31, 2023 we had total current assets of \$ 18.2 million and current liabilities of \$ 7.4 million, resulting in net working capital of \$ 10.8 million. At December 31, 2023, we had cash and cash equivalents, short-term investments, interest receivable on short-term investments, net proceeds on the sale of net operating losses and money market investments of \$ 17.0 million. At December 31, 2022 we had total current assets of \$ 37.2 million and current liabilities of \$ 10.1 million, resulting in net working capital of \$ 27.1 million. At December 31, 2022, we had cash and cash equivalents, short-term investments, interest receivable on short-term investments, net proceeds on the sale of net operating losses and money market investments (\$ 6.0 million of which is restricted cash included in other assets) of \$ 40.4 million. At December 31, 2021 we had total current assets of \$ 51.9 million and current liabilities of \$ 6.8 million, resulting in net working capital of \$ 45.1 million. We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its technologies. The Company believes it has sufficient capital resources to fund its operations into 2025. Net cash used in operating activities for 2022-2023 was \$ 23.19, 1.0 million. Our net loss of \$ 35.19, 9.5 million for 2022-2023 included the following non-cash transactions of: (i) \$ 2.0, 7.8 million in non-cash stock-based compensation expense, (ii) \$ 13.4 million non-cash charge from the write-off of IPR & D, and (iii) \$ 0.2 million in non-cash interest expense. The \$ 23.1 million net cash used in operating activities was funded from cash and cash equivalents, short-term investments, and cash proceeds received in equity financings during 2022. At December 31, 2022-2023, we had cash and cash equivalents, short-term investments, interest receivable on short-term investments, receivable from the sale of New Jersey NOLs operating losses and money market investments (of \$ 6.17, 0 million of which is restricted cash included in other assets) of \$ 40.4 million. The Company believes it has sufficient capital resources to fund its operations into 2025. See Financing Overview. The Company may seek additional capital through further public or private equity offerings, debt financing, additional strategic alliance and licensing arrangements, collaborative arrangements, or some combination of these financing alternatives. If we raise additional funds through the issuance of equity securities, the percentage ownership of our stockholders could be significantly diluted, and the newly issued equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we raise funds through the issuance of debt securities, those securities may have rights, preferences, and privileges senior to those of our common stock. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, we may need to relinquish rights to certain of our existing or future technologies, drug candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our technologies, drug candidates, or products on terms that are not favorable to us. The overall status of the economic climate could also result in the terms of any equity offering, debt financing, or alliance, license, or other arrangement being even less favorable to us and our stockholders than if the overall economic climate were stronger. We also will continue to look for government sponsored research collaborations and grants to help offset future anticipated losses from operations and, to a lesser extent, interest income. If adequate funds are not available through either the capital markets, strategic alliances, or collaborators, we may be required to delay or, reduce the scope of, or terminate our research,

development, clinical programs, manufacturing, or commercialization efforts, or effect additional changes to our facilities or personnel, or obtain funds through other arrangements that may require us to relinquish some of our assets or rights to certain of our existing or future technologies, drug candidates, or products on terms not favorable to us. Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Management's plan includes raising funds from the issuance and sale of its common stock via its ATM program and other funding transactions. However, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The Company's financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

Off-Balance Sheet Arrangements We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The RISKWe primary objective are a smaller reporting company as defined by Rule 12b-2 of our cash investment activities is the Exchange Act and are not required to provide preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Some of the securities that we invest in may be subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, the principal amount of our investment will probably decline. A hypothetical 50-basis point increase in interest rates reduces the fair value of our available-for-sale securities at December 31, 2022 by an immaterial amount. To minimize this item risk in the future, we intend to maintain our portfolio of cash equivalents and marketable securities in a variety of securities, including commercial paper, government, and non-government debt securities and/or money market funds that invest in such securities. We have no holdings of derivative financial or commodity instruments. As of December 31, 2022, our investments consisted of investments in government backed notes and obligations or in money market accounts and checking funds with variable market rates of interest. We believe our credit risk is immaterial. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Financial financial Statements statements, supplementary data and report of independent registered public accounting firm **required to be filed pursuant to this Item 8** are appended to filed as part of this Annual report **Report beginning on pages page F-1 through F-32 and incorporated herein by reference.** ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9A. CONTROLS AND PROCEDURES (a) Disclosure Controls and Procedures We have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15 (e) and 15d-15 (e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") under the supervision, and with the participation, of our management, including our principal executive officer and principal financial officer. Based on that evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2022-2023, which is the end of the period covered by this Annual Report, our disclosure controls and procedures **are were** effective. (b) Management's Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15 (f) and 15d-15 (f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed by, or under the supervision of, our chief executive officer and chief financial officer, or persons performing similar functions, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the U. S. of America (GAAP). Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements. Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2022-2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 Internal Control-Integrated Framework. Based on its evaluation, management has concluded that the Company's internal control over financial reporting is effective as of December 31, 2022-2023. Pursuant to Regulation S-K Item 308 (b), this Annual Report does not include an attestation report of **our the company Company**'s registered public accounting firm regarding internal control over financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well designed and operated can provide only reasonable, but not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost. (c) Changes in Internal Control over Financial Reporting There have been no changes in our internal control over financial reporting in the fiscal year quarter ended December 31, 2022-2023 that, which were identified in connection with our management's evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION

ITEM 10b5-1 Trading Plans During the year ended December 31, 2023, no directors or executive officers entered into, modified or terminated, contracts, instructions or written plans for the sale or purchase of the Company's securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1. ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not applicable.

PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE **The GOVERNANCE** Our Board of Directors currently consists of six members and is divided into three classes of directors serving staggered three-year terms. Directors for each class are elected at the Annual Meeting of Stockholders held in the year in which the term for their class expires and hold office for a three-year term and until their successors are duly elected and qualified, or their earlier death, resignation or removal. In accordance with our amended and restated certificate of incorporation and bylaws, our Board may fill any vacancy on the Board by appointment. Set forth below is certain information regarding our Company's current directors, as well as our non-director executive officers.

NAME AGE POSITION (S) CLASS Frederick J. Fritz Director I Christine Pellizzari Director I James E. Dentzer Director II Stacy R. Lindborg, Ph. D. Director II Donald P. Braun, Ph. D. Director III Michael H. Tardugno Executive Chairman III Khurshheed Anwer, Ph. D. Executive Vice President and Chief Scientific Officer Sébastien Hazard, M. D. Executive Vice President and Chief Medical Officer Jeffrey W. Church Executive Vice President and Chief Financial Officer

57 Class I Directors (Term expires in 2026) Mr. Frederick J. Fritz. Mr. Fritz was appointed to our Board of Directors in July 2011. Mr. Fritz has served as CEO and Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market, since 2006. Mr. Fritz joined NeuroDx from Valeo Medical, a biotechnology company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, Inc., a medical device company spun out of Sarnoff Corporation. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995 to 1997. Mr. Fritz holds a bachelor's degree in engineering (summa cum laude) from University of Illinois and an MBA degree from Harvard University. Ms. Christine A. Pellizzari. Ms. Pellizzari was appointed to our Board of Directors in June 2021. Ms. Pellizzari has served as the Chief Legal Officer of Science 37 since July 2021. Prior to joining Science 37, Ms. Pellizzari served as the General Counsel and Corporate Secretary of Insmid, Inc., (Nasdaq: INSM) a publicly traded biotech company focused on serious and rare diseases, from 2013 to 2018 and as Chief Legal Officer from 2018 to 2021. From 2007 through 2012 Ms. Pellizzari held various legal positions of increasing responsibility at Aegerion Pharmaceuticals, most recently as Executive Vice President, General Counsel and Corporate Secretary. Prior to Aegerion, Ms. Pellizzari was Senior Vice President, General Counsel and Secretary at Dendrite International, Inc., a formerly publicly traded company that provided sales effectiveness, promotional and compliance solutions to the pharmaceutical industry. Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer, where she specialized in health care transactions and related regulatory matters. Ms. Pellizzari has nearly three decades of relevant experience, including having served for over 25 years as Chief Legal Officer and General Counsel of publicly traded companies in biopharmaceutical and related industries. Ms. Pellizzari also serves on the board of directors of Tempest Therapeutics, a public clinical-stage oncology company and Neurosense Therapeutics, a public clinical-stage development company advancing treatments for severe neurodegenerative diseases. Ms. Pellizzari received her Bachelor of Arts, cum laude, from the University of Massachusetts (Amherst) and her Juris Doctor degree from the University of Colorado School of Law. She is a member of Global Leaders in Law, Executive Women in Bio, Women Corporate Directors, National Association of Corporate Directors, Association of Corporate Counsel, Society for Corporate Governance and National Association of Stock Plan Professionals. **Class II Directors (Term expires in 2024)** Mr. James E. Dentzer. Mr. Dentzer was appointed to our Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From

March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BIIB), a biotechnology company, and six years in various senior financial roles at E. I. du Pont de Nemours and Company, a chemical, petroleum and biotechnology company, in the U. S. and Asia. Mr. Dentzer holds a B. A. degree in Philosophy from Boston College and an M. B. A. from the University of Chicago. Dr. Stacy R. Lindborg, Dr. Lindborg was appointed to our Board of Directors in June 2021. Dr. Lindborg brings to Imunon more than 25 years of pharmaceutical industry experience with a particular focus on R & D, executive management and strategy. She has worked with biologics, small molecules and cell therapies to address a broad range of diseases and disorders, including multiple Orphan drug products, along with extensive experience in early-stage development having taken molecules from first in man studies into the clinic through approval and launch. Dr. Lindborg's holds the position of co-Chief Executive Officer at Brainstorm Cell Therapeutics (Nasdaq: BCLI), which she joined in 2020. From 2012 to 2020 she held positions of increasing responsibility at Biogen, where she worked in biostatistics and biometrics, and served as Vice President for Global Analytics and Data Sciences. Dr. Lindborg joined Eli Lilly and Company (NYSE: LLY) in 1996 moving through the organization to serve from 2010 to 2012 as Head of R & D Strategy with responsibility for characterizing the productivity of the portfolio and driving key R & D strategy projects including the annual R & D Long-Range Plan. Dr. Lindborg is a graduate of Baylor University where she received a Ph. D. and M. A. in statistics and a B. A. in psychology with a minor in mathematics. She has authored more than fifty abstracts, 200 presentations and 45 manuscripts that have been published in peer-reviewed journals. She serves on several industry advisory boards related to statistics and biotechnology. 58 Class III Directors (Term expires in 2025) Dr. Donald P. Braun, Dr. Braun was appointed to our Board of Directors in December 2015. Dr. Braun has over 35 years of research experience in oncology, cancer immunology, cancer immunotherapy, and inflammatory diseases. He is the author of more than 120 published peer-reviewed manuscripts, twenty-five reviews and book chapters, and co-editor of a book on the role of prostaglandins and other COX 2 metabolites in cancer patient immunity and immunotherapy. He served from 2006 to 2014 as Vice President Clinical Research, after which he served as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America until his retirement in May 2016. Prior to this role, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago from 1978 to 1999, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio from 1999 to 2006. He received his Ph. D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago. Dr. Braun has served as an advisor to numerous public agencies and private corporations concerned with cancer therapeutics and diagnostics. At the National Cancer Institute, Dr. Braun served as a member of the Experimental Therapeutics Study Section; the Small Business Innovation Grant Review Study Section; and the Experimental Therapy program for "Molecular Targets in Lung Cancer." He served as a member of the Immunology and Immunotherapy Study Section of the American Cancer Society-National Division; as a Member of the Ohio Cancer Incidence Surveillance System; as a Member of the Biomedical Research Technology Transfer Commission for the State of Ohio; and as an advisor to the State of Arizona's Disease Research Control Commission. Dr. Braun has also served as a consultant to numerous pharmaceutical and biotechnology companies developing cancer treatments and diagnostics including Pfizer Inc. (NYSE: PFE), Sterling Winthrop, Abbott Laboratories (NYSE: ABT), Boehringer Mannheim, Serono Corporation, Biomira Inc., Centocor and Merck KGA. Mr. Michael H. Tardugno, Mr. Tardugno was appointed President and Chief Executive Officer of the Company on January 3, 2007, and was elected to the Board of Directors on January 22, 2007. In October of 2014, Mr. Tardugno was appointed by our Board of Directors as our Chairman. Effective July 18, 2022, Mr. Tardugno transitioned from the roles of President, Chief Executive Officer and Chairman to the position of Executive Chairman of the Board. Prior to joining the Company and for the period from February 2005 to December 2006, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies, Inc., a subsidiary of Mylan Inc. From 1998 to 2005, Mr. Tardugno was Executive Vice President of Songbird Hearing, Inc., a medical device company spun out of Sarnoff Corporation. From 1996 to 1998, he was Senior Vice President of Technical Operations worldwide for a division of Bristol-Myers Squibb (NYSE: BMY), and from 1977 to 1995, he held increasingly senior executive positions including Senior Vice President of Worldwide Technology Development with Bausch & Lomb (NYSE, TSX: BLCO) and Abbott Laboratories (NYSE: ABT). Mr. Tardugno holds a B. S. degree from St. Bonaventure University and completed the Harvard Business School Program for Management Development. Executive Officers The following are the biographical summaries for each of our executive officers. Each executive officer is elected by, and serves at the pleasure of, our Board of Directors. Khurshed Anwer, Ph. D. Dr. Anwer joined us in June 2014 as Executive Vice President and Chief Scientific Officer, in connection with our acquisition of all the assets of EGWU, Inc. (formerly known as Egen, Inc.), an Alabama corporation (or "EGEN"). Before joining the Company, Dr. Anwer served as EGEN's President and Chief Scientific Officer, a position he held since 2009. He joined EGEN in July 2002 as Vice President of Research and Development and directed EGEN's clinical and research and development functions. Before joining EGEN, Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. from July 2000 to June 2002. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of non-viral gene therapy. He has authored more than 40 publications in the area of non-viral gene therapy, resulting from his active career in research and development. Dr. Anwer holds a Ph. D. in physiology / pharmacology from Ohio University and received post-doctoral training from the University of Texas Health Science Center at Houston. Dr. Anwer also has a master's in business administration from the University of Alabama. 59 Sébastien Hazard, M. D. On December 7, 2023, Dr. Hazard was appointed as Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023. Immediately prior to joining the Company, Dr. Hazard served as Senior Vice President, Head of Clinical Development at Bicycle Therapeutics plc (Nasdaq: BCYC) from April 2021 through September 2023. Prior to joining Bicycle Therapeutics, Dr. Hazard served as Clinical Development Lead at GSK from June 2019 to April 2021. He also served as Senior Medical Director of Clinical Development from July 2018 to May 2019, and Senior Medical Director of Global Medical Affairs from August 2016 to July 2018 at TESARO, Inc. Dr. Hazard held various positions within Genentech, including Medical Director in Lung Cancer of U. S. Medical Affairs from November 2012 to July 2016. Earlier in his career Dr. Hazard served as an advisor to the head of the French Drug Agency and to the French Health Minister's cabinet. Dr. Hazard holds a Doctorate in Medicine, Internal Medicine and Public Health from Paris VI Pitie Salpetriere, an Executive M. B. A. from INSEAD and a master's degree in epidemiology and statistics applied to clinical research from Paris VI University. Mr. Jeffrey W. Church, Mr. Church joined us in July 2010 as Vice President, Chief Financial Officer and Corporate Secretary. Mr. Church was appointed as our Senior Vice President, Corporate Strategy and Investor Relations in July 2011. In July 2013, Mr. Church was reappointed as Senior Vice President and Chief Financial Officer. In December 2018, Mr. Church was promoted to Executive Vice President. Immediately prior to joining the Company, Mr. Church served as Chief Financial Officer and Corporate Secretary of Alba Therapeutics Corporation, a privately held life science company from 2007 until 2010. From 2006 until 2007, he served as Vice President, Chief Financial Officer and Corporate Secretary for Novavax, Inc. (Nasdaq: NVAX), a vaccine development company listed on The Nasdaq Global Select Market. From 1998 until 2006, he served as Vice President, CFO and Corporate Secretary for GenVec, Inc., a biotechnology company formerly listed on The Nasdaq Capital Market. Prior to that, he held senior financial positions at BioSpherics Corporation and Meridian Medical Technologies, both formerly publicly traded companies. He started his career with Price Waterhouse from 1979 until 1986. Mr. Church holds a B. S. degree in accounting from the University of Maryland. Section 16 (a) Beneficial Ownership Reporting Compliance Section 16 (a) of the Exchange Act requires our executive officers, directors and persons who own more than 10 % of our common stock to file reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company with the SEC. Executive officers, directors and greater than 10 % stockholders are required by SEC regulations this Item 10 is herein incorporated by reference to furnish us with copies of all Section 16 (a) forms the they definitive Proxy Statement file. To our knowledge, based solely on a review of the copies of reports furnished to be filed us, we believe that during the year ended December 31, 2023, our executive officers, directors and greater than 10 % stockholders complied with all Section 16 (a) filing requirements. Code the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Ethics Annual Report. Our Code of Ethics and Business Conduct is applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Ethics and Business Conduct is posted on our website at www.imunon.com. Corporate Governance Audit Committee Our Audit Committee consists of Mr. James A. Dentzer (Chair), Mr. Frederick J. Fritz and Ms. Christine Pellizzari. Our Audit Committee operates under a written charter as amended and restated effective January 24, 2023. A copy of that charter, as may be amended from time to time, is available on our web site, located at <http://www.imunon.com>. Additional copies of the charter are available upon written request to us. 60 Our Audit Committee assists our Board

of Directors in fulfilling its responsibility to oversee management's implementation of our financial reporting process. In discharging its oversight role, the Audit Committee reviewed and discussed the audited financial statements contained in our 2023 Annual Report on Form 10-K with our management and independent registered public accounting firm. Management is responsible for the financial statements and the reporting process, including the system of internal controls. Our independent registered public accounting firm is responsible for expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the U. S. Our Board has determined that all members of the Audit Committee meet the independence standards established by the SEC and Nasdaq. Our Board has determined that Mr. Dentzer is qualified to serve as the "audit committee financial expert" as defined by Item 407 (d) (5) of Regulation S-K and that Mr. Fritz and Ms. Pellizzari meet the financial literacy requirements under applicable Nasdaq rules. Nomination of Directors There have been no changes to the procedures by which stockholders may recommend nominees to our Board of Directors. Insider Trading Policy Our insider trading policy is designed to promote compliance with insider trading laws, rules and regulations and, among other things, prohibits our officers, directors, and employees from, among other things, engaging in short sales, transactions in derivative securities (including put and call options) or other forms of hedging transactions (i. e., zero- cost collars, equity swaps, exchange funds and forward sale contracts) that are designed to hedge or offset any decrease in the market value of equity securities (1) granted to the executive officer or director by the Company as part of the compensation of such individual, or (2) held, directly or indirectly, by the executive officer or director. 61

ITEM 11. EXECUTIVE COMPENSATION

COMPENSATION SUMMARY The following table sets forth information required regarding the total compensation for services rendered in all capacities during the years ended December 31, 2023 and 2022, awarded to, paid to, or earned by this Item each "Named Executive Officer" serving as of December 31, 2023. All compensation awarded to, earned by, or paid to IMUNON's Named Executive Officers are included in the table below for the years ended December 31, 2023 and 2022: Name and Principal Position Year Salary Bonus Stock Awards Option Awards (1) (2) Non- Equity Incentive Plan Compensation (2) All Other Compensation (3) Total (\$) Corinne Le Goff (4) 2023 \$ 658, 080 \$ - \$ - \$ 107, 775 \$ 765, 855 2022 \$ 1, 055, 814 \$ 264, 000 \$ - \$ 97, 500 \$ 308, 564 \$ 157, 250 \$ 56, 480 \$ 883, 794 Khurshed Anwer (5) 2023 \$ 412, 760 \$ - \$ 47, 900 \$ 125, 281 \$ 94, 218 \$ 680, 159 Executive VP & CSO 2022 \$ 382, 629 \$ - \$ 19, 500 \$ 118, 286 \$ 139, 737 \$ 18, 506 \$ 678, 658 Jeffrey Church (6) 2023 \$ 441, 296 \$ - \$ 47, 900 \$ 115, 726 \$ 75, 000 \$ 679, 922 Executive VP & CFO 2022 \$ 409, 822 \$ - \$ 87, 715 \$ 139, 094 \$ - \$ 636, 631

(1) The value reported for option awards is herein incorporated the aggregate grant date fair value of stock options granted to the Named Executive Officers in the years shown, determined in accordance with FASB ASC Topic 718, disregarding adjustments for forfeiture assumptions. The assumptions for making the valuation determinations are set forth in Note 12 to the Company's financial statements for the year ended December 31, 2022 (2) Executives' bonuses under our annual incentive program are based on the achievement of specific performance measures established at the beginning of the fiscal year by reference our Compensation Committee. Historically, our Compensation Committee has awarded the annual incentive bonus for each year in the first quarter of the following year. In the first quarter of 2024, our Compensation Committee approved the amount and the payment of the incentive bonus for 2023 for each of the Named Executive Officers in the form of Non- Equity (Cash) Incentive Plan Compensation and stock awards. (3) This column includes other compensation as indicated below and matching and discretionary contributions made by the Company for the Named Executive Officers under our 401 (k) plan. Our matching contribution is equal to 50 % of the employee's deferrals under the plan up to 6 % of the employee's compensation, subject to applicable IRS limitations, and are made in shares of our common stock. (4) Dr. Le Goff joined the Company as President and Chief Executive Officer and as a director effective as of July 18, 2022 and stepped down from these positions, effective March 15, 2024. For Dr. Le Goff, "All Other Compensation" for 2023 consists of a 401 (k)- plan matching contribution of \$ 15, 000 in our common stock. (5) For Dr. Anwer, "All Other Compensation" for 2023 consists of \$ 75, 000 retention bonus paid in July 2023, \$ 6, 237 for discretionary spending allowance and a 401 (k)- plan matching contribution of \$ 12, 981 in our common stock. (6) For Mr. Church "All Other Compensation" for 2023 consists of \$ 75, 000 for a retention bonus paid in July 2023. 62

Narrative Disclosure to 2023 Summary Compensation Table Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer, Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff's targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company's common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year's salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her positions as President, Chief Executive Officer and Director of the Company. Employment Agreements with Other Named Executive Officers Jeffrey Church The Company and Mr. Church entered into an employment offer letter on June 15, 2010. Mr. Church's employment is "at- will;" however, subject to Mr. Church's promotion to Executive Vice President in January 2019, if we terminate Mr. Church's employment for any reason other than just cause, we will pay Mr. Church a salary continuation and COBRA premiums for up to twelve months. The salary and COBRA premiums will cease at the end of the twelve- month period or if he finds new employment prior to the twelve- month period, the benefit will be reduced by the amount of compensation which he will receive from any new employer. Mr. Church's right to receive these severance benefits is subject to his providing a release of claims in favor of the Company. The Company and Dr. Anwer entered into an employment offer letter effective as of June 20, 2014. Dr. Anwer's employment with us is "at- will;" however, subject to the retention and severance agreement between the Company and Dr. Anwer dated as of May 28, 2014, if we terminate Dr. Anwer's employment without cause (as such term is defined in the retention and severance agreement), he will be entitled to receive cash severance equal to 12 months of his base salary and reimbursement of his COBRA premiums for up to 12 months. Dr. Anwer's right to receive these severance benefits is subject to his providing a release of claims in favor of the Company. CIC Agreements We have entered into amended and restated double- trigger change in control severance agreements (CIC Agreements) with each of the Named Executive Officers (other than Dr. Anwer, who is not subject to such an agreement) to provide severance benefits to these executives should their employment terminate in certain circumstances in connection with a change in control of the Company (a "CIC"). Under the amended and restated CIC Agreements, in the event that, on or within two years after a CIC, we terminate the executive's employment without cause or in the event that the executive terminates his employment for good reason, the executive would be entitled to receive a cash lump sum payment equal to two (2) times the sum of (1) the executive's annual base salary and (2) the executive's target annual bonus for the fiscal year in which the termination occurs. (For these purposes, the terms "cause," "good reason" and "change in control" are each defined in the CIC Agreement.) In addition, we will pay or reimburse the executive for the cost of COBRA premiums and life insurance coverage for the executive and his eligible dependents, in each case for a period of up to two years following the termination. The executive would also be entitled to full acceleration of his the then definitive Proxy Statement - outstanding equity awards granted to him by us. However, as to any equity award agreement that is subject to performance- based vesting requirements, the vesting of such an award will continue to be filed governed by its terms. In the case of options or similar awards, the award would generally remain exercisable for the remainder of the original term of the award (or, in the case of awards that vested after the date of the CIC, for the lesser of 12 months following the last day such award would have been exercisable under the applicable award agreement and the remainder of the original term). The benefits provided under the CIC Agreement are in addition to, and not in lieu of, any severance benefits the executive may be entitled to receive in connection with the termination of his employment under any other agreement with the Company. The executive's right to benefits under the CIC Agreement is subject to his execution of a release of claims in favor of the Company upon the termination of his employment. The CIC Agreements do not provide for any tax gross ups. 63

Potential Payments Upon Termination or Change In Control As described above under "Narrative Disclosure to 2023 Summary Compensation Table," the Company entered into agreements with each of the Named Executive Officers providing for benefits payable to the executives in connection with a termination of their employment. The Company also entered into agreements with Dr. Le Goff and Mr. Church providing for benefits payable to the executives in connection with a termination of employment following a CIC of the Company. If in the event the Named Executive Officer is entitled to receive severance benefits in connection with a termination of employment under both their severance agreement and their CIC agreement, the executive shall be entitled to receive the benefits from both agreements. The first table below indicates the benefits that would have been payable to each executive if a termination of employment in the circumstances described above had occurred on December 31, 2023, outside of a CIC. The second table below indicates the benefits that would have been payable to each executive if a change in control of the Company and such a termination of employment had occurred on that date. Severance Benefits (Outside of a Change in Control) Name Cash Severance Continuation of Health / Life Benefit Equity Acceleration Total Corinne Le Goff \$ 477, 360 \$ 30, 189 - \$ 507, 549 Khurshed Anwer \$ 400, 899 \$ 28, 242 - \$ 429, 141 Jeffrey W. Church \$ 428, 615 \$ 12, 921 - \$ 441, 536 Change of Control Severance Benefits Name Cash Severance Continuation of

Health / Life Benefit Equity Acceleration Total Corinne Le Goff \$ 477,360 \$ 30,189 – \$ 507,549 Jeffrey W. Church \$ 1,242,984 \$ 25,842 – \$ 1,268,826

Material Terms of Option Grants During 2023 Each of the stock options awarded to the Named Executive Officers in 2023 was granted under, and is subject to, the terms of the IMUNON, INC. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan is administered by the Compensation Committee, which has authority to interpret the plan provisions and make all required determinations under the plan. This authority includes making required proportionate adjustments to outstanding awards upon the occurrence of certain corporate events such as reorganizations, mergers, and stock splits, and making provision to ensure that any tax withholding obligations incurred in respect of awards are satisfied. Awards granted under the plan are generally only transferable to a beneficiary of a Named Executive Officer upon his death. Under the terms of the 2018 Plan, if there is a change in control of the Company, each Named Executive Officer’s outstanding awards granted under the plan will generally terminate, unless the Compensation Committee provides for the substitution, assumption, exchange or other continuation or settlement (in cash, securities, or property) of the outstanding awards. The Compensation Committee has the discretion to provide for outstanding awards to become vested in connection with a change in control. Each option granted to the Named Executive Officers in 2023 was granted with a per-share exercise price equal to the closing price of our common stock on the grant date. Each option is scheduled to vest in three installments, with one-third vesting on the date of grant and the balance vesting in equal annual installments over each of the next two years, subject in each case to the executive’s continued employment through the applicable vesting date and has a maximum term of ten years. However, vested options may terminate earlier in connection with a change in control transaction or a termination of the Named Executive Officer’s employment. Subject to any accelerated vesting that may apply in the circumstances, the unvested portion of the option will immediately terminate upon a termination of the Named Executive Officer’s employment.

64 Outstanding Equity Awards at Year-End The following table summarizes the unexercised stock options held by each of the Named Executive Officers as of December 31, 2023. None of the Named Executive Officers held any other outstanding stock awards as of December 31, 2023.

Option Awards Name	Grant Date	No. of Securities Underlying Unexercised Options (#)	Exercisable	No. of Securities Underlying Unexercised Options (#)	Unexercisable	Option Exercise Price (\$)	Option Expiration Date
Corinne Le Goff	7/18/2022	44,250	132,750	(2)	\$ 1.95	7/18/2032	(3)
Jeffrey W. Church	10/3/2019	2,334	25,801	3	\$ 1.32	3/17/2033	(3)
Khurshed Anwer	10/3/2019	2,832	25,801	3	\$ 1.93	6/13/2032	3/17/2023
Corinne Le Goff	7/18/2022	44,250	132,750	(2)	\$ 1.95	7/18/2032	(3)
Jeffrey W. Church	10/3/2019	2,334	25,801	3	\$ 1.32	3/17/2033	(3)
Khurshed Anwer	10/3/2019	2,832	25,801	3	\$ 1.93	6/13/2032	3/17/2023

Each of these stock option grants vest in three equal installments, with one-third of the grant vesting each immediately, on the first anniversary, and Exchange Commission pursuant on the second anniversary of the date of grant. (2) Each of these stock option grants vest in four equal installments, with one-fourth of the grant vesting each on the first, second, third, and fourth anniversary of the date of grant. (3) Dr. Le Goff served as President and Chief Executive Officer of the Company until March 15, 2024. All of the equity awards held by Dr. Le Goff that had vested prior to Regulation 14A within 120 days after March 15, 2024 may be exercised by Dr. Le Goff until September 11, 2024, at which time they will automatically be forfeited if not exercised. All stock options and stock awards (and similar equity rights) that had not vested as of March 15, 2024 were forfeited by Dr. Le Goff.

Director Compensation The following table sets forth the cash and non-cash compensation paid to the Company’s directors who were not employed by the Company or any of its subsidiaries (“Non-Employee Directors”) for the year ended December 31, 2023, the Other than as set forth in the table, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the Non-Employee Directors in 2023. The compensation paid to any director who was also one of our employees during fiscal year covered 2023 is presented in the “2023 Summary Compensation Table” and the information that follows that table. Such employee directors did not receive separate compensation for their service on the Board of Directors or any of its Committees. Mr. Tardugno and Dr. Le Goff are not shown in this table because they were compensated as officers for the years shown and did not receive any additional director compensation.

Name	Fees Earned (\$)	Option Awards (\$)	Total (\$)
James E. Dentzer	58,800	2,395	61,195
Frederick J. Fritz	103,800	2,395	106,195
Donald P. Braun	70,500	2,395	72,895
Stacy R. Lindborg	41,700	2,395	44,095
Christine A. Pellizzari	45,300	2,395	47,695

The value reported for Option Awards is the aggregate grant date fair value of stock options granted to each Director in 2023, determined in accordance with FASB ASC Topic 718. The assumptions for making the valuation determinations are set forth in Note 12 to our financial statements. As of December 31, 2023, Mr. Dentzer had 4,667 option awards outstanding; Mr. Fritz had 18,333 option awards outstanding; Dr. Braun had 15,833 option awards outstanding; and Dr. Lindborg and Ms. Pellizzari each had 9,666 option awards outstanding.

65 The following table sets forth stock option grants awarded to the Company’s Non-Employee Directors for the year ended December 31, 2023. Employee directors do not receive separate equity awards for service on the Board of Directors or any of the Board committees.

Director Stock Option and Grant Awards Table Name	Number of Options Granted (#)	(1) Exercise Price (\$)	Grant Date	Expiration Date	Grant Date Fair Value (\$)
James E. Dentzer	2,000	\$ 1.32	3/17/2023	3/17/2033	\$ 1.20
Frederick J. Fritz	2,000	\$ 1.32	3/17/2023	3/17/2033	\$ 1.20
Donald P. Braun	2,000	\$ 1.32	3/17/2023	3/17/2033	\$ 1.20
Stacy R. Lindborg	2,000	\$ 1.32	3/17/2023	3/17/2033	\$ 1.20
Christine A. Pellizzari	2,000	\$ 1.32	3/17/2023	3/17/2033	\$ 1.20

Each of these stock option grants vest in three equal installments, with one-third of the grant vesting on the date of grant and one-third of the grant vesting on each of the first and second anniversary of the date of grant, subject to the applicable director’s continued service as a member of our Board through each applicable vesting date. During the year ended December 31, 2023, each Non-Employee Director of the Company received annual cash compensation in the amount of \$ 30,500 payable in quarterly installments, and an additional \$ 2,200 for attendance at regular meetings of the Board of Directors and \$ 1,200 for each meeting of a committee of the Board of Directors that was not held in conjunction with a meeting of the Board of Directors. Each Non-Employee director is reimbursed for the out-of-pocket costs of attending meetings of the Board of Directors and of committees of the Board of Directors. In 2023, the Chairman of the Audit Committee received an additional annual cash fee of \$ 13,500 and the Chairman of the Compensation Committee received an additional annual cash fee of \$ 10,500.

66 Acting on behalf of the Board of Directors, Mr. Fritz also received fees totaling \$ 48,000 in 2023 for his role as a Board Liaison to our Board of Directors. Mr. Fritz’s responsibilities as Board Liaison include the following: (i) serve as an initial sounding board for our management regarding issues, matters, or communications to be brought or potentially to be brought before the Board of Directors; (ii) provide input and feedback to management regarding strategic matters, business matters, major scientific, clinical, collaboration, or corporate development matters, key personnel matters, or other items of significance regarding which management would like to obtain initial or further Board guidance, including, but not limited to, guidance regarding timing and content of communications regarding such matters or items with the full Board or any of its committees; (iii) remain accessible to management to provide guidance on business or strategy issues or other issues of significance on an as-needed basis; (iv) participate in meetings and relevant discussions as requested by management; (v) conduct general advisory or liaison services to the Board, including relaying to management requests from other members of the Board regarding desired additional information or clarification or suggestions or feedback regarding improvement in Board processes or communications; (vi) serve as a conduit for informal communications between management and the Board; and (vii) any other such services established by the Board from time to time. Acting on behalf of our Board of Directors, Dr. Braun also received fees totaling \$ 30,000 in 2023 for this role as a strategic advisor to our Executive Chairman and our Chief Executive Officer. Dr. Braun’s responsibilities as a strategic advisor include the following: (i) provide strategic and tactical advice to our Chief Executive Officer; (ii) evaluate international subsidiary options; (iii) develop strategies to secure business relationships other than in the U. S.; and (iv) having done both (ii) and (iii), develop high potential ex-US market strategies that address the objectives for broad and profitable sales of its commercial products. Stock Ownership Guidelines for Non-Employee and Executive Directors Our Board of Directors believes that, as a matter of sound corporate governance, non-employee and executive directors should have a significant personal financial stake in our performance. Consequently, in February 2011, our Board of Directors adopted stock ownership guidelines for non-employee and executive directors. Our corporate governance guidelines require that each non-employee director acquire and hold shares of our common stock having an aggregate value equal to two times the director’s total compensation in the first year of service and that our executive director acquire and hold shares of our common stock having an aggregate value equal to the executive director’s total compensation in the first year of service. Each director is expected to satisfy the applicable ownership guideline within three years after his or her appointment to the Board. Shares of our common stock that count toward satisfaction of these ownership guidelines include, unless beneficial ownership therein is disclaimed: (i) shares owned outright by the director or executive officer or their immediate family members residing in the same household, whether held individually or jointly; (ii) shares held in a trust, family limited partnership or similar entity solely for the benefit of the director or executive officer and / or their immediate family members; (iii) shares of restricted stock and restricted stock units awarded under our equity incentive plans, including vested and unvested awards; and (iv) shares acquired upon stock option exercise, but not shares underlying unexercised stock options.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The following table is furnished by the Company and sets forth certain information required known to the Company regarding the beneficial ownership of the Company’s common stock as of March 26, 2024 by: • each person or group known by us to own beneficially more than 5

% of the Company's outstanding common stock; ● each of our directors, as well as each executive officer named in the Summary Compensation Table appearing under the heading "Executive Compensation;" and ● our directors and executive officers as a group. We determine beneficial ownership in accordance with the rules of the SEC. Under SEC rules, beneficial ownership for purposes of this Item takes into account shares as to which the individual has voting or investment power as well as shares that may be acquired within 60 days of March 26, 2024. Shares of common stock subject to options that are currently exercisable or that become exercisable within 60 days of March 26, 2024, are treated as outstanding and beneficially owned by the holder of such options. However, these shares are not treated as outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated or as to the interests of spouses, the persons included in the table have sole voting and investment power with respect to all shares beneficially owned thereby. Percentage ownership calculations are based on 9,399,789 shares outstanding as of March 26, 2024.

NAME OF BENEFICIAL OWNER	NUMBER OF SHARES OF COMMON STOCK BENEFICIALLY OWNED	PERCENT OF SHARES OF COMMON STOCK OUTSTANDING
James E. Dentzer	5,361	0.057%
Stacy R. Lindborg	10,416	0.111%
Frederick J. Fritz	28,682	0.305%
Donald P. Braun	15,430	0.164%
Christine Pellizzari	10,416	0.111%
Michael H. Tardugno	183,763	1.955%
Corinne Le Goff	12,127	0.129%
Khurshed Anwer	78,188	0.841%
Jeffrey W. Church	78,450	0.845%
Directors and Executive Officers as a group (9 persons)	410,707	4.37%

The address of each of the individuals named is herein incorporated by reference to IMUNON, INC., 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648. * Less than one percent. (1) Includes 5,361 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (2) Includes 10,416 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (3) Includes 11,766 shares of common stock and 16,916 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (4) Includes 597 shares of common stock (reflecting the reverse stock split effected by reference to the Company on February 28, 2022 at a ratio of 15:1) and 14,833 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (5) Includes 10,416 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (6) Includes 16,513 shares of common stock and 167,250 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (7) Includes 53,000 shares of common stock and 74,250 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. Dr. Le Goff served as President and Chief Executive Officer of the Company until March 15, 2024. All of the options held by Dr. Le Goff that had vested prior to March 15, 2024 may be exercised by Dr. Le Goff until September 11, 2024, at which time they will automatically be forfeited if not exercised. All stock options and stock awards (and similar equity rights) that had not vested as of March 15, 2024 were forfeited by Dr. Le Goff. (8) Includes 2,855 shares of common stock (reflecting the reverse stock split effected by the Company on February 28, 2022 at a ratio of 15:1) and 75,333 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (9) Includes 3,617 shares of common stock (reflecting the reverse stock split effected by the Company on February 28, 2022 at a ratio of 15:1) and 74,833 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. (10) Includes 375,359 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024.

Equity Compensation Plan Information as of December 31, 2023

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of Securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
(a) Equity compensation plans approved by securityholders	772,297	\$ 3.09	1,202,776
(b) Equity compensation plans not approved by securityholders	294,751	\$ 1.59	1,067,048
(c) Total	1,067,048	\$ 2.68	2,269,824

(1) Includes both vested and unvested options to purchase common stock and unvested stock grants under the 2018 Plan. These awards have a weighted average remaining term of 8.7 years. (2) Represents shares available for award grant purposes under the 2018 Plan. Subject to certain express limits of the plan, shares available under the plan generally may be used for any type of award authorized under that plan including options, stock appreciation rights, restricted stock and other forms of awards granted or denominated in shares of our common stock or units of our common stock. (3) Includes both vested and unvested options to purchase common stock and unvested stock grants under inducement grants provided certain employees as an inducement to accept employment with the Securities and Exchange Commission pursuant to Company. These awards have a weighted average remaining term of 9.0 years. These grants are similar to Regulation 14A within 120 days after the those end of granted under the 2018 Plan fiscal year covered by this Annual Report.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

INDEPENDENCE Related information - Person Transactions Our Code of Ethics requires all of our directors, officers and employees to give their complete loyalty to the best interests of the Company and to avoid any action that may involve, or that even may appear to involve, a conflict of interest with the Company. The Code of Ethics also requires any of our directors, officers or employees who become aware of a conflict or potential conflict to bring it to the attention of supervisor, manager or other appropriate personnel or consult the compliance procedures provided in the Code of Ethics. The Board of Directors reviews and approves or ratifies all relationships and transactions between us and (i) any of our directors or executive officers, (ii) any nominee for election as a director, (iii) any securityholder who is known to us to own beneficially or of record more than five percent of our common stock or (iv) any member of the immediate family of any of the foregoing. On November 16, 2022, the Company entered into a Convertible Note Purchase Agreement with Transomic Technologies, Inc. ("Transomic") whereby the Company purchased \$375,000 of convertible notes secured by certain assets held by Transomic and warrants. As a result of this investment in Transomic, Imunon's executive chairman, Mr. Michael Tardugno, was appointed to the Board of Directors of Transomic. The Company is disclosing herein incorporated by reference to the definitive Proxy Statement to notes receivable as a related party transaction. In December 2023, Transomic filed a formal certificate of dissolution of the company resulting in a complete write off of the convertible note and related warrants. Director Independence In accordance with the rules of the SEC and Nasdaq, the Company requires that at least a majority of the directors serving at any time on the Board of Directors be independent. The Board has determined that filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report six currently serving directors, five directors (Drs. Braun and Lindborg, Messrs. Dentzer and Fritz and Ms. Pellizzari) are independent under applicable SEC and Nasdaq rules.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Withum, Brown Smith PC ("Withum")	2023	2022
Audit Fees	\$ 150,000	\$ 158,500
Audit Related Fees	\$ 9,705	\$ 14,246
Tax Fees	\$ 13,750	\$ 10,800
All Other Fees	\$ 78,885	\$ 31,111
Total Fees	\$ 252,340	\$ 195,396

100% of the fees for professional services rendered by this firm for the audits of our annual financial statements in our Annual Reports on Form 10-K and for reviews of the quarterly financial statements included in the Company's Quarterly Reports on Form 10-Q. Audit related fees pertain to the work performed during our equity offerings in 2023 and 2022. Tax fees consist of fees for preparation of the Company's federal and state tax returns. All other fees consist of fees for attendance at the Company's annual meetings, review of registration statements and similar matters. Services by Employees of Withum No part of Withum's engagement to audit the Company's financial statements for the years ended December 31, 2023 and 2022 was attributable to work performed by persons other than Withum's full-time, permanent employees. Audit Committee Policy on Approval of Audit and Non-Audit Services It is herein incorporated the policy of the Audit Committee to pre-approve all audit and permissible non-audit services provided by reference our independent accountants, in accordance with rules prescribed by the SEC. These services may include audit services, audit-related services, tax services, and other services. Pre-approval is based on a written proposal, accompanied by a cost estimate, and estimated budget. The Audit Committee has delegated to its chairman the authority definitive Proxy Statement to be filed pre-approve audit and non-audit services with the Securities and an Exchange Commission pursuant estimated cost of up to Regulation 14A within 120 days after \$25,000, provided the exercise of such authority is reported to the Audit Committee at its next regular meeting. The Audit Committee reserves the right, from time to time, to delegate pre-approval authority to the other end of the fiscal year covered its members, so long as such members are independent directors. All audit and permissible non-audit services during 2023 and 2022 were approved by this Annual Report the Audit Committee in accordance with its pre-approval policy and the approval requirements of the SEC.

PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) The following documents are filed as part of this Annual Report: 1. FINANCIAL STATEMENTS The following is a list of the consolidated financial statements of Imunon, Inc. filed with this Annual Report, together with the reports of our independent registered public accountants and Management's Report on Internal Control over Financial Reporting. Page REPORTS Reports of Independent Registered Public Accounting Firms - Firm F-1 FINANCIAL STATEMENTS Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-5 Consolidated Statements of Comprehensive Loss F-6 Consolidated Statements of Cash Flows F-7 Consolidated Statements of Changes in Stockholders' Equity F-9 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS F-112. FINANCIAL STATEMENT SCHEDULES All financial statement schedules are omitted because the information is inapplicable or

presented in the notes to the consolidated **Financial-financial Statements-statements**. 71 3. EXHIBITS The following documents are included as exhibits to this report: EXHIBIT NO. DESCRIPTION 2. 1 * Asset Purchase Agreement dated as of June 6, 2014, by and between Imunon, Inc. and EGEN, Inc., incorporated herein by reference to Exhibit 2. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2014 (SEC File No. 001- 15911). 2. 2 Amendment to Asset Purchase Agreement between Celsion Corporation and EGWU, Inc., dated March 28, 2019 incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed on April 1, 2019 (SEC File No. 001- 15911). 3. 1 Amended and Restated Certificate of Incorporation of Imunon, dated March 24, 2023, incorporated herein by reference to Exhibit 3. 1 to the Current Report on Form 8-K of the Company filed on March 24, 2023 (SEC File No. 001- 15911). 3. 2 Amended and Restated Bylaws of the Company, effective on **September 19, March 15, 2022-2024**, incorporated by reference to Exhibit 3. **3-1** to the Current Report on Form 8-K of the Company, filed on **September 19, March 18, 2022-2024** (SEC File No. 001- 15911). 4. 1 Form of Representative's Common Stock Purchase Warrant, incorporated herein by reference to Exhibit 4. 2 to the Current Report on Form 8-K of the Company, filed on October 31, 2017 (SEC File No. 001- 15911). 4. 2 Form of Placement Agent Common Stock Purchase Warrant incorporated herein by reference to Exhibit 4. 4 to the Current Report on Form 8-K of the Company, filed on July 11, 2017 (SEC File No. 001- 15911). 4. 3 Form of Amended and Restated Warrant (issued under First Amendment of Venture Loan and Security Agreement, dated as of August 1, 2020, by and among Imunon, Inc., Horizon Funding I, LLC, Horizon Funding Trust 2019- 1, and Horizon Technology Finance Corporation, as Collateral Agent), incorporated herein by reference to Exhibit 4. 1 to the Current Report on Form 8-K of the Company, filed on September 4, 2020 (SEC File No. 001- 15911). 4. 4 Form of Exchange Warrant, incorporated herein by reference to Exhibit 4. 1 to the Current Report on Form 8-K of the Company, filed on March 13, 2020 (SEC File No. 001- 15911). 14. 5 Warrant to purchase Shares of Common Stock of Celsion Corporation between Celsion Corporation and EGWU, Inc., dated March 28, 2019, incorporated herein by reference to Exhibit 4. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2019 (SEC File No. 001- 15911). 4. 6 Description of Securities of the Registrant, incorporated herein by reference to Exhibit 4. 5 to the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2019. 10. 1 * * * Imunon, Inc. 2007 Stock Incentive Plan, as amended, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed on May 16, 2017 (SEC File No. 001- 15911). 10. 2 Form Inducement Offer to Exercise Common Stock Purchase Warrants, incorporated herein by reference to Exhibit 10. 3 to the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2017 (SEC File No. 001- 15911). 10. 3 * * * Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed May 15, 2018 (SEC File No. 001- 15911). 10. 4 * * * First Amendment to the Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed on May 15, 2019 (SEC File No. 001- 15911). 10. 5 * * * Second Amendment to the Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed on June 16, 2020 (SEC File No. 001- 15911). 10. 6 * * * Third Amendment to the Celsion Corporation 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed with the Commission on June 10, 2021 (SEC File No. 001- 15911). **72** 10. 7 * * * Employment Offer Letter, entered into on June 15, 2010, between the Company and Jeffrey W. Church, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed on June 18, 2010 (SEC File No. 001- 15911). 10. 8 * * * Employment Offer Letter effective as of June 2, 2014, between the Company and Khursheed Anwer incorporated herein by reference to Exhibit 10. 27 to the Annual Report of the Company for the year ended December 31, 2014 (SEC File No. 001- 15911). 10. 9 * * * Employment Agreement between the Company and Michael H. Tardugno, effective as of July 18, 2022, incorporated herein by reference to Exhibit 10. 2 to the Current Report on Form 8-K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001- 15911). 10. 10 * * * Employment Agreement between the Company Corporation and Corinne Le Goff, effective as of July 18, 2022 incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001- 15911). 10. 11 * * * Amended and Restated Change in Control Agreement dated as of September 6, 2016, by and between the Company and Michael H. Tardugno, incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (SEC File No. 001- 15911). 10. 12 * * * Amended and Restated Change in Control Agreement dated as of September 6, 2016, by and between the Company and Jeffrey W. Church, incorporated herein by reference to Exhibit 10. 3 to the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (SEC File No. 001- 15911). 10. 13 * **Patent License Development, Product Supply and Commercialization Agreement**, **effective December 5, 2008, by and** between the Company and **Yakult Honsha Co. Duke University dated November 10, 1999-Ltd.**, incorporated herein by reference to Exhibit 10. **9** to the Annual Report of the Company for the year ended September 30, 1999 (SEC File No. 001- 15911). 10. 14 * **License Agreement dated July 18, 2003, between the Company and Duke University, incorporated herein by reference to Exhibit 10. 1 to the Registration Statement on Form S-3 (File No. 333- 108318) filed on August 28, 2003 (SEC File No. 001- 15911).** 10. 15 * **Development, Product Supply and Commercialization Agreement, effective December 5, 2008, by and between the Company and Yakult Honsha Co., Ltd., incorporated herein by reference to Exhibit 10. 15 to the Annual Report of the Company for the year ended December 31, 2008 (SEC File No. 001- 15911).** 10. **16-14** * The 2nd Amendment to The Development, Product Supply and Commercialization Agreement, effective January 7, 2011, by and between the Company and Yakult Honsha Co., Ltd. incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed on January 18, 2011 (SEC File No. 001- 15911). 10. **17-15** * Technology Development Agreement effective as of May 7, 2012, by and between Imunon, Inc. and Zhejiang Hisun Pharmaceutical Co. Ltd., incorporated herein by reference to Exhibit 10. 2 to the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2012 (SEC File No. 001- 15911). 10. **18-16** * Technology Development Contract dated as of January 18, 2013, by and between Imunon, Inc. and Zhejiang Hisun Pharmaceutical Co. Ltd., incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2013 (SEC File No. 001- 15911). **73** 10. **19-17** Lease Agreement, executed July 21, 2011, by and between Imunon, Inc. and Brandywine Operating Partnership, L. P., incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company filed on July 25, 2011 (SEC File No. 001- 15911). 10. **20-18** First Amendment to Lease Agreement, executed April 20, 2017, by and between Imunon, Inc. and Lenox Drive Office Park, LLC, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 10-Q of the Company filed on November 14, 2017 (SEC File No. 001- 15911). 10. **21-19** Second Amendment to Lease Agreement, dated January 9, 2019, by and between Celsion Corporation and Lenox Drive Office Park, LLC, successor in interest to Brandywine Operating Partnership, L. P., incorporated herein by reference to Exhibit 10-Q to the Current Report on Form 10-Q of the Company for the quarter ended March 31, 2019 (SEC File No. 001- 15911). 10. **22-20** Lease Agreement dated January 15, 2018, by and between Imunon, Inc. and HudsonAlpha Institute of Biotechnology for office and lab space located in Huntsville, Alabama incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2018 (SEC File No. 001- 15911). 10. **21** **23** **Registration Rights Agreement dated as of June 20, 2014, by and between Celsion Corporation and Egen, Inc., incorporated herein by reference to Exhibit 4. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2014 (SEC File No. 001- 15911).** 10. 24 **Form of Securities Purchase Agreement incorporated herein by reference to Exhibit 10. 33 to the Registration Statement on Form S-1 of the Company filed on February 13, 2017 (SEC File No. 001- 15911).** 10. 25 **Loan Facility Agreement, dated as of June 18, 2021, by and between the Company and Silicon Valley Bank.** 10. 26 Settlement Agreement and Release, by and between the plaintiff to the shareholder action captioned O' Connor v. Braun, et al., N. J. Super., Dkt. No. MERC- 00068- 19, William J. O' Connor, derivatively on behalf of Imunon, Inc. and individually on behalf of himself and all other similarly situated stockholders of Imunon, Inc. and defendants, incorporated herein by reference to Exhibit 10. 2 to the Current Report on Form 8-K of the Company, filed on June 16, 2020 (SEC File No. 001- 15911). 10. **27-22** Form of Exercise Agreement, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed on March 13, 2020 (SEC File No. 001- 15911). 10. **28-23** At the Market Offering Agreement, dated May 25, 2022 by and between Celsion Corporation and H. C. Wainwright & Co. LLC, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8-K of the Company, filed on May 25, 2022, (SEC File NO. 001- 15911). 21. 1 Subsidiaries of Imunon, Inc. 23. 1 Consent of WithumSmith Brown, PC, independent registered public accounting firm for the Company. 31. 1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. 31. 2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. 32. 1 Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. 32. 2 Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **97 Compensation Recovery Policy** 101. INS Inline XBRL Instance Document 101. SCH Inline XBRL Taxonomy Extension Schema Document 101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Cover Page Interactive Data File (embedded within the Inline XBRL document) 101 * * The following materials from the Company's Annual Report for the fiscal year ended December 31, **2022-2023**, formatted in XBRL (Extensible Business Reporting Language): (i) the audited Consolidated Balance Sheets, (ii) the audited Consolidated Statements of Operations, (iii) the audited Consolidated Statements of Comprehensive Loss, (iv) the audited Consolidated Statements of Cash Flows, (v) the audited Consolidated Statements of Changes in Stockholders' Equity and (vi) Notes to Financial Statements. * Portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 24b- 2 of the Securities Exchange Act of 1934, amended, and the omitted material has been separately filed with the Securities and Exchange Commission. Filed herewith. Furnished herewith. * * XBRL information is filed herewith. * * * Management contract or compensatory plan or arrangement. ITEM 16. FORM 10-K **SUMMARY SIGNATURES SUMMARY 74 SIGNATURES**

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMUNON, INC. Registrant March 30-28, 2023-2024 By: /s/ **Michael H. Tardugno Michael H. Tardugno** Corrine Le Goff Corrine Le Goff President and Chief Executive **Chairman of the Board** Pursuant Officer March 30, 2023 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: Name Position Date /s/ MICHAEL H. TARDUGNO Executive Chairman of the Board March 30-28, 2023-2024 (Michael H. Tardugno) /s/ CORRINE LE GOFF President and Chief Executive Officer March 30, 2023 (Corrine Le Goff) /s/ JEFFREY W. CHURCH Executive Vice President and Chief March 30-28, 2023-2024 (Jeffrey W. Church) Financial Officer /s/ KIMBERLY A. BRAGG-GRAPER Vice President of Finance & Contoller March 30-28, 2023-2024 (Kimberly A. Graper Bragg) /s/ AUGUSTINE CHOW Director March 30, 2023 (Augustine Chow, Ph. D.-) /s/ FREDERICK J. FRITZ Director March 30-28, 2023-2024 (Frederick J. Fritz) /s/ JAMES E. DENTZER Director March 30-28, 2023-2024 (James E. Dentzer) /s/ DONALD BRAUN Director March 30-28, 2023-2024 (Donald Braun, Ph. D.) /s/ CHRISTINE PELLIZZARI Director March 30-28, 2023-2024 (Christine A. Pellizzari) /s/ STACY R. LINDBORG Director March 30-28, 2023-2024 (Dr. Stacy R Lindborg) 75 Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders of Imunon Inc. -Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Imunon Inc. (the "Company") as of December 31, 2023 and 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, changes in stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2022-2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company Imunon Inc. as of December 31, 2023 and 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022-2023, in conformity with accounting principles generally accepted in the United States of America. **Substantial Doubt Regarding Going Concern** The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the entity has suffered recurring losses from operations, has experienced cash used from operations, and has an accumulated deficit, that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion -These consolidated financial statements are the responsibility of the Company entity's management. Our responsibility is to express an opinion on the these consolidated Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company Imunon Inc. in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company Imunon Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company entity's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion opinions on the critical audit matters or on the accounts or disclosures to which they relate. **F-1 Going Concern Valuation Evaluation of In-process research and development (IPR & D)** Description of the Matter As described further in Note 6-2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has an accumulated deficit, and expects its operating losses to continue for the foreseeable future. Accordingly, the Company has determined that these factors raise substantial doubt as to the Company's ability to continue as a going concern in-process research and development asset ("IPR & D") is tested for impairment a period of on one December 31 of each year from the issuance of these financial statements. Management intends to seek opportunities to fund its business by way of public tests indefinite-lived intangible assets for impairment between annual tests if an event occurs or private offerings circumstances change that would indicate the carrying amount may be impaired. An impairment loss is recognized when the asset's carrying value exceeds its fair value. The Company conducted a valuation analysis of its IPR & D for the ovarian cancer indication as of December 31, 2022. Based on the assessment performed as of December 31, 2022, management determined that the fair value of the IPR & D asset did not exceed its carrying value and based on their quantitative analysis, management determined that the asset was fully impaired. The Company uses the market capitalization to estimate the fair value of the reporting unit, which is based on the Company's stock in order to satisfy the Company's obligations as they come due for at least one year-end stock price and shares of stock from the consolidated financial statement issuance date. Further, there is no guarantee that the Company will be successful are freely tradeable. As further discussed in Note 6, during the these endeavors year ended December 31, 2022, the Company recorded a \$13.4 million IPR & D impairment charge. Auditing the IPR & D involved subjective auditor judgment and effort in performing procedures relating to management's conclusions about whether significant assumptions. In addition, the audit involved the use of professionals with specialized skill and knowledge in performing these there procedures are conditions and evaluating events that raise substantial doubt about the entity's ability to continue audit evidence obtained. How the Critical Matter Was - as a going concern Addressed in the Audit Addressing the matter involved performing procedures and evaluating audit evidence in connection with within forming our overall opinion on one year after the consolidated financial statements are issued is subjective and requires especially challenging auditor judgment. These procedures included testing management How We Addressed the Matter in Our Audit We obtained an understanding of controls over the Company's process for developing determining the their fair value estimate ability to continue as a going concern. We determined This included testing the Company completeness, accuracy, and relevance of underlying data used. Evaluating management's ability assumptions included assessing the reasonableness of key assumptions by considering the historical results of peer companies, consistency with third-party industry data, and whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to continue assist in evaluating the appropriateness of the multi-period excess earnings approach. Valuation of earn-out milestone liability As described in Note 13 to the financial statements, the Company derecognized the \$5.4 million Earn-out milestone liability during 2022. The liability represented the value of additional amounts that management believed may be paid related to the acquisition of EGEN, Inc upon achievement of certain milestones. We identified the measurement of the Earn-out milestone liability as a going concern is a critical audit matter because auditing due to the estimation and uncertainty regarding the Company's available capital derecognition of the liability involved challenging and complex the risk of bias in management's judgments judgments regarding clinical data and assumptions in their determination. Our audit procedures related to considering whether support that milestones were not met. To test the results of Earn-out milestone liability, our audit procedures, when considered in the aggregate, indicate whether there is substantial doubt about the Company's ability to continue as a going concern for reasonable period of time included the following procedures among others- other -inspecting procedures: • Evaluating the terms financial condition of the executed agreement and testing Company, including liquidity sources as of the data date utilized by of the auditor's opinion (the "assessment date"). • Examining and evaluating underlying evidence with respect to this assessment date evaluation. • Evaluating conditional and unconditional obligations due or anticipated to become due during the period of 12 months from the date of the filing of these financial statements (the "look forward period") and examining and evaluating underlying evidence with respect to this evaluation. • Evaluating the Company's assessment of its cash flows during the look forward period and examining and evaluating underlying evidence with respect to this evaluation. • Inquiring of Company management as to make whether there are any determination discussed above. We evaluated the other key judgments considering external data sources adverse conditions or events which could raise substantial doubt regarding the Company's ability to continue as a going concern and contractual terms. Our procedures included evaluating such events the data sources used by management in determining their judgments and, where necessary, included as applicable. • Performing an assessment regarding evaluation of available information that either corroborated or contradicted management's conclusions plans to alleviate substantial doubt regarding the Company's ability to continue as a going concern and examining and evaluating underlying evidence with respect to this assessment, as applicable. • Evaluated the adequacy of the Company's financial statements disclosures regarding liquidity and going concern to determine in which such disclosures were in accordance with U. S. generally accepted accounting principles. /s/ WithumSmith Brown, PC WithumSmith Brown, PC We have served as the Company Imunon Inc.'s auditor since 2017. Princeton East Brunswick, New Jersey March 30-27, 2023-2024

PCAOB ID Number 100 F-2 IMUNON, INC. CONSOLIDATED BALANCE SHEETS 2023 2022 2021-December 31, 2023 2022 2021-ASSETS Current assets: Cash and cash equivalents \$ 5,838,566 \$ 11,492,841 \$ 19,586,272 Investment in debt securities- available for sale, at fair value 9,857,087 21,254,485 29,803,095 Accrued interest receivable on investment securities 128,932 108,844 Money market investments, restricted cash 1,500,000 Advances and deposits on clinical programs and other current assets 2,778,545,051 2,403,433 2,447,413 Total current assets 37,181,154 240,704,366 779,691 51,945,624 Property and equipment (at cost, less accumulated depreciation and amortization) 751,906 548,301 477,011 Other assets: Money market investments, restricted cash 4,500,000 6,000,000 Deferred income tax asset 1,280,385 1,567,026 1,382,446 In-process research and development, net 13,366,234 Operating lease right-of-use assets, net 1,595,074 155,876 690,995 Deposits and other assets 50,000 183,425 489,000 Total other assets 2,925,459 6,272,647 902,216 24,164 Total assets \$ 21,918,069 \$ 43,975,894 \$ 74,046,799 See accompanying notes to the consolidated financial statements. F- 3 (Continued) December 31, 2023 2022 2021 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable – trade \$ 3,515,192 \$ 3,586,623 \$ 2,547,251 Other accrued liabilities 3,390,521 4,794,936 3,173,537 Notes payable – current portion, net of deferred financing costs 1,424,774 Operating lease liability 485,421 230,749 548,870 Deferred revenue-current portion 500,000 Total current liabilities 7,391,134 10,037,082 6,769,658 Earn-out milestone liability 5,396,000 Notes payable – non-current portion, net of deferred financing costs 4,610,946 5,854,461 Operating lease liability 1,424,774 Total liabilities 8,530,427 14,648,028 18,250,868 Commitments and contingencies – Stockholders' equity: Preferred Stock- \$ 0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022 and 2021) – Common stock- \$ 0.01 par value (112,500,000 shares authorized; 9,399,811 and 7,436,219 and 5,770,538 shares issued at December 31, 2023 and 2022 and 2021, respectively, and 9,399,789 and 7,436,197 and 5,770,516 shares outstanding at December 31, 2023 and 2022 and 2021, respectively) 93,998 74,362 57,705 Additional paid-in capital 401,500,838 397,980,023 388,600,979 Accumulated other comprehensive income (loss) 60,796 26,494 (7,974) Accumulated deficit (388,182,802) (368,667,825) (332,769,591) Total stockholders' equity before treasury stock 13,472,830 29,413,054 55,881,119 Treasury stock, at cost (22 shares at December 31, 2023 and 2022 and 2021) (85,188) (85,188) Total stockholders' equity 13,387,642 29,327,866 55,795,931 Total liabilities and stockholders' equity \$ 21,918,069 \$ 43,975,894 \$ 74,046,799 F- 4 CONSOLIDATED STATEMENTS OF OPERATIONS 2023 2022 2021-Years Ended December 31, 2023 2022 2021 Technology development and licensing revenue \$ 500,000 \$ 500,000 Operating expenses: Research and development 11,287,691 11,733,666 10,619,287 General and administrative 9,742,739 13,687,899 10,887,903 Total operating expenses 21,030,430 25,421,565 21,507,190 Loss from operations (21,030,430) (24,921,565) (21,007,190) Other income (expense): Gain from change in earn-out milestone liability 5,396,000 1,622,000 Impairment of goodwill and in-process research and development (13,366,234) (1,976,101) Loss on debt extinguishment (234,329) 419,158 Investment income, net 1,157,625 453,356 10,996 Interest expense (197,080) (5,028,618) (569,881) Other (loss) income (396,319) 1,801 1,899 Total other income (expense), net 235,068 (12,543,695) (1,145,506) Loss before income tax benefit (20,795,362) (37,465,260) (22,152,696) Income tax benefit 1,280,385 1,567,026 1,382,446 Net loss \$ (19,514,977) \$ (35,898,234) \$ (20,769,250) Net loss per common share- basic and diluted \$ (2.16) \$ (3.03) \$ (3.83) Weighted average common shares outstanding- basic and diluted 9,045,320 7,142,970 F- 5 426,953 CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 2023 2022 2021-Years Ended December 31, 2023 2022 2021 Net Other comprehensive loss \$ (35,898,234) \$ (20,769,250) Changes in: Realized gains on investment securities recognized in investment income, net 43,431 801 508 7,149 49,222 Unrealized loss (gain) on investment securities (17, net (397,499) (0) 14,754) 825 Other Change in realized and unrealized gains on available for sale securities, net 34,302 34,468 Net loss (19,514,977) (35,898,234) Total comprehensive income, net 26,494 7,974 Comprehensive loss \$ (19,480,675) \$ (35,871,863) 740 766 F- 6 \$ (20,761,276) CONSOLIDATED STATEMENTS OF CASH FLOWS 2023 2022 2021-Years Ended December 31, 2023 2022 2021 Cash flows from operating activities: Net loss \$ (19,514,977) \$ (35,898,234) \$ (20,769,250) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 248,154 196,510 Amortization of right-of-use assets 471,629 702,851 535,918 Recognition of deferred revenue (500,000) Realized and unrealized losses, net, on investment securities 34,302 34,468 Change in fair value of earn-out milestone liability (5,396,000) (1,622,000) Stock-based compensation 759,013 2,673,047 034 3,759,737 Change in deferred income tax asset 286,462 377,641 (183,580) Loss on extinguishment of debt 329,158 Write-off of note receivable (Transomic) 375,000 Impairment of goodwill and in-process research and development 13,366,234 1,976,101 Amortization of deferred finance charges and debt discount associated with note payable 55,122 181,259 237,258 Net changes in: Accrued interest receivable on investment securities 68,136 (20,088) (108,844) Advances and deposits on clinical programs and other current assets (514,141) 600,619 43 (786,980) 718 Other assets 123,489 124,241 728 511 Accounts payable and trade 1,039,372 302,404 Other accrued liabilities (1,072,992) 929 529 247,142 Deferred revenue (500,000) 2 (500,000) 111,901 Net cash used in operating activities (19,022,148) (23,131,096) 895 376 (16,223,603) Cash flows from investing activities: Purchases of investment in debt securities (13,541,806) (48,191,226) 390 922 (53,811,069) Proceeds from sale and maturity of investment in debt securities 25,000,000 56,775,000 24,000 Purchases of property and equipment (451,759) (267,800) (311,613) Net cash used in provided by investing activities 11,006,435 8,315 280 810 278 (30,122,682) Cash flows from financing activities: Proceeds from redeemable convertible preferred stock offering 28,500,000 Payment upon redemption of redeemable convertible preferred stock (28,500,000) Proceeds from issuance sale of common stock equity, net of issuance costs 2,781,438 6,722,654 Payoff 667 52,688,946 Proceeds from issuance of the SVB loan and accrued common stock upon exercise of warrants 1,508,666 Proceeds from issuance of common stock upon exercise of stock options 4,725 Proceeds from notes payable 5,756,630 Payments on notes payable including end-of-term fees (5,619,420) 587,000 Net cash (used in) provided by financing activities (3,638,562) 6,722,667 54 654 Net (768,380) Change change in cash, cash equivalents and restricted cash (11,654,275) (8,093,431) 8,422,095 Cash, cash equivalents and restricted cash at beginning of year 17,492,841 25,586,272 17,164,177 Cash, cash equivalents and restricted cash at end of year \$ 5,838,566 \$ 17,492,841 F- 7 \$ 25,586,272 Years Ended December 31, 2023 2022 2021 Supplemental disclosure of cash flow information: Cash paid for: Income taxes paid \$ 2,500 2,000 Interest \$ (179,542) \$ 4,847,359 Non-Cash Investing and Financing Activities Recognition of right of use asset and liability \$ 1 (357,911,049 277) Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from lease payments \$ 601,495 \$ 568,269 Realized and unrealized gains, net, on investment in debt securities \$ 26,494 \$ 7,974 F- 8 CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY YEAR ENDED DECEMBER 31, 18, 436,611, 081 219 \$ 74,362 397,980,023 22 \$ (85,188) \$ 26,494 \$ (368,667,825) \$ 29,327,866 Net loss (19,20,514,769,977 250) (19,20,514,769,977 250) Sale of equity through equity financing facilities 1,904,142 19,041 2,762 975 397 503 29,755 52,659,191 2 52 781 688 438 946 Issuance of common stock upon exercise of restricted options 59 500 5 4 720 450 595 4,725 Shares issued pursuant to warrant exercises 81,111 811 1,507,855 595 1,508,666 Realized and unrealized gains and losses, net, on investment securities 34 (7,302,974) 34 (7,302,974) Stock-based compensation expense 758 3 418 759,737 758 3 418 759,737 Balance at December 31, 2023 2021 5 9,399 770, 516 2022 Shares Amount Shares Amount Capital Shares Amount (Loss) Deficit Total Series A & B Preferred Common Stock Outstanding Additional Paid-in Treasury Stock Accum. Other Compr. Income Accumulated Shares Amount Shares Amount Capital Shares Amount (Loss) Deficit Total Balance at January 1, 2022- \$ 5,770,516 \$ 57,705 \$ 388,600,979 22 \$ (85,188) \$ (7,974) \$ (332,769,591) \$ 55,795,931 Balance- \$ 5,770,516 \$ 57,705 \$ 388,600,979 22 \$ (85,188) \$ (7,974) \$ (332,769,591) \$ 55,795,931 Net loss (35,898,234) (35,898,234) Effect of reverse stock split (27) Issuance of preferred stock upon financing 100,000 28,500,000 285,000 Redemption of preferred stock (100,000) (28,500,000) (28,500,000) Sale of equity through equity financing facilities 1,664,349 16,644 6,706,010 6,722,654 Issuance of common stock for restricted options 1,381 13 13 Realized and unrealized gains and losses, net, on investment securities 34,468 34,468 Stock-based compensation expense 2,673,034 2,673,034 Balance at December 31, 2022- \$ 7,436,219 \$ 74,362 \$ 397,980,023 22 \$ (85,188) \$ 26,494 \$ (368,667,825) \$ 29,327,866 YEAR ENDED DECEMBER 31, 2021 Shares Amount Capital Shares Amount (Loss) Deficit Total Common Stock Outstanding Additional Paid-in Treasury Stock Accum. Other Compr. Accumulated Shares Amount Capital Shares Amount (Loss) Deficit Total Balance at January 1, 2021 2,713,402 27 7 134 436,219 330 74 669 362 397 476 980,023 22 (85,188) 26 (85,494 188) (368,667,825) 29 (312,000 327,341) 866 See accompanying notes to the consolidated financial 18,611,081 Net loss..... 2021 5,770,516 statements, 57,705 \$ 388,600,979 22 \$ (85,188) \$ (7,974) \$ (332,769,591) \$ 55,795,931 F- 10 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 2023 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. ("Imunon" or the "Company"); reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN," effective as of the opening of trading on September 21, 2022. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platforms developing its non-viral DNA technologies across four modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a

promising platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and. The third modality, FixPlas®, concerns the application of Imunon's DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neopeptide cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase H2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical proof-of-concept studies on for the development of a nucleic acid COVID-19 booster vaccine (IMNN candidate targeting SARS-CoV-2 101) and a treatment for the Lassa virus (IMNN-102) in order to validate its PLACCINE platform. Imunon's platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these platforms modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. Basis of Presentation The accompanying consolidated financial statements ("Financial Statements") of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and CLSN Laboratories, Inc. and Imunon. The Company in 2023 dissolved Celsion GmbH. All significant intercompany balances and transactions have been eliminated in consolidation. The preparation of the financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company's Financial Statements and accompanying notes. Actual results could differ materially from these estimates. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these Financial Statements have been evaluated for their possible impact on the Financial Statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the Financial Statements other than those arising in the ordinary course of business. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets and goodwill evaluation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. F-11 Revenue Recognition The Company's sole revenue stream is was related to the Hisun agreement described in Note 18, and whose contract has expired. There were no accounts receivable as of December 31, 2023 and 2022. Contract liabilities from the Hisun agreement amounted to \$0.5 million as of December 31, 2021. Contract liabilities values represent the value of cash received before the services were provided. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance. Fair Value of Financial Instruments The carrying values of financial investment-instruments securities approximate their respective fair values. Management believes that the carrying amounts of the Company's financial investment-instruments securities, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification ("ASC") 320, Investments-Debt and Equity Securities. Available-for-sale securities consist of debt securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders' equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company's short-term investments consist of corporate bonds. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately \$ 248,000 and \$ 197,000 and \$ 130,000 for the years ended December 31, 2023 and 2022 and 2021, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2023 or 2022 or 2021. Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature. During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. F-12 Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in-process research and development. F-12 Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per Share of Common Share-Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023, 2022 and 2021, the total number of shares of common stock issuable upon exercise of warrants and equity awards is was 1,255,642 and 988,389 and 618,800, respectively. For the years ended December 31, 2023 and 2022 and 2021, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive. Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and / or penalties related to income tax matters in the income tax expense category. F-13 As more fully discussed in Note 10, on September 19, November 28, 2022-2023, the Company received approval from the New Jersey Economic Development Authority to sell \$ 1.6-3 million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, 2022-2023 for the net proceeds (approximately \$ 1.6-3 million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on October 31, November 28, 2022-2023, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On January 10, March 22, 2023-2024, the Company received approximately \$ 1.6-3 million upon completion of the sale of the 2023 NOLs. During 2022 NOLs. During 2021, the Company received approval to sell \$ 1.5-6 million of its New Jersey NOLs, receiving net proceeds of approximately \$ 1.4-6 million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ 1-0.9-4 million in net operating losses under this maximum

lifetime benefit (see Note 2). **F-13** Stock-Based Compensation In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation, which simplifies various aspects of accounting for share-based payments. The areas for simplification involve several aspects of the accounting for share-based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures in compensation cost when they occur. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In **June 2016-December 2023**, the FASB issued ASU No. **2016-2023-13-09**, **Improvements to Income Tax Disclosures Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments**, which **requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and** modifies the other income tax measurement of expected credit losses on certain financial instruments. The Company adopted ASU 2016-13 in its first quarter of 2021 utilizing the modified retrospective transition method. Based on the composition of the Company's investment portfolio and current market conditions, the adoption of ASU 2016-13 did not have a material impact on its Financial Statements. In May 2021, the FASB issued ASU No. **2021-2023-09-04**, Earnings Per Share (Topic 260), Debt Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder's accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, **2021-2024 and allows**, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or **for adoption** exchanges occurring on or after the effective date of the amendments **a prospective basis, with a retrospective option**. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted **is currently evaluating the impact of the ASU 2021-04 on its income tax disclosures within the consolidated Financial financial Statements statements**. **F-14-2. FINANCIAL CONDITION AND LIQUIDITY-GOING CONCERN UNCERTAINTY** Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the **FDA U. S. Food and Drug Administration**. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. **As of For the year ended December 31, 2022-2023, the Company had a net loss of \$ 19.5 million and used \$ 19.0 million to fund operations. As of December 31, 2023**, the Company has incurred approximately \$ **369-388** million of cumulative net losses. As of December 31, **2022-2023**, the Company had \$ **32-15, 8-7** million in cash and cash equivalents, short-term investments, and interest receivable and \$ **1.6-3** million net proceeds **on from** the sale of **its New Jersey** net operating losses and \$ **6.0** million in restricted cash required to maintain on deposit with SVB as cash collateral for the SVB debt. The Company has substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its **drug candidates and technologies**. The Company **believes expects its operating losses to continue for the foreseeable future as it has sufficient capital resources continues its product development efforts, and when it undertakes marketing and sales activities. The Company's ability to fund achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The Company expects that its operations operating into 2025 results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company's control**. The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the ongoing COVID-19 pandemic. **The disruptions caused by COVID-19 may also disrupt the Russian invasion clinical trials process and enrollment of patients. This may delay commercialization efforts-Ukraine and the unrest in the Middle East**. The Company continues to monitor its operating activities in light of these events, and it is reasonably possible that **the these virus events could have result in a variety negative effect on the Company's financial condition and results of operations risks to the business**. The specific impact, if any, is not readily determinable as of the date of these **consolidated** Financial Statements. **F-14-5** Since 2018, the Company has annually submitted applications to sell a portion of the Company's State of New Jersey net operating losses as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. As part of the Technology Business Tax Certificate Program, the Company sold \$ 1.6 million and \$ 1.5 million of its New Jersey NOLs in 2022 and 2021, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1.6 million in 2022 and \$ 1.4 million in 2021. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$ 1.9 million in net operating losses under this maximum lifetime benefit. In June 2018, the Company entered into a Credit Agreement with Horizon Technology Finance Corporation ("Horizon") that provided \$ 10 million in capital (the "Horizon Credit Agreement"). The obligations under the Horizon Credit Agreement are secured by a first-priority security interest in substantially all assets of Imunon other than intellectual property assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus 7.625%) for the first 24 months through July 2020, followed by a 21-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity date on April 1, 2023. On August 28, 2020, in connection with an Amendment to the Horizon Credit Agreement, Imunon repaid \$ 5 million of the \$ 10 million loan and \$ 0.2 million in related end-of-term charges, and the remaining \$ 5 million in obligations were restructured. As more fully discussed in Note 9 to these Financial Statements, in June 2021, the Company entered into a \$ 10 million loan facility with Silicon Valley Bank ("SVB"). The Company immediately used \$ 6 million from this facility to retire all outstanding indebtedness with Horizon. Concurrently with this retirement, the Company was required to fund a restricted cash account in the amount of \$ 6 million. The funding is in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 7.75%). Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company's shares or debt, the sale of the Company's New Jersey NOLs and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted. **The actual amount See Note 11 for a discussion of funds the Company will need to operate is subject to many factors, some of which are beyond the Company's control. The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company's control. These factors include the following: • the progress of research activities; • the number and scope of research programs; • the progress of preclinical and clinical development activities; • the progress of the development efforts of parties with whom the Company has entered into research and development agreements; • the costs associated with additional clinical trials of drug candidates; • the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; • the ability to achieve milestones under licensing arrangements; • the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and • the costs and timing of regulatory approvals. On July 13, 2023, the consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company's business plan including, but not limited to: • the Company's financial position for the year ended December 31, 2020-2023; • significant events and transaction the Company announced that it has received a recommendation entered into since December 31, 2023; • the Company's cash flow and cash usage forecasts for the period one year from the independent DMC to consider stopping the global Phase III OPTIMA Study of ThermoDox in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation issuance date of this Annual Report on Form 10-K; • the Company's capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and • continued support of the Company's stockholders. As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact**

our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of Series A Preferred Stock. The report of our independent registered public accounting firm for the year ended December 31, 2023 includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. A Preferred Stock fundamental component of the ability to continue as a going concern is the Company's ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives: • it has assessed its current expenditures and Series B Preferred Stock will be reducing the current spending requirements where necessary; • it will pursue additional capital funding in the public and private markets through equity sales and / or debt facilities; • it will pursue possible partnerships and collaborations; and • it will pursue potential out licensing for its drug candidates. F- 15 Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months.

3. INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE Investments in debt securities available for sale with a fair value of \$ 9, 857, 087 and \$ 21, 254, 485 and \$ 29, 803, 095 as of December 31, 2023 and 2022 and 2021, respectively, consisted of U. S. Treasury securities and corporate debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive loss. Investments in The Company reviews its debt securities available classified as short- term investments on a regular basis for sale are evaluated periodically to impairment. For debt securities in unrealized loss positions, the Company determines whether a any portion of the decline in their fair value below the amortized cost basis is other due to credit- related factors if it neither intends to sell nor anticipates that it is more likely than temporary not that it will be required to sell prior to recovery of the amortized cost basis. The Company considers factors term "other than temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the extent to which magnitude and duration of the decline, market value as has well as been less than the cost, any noted failure of the issuer to make scheduled payments, changes to the rating of the security and the other reasons relevant credit- related factors in determining whether or not a credit loss exists. During fiscal 2023 and 2022, the Company did not recognize an allowance for the decline to predict credit whether the - related loss losses on any in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of our investments the security is reduced and a corresponding charge to earnings is recognized. A summary of the cost, fair value and maturities of the Company's short- term investments is as follows:

SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short- term investments U. S. Treasury securities \$ -9, 796, 291 \$ -9, 857, 087 \$ -14, 786, 982 \$ -14, 778, 705 Corporate debt securities 21, 227, 991 21, 254, 485 15- Total \$ 9, 024 796, 291 \$ 9, 857, 087 15- 087 15- 024, 390 Total \$ 21, 227, 991 \$ 21, 254, 485 \$ 29, 811, 069 \$ 29, 803, 095 F- 16 December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short- term investment maturities Within 3 months \$ 2, 467, 518 \$ 2, 490, 775 \$ 4, 005, 559 \$ 3, 994, 590 \$ 19, 798, 177 \$ 19, 799, 835 Between 3- 12 months 7, 328, 773 7, 366, 312 17, 222, 432 17, 259, 895 40, 012, 892 40, 003, 260 Total \$ 9, 796, 291 \$ 9, 857, 087 \$ 21, 227, 991 \$ 21, 254, 485 \$ 29, 811, 069 \$ 29, 803, 095 The following table shows the Company's investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022 and 2021. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2022 2023 December 31, 2021-2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains \$ 9, 857, 087 \$ 60, 796 \$ 13, 278, 505 \$ 43, 508 \$ 8, 999, 580 \$ 3, 499 Investments in debt securities with unrealized losses - \$ -7, 975, 980 (17, 014) Total \$ 9 (17, 857 014) 20, 803 087 \$ 60, 796 515 (11, 473) Total \$ 21, 254, 485 \$ 26, 494 F- 16 \$ 29, 803, 095 \$ (7, 974) Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023 2022 2021 Interest and dividends accrued and paid \$ 725, 824 \$ 502, 578 \$ 18, 145 Realized losses 431, 801 (49, 222) Realized gains (7 losses) 431, 801 (149, 49, 222) Investment income, net \$ 1, 157, 625 \$ 453, 356 \$ 10, 996-4. RESTRICTED CASH As a condition of the SVB Loan Facility entered into on June 18, 2021, as further discussed in Note 11-9, the Company is was required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100 % of the aggregate outstanding amount of the SVB loan facility. SVB may could restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The loan was repaid in full during the quarter ended June 30, 2023, thus removing this requirement. The required reserve totaled \$ 6. 0 million as of December 31, 2022 and 2021. This amount is presented in part as restricted cash for \$ 1. 5 million in current assets and \$ 4. 5 million in other non- current assets on the accompanying condensed consolidated balance sheets. On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. Although the Department of the Treasury, the Federal Reserve and the FDIC stated all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, or any other financial institution that is placed into receivership by the FDIC may be impacted by other disruptions to the U. S. banking system caused by the recent developments involving SVB. F- 17 The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2022-2023 December 31, 2021-2022 Cash and cash equivalents \$ 5, 838, 566 \$ 11, 492, 841 \$ 19, 586, 272 Money market investments, restricted - 6, 000, 000 6, 000, 000 Total \$ 5, 838, 566 \$ 17, 492, 841 \$ 25, 586, 272 5. FAIR VALUES OF FINANCIAL INSTRUMENTS FASB ASC Section 820, Fair Value Measurements and Disclosures, establishes a three- level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity's own assumptions that market participants would use in pricing an asset or liability. F- 17 Cash and cash equivalents and other current assets, accounts payable and other accrued liabilities are reflected in the consolidated balance sheets at their approximate estimated fair values primarily due to their short- term nature. The fair values of securities available for sale are determined by relying on the securities' relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2023 and 2022 and 2021. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the years ended December 31, 2023 and 2022 and 2021. The changes in Level 3 liabilities were the result of changes in the fair value of the earn- out milestone liability included in earnings and in- process R & D. The earnout milestone liability at December 31, 2021 is valued using a risk- adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets / Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2023 Corporate debt securities, available for sale \$ 9, 857, 087 \$ 9, 857, 087 \$ - \$ - Recurring items as of December 31, 2022 Corporate debt securities and U. S. treasury obligations, available for sale \$ 21, 254, 485 \$ 21, 254, 485 \$ - \$ - Non- recurring items as of December 31, 2022 In- process R & D (Note 6) \$ - \$ - \$ - \$ - Liabilities: Recurring items as of December 31, 2021 Corporate debt securities and U. S. treasury obligations, available for sale \$ 29, 803, 095 \$ 29, 803, 095 \$ - \$ - Non- recurring items as of December 31, 2021 In- process R & D (Note 6) \$ 13, 366, 234 \$ - \$ - \$ - \$ 13, 366, 234 Liabilities: Recurring items as of December 31, 2022 Earn- out milestone liability (Note 13) \$ - \$ - \$ - \$ - Recurring items as of December 31, 2021 Earn- out milestone liability (Note 13) \$ 5, 396, 000 \$ 5, 396, 000 F- 18 6. INTANGIBLE ASSETS In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation ("EGEN"), which changed its company name to EGWU, Inc. after the closing of the acquisition (the "EGEN Acquisition"). The Company acquired all of EGEN's right, title and interest in and to substantially all of the assets of EGEN,

including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. **F-18** Acquired In-process Research and Development. Acquired in-process research and development ("IPR & D") consists of EGEN's drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR & D drug technology platforms was estimated to be \$24.2 million as of the acquisition date. As of the closing of the acquisition, the IPR & D was considered indefinite lived intangible assets and will not be amortized. IPR & D ~~is~~ **was** reviewed for impairment at least annually as of the third quarter ended September 30, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. The Company's IPR & D consisted of three core elements, its RNA delivery system, its glioblastoma multiforme cancer ("GBM") drug candidate and its ovarian cancer indication. As of ~~September 30~~ **December 31, 2021-2022**, the Company assessed whether there were indicators of impairment for the Company's IPR & D and determined that ~~no~~ **the** IPR & D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in **2022 and 2021** and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company's IPR & D assets, the Company concluded ~~no~~ **the** IPR & D asset was impaired during ~~that period~~. **Due to the fourth quarter continuing slowdown in investment by public capital markets in the biotech industry and its impact on market capitalization rates in this sector, the Company conducted a valuation analysis of 2022. As its IPR & D for the ovarian cancer indication as of December 31, 2021-2022. Based on this valuation analysis, the Company has concluded that it is not more likely than not that the asset is impaired as of December 31, 2021. As such, no impairment charges for IPR & D related to the ovarian cancer indication were recorded during 2021.** Covenants Not to Compete Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants ("Covenant Not To Compete") to the Company whereby EGEN agreed, during the period ending on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not to enter into any business, directly or indirectly, which competes with the business of the Company nor would it contact, solicit or approach any of the employees of the Company for purposes of offering employment. The Covenant Not to Compete which was valued at approximately \$1.6 million at the date of the EGEN Acquisition has a definitive life and is amortized on a straight-line basis over its life of 7 years. The Company recognized amortization expense of \$113,660 in 2021. The Covenant Not to Compete was fully amortized by the end of 2021. ~~F-19~~ The purchase price exceeded the estimated fair value of the net assets acquired by approximately \$2.0 million which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least annually as of the Company's third quarter ended September 30 or sooner if the Company believes indicators of impairment exist. As of September 30, 2021, the Company's fair value exceeded its carrying value and as such no impairment was recognized for Goodwill through the third quarter of 2021. Due to the continuing slowdown in investment in 2021 by public capital markets in the biotech industry and its impact on market capitalization rates in this sector, Goodwill was reviewed for impairment as of December 31, 2021. Based on this assessment, Company concluded that Goodwill was impaired. As of December 31, 2021, the Company wrote off the ~~\$ 2-13~~ **0-4** million carrying value of this asset, thereby recognizing a non-cash charge of ~~\$ 2-13~~ **0-4** million in the fourth quarter of **2021-2022**. The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the ~~two years~~ **year** ended December 31, 2022: SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR & D Goodwill Covenant Not to Compete Balance at January 1, 2021-2022, net \$ 13,366,234 **Balance \$ 1,976,101 \$ 113-13,366,660 Amortization--(113-234,660) Impairment charge -(113,976,366, 401-234)** -Balance at December 31, 2021, net 13,366,234 -Balance 13,366,234 -Impairment charge (13,366,234) -**Balance at December 31, 2022, net \$ - \$ -Balance \$ - \$ -** 7. PROPERTY AND EQUIPMENT Property and equipment at December 31, **2023 and 2022 and 2021** consist of the following: SUMMARY OF PROPERTY AND EQUIPMENT **2023 2022 2021** December 31, **2023 2022 2021** Machinery and equipment (5-7 year life) \$ 2,055,192 \$ 2,468,388 **Machinery and equipment (5-7 year life) \$ 3-2,406,055, 069-192 \$ 2,468,388** Furniture and fixtures (3-5 year life) **191,932** 350,481 **383,477** Leasehold improvements (5-7 year life) **607,054** 373,194 **343,203** Property and equipment gross **2,854,178** 3,192,063 **3,832,749** Less accumulated depreciation and amortization **(2,102,272) (2,643,762) (3,355,738)** Total **\$ 751,906** \$ 548,301 **\$ 477,011** 8. OTHER ACCRUED LIABILITIES Other accrued liabilities at December 31, **2023 and 2022 and 2021** include the following: SCHEDULE OF OTHER ACCRUED LIABILITIES **2023 2022 2021** December 31, **2023 2022 2021** -Amounts due to contract research organizations and other contractual agreements **\$ 1,442,659** \$ 2,196,711 **\$ 1,401,356** Accrued payroll and related benefits **1,693,383** 2,139,927 **1,636,727** Accrued interest **37,583** **16,792** Accrued professional fees **234,479** 215,402 **87,250** Other **20,000** 205,313 **31,412** Total **\$ 3,390,521** \$ 4,794,936 **\$ 3,173,537** ~~F-20~~ **19** 9. NOTES PAYABLE The SVB Loan Facility On June 18, 2021, the Company entered into a \$10 million loan facility (the "SVB Loan Facility") with Silicon Valley Bank ("SVB"). Imunon immediately drew down \$6 million from the SVB Loan Facility and used the funds to retire all outstanding indebtedness with Horizon as further discussed below. **Technology Finance Corporation pursuant to a loan agreement entered into on June 27, 2018, under which the Company had drawn down \$10 million and repaid \$5 million in August 2020.** Concurrently with this transaction, the Company used \$6.0 million of other available funds to establish a restricted cash account which **services served** as security for the SVB Loan Facility. The SVB Loan Facility **is was** in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 7.75%). A final payment equal to 3% of the total \$10 million commitment amount **is was** due upon maturity or prepayment of the SVB Loan Facility. There was no facility commitment fee, and no stock or warrants were issued to SVB. Payments under the loan agreement **are were** interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling \$243,370 which **is was** recorded and classified as debt discount and **was** **are being** amortized as interest expense using the effective interest method over the life of the loan. Also, in connection with the SVB Loan Facility, ~~the Company is required to pay an end-of-term fee equal to 3.0% of the original loan amount at time of maturity. Therefore, these amounts totaling \$300,000 are being amortized as interest expense using the effective interest method over the life of the loan.~~ During the years ended December 31, 2022 and 2021, the Company incurred interest expense of \$295,792 and \$106,709 and amortized \$181,259 and \$97,831, respectively, as interest expense for debt discounts and end-of-term fee in connection with the SVB Loan Facility. The following is a schedule of future principal payments, net of unamortized debt discounts and amortized end-of-term fee, due on the SVB Loan Facility: SCHEDULE OF FUTURE PRINCIPAL PAYMENTS, NET OF UNAMORTIZED DEBT DISCOUNTS As of December 31, 2023 \$ 1,500,000 2024 \$ 3,000,000 2025 and thereafter \$ 1,500,000 Subtotal of future principal payments \$ 6,000,000 Amortized end-of-term fee, net (35,720) Total \$ 5,964,280 Horizon Credit Agreement On June 27, 2018, the Company entered into a loan agreement with Horizon Technology Finance Corporation ("Horizon") that provided \$10 million in new capital (the "Horizon Credit Agreement"). The Company drew down \$10 million upon closing of the Horizon Credit Agreement on June 27, 2018. On August 28, 2020, Horizon and the Company amended the Horizon Credit Agreement (the "Amendment") whereby Imunon repaid \$5 million of the \$10 million loan and \$0.2 million in related end-of-term charges, and the remaining \$5 million in obligations were restructured as set forth below. ~~F-21~~ Pursuant to the Amendment, the remaining \$5 million in obligations of Imunon under the Horizon Credit Agreement was secured by a first-priority security interest in substantially all assets of Imunon other than intellectual property assets. The obligations bore interest at a rate calculated based on an amount by which the one-month LIBOR exceeds 2% plus 7.625%. In no event could the interest rate be less than 9.625%. Payments pursuant to the Amendment were interest only for the first 12 months after August 1, 2020, followed by a 21-month amortization period of principal and interest through the scheduled maturity date on April 1, 2023. In addition, the remaining \$5 million in obligations was subject to an end-of-term fee equal, in the aggregate, to \$275,000, which amount was payable upon the maturity of the obligations or upon the date of final payment or default, as applicable. In connection with the Amendment, Imunon agreed to a liquidity covenant which provided that, at all times, Imunon maintain unrestricted cash and/or cash equivalents on deposit in accounts over which the applicable lenders maintained an account control agreement in an amount not less than \$2.5 million. In addition, pursuant to the Amendment, Imunon agreed to provide evidence to Horizon on or before March 31, 2021, that it received aggregate cash proceeds of not less than \$5 million from the sale of equity, debt, its New Jersey NOLs, or a combination thereof, subsequent to the date of the Amendment. The Company met this requirement during the fourth quarter of 2020. In connection with the Horizon Credit Agreement, the Company incurred financing fees and expenses totaling \$175,000 which were recorded and classified as debt discount. In addition, the Company paid loan origination fees of \$100,000 which were recorded and classified as debt discount. These debt discount amounts totaling \$782,116 were being amortized as interest expense using the effective interest method over the life of the loan. Also, in connection with each of the Horizon Credit Agreement, the Company was required to pay an end-of-term charge **fee** equal to **4-3** 0% of the original loan amount at time of maturity. Therefore, ~~those these~~ amounts totaling \$400,300,000 were being amortized as interest expense using the effective interest method over the life of the loan. **During** **As a fee in connection with the Horizon Credit Agreement, Imunon issued Horizon warrants exercisable for a total of 12,674 shares of Imunon's common stock (the "Existing Warrants") at a per share exercise price of \$39.45. The Existing Warrants were immediately exercisable for cash or by net exercise from the date of grant and will expire after ten years from the date of grant. The Company valued the Existing Warrants issued using the Black-Scholes option pricing model and recorded a total of \$507,116 as a direct deduction from the debt liability, consistent with the presentation of debt discounts, and are being amortized as interest expense using the effective interest method over the life of the loan. Pursuant to the Amendment, one-half of the aggregate Existing Warrants, exercisable for a total of 6,337 shares of Imunon's common stock, have been canceled, and, in connection with the Amendment, Imunon issued Horizon new warrants exercisable at a per share exercise price equal to \$15.15 for a total of 16,501 shares**

of Imunon's common stock (the "New Warrants" and, together with the Existing Warrants, the "Warrants"). The remaining 6,337 Existing Warrants issued in connection with the Horizon Credit Agreement remain outstanding at the exercise price of \$ 39.45 per share. The New Warrants were immediately exercisable for cash or by net exercise from the date of grant and will expire after ten years from the date of grant. The Horizon Credit Agreement contains customary representations, warranties and affirmative and negative covenants including, among other things, covenants that limit or restrict Imunon's ability to grant liens; incur indebtedness; make certain restricted payments, merge, or consolidate and make dispositions of assets. The Amendment was evaluated in accordance with FASB ASC 470-50, Debt Modifications and Extinguishments, for debt modification and extinguishment accounting. The Company accounted for the \$ 5 million it repaid as a debt extinguishment thereby reducing the principal obligations accordingly. The Company accounted for the remaining \$ 5 million of obligation under the Amendment as a debt modification to the initial agreement with respect to the minor changes in cash flows. Also, in connection with the \$ 5 million remaining obligations, the Company recorded \$ 5,000 of financing fees and the New Warrant fair value of \$ 247,548 as additional debt discount on the \$ 5 million remaining obligation. Therefore, approximately \$ 109,706 of unamortized debt discount will be amortized over the remaining life of the new obligations. The \$ 275,000 of end-of-term fees, net of previously amortized end of term fees totaling \$ 142,605 previously accrued on the original note associated with the \$ 5 million remaining obligation, will be amortized as interest expense over the remaining life of the new obligations. During the year ended December 31, 2021-2023 and 2022, the Company incurred \$ 225,920 in interest expense of \$ 197,080 and \$ 295,792 and amortized \$ 139,329, 428,158 and \$ 181,259, respectively, as interest expense for debt discounts and end-of-term charges fee in connection with the Horizon Credit Agreement. F-22 On June 18, 2021, as a condition of entering into the SVB Loan Facility, On April 21, 2023, the Company paid repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility Horizon Credit Agreement, as amended. The following is a schedule of the amounts paid to Horizon SVB on June 18 April 21, 2021-2023: SCHEDULE OF DEBT Principal balance at June 18 April 21, 2021-2023 \$ 5-6, 000, 000 Early termination fees 150-120, 000 End of term charges 275-300, 000 Total payoff amount \$ 5-6, 425-420, 000 During the year ended December 31, 2021-2023, the Company recorded a loss of \$ 234-329, 419 158 on the early termination of the SVB Loan Facility Horizon Credit Agreement, as amended, which represented the early termination fee and the end of the term fees, net of previously amortized interest expense totaling \$ 190-334, 581-212 on the date of its payoff. 10. INCOME TAXES The income tax benefit for the years ended December 31, 2023 and 2022 and 2021 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 2021-Federal Current \$ - Deferred-- State and Local-- Current-- Deferred (1, 280, 385) (1, 567, 026) (-1, 383, 446) Total \$ (1, 280, 385) \$ (1, 567, 026) F-20 \$ (-1, 383, 446)-A reconciliation of the Company's statutory tax rate to the effective rate for the years ended December 31, 2023 and 2022 and 2021 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2023 2022 2021-Federal statutory rate 21.0 % 21.0 % State taxes, net of federal tax benefit 7.1 7.8-1 Permanent differences (3.1) 29.8 True-Up (-15-105, 0) - Other (-2.9) - Change in valuation allowance and deferred rate change, net 89.0 (53.8) (-7.6) Effective tax rate 6.1 % 4.1 6 % 6.2 % The components of the Company's deferred tax asset as of December 31, 2023 and 2022 and 2021 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 2021-December 31, 2023 2022 2021-Net operating loss carryforwards \$ 79-67, 800 310, 000 \$ 64-79, 915-800, 000 Section 174 4, 929, 000- Other deferred tax assets, net 2, 016, 000 13, 287, 000 5, 213, 000 Subtotal 74, 255, 000 93, 087, 000 70, 128, 000 Valuation allowance (72, 974, 615) (91, 519, 974) (-68, 744, 554) Total deferred tax asset \$ 1, 567-280, 026-385 \$ 1, 383-567, 446-026 The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company's ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. The Company has established a valuation reserve for its deferred income tax assets other than those related to its New Jersey NOLs. At December 31, 2021-2023, after its evaluation of its New Jersey NOLs as discussed more fully below, the Company reduced the valuation reserve and recognized \$ 1. 6-3 million as a deferred income tax asset. Such tax assets are available to be recognized and benefit future periods. As of December 31, 2022-2023, the Company had federal net operating loss carryforwards of approximately \$ 330-307 million, net of net operating losses utilized in prior years of which \$ 225-218 million, if unused, will expire starting in 2023-2024 through 2037. The Federal federal NOLs net operating loss generated for the years ended after December 31, 2018-2017, 2019, 2020, and 2021 of approximately \$ 64-78 million can be carried forward indefinitely. As However, the deduction for net operating losses incurred in tax years beginning after January 1, 2018 is limited to 80 % of annual taxable income. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (" CARES Act ") was enacted in response to the COVID-19 pandemic. The CARES Act provides for economic and cash liquidity stimulus through various means including payroll tax credits, payroll tax deferral, short-term changes in tax deductibility of interest expenses among other things. The Act also permits NOL carryovers and carrybacks to offset 100 % of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80 % of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018 through 2021-2023 to be carried back to each of the five preceding tax years. The Company evaluated the various aspects of the CARES Act and determined that there was no material effect on the Financial Statements. As of December 31, 2022, the Company had state net operating loss carryforwards of approximately \$ 58-44 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2041-2042. F-Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (" R & E ") activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R & E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R & E activities in the US must be amortized over a 5-23 During year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15- year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company's income tax returns for 2019 to 2022, 2021 are still open and in subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions that are expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more- likely- than- not to be sustained upon examination by taxing authorities. As of December 31, 2023, and 2022, there were no unrecognized tax benefits. The Company performed recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year. Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company's ability to utilize these carryforwards. The Company has completed an analyses analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership. Due to the existence of full valuation allowance, limitations under as defined by Section 382 of the Internal Revenue Code that would limit its ability to utilize certain net operating loss and 383 will not impact tax credit carry forwards. The Company determined that it experienced ownership changes, as defined by Section 382, in connection with certain common stock offerings in July 2011, February 2013, June 2013, June 2015, February 2017, June 2017, October 2017, August 2018, February 2020, January 2021 and November 2022. As a result, the utilization of the Company's federal effective tax net operating loss carry forwards generated rate. Further analyses will be performed prior to recognizing the benefits ownership changes are limited. As of any December 31, 2022, the Company has net operating loss carry forwards for U. S. federal and state tax purposes of approximately \$ 325 million, before excluding net operating losses that have been limited as a result of Section 382 limitations. The annual limitation due to Section 382 for or credits net operating loss carry forward utilization is approximately \$ 4.2 million per year for approximately \$ 90 million in net operating loss carry forwards existing at the ownership change occurring in July 2011, approximately \$ 1. 4 million per year for approximately \$ 34 million of additional net operating losses occurring from July 2011 to the ownership change that occurred in February 2013, approximately \$ 1. 5 million per year for approximately \$ 4 million of additional net operating losses occurring from February 2013 to the ownership change that occurred in June 2013, approximately \$ 1. 6 million per year for approximately \$ 40 million of additional net operating losses occurring from June 2013 to the ownership change that occurred in June 2015, approximately \$ 0. 3 million per year for approximately \$ 35 million of additional net operating losses occurring from June 2015 to the ownership change that occurred in February 2017, approximately \$ 0. 3 million per year for approximately \$ 7 million of additional net operating losses occurring from February 2017 to the ownership change that occurred in June 2017, approximately \$ 0. 8 million per year for approximately \$ 5 million of additional net operating losses occurring from June 2017 to the ownership change that occurred in October 2017, approximately \$ 1. 5 million per year for approximately \$ 30 million of additional net operating losses occurring from October 2017 to the ownership change that occurred in August 2018, approximately \$ 0. 8 million per year for approximately \$ 15 million of additional net operating losses occurring from August 2018 to the ownership change that occurred in February 2020 and approximately \$ 2. 0 million per year for approximately \$ 40 million of additional net operating losses occurring from February 2020 to the ownership change that occurred in January 2021 and approximately \$ 28. 0 million per year for approximately \$ 30 million of additional net operating losses occurring from January 2021 to the ownership change that occurred in November 2023.

The utilization of these **the financial statements** net operating loss carry forwards may be further limited if the Company experiences future ownership changes as defined in Section 382 of the Internal Revenue Code. Sale of New Jersey Net Operating Losses Since 2018, the Company has annually submitted applications to sell a portion of the Company's New Jersey NOLs as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. As part of the Technology Business Tax Certificate Program, the Company sold \$ 1. 6-3 million and \$ 1. 5-6 million of its New Jersey NOLs in 2023 and 2022 and 2021, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1. 3 million in 2023 and \$ 1. 6 million in 2022 and \$ 1. 4 million in 2021. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$ 4-0. 9-3 million in net operating losses under this maximum lifetime benefit. F- 24-21

11. STOCKHOLDERS' EQUITY On March 19, 2021, the Company filed with the SEC a \$ 100 million shelf registration statement on Form S- 3 (the " 2021 Registration Statement ") that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock **in an amount up to \$ 100 million**. **This shelf The 2021 registration-Registration Statement** was declared effective on March 30, 2021. **The 2021 Registration Statement was intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. However, as of the date of these financial statements and so long as the Company's public float remains below \$ 75 million, it is subject to limitations with respect to the use of the 2021 Registration Statement and any other shelf registration statement that it files with the SEC pursuant to General Instruction I. B. 6 of Form S- 3 (the " Baby Shelf Limitation "), which limits the amount that the Company can offer to up to one- third of its public float during any trailing 12- month period. The Company would be no longer subject to the Baby Shelf Limitation if its public float exceeds \$ 75 million**. On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company's common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol " IMNN " effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15- for- 1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15- for- 1 reverse stock split. In addition, at the market open on March 1, 2022, the Company's common stock started trading under a new CUSIP number 15117N602 although the Company's ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company's stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment were: • To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock- based acquisitions of new technology and product development candidates. The availability of additional shares of **Common common Stock stock** would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of **Common common Stock stock**; and • To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$ 1. 00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company's **Common common Stock stock** fell below \$ 1. 00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company's **Common common Stock stock** is at least \$ 1. 00 per share for a minimum of ten consecutive business days during the 180- day compliance period. F- 22

Immediately prior to the reverse stock split, the Company had 86, 557, 736 shares of common stock outstanding which consolidated into 5, 770, 516 shares of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company's overall exposure for such payouts consisting of a nominal amount. The amount of the Company's outstanding convertible preferred stock were not affected by the reverse stock split. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 6. 6 million to approximately 0. 4 million and outstanding warrants being reduced from approximately 2. 5 million to approximately 0. 2 million. F- 25

At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market Offering Agreement (the " Agreement ") with H. C. Wainwright & Co., LLC, as sales agent (" Wainwright "), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company's common stock having an aggregate offering price of up to \$ 7, 500, 000. **During 2022 the Company sold 336, 075 shares of stock for net proceeds of \$ 503, 798**. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. **The In 2023, the Company has sold did not sell any shares under the Agreement with Wainwright in the first nine months of 2022. From October 1, 904 2022 through the date of December 31, 142 2022, the Company sold 336, 075 shares of stock for net proceeds of \$ 503, 798. In 2023, the Company has sold 1, 653, 392 shares of stock for net proceeds of \$ 2, 465, 781. 438 656. Capital on Demand/TM Sales Agreement** On December 4, 2018, the Company entered into the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through JonesTrading shares of Common Stock having an aggregate offering price of up to \$ 16. 0 million. During 2021, the Company has sold 0. 5 million shares under the Capital on Demand Agreement, receiving approximately \$ 6. 9 million in gross proceeds under the Capital on Demand Agreement. The Capital on Demand Agreement with JonesTrading was terminated in the first quarter of 2021. January 2021 Registered Direct Offering On January 22, 2021, the Company entered into a Securities Purchase Agreement (the " January 2021 Purchase Agreement ") with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the " January 2021 Offering "), an aggregate of 1, 728, 395 shares of the Company's common stock at an offering price of \$ 20. 25 per share for gross proceeds of approximately \$ 35 million before the deduction of the January 2021 Placement Agents (as defined below) fee and offering expenses. The closing of the January 2021 Offering occurred on January 26, 2021. In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (" AGP, " and together with Brookline Capital Markets, the " January 2021 Placement Agents ") pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7 % of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed \$ 82, 500. March 2021 Registered Direct Offering On March 31, 2021, the Company entered into a Securities Purchase Agreement (the " March 2021 Purchase Agreement ") with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the " March 2021 Offering "), an aggregate of 769, 230 shares of the Company's common stock, at an offering price of \$ 19. 50 per share for gross proceeds of approximately \$ 15 million before the deduction of the placement agents fee and offering expenses. The closing of the offering occurred on April 5, 2021. In connection with the March 2021 Offering, the Company entered into a placement agent agreement (the " March 2021 Placement Agent Agreement ") with AGP, as lead placement agent (together with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Areadia Securities, LLC, serving as co- placement agents, the " March 2021 Placement Agents "), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7 % of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed \$ 82, 500. Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the " Preferred Stock Purchase Agreement ") with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the " Preferred Offerings "), (i) 50, 000 shares of the Company's Series A Convertible Redeemable Preferred Stock, par value \$ 0. 01 per share (the " Series A Preferred Stock "), and (ii) 50, 000 shares of the Company's Series B Convertible Redeemable Preferred Stock, par value \$ 0. 01 per share (the " Series B Preferred Stock " and together with the Series A Preferred Stock, the " Preferred Stock "), in each case at an offering price of \$ 285 per share, representing a 5 % original issue discount to the stated value of \$ 300 per share, for gross proceeds of each Preferred Offering of \$ 14. 25 million, or approximately \$ 28. 50 million in the aggregate for the Preferred Offerings, before the deduction of the Placement Agent's (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 13. 65 per share, into 1, 098, 901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 15. 00 per share, into 1, 000, 000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. F- 26

On March 3, 2022, the Company redeemed for cash at a price equal to 105 % of the \$ 300 stated value per share all of its 50, 000 outstanding shares of Series A Preferred Stock and its 50, 000 Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Imunon's only class of outstanding stock is its common. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the " Placement Agent Agreement ") with AGP pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1, 000, 000 and reimburse the AGP

for certain of their expenses in an amount not to exceed \$ 110,000. April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the " April 2022 Purchase Agreement ") with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the " April 2022 Offering "), an aggregate of 1,328,274 shares of the Company's common stock at an offering price of \$ 5.27 per share for gross proceeds of \$ 7.0 million before the deduction of the April 2022 Placement Agent (as defined below) fees and offering expenses. The closing of the April 2022 Offering occurred on April 8, 2022. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the " April 2022 Placement Agent ") pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5 % of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. **F-23** 12. STOCK- BASED COMPENSATION The Company has long- term compensation plans that permit the granting of equity- based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the " 2018 Plan "). The 2018 Plan, as adopted, permits the granting of 180,000 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing. At the 2019 Annual Stockholders Meeting of the Company held on May 14, 2019, stockholders approved an amendment to the 2018 Plan whereby the Company increased the number of common stock shares available by 80,000 to a total of 260,000 under the 2018 Plan, as amended. At the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 166,667 to a total of 426,667 under the 2018 Plan, as amended. At the 2021 Annual Stockholders Meeting of the Company held on June 10, 2021, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 513,333 to a total of 940,000 under the 2018 Plan, as amended. **At the 2023 Annual Stockholders Meeting of the Company held on June 14, 2023, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 1,030,000 to a total of 1,970,000 under the 2018 Plan, as amended.** The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100 % of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10 % of the outstanding stock of Imunon must be at least 110 % of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. **F-27** As of December 31, ~~2022~~ **2023**, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the " Inducement Option Grants ") to purchase a total of ~~204,294~~ **501,751** shares of Imunon common stock and (ii) inducement restricted stock awards (the " Inducement Stock Grants ") totaling ~~69,911~~ **250,350** shares of Imunon common stock. Each award has a grant date of the date of grant. Each Inducement Option Grant has a weighted exercise price of \$ 1. ~~76~~ **59** per share. Each Inducement Option Grant vests over three years, with one- third vesting on the one- year anniversary of the employee's first day of employment with the Company and one- third vesting on the second and third anniversaries thereafter, subject to the new employee's continued service relationship with the Company on each such date. Each Inducement Option Grant has a ten- year term and is subject to the terms and conditions of the applicable stock option agreement. Each of Inducement Stock Grant vested on the one- year anniversary of the employee's first day of employment with the Company is subject to the new employee's continued service relationship with the Company through such date and is subject to the terms and conditions of the applicable restricted stock agreement. As of December 31, ~~2022~~ **2023**, there were a total of ~~945,197~~ **975,073** shares of Imunon common stock reserved for issuance under the 2018 Plan, which were comprised of ~~556,768~~ **419,731** shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and ~~388,195~~ **406,342** shares of Imunon common stock available for future issuance under the 2018 Plan. As of December 31, ~~2022~~ **2023**, there are a total of ~~263,294~~ **751** shares of Imunon common stock subject to outstanding inducement awards. Total compensation cost related to stock options and restricted stock awards was approximately \$ ~~0.8 million and \$ 2.7 million~~ **and \$ 3.8 million** during ~~2023 and 2022~~ **and 2021**, respectively. Of these amounts, \$ 0. ~~2 million and \$ 0.9 million~~ **and \$ 1.4 million** were charged to research and development expenses during ~~2023 and 2022~~ **and 2021**, respectively, and \$ ~~0.6 million~~ **and \$ 1.8 million** and \$ ~~2.4 million~~ **and \$ 2.4 million** were charged to general and administrative expenses during ~~2023 and 2022~~ **and 2021**, respectively. **F-24** A summary of stock option awards as of December 31, ~~2022~~ **2023** and changes during the two- year period ended December 31, ~~2022~~ **2023** is presented below: SUMMARY OF STOCK ~~OPTION~~ **STOCK** ~~OPTION~~ **STOCK** Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, ~~2021~~ **2022** ~~308,313~~ **41** ~~55~~ **Options granted 148,016** ~~\$ 32.09~~ **Options exercised (500)** ~~\$ 9.45~~ **Options canceled or expired (14,404)** ~~\$ 38.23~~ **Outstanding at December 31, 2021** ~~441,425~~ **\$ 38.50** ~~Options granted 716,156~~ ~~\$ 2.72~~ **Options canceled or expired (397,361)** ~~\$ 39.06~~ **Outstanding at December 31, 2022** ~~760,220~~ **\$ 4.55** **Options granted 432,500** ~~\$ 1.23~~ **Options canceled or expired (129,238)** ~~\$ 9.25~~ **Outstanding at December 31, 2023** ~~1,063,482~~ **\$ 2.61** ~~\$ 8.8~~ **\$ -** Exercisable at December 31, ~~2022~~ **2023** ~~204,453~~ ~~935,766~~ ~~\$ 3.64~~ ~~\$ 5.07~~ ~~\$ 8.9~~ **F-28** A summary of the status of the Company's non- vested restricted stock awards as of December 31, ~~2022~~ **2023** and changes during the two- year period ended December 31, ~~2022~~ **2023**, is presented below: SUMMARY OF NON- VESTED RESTRICTED STOCK ~~AWARDS~~ **RESTRICTED** ~~AWARDS~~ **RESTRICTED** Stock Number Outstanding Weighted Average Grant Date Fair Value Non- vested stock awards outstanding at January 1, ~~2021~~ **2022** ~~83,481~~ ~~\$ 1.26~~ **Granted 69,650** ~~\$ 1.92~~ **Vested and issued (1,381)** ~~\$ 12.04~~ **Forfeited (100)** ~~\$ 9.45~~ **Granted 1,464** ~~\$ 13.48~~ **Forfeited (66)** ~~\$ 33.00~~ **Non-vested stock awards outstanding at December 31, 2021 ~~1,481~~ ~~\$ 12.36~~ **Granted 69,650** ~~\$ 1.92~~ **Granted 22,100** ~~\$ 0.92~~ **Vested and issued (59,450)** ~~\$ 1.38~~ **1,91** ~~Forfeited (200)~~ ~~\$ 12.4~~ ~~60~~ ~~04~~ ~~Forfeited (100)~~ ~~\$ 9.45~~ **Non- vested stock awards outstanding at December 31, 2022 ~~2023~~ ~~69,321~~ ~~650,100~~ ~~\$ 1.92~~ ~~23~~ A summary of stock options outstanding at December 31, ~~2022~~ **2023** by price range is as follows: SUMMARY OF STOCK ~~OPTION~~ **STOCK** ~~OPTION~~ **STOCK** Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to \$ ~~1.95~~ ~~689~~ ~~113~~ ~~9.1~~ ~~\$ 1.74~~ ~~315~~ ~~867~~ ~~8.8~~ ~~\$ 1.71~~ ~~1.96~~ ~~\$ 10.00~~ ~~709~~ ~~347~~ ~~952~~ ~~9~~ ~~975~~ ~~8.4~~ ~~41~~ ~~\$ 2.78~~ ~~166~~ ~~301~~ ~~9.33~~ ~~\$ 3.27~~ ~~11~~ ~~113~~ ~~936~~ ~~8.2~~ ~~\$ 10.4~~ ~~63~~ ~~01~~ ~~\$ 25.00~~ ~~10,500~~ ~~8.08~~ ~~\$ 18.42~~ ~~5,597~~ ~~7.82~~ ~~\$ 18.54~~ ~~Above \$ 10.01~~ ~~26,394~~ ~~6.3~~ ~~\$ 23.69~~ ~~23,963~~ ~~6.1~~ ~~\$ 24.29~~ ~~1,063,482~~ ~~453,766~~ ~~F-25~~ ~~01~~ ~~39~~ ~~9,768~~ ~~6.67~~ ~~\$ 32.43~~ ~~30,037~~ ~~6.52~~ ~~\$ 33.62~~ ~~760,220~~ ~~201,935~~ The fair values of stock options granted were estimated at the date of grant using the Black- Scholes option pricing model. The Black- Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon's stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black- Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, ~~2023~~ ~~2022~~ ~~2021~~ Risk- free interest rate ~~3.39 % to 4.81 %~~ ~~1.74 % to 3.97 %~~ ~~1.54 % to 1.74 %~~ Expected volatility 100.0 % to 113. ~~9~~ ~~6~~ ~~%~~ ~~106~~ ~~100.8~~ ~~0~~ ~~%~~ to 113. ~~2~~ ~~9~~ ~~%~~ Expected life (in years) 7.5 to 10.0 7.5 to 10.0 Expected dividend yield 0.0 % 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company's stock price. As of December 31, ~~2022~~ **2023**, there was \$ 0. ~~7~~ ~~4~~ ~~million~~ of total unrecognized compensation cost related to non- vested stock- based compensation arrangements. That cost is expected to be recognized over a weighted- average period of ~~2~~ ~~1~~ ~~.~~ ~~8~~ ~~years~~. 13. EARN- OUT MILESTONE LIABILITY The total aggregate purchase price for the EGEN Acquisition included potential future ~~Earn-earn~~ ~~out~~ ~~Payments~~ ~~payments~~ contingent upon achievement of certain milestones. The difference between the aggregate \$ 30.4 million in future ~~Earn-earn~~ ~~out~~ ~~Payments~~ ~~payments~~ and the \$ 13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk- adjusted assessment of each milestone (10 % to 67 %) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). The earn- out milestone liability is fair valued at the end of each quarter and any change in their value will be recognized in the Financial Statements. On March 28, 2019, the Company and EGWU, Inc., entered into the Amended Asset Purchase Agreement. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of \$ 12.4 million has been modified. The Company had the option to make the payment upon achievement of the milestones as follows: a) \$ 7.0 million in cash within 10 business days of achieving the milestone; or b) \$ 12.4 million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. **F-At December 31, 2022, the Company wrote off the earn- out milestone liability as a result of the requirements not being achieved and recognized a non- cash gain of \$ 5.4 million during 2022 as a result of the change in the fair value of the earn- out milestone liability. The Company fair value of the milestone liability is zero at December 31, 2023.** The following is a summary of the changes in the earn- out milestone liability for ~~2021~~ ~~and~~ ~~2022~~: SCHEDULE OF CHANGES IN EARN- OUT MILESTONE ~~LIABILITY~~ ~~Balance~~ ~~LIABILITY~~ ~~Balance~~ at January 1, ~~2021~~ ~~2022~~ ~~\$ 7,018,000~~ ~~Non- cash loss from the adjustment for the change in fair value included in 2021 net loss (1,622,000)~~ ~~Balance at December 31, 2021~~ ~~5,396,000~~ ~~Non- cash gain from the adjustment for the change in fair value included in 2022 net loss (5,396,000)~~ ~~Balance at December 31, 2022~~ ~~\$ -~~ **F-26** 14. WARRANTS Following is a summary of all warrant activity for the two years ended December 31, ~~2022~~ **2023**: SUMMARY OF WARRANT ~~ACTIVITY~~ ~~Warrants~~ ~~ACTIVITY~~ ~~Warrants~~****

Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2021-2022 256,903 \$ 20.10 Warrants exercised during 2021 (Note 11) (81,111) \$ 18.60 Warrants outstanding and exercisable at December 31, 2021-175,792 \$ 20.96 Warrants expired during 2022 (7,273) \$ 48.30 Warrants outstanding and exercisable at December 31, 2022 168,519 ~~\$ 19.78~~ **Warrants expired during 2023 (8,459) \$ 37.29 Warrants outstanding and exercisable at December 31, 2023 160,060 \$ 18.86** Aggregate intrinsic value of outstanding warrants at December 31, 2022-2023 \$ -0- Weighted average remaining contractual terms (years) 3-2. ~~2.0~~ **Warrants to exercise 4,059 shares of common stock at an exercise price of \$ 31.05 per share expired on January 11, 2023.** In connection with the February 2020 Registered Direct financing (see Note 11), the Company issued warrants to purchase 213,333 shares of common stock in February 2020 of which 81,111 of these were exercised during 2021. In connection with the Horizon Credit Agreement Amendment, the Company cancelled warrants to purchase 6,337 shares of common stock and issued warrants to purchase 16,501 shares of common stock in August 2020. Pursuant to a consulting agreement dated September 21, 2020, the Company issued warrants to purchase 5,000 shares of common stock vesting immediately and having a 4-year term. The shares underlying these warrants are unregistered and have a strike price of \$ 11.85 per share. The Company fair valued these warrants at \$ 9.00 per share, recognizing \$ 45,000 as professional fee expense.

15. IMUNON EMPLOYEE BENEFIT PLANS Imunon maintains a defined-contribution plan under Section 401 (k) of the Internal Revenue Code. The plan covers substantially all employees over the age of twenty-one. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. The Company makes a matching contribution up to a maximum of 3% of an employee's annual salary. The Company's total matching contributions for the year ended December 31, 2021-2023 was and 2022 were \$ 142,000 and \$ 117,000 and \$ 107,000, respectively. **The 16. LEASES Lawrenceville, New Jersey Lease In August 2023, the Company renewed its Lawrenceville office** also provided a discretionary contribution totaling \$ 172,000 in 2021. The discretionary contribution represented 5% of each eligible participant's annual salary in 2021 and was paid out in January of the following year. F-30 16. LEASES In 2011, the Company executed a lease (the "Lease") with Brandywine Operating Partnership, L.P. (Brandywine), a Delaware limited partnership, for a ~~24-~~ **10,870-square foot premises located in Lawrenceville, New Jersey and relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland.** The Lease had an initial term of 66 months ~~month~~. In late 2015, Lenox Drive Office Park LLC, purchased the real estate and office building and assumed the Lease. This Lease was set to expire on April 30, 2017. In April 2017, the Company and the landlord amended the Lease effective May 1, 2017. The 1st Lease Amendment extended the term of the agreement for an additional 64 months, reduced the premises to 7,565 square feet, reduced the monthly rent and provided four months free rent. The monthly rent ranged from approximately \$ 18,900 in the first year to approximately \$ 20,500 in the final year of the 1st Lease Amendment. Effective January 9, 2019, the Company amended the terms of the 1st Lease Amendment to increase the size of the premises by 2,285 square feet to 9,850 square feet and extended the lease term by one year to September 1, 2023. The Company had a one-time option to cancel the lease after 40 months as part of the 1st Lease Amendment, which was extended with the 2nd Lease Amendment. The option to cancel the lease expired on August 31, 2020. The monthly rent **payments of under the 2nd Lease Amendment ranges from approximately \$ 25-22,983 035 in the first year to approximately \$ 27-23,394 088 in the final year of the lease.** In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11,500 square foot premises located in Huntsville, Alabama. In January 2018, the Company and the Huntsville landlord entered into a new 60-month lease **Lease which reduced the premises to 9,049 square feet with rent payments of approximately \$ 18,100 per month.** On June 9, 2021 and, as amended on July 7, 2021, the Company and the Huntsville landlord entered into a 22-month lease for an additional 2,197 square foot premises with rent payments of approximately \$ 5,500 per month. In January 2023, the Company renewed Huntsville for a 60-month lease agreement for 11,420 square feet with rent payments of approximately \$ 28,550. The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, 2022-2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2023-2024 \$ 238-626, 609-323 2024-2025 543, 009 2026 362, 976 2027 370, 236 2028 and thereafter-**Thereafter -30,903** Subtotal future lease payments 238-1, 609-933, 447 Less imputed interest (7-308, 860-733) Total lease liabilities \$ 230-1, 749-624, 714 Weighted average remaining life 0-3, 61-5 years Weighted average discount rate 9.98% **For 2023, operating lease expense was \$ 646,633 and cash paid for operating leases included in operating cash flows was \$ 644,593.** For 2022, operating lease expense was \$ 587,744 and cash paid for operating leases included in operating cash flows was \$ 601,495. For 2021, operating lease expense was \$ 560,513 and cash paid for operating leases included in operating cash flows was \$ 568,269. Amortization expense was approximately \$ 472,000 and \$ 535,000 and \$ 573,000 for the years ended December 31, 2023 and 2022 and 2021, respectively. F-34-27

17. COMMITMENTS AND CONTINGENCIES On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the "Spar Individual Defendants") in the U. S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff ~~alleges~~ **alleges** that the Company and Spar Individual Defendants made false and misleading statements regarding one of the Company's drug candidates, ThermoDox®, and ~~brings brought~~ **brings brought** claims for damages under Section 10 (b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Rule 10b-5 promulgated thereunder against all ~~Defendants-defendants~~ **Defendants-defendants**, and under Section 20 (a) of the Exchange Act of 1934 against the Spar Individual Defendants. ~~The Company believes that the case is without merit and intends to defend it vigorously.~~ **At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined.** On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted **the Plaintiff plaintiff** leave to file an amended complaint within 30 days. **The Plaintiff plaintiff** did not file an amended complaint within the 30-day deadline. **In September 2023, the U. S. District Court issued and an Order for the Company and Spar Individual Defendants therefore intend to seek dismissal Dismissal with without prejudice of the action.**

18. TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS On May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. ("Hisun") for the production of ThermoDox® in **mainland China, Hong Kong and Macau** (the "China territory"). In accordance with the terms of the agreement, Hisun ~~is~~ **will be** responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Imunon consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Imunon ~~will is obligated to~~ **will be obligated to** repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to meet certain performance requirements under the agreement. The agreement ~~will was~~ **will be** initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, **the agreement provided that Hisun will would** collaborate with Imunon around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (CHINA FDA). On January 18, 2013, the Company entered into a technology development contract with Hisun, pursuant to which Hisun paid ~~it Imunon~~ **Imunon** a non-refundable research and development fee of \$ 5 million to support development of ThermoDox® in **mainland China, Hong Kong and Macau** (the China territory). Following the Company's announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Imunon and Hisun ~~have~~ **have** agreed that the Technology Development Contract entered into on January 18, 2013 ~~will would~~ **will be** remain in effect while the parties ~~continue~~ **continue** ~~continued~~ **continued** to collaborate and ~~are evaluating evaluate~~ **are evaluating evaluate** the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the HCC clinical indication and other activities to further the development of ThermoDox® for the Greater China market. The \$ 5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 ~~was has been~~ **was has been** recorded as deferred revenue and was amortized over the 10-year term of the agreement, until such time as the parties ~~would~~ **would** find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT Study ~~study data~~ **study data**. **The Hisun agreement has expired.**

19. RELATED PARTY TRANSACTION On November 16, 2022 the Company entered into a Convertible ~~convertible~~ **convertible** Note ~~note~~ **note** Purchase ~~purchase~~ **purchase** Agreement ~~agreement~~ **agreement** with Transomic Technologies, Inc. ("Transomic") whereby the Company purchased \$ 375,000 of convertible notes secured by certain assets held by Transomic and warrants. **Imunon purchased product from Transomic** The Notes, which are included in prepaid expense and other current assets bear interest at 5% per annum, with interest and principal due on December 31, 2026. The notes are classified as available-for ~~research~~ **research** sale. The warrants are exercisable upon closing and ~~development~~ **development** purposes - primarily delivery vectors expire 36 months from the date of issuance or for its vaccine program November 22, 2025. As a result of Mr. Tardugno ~~this investment in Transomic, Imunon's~~ **this investment in Transomic, Imunon's** executive chairman, Mr. Michael Tardugno, was ~~appointment-~~ **appointed-** appointed to the Board of ~~Directors of~~ **Directors of** Transomic, ~~the~~ **the**. The Company ~~disclosed~~ **disclosed** is disclosing the notes receivable as a related party transaction. **In**

20. SUBSEQUENT EVENTS The Company has evaluated its subsequent events from December 31, 2022-2023 **Transomic filed** through the date these consolidated financial statements were issued, determining all subsequent events have been disclosed. Exhibit 10-25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this "Agreement") is dated as of the Effective Date between SILICON VALLEY BANK, a **formal** California corporation ("Bank"), and the borrower listed on Schedule I hereto ("Borrower"). The parties agree as follows: LOAN AND TERMS OF PAYMENT 1.1 Term Loan. (a) Availability. Subject to the terms and conditions of this Agreement, upon Borrower's request, during the Draw Period, Bank shall make term loan advances not exceeding the Term Loan Availability Amount (each such advance is referred to herein as a "Term Loan Advance" and, collectively, as the "Term Loan Advances"). Borrower may request Term Loan Advances as set forth on Schedule I hereto. (b) Repayment. Borrower shall repay each Term Loan Advance as set forth in Schedule I hereto. All outstanding principal and accrued and unpaid interest under each Term Loan Advance, and all other outstanding Obligations with respect to such Term Loan Advance, are due and payable in full on the Term Loan Maturity Date. (c) Permitted Prepayment.

Borrower shall have the option to prepay all or any portion of the Term Loan Advances, provided Borrower (i) delivers written notice to Bank of its election to prepay all or a portion of the Term Loan Advances, which such prepayment portion shall be an aggregate principal amount of at least \$ 5,000,000.00, at least 10 days prior to such prepayment along with a notice of the portion of the principal amount being prepaid, and (ii) pays, on the date of such prepayment (A) the outstanding principal plus accrued and unpaid interest with respect to the portion of the Term Loan Advances, (B) the Prepayment Fee with respect to the portion of the Term Loan Advances being prepaid, (C) the Final Payment with respect to the portion of the Term Loan Advances being prepaid, and (D) all other sums, if any, that shall have become due and payable with respect to the portion of the Term Loan Advances being prepaid, including interest at the Default Rate with respect to any past due amounts. (d) Mandatory Prepayment upon an Acceleration. If the Term Loan Advances are accelerated by Bank following the occurrence and during the continuance of an Event of Default, Borrower shall immediately pay to Bank an amount equal to the sum of (i) all outstanding principal plus accrued and unpaid interest with respect to the Term Loan Advances, (ii) the Prepayment Fee, (iii) the Final Payment, and (iv) all other sums, if any, that shall have become due and payable with respect to the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. 1.2 Payment of Interest on the Credit Extensions. (a) Interest Payments. Interest on the principal amount of each Term Loan Advance is payable as set forth on Schedule I hereto. (b) Interest Rate. (i) Subject to Section 1.2 (c), the outstanding principal amount of any Term Loan Advance shall accrue interest as set forth on Schedule I hereto. (ii) All-In Rate. Notwithstanding any terms in this Agreement to the contrary, if at any time the interest rate applicable to any Obligations is less than 0.0%, such interest rate shall be deemed to be 0.0% for all purposes of this Agreement. (c) Default Rate. Immediately upon the occurrence and during the continuance of an Event of Default, the outstanding Obligations shall bear interest at a rate per annum which is 3.0% above the rate that is otherwise applicable thereto (the "Default Rate") unless Bank otherwise elects, in its sole discretion, to impose a lesser increase or no increase. Fees and expenses which are required to be paid by Borrower pursuant to the Loan Documents (including, without limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate equal to the highest rate applicable to the Obligations. Payment or acceptance of the increased interest rate provided in this Section 1.2 (c) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Bank. (d) Adjustment to Interest Rate. Each change in the interest rate applicable to any amounts payable under the Loan Documents based on changes to the Prime Rate shall be effective on the effective date of any change to the Prime Rate and to the extent of such change. (e) Interest Computation. Interest shall be computed as set forth on Schedule I hereto. In computing interest, the date of the making of any Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension. 1.3 Fees. Borrower shall pay to Bank: (a) Prepayment Fee. The Prepayment Fee, when due hereunder, which shall be fully earned and non-refundable as of such date; (b) Final Payment. The Final Payment, when due hereunder, which shall be fully earned and non-refundable as of such date; and (c) Bank Expenses. All Bank Expenses incurred through and after the Effective Date, when due (or, if no stated due date, upon demand by Bank). Unless otherwise provided in this Agreement or in a separate writing by Bank, Borrower shall not be entitled to any credit, rebate, or repayment of any fees earned by Bank pursuant to this Agreement, notwithstanding any termination of this Agreement or the suspension or termination of Bank's obligation to make loans and advances hereunder. Bank may deduct amounts owing by Borrower under the clauses of this Section 1.3 pursuant to the terms of Section 1.4 (e). Bank shall provide Borrower written notice of deductions made pursuant to the terms of the clauses of this Section 1.3. 1.4 Payments; Application of Payments; Debit of Accounts. (a) All payments (including prepayments) to be made by Borrower under any Loan Document shall be made in immediately available funds in Dollars, without setoff, counterclaim, or deduction, before 12:00 p. m. Eastern time on the date when due. Payments of principal and / or interest received after 12:00 p. m. Eastern time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment shall be due the next Business Day, and additional fees or interest, as applicable, shall continue to accrue until paid. (b) Bank has the right to determine in its commercially reasonable discretion the order and manner in which all payments with respect to the Obligations may be applied. Borrower shall have no right to specify the order or the accounts to which Bank shall allocate or apply any payments required to be made by Borrower to Bank or otherwise received by Bank under this Agreement when any such allocation or application is not specified elsewhere in this Agreement. (c) Bank may debit any of Borrower's deposit accounts maintained with Bank, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes Bank when due under the Loan Documents. These debits shall not constitute a set-off. 1.5 Change in Circumstances. (a) Increased Costs. If any Change in Law shall: (i) impose, modify, or deem applicable any reserve, special deposit, compulsory loan, insurance charge, or similar requirement against assets of, deposits with or for the account of, or advances, loans, or other credit extended or participated in by, Bank, (ii) subject Bank to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes, and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitment, or other obligations, or its deposits, reserves, other liabilities, or capital attributable thereto, or (iii) impose on Bank any other condition, cost, or expense (other than Taxes) affecting this Agreement or Credit Extensions made by Bank, and the result of any of the foregoing shall be to increase the cost to Bank of making, converting to, continuing, or maintaining any Credit Extension (or of maintaining its obligation to make any such Credit Extension); or to reduce the amount of any sum received or receivable by Bank hereunder (whether of principal, interest, or any other amount) then, upon written request of Bank, Borrower shall promptly pay to Bank such additional amount or amounts as will compensate Bank for such additional costs incurred or reduction suffered. (b) Capital Requirements. If Bank determines that any Change in Law affecting Bank regarding capital or liquidity requirements, has or would have the effect of reducing the rate of return on Bank's capital as a consequence of this Agreement, any term loan facility, or the Credit Extensions made by Bank to a level below that which Bank could have achieved but for such Change in Law (taking into consideration Bank's policies with respect to capital adequacy and liquidity), then from time to time upon written request of Bank, Borrower shall promptly pay to Bank such additional amount or amounts as will compensate Bank for any such reduction suffered. (c) Delay in Requests. Failure or delay on the part of Bank to demand compensation pursuant to this Section 1.5 shall not constitute a waiver of Bank's right to demand such compensation; provided that Borrower shall not be required to compensate Bank pursuant to subsection (a) for any increased costs incurred or reductions suffered more than 9 months prior to the date that Bank notifies Borrower of the Change in Law giving rise to such increased costs or reductions (except that if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 9-month period shall be extended to include the period of retroactive effect). 1.6 Taxes. (a) Payments Free of Taxes. Any and all payments by or on account of any obligation of Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by Applicable Law. If any Applicable Law (as determined in the good-faith discretion of Borrower) requires the deduction or withholding of any Tax from any such payment by Borrower, then (i) Borrower shall be entitled to make such deduction or withholding, (ii) Borrower shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and (iii) if such Tax is an Indemnified Tax, the sum payable by Borrower shall be increased as necessary so that, after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 1.6), Bank receives an amount equal to the sum it would have received had no such deduction or withholding been made. (b) Payment of Other Taxes by Borrower. Without limiting the provisions of subsection (a) above, Borrower shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with Applicable Law. (c) Tax Indemnification. Without limiting the provisions of subsections (a) and (b) above, Borrower shall, and does hereby, indemnify Bank, within 30 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 1.6) payable or paid by Bank or required to be withheld or deducted from a payment to Bank and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of **dissolution** such payment or liability delivered to Borrower by Bank shall be conclusive absent manifest error. (d) Evidence of Payments. As soon as practicable after any payment of Taxes by Borrower to a Governmental Authority pursuant to this Section 1.6, Borrower shall deliver to Bank a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment, or other evidence of such payment reasonably satisfactory to Bank. (e) Status of Bank. If Bank (including any assignee or successor) is entitled to an exemption from or reduction of withholding tax with respect to payments made under any Loan Document, Bank shall deliver to Borrower, at the time or times reasonably requested by Borrower, such properly completed and executed documentation reasonably requested by Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, Bank, if reasonably requested by Borrower, shall deliver such other documentation prescribed by Applicable Law or reasonably requested by Borrower as will enable Borrower to determine whether or not Bank is subject to backup withholding or information reporting requirements. Without limiting the generality of the foregoing, Bank shall deliver whichever of IRS Form W-9, IRS Form W-8BEN-E, IRS Form W-8ECI or W-8IMY is applicable, as well as any applicable supporting documentation or certifications. 1.7 Procedures for Borrowing. (a) Term Loan Advances. Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan Advance set forth in this Agreement (which must be satisfied no later than 12:00 p. m. Eastern time on the applicable Funding Date), to obtain a Term Loan Advance, Borrower (via an individual duly authorized by an Administrator) shall notify Bank (which notice shall be irrevocable) by 12:00 p. m. Eastern time at least 2 Business Days prior to the Funding Date of the Term Loan Advance. Such notice shall be made by electronic mail or by telephone and, together with any such notification, Borrower shall deliver to Bank by electronic mail a completed Payment / Advance Form executed by an Authorized Signer and such other reports and information as Bank may reasonably request. Bank may rely on any telephone notice given by a person whom Bank believes is an Authorized

Signer. Borrower will indemnify Bank for any loss Bank suffers due to such belief or reliance. Bank shall have received satisfactory evidence that the Board has approved that such Authorized Signer may provide such notices and request such Term Loan Advance (which requirement may be deemed satisfied by the prior delivery of Borrowing Resolutions or a secretary's certificate that certifies as to such Board approval). (b) Bank shall credit proceeds of a Credit Extension to the Designated Deposit Account. Bank may make Advances and Term Loan Advances under this Agreement based on instructions from an Authorized Signer or without instructions if such Advances or Term Loan Advances are necessary to meet Obligations which have become due. CONDITIONS OF CREDIT EXTENSIONS

2.1 Conditions Precedent to Initial Credit Extension. Bank's obligation to make the initial Credit Extension is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, such documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate, including, without limitation: (a) duly executed Loan Documents; (b) the Operating Documents of Borrower and long-form good standing certificates of Borrower certified by the Secretary of State of the State of Delaware and the Secretary of State of the State of New Jersey, in which Borrower is qualified to conduct business, in each case as of a date no earlier than 30 days prior to the Effective Date; (c) certificate duly executed by a Responsible Officer or secretary of Borrower with respect to Borrower's (i) Operating Documents and (ii) Borrowing Resolutions; (d) duly executed payoff letter from Horizon Finance; (e) certified copies, dated as of a recent date, of searches for financing statements filed in the central filing office of the State of Delaware, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released; (f) the Cash Collateral Account shall have been opened and the Minimum Threshold Amount shall have been deposited therein; (g) evidence that (i) the Liens securing Indebtedness owed by Borrower to Horizon Finance will be terminated and (ii) the documents and / or filings evidencing the perfection of such Liens, including without limitation any financing statements and / or control agreements, have or will, concurrently with the initial Credit Extension, be terminated; (h) duly executed Perfection Certificate of Borrower; (i) duly executed Cash Pledge Agreement, in form and substance acceptable to Bank; (j) evidence satisfactory to Bank that the insurance policies required by Section 5.6 hereof are in full force and effect; and (k) payment of the fees and Bank Expenses then due as specified in Section 1.3 hereof.

2.2 Conditions Precedent to All Credit Extensions. Bank's obligation to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent: (a) receipt of Borrower's Credit Extension request and the related materials and documents as required by and in accordance with Section 1.7; (b) the representations and warranties in this Agreement shall be true and correct in all material respects as of the date of any Credit Extension request and as of the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true and correct in all material respects as of such date, and no Default or Event of Default shall have occurred and be continuing or result from the Credit Extension. Each Credit Extension is Borrower's representation and warranty on that date that the representations and warranties in this Agreement remain true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true and correct in all material respects as of such date; and (c) a Material Adverse Change shall not have occurred and be continuing.

2.3 Covenant to Deliver. Borrower shall deliver to Bank each item required to be delivered to Bank under this Agreement as a condition precedent to any Credit Extension. A Credit Extension made prior to the receipt by Bank of any such item shall not constitute a waiver by Bank of Borrower's obligation to deliver such item, and the making of any Credit Extension in the absence of a required item shall be in Bank's sole discretion.

CREATION OF SECURITY INTEREST

3.1 Grant of Security Interest. (a) Borrower hereby grants Bank, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. (b) The Collateral may also be subject to Permitted Liens.

3.2 Authorization to File Financing Statements. Borrower hereby authorizes Bank to file financing statements, without notice to Borrower, with all jurisdictions deemed necessary or appropriate by Bank to perfect or protect Bank's interest or rights hereunder, including a notice that any disposition of the Collateral (other than permitted herein), by either Borrower or any other Person, shall be deemed to violate the rights of Bank under the Code. Upon written request by Borrower, Bank shall provide Borrower with filed copies of all financing statements.

3.3 Termination. If this Agreement is terminated, Bank's Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as Bank's obligation to make Credit Extensions has terminated, the security interest of Bank in the Collateral shall automatically terminate without any further action by any Person and all rights therein shall revert to Borrower; and Bank shall, at Borrower's sole cost and expense, provide payoff and release documentation to evidence the termination of its security interest in the Collateral. In the event (a) all Obligations (other than inchoate indemnity obligations), are satisfied in full, and (b) this Agreement is terminated, Bank shall terminate the security interest granted herein.

REPRESENTATIONS AND WARRANTIES Borrower represents and warrants as follows:

4.1 Due Organization, Authorization, Power and Authority. (a) Borrower and each of its Subsidiaries are each duly existing and in good standing as a Registered Organization in their respective jurisdiction of formation and are qualified and licensed to do business and are in good standing in any jurisdiction in which the conduct of their respective business or their ownership of property requires that they be qualified, except where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower's business or operations. (b) All information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is true and correct (it being understood and agreed that Borrower may from time to time update certain information in the Perfection Certificate after the Effective Date to the extent permitted by one or more specific provisions in this Agreement and the Perfection Certificate shall be deemed to be updated to the extent such notice is provided to Bank of such permitted update). (c) The execution, delivery, and performance by Borrower and each of its Subsidiaries of the Loan Documents to which they are parties have been duly authorized, and do not (i) conflict with any of Borrower's or any such Subsidiary's organizational documents, (ii) contravene, conflict with, constitute a default under, or violate any material Applicable Law, (iii) contravene, conflict with, or violate any applicable order, writ, judgment, injunction, decree, determination, or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) and except as could not reasonably be expected to have a material adverse effect on Borrower's business or operations, or (v) conflict with, contravene, constitute a default or breach under, or result in or permit the termination or acceleration of, any material agreement by which Borrower or any of its Subsidiaries is bound. Neither Borrower nor any of the Guarantors are in default under any agreement to which it is a party or by which it is bound in which the default could reasonably be expected to have a material adverse effect on Borrower's or any of the Guarantors' business or operations.

4.2 Collateral. (a) The security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral (subject to Permitted Liens). Borrower has good title to, rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens except Permitted Liens. (b) Borrower has no Collateral Accounts at or with any bank or financial institution other than Bank or Bank's Affiliates except for the Collateral Accounts described in the Perfection Certificate delivered to Bank in connection herewith. (c) The Collateral is not in the possession of any third-party bailee (such as a warehouse) except as otherwise provided in the Perfection Certificate or as permitted pursuant to Section 6.2. None of the components of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate or as permitted pursuant to Section 6.2.

4.3 Litigation. Other than as set forth in the Perfection Certificate or as disclosed to Bank pursuant to Section 5.3 (h), there are no actions, investigations, or proceedings pending or, to the knowledge of any Responsible Officer, threatened in writing by or against Borrower or any of its Subsidiaries involving more than, individually or in the aggregate, \$150,000.00.

4.4 Financial Statements; Financial Condition. All consolidated financial statements for Borrower and any of its Subsidiaries delivered to Bank by submission to the Financial Statement Repository or otherwise submitted to Bank fairly present in all material respects Borrower's consolidated financial condition and Borrower's consolidated results of operations for the periods covered thereby, subject, in the case of unaudited financial statements, to normal year-end adjustments and the absence of footnote disclosures. There has not been any material deterioration in Borrower's consolidated financial condition since the date of the most recent financial statements submitted to the Financial Statement Repository or otherwise submitted to Bank.

4.5 Solvency. The fair salable value of Borrower's consolidated assets (including goodwill minus disposition costs) exceeds the fair value of Borrower's liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower and each of its Subsidiaries are able to pay their debts on a consolidated basis (including trade debts) as they mature.

4.6 Regulatory Compliance. Borrower is not an "investment company" or a company "controlled" by an "investment company" under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T, and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries (a) have complied in all material respects with all Applicable Law, and (b) have not violated any Applicable Law, the violation of which could reasonably be expected to have a material adverse effect on Borrower's business or operations. Borrower and each of its Subsidiaries have duly complied with, and their respective facilities, business, assets, property, leaseholds, real property, and Equipment are in compliance with, Environmental Laws, except where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower's business or operations; there have been no outstanding citations, notices, or orders of non-compliance issued to Borrower or any of its Subsidiaries or relating to their

respective facilities, businesses, assets, property, leaseholds, real property, or Equipment under such Environmental Laws, except where it could not reasonably be expected to have a material adverse effect on Borrower's business or operations. Borrower and each of its Subsidiaries have obtained all consents, approvals, and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, except where the failure to obtain or make or file the same would not reasonably be expected to have a material adverse effect on Borrower's business or operations.

4.7 Subsidiaries; Investments. Borrower does not own any stock, partnership, or other ownership interest or other equity securities except for Permitted Investments.

4.8 Tax Returns and Payments; Pension Contributions. (a) Borrower and each of its Subsidiaries have timely filed, or submitted extensions for, all required tax returns and reports, and Borrower and each of its Subsidiaries have timely paid all foreign, federal, state, and local taxes, assessments, deposits, and contributions owed by Borrower and each of its Subsidiaries except (a) to the extent such taxes are being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, so long as such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made therefor, or (b) if such taxes, assessments, deposits, and contributions do not, individually or in the aggregate, exceed \$ 50,000.00. Borrower is unaware of any claims or adjustments proposed for any of Borrower's or any of its Subsidiary's prior tax years which could result in additional taxes becoming due and payable by Borrower or any of its Subsidiaries in excess of \$ 50,000.00 in the aggregate. (b) Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing, and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries has withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.

4.9 Full Disclosure. No written representation, warranty, or other statement of Borrower or any of its Subsidiaries in any report, certificate, or written statement submitted to the Financial Statement Repository or otherwise submitted to Bank, as of the date such representation, warranty, or other statement was made, taken together with all such reports, certificates, and written statements submitted to the Financial Statement Repository or otherwise submitted to Bank, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the reports, certificates, or written statements not misleading in light of the circumstances under which they were made (it being recognized by Bank that the projections and forecasts provided by Borrower or any of its Subsidiaries in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).

4.10 Sanctions. Neither Borrower nor any of its Subsidiaries is: (a) in violation of any Sanctions; or (b) a Sanctioned Person. Neither Borrower nor any of its Subsidiaries, directors, officers, employees, agents, or Affiliates: (i) conducts any business or engages in any transaction or dealing with any Sanctioned Person; including making or receiving any contribution of funds, goods, or services to or for the benefit of any Sanctioned Person; (ii) deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked pursuant to any Sanctions; (iii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Sanctions; or (iv) otherwise engages in any transaction that could cause Bank to violate any Sanctions.

AFFIRMATIVE COVENANTS Borrower shall do all of the following:

5.1 Use of Proceeds. Cause the proceeds of the Credit Extensions to be used solely (a) to repay the Horizon Obligations, (b) as working capital or (c) to fund its general business and corporate purposes, and not for personal, family, household or agricultural purposes.

5.2 Government Compliance. (a) Maintain its and all of its Subsidiaries' legal existence (except as permitted under Section 6.3 with respect to Subsidiaries only) and good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on Borrower's business or operations. Borrower shall comply, and have each Subsidiary comply, in all material respects, with all laws, ordinances, and regulations to which it is subject. (b) Obtain all of the Governmental Approvals necessary for the performance by Borrower and each of its Subsidiaries of their obligations under the Loan Documents to which they are parties, including any grant of a security interest in the Collateral to Bank. Borrower shall promptly provide copies of any such obtained Governmental Approvals to Bank.

5.3 Financial Statements, Reports. Deliver to Bank by submitting to the Financial Statement Repository: (a) Quarterly Compliance Statement. Within 45 days after the last day of each fiscal quarter and together with the statements set forth in Section 5.3 (b), a duly completed Compliance Statement, confirming that, as of the end of such fiscal quarter, Borrower was in full compliance with all of the terms and conditions of this Agreement, and such other information as Bank may reasonably request; (b) 10-Q reports. Within 45 days after the end of the first three fiscal quarters of Borrower, a company prepared consolidated balance sheet and income statement covering Borrower's consolidated operations for such quarter, consistent with such quarterly financial statements submitted to the SEC, in a form acceptable to Bank. (c) Annual Operating Budget and Financial Projections. Within 90 days after the end of each fiscal year of Borrower, and contemporaneously with any updates or amendments thereto, (A) annual operating budgets (including income statements, balance sheets, and cash flow statements, by month) for the current fiscal year of Borrower, and (B) annual financial projections for the current fiscal year (on a quarterly basis), in each case as approved by the Board, together with any related business forecasts used in the preparation of such annual financial projections; (d) 10-K Reports and Annual Audited Financial Statements. As soon as available, and in any event within 90 days following the end of Borrower's fiscal year, Borrower's 10-K report, together with audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent certified public accounting firm reasonably acceptable to Bank; (e) SEC Filings. Promptly filing, notification of the filing and copies of all periodic and other reports, proxy statements, and other materials filed by Borrower and / or any of its Subsidiaries or any Guarantor with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC, or with any national securities exchange, or distributed to its shareholders, as the case may be. Documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and, if so delivered, shall be deemed to have been delivered on the date on which Borrower or any of its Subsidiaries posts such documents, or provides a link thereto, on Borrower's or any of its Subsidiaries' website on the internet at Borrower's or any of its Subsidiaries' website address; provided, however, Borrower shall promptly notify Bank in writing (which may be by electronic mail) of the posting of any such documents; (f) Security Holder and Subordinated Debt Holder Reports. Promptly upon delivery, copies of all material statements, reports, and notices generally made available to Borrower's security holders or to any holders of Subordinated Debt (solely in their capacities as security holders or holders of Subordinated Debt and not in any other role); (g) Beneficial Ownership Information. If applicable to Borrower, upon request by Bank, Borrower shall provide prompt written notice of any changes to the beneficial ownership information set out in Section 14 of the Perfection Certificate. Borrower understands and acknowledges that Bank relies on such true, accurate, and up-to-date beneficial ownership information to meet Bank's regulatory obligations to obtain, verify, and record information about the beneficial owners of its legal entity customers; (h) Legal Action Notice. Prompt written notice of any legal actions, investigations, or proceedings pending or threatened in writing against Borrower or any of its Subsidiaries that could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of, individually or in the aggregate, \$ 150,000.00 or more; (i) Tort Claim Notice. If Borrower shall acquire a commercial tort claim in excess of \$ 150,000.00, Borrower shall promptly notify Bank in a writing signed by Borrower of the general details thereof, and grant to Bank in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank; (j) Government Filings. Promptly after the same are sent or received, copies of all material correspondence, reports, documents, and other filings by Borrower or any of its Subsidiaries with any Governmental Authority regarding compliance with or maintenance of Governmental Approvals or Applicable Law or that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals or otherwise on the business of Borrower or any of its Subsidiaries; (k) Registered Organization. If Borrower is not a Registered Organization as of the Effective Date but later becomes one, promptly notify Bank of such occurrence and provide Bank with Borrower's organizational identification number; (l) Default. Prompt written notice of the occurrence of a Default or Event of Default; and (m) Other Information. Promptly, from time to time, such other information regarding Borrower or any of its Subsidiaries or compliance with the terms of any Loan Documents as reasonably requested by Bank. Any submission by Borrower of a Compliance Statement or any other financial statement submitted to the Financial Statement Repository pursuant to this Section 5.3 or otherwise submitted to Bank shall be deemed to be a representation by Borrower that (i) as of the date of such Compliance Statement or other financial statement, the information and calculations set forth therein are true and correct, (ii) as of the end of the compliance period set forth in such submission, Borrower is in complete compliance with all required covenants except as noted in such Compliance Statement or other financial statement, as applicable, (iii) as of the date of such submission, no Events of Default have occurred or are continuing, (iv) all representations and warranties other than any representations or warranties that are made as of a specific date in Section 4 remain true and correct in all material respects as of the date of such submission except as noted in such Compliance Statement or other financial statement, as applicable, (v) as of the date of such submission, Borrower and each of its Subsidiaries has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state, and local taxes, assessments, deposits, and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 4.8, and (vi) as of the date of such submission, no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Bank.

5.4 Taxes; Pensions. (a) Timely file, and require each of its Subsidiaries to timely file (in each case, unless subject to a valid extension), all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state, and local taxes, assessments, deposits, and contributions owed by Borrower and each of its Subsidiaries, except for (i) taxes that do not exceed \$ 50,000.00

and (ii) deferred payment of any taxes contested pursuant to the terms of Section 4. 8 (a) hereof, and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay, and require each of its Subsidiaries to pay, all amounts necessary to fund all present pension, profit sharing, and deferred compensation plans in accordance with their terms. (b) To the extent Borrower or any of its Subsidiaries defers payment of any contested taxes, the Borrower shall (i) notify Bank in writing of the commencement of, and any material development in, the proceedings, and (ii) post bonds or take any other steps required to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a "Permitted Lien." 5. 5 Access to Collateral; Books and Records. At reasonable times, on five (5) Business Days' prior notice (provided no notice is required if an Event of Default has occurred and is continuing), Bank, or its agents, shall have the right to inspect the Collateral and the right to audit and copy Borrower's Books. Such inspections and audits shall be conducted no more often than once every 12 months, unless an Event of Default has occurred and is continuing, in which case such inspections and audits shall occur as often as Bank shall determine is necessary. The foregoing inspections and audits shall be conducted at Borrower's expense and the charge therefor shall be \$ 1, 000. 00 per person per day (or such higher amount as shall represent Bank's then-current standard charge for the same), plus out-of-pocket expenses. In the event Borrower and Bank schedule an audit more than eight (8) days in advance, and Borrower cancels or seeks to or reschedules the audit with less than eight (8) days written notice to Bank, then (without limiting any of Bank's rights or remedies) Borrower shall pay Bank a fee of \$ 2, 000. 00 plus any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation or rescheduling. 5. 6 Insurance. (a) Keep its business and the Collateral insured for risks and in amounts standard for companies in Borrower's industry and location and as Bank may reasonably request. Insurance policies shall be in a form, with financially sound and reputable insurance companies that are not Affiliates of Borrower, and in amounts that are reasonably satisfactory to Bank. (b) All liability policies (other than D & O liability insurance, worker's compensation insurance and business interruption insurance) shall show, or have endorsements showing, Bank as an additional insured. (c) Ensure that proceeds payable under any property policy are, at Bank's option, payable to Bank on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying proceeds of any casualty policy up to \$ 100, 000. 00 with respect to any loss, but not exceeding \$ 200, 000. 00 in the aggregate for all losses under all casualty policies in one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Bank has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Bank, be payable to Bank on account of the Obligations. (d) At Bank's request, Borrower shall deliver certified copies of insurance policies and evidence of all premium payments. Each provider of any such insurance required under this Section 5. 5 shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to Bank, that it will give Bank 30 days' prior written notice before any such policy or policies shall be canceled or altered in any material respect. If Borrower fails to obtain insurance as required under this Section 5. 5 or to pay any amount or furnish any required proof of payment to third persons and Bank, Bank may make all or part of such payment or obtain such insurance policies required in this Section 5. 5, and take any action under the policies Bank deems prudent. 5. 7 Accounts. (a) Maintain all of Borrower's, any of its Subsidiaries', and any Guarantor's operating accounts with Bank. In addition to the foregoing, Borrower shall, at all times have on deposit as cash collateral in a segregated money market bank account (the "Cash Collateral Account") in the name of Borrower and maintained with Bank, unrestricted and unencumbered cash (other than lien in favor of Bank) in an amount of at least 100 % of the aggregate outstanding amount of the Term Loan Advances (the "Minimum Threshold Amount"). Bank may restrict withdrawals or transfers by or on behalf of Borrower that would violate this Section 5. 7 (a) regardless of whether an Event of Default exists at such time. (b) In addition to the foregoing, Borrower, any Subsidiary of Borrower, and any Guarantor shall obtain any letter of credit exclusively from Bank. (c) In addition to and without limiting the restrictions in (a), Borrower shall provide Bank 5 days' prior written notice before establishing any Collateral Account at or with any bank or financial institution other than Bank or Bank's Affiliates. For each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution (other than Bank) at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Bank's Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated without the prior written consent of Bank. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes, and other employee wage and benefit payments to or for the benefit of Borrower's employees and identified to Bank by Borrower as such. 5. 8 Protection of Intellectual Property Rights. (i) Protect, defend, and maintain the validity and enforceability of Borrower's and each Subsidiary's Intellectual Property, except to the extent that such failure to do so would not reasonably be expected to have a material adverse effect on Borrower's business or operations; (ii) promptly advise Bank in writing of infringements or any other event that could reasonably be expected to materially and adversely affect the value of Borrower's and each Subsidiary's Intellectual Property material to Borrower's business; and (iii) not allow any Intellectual Property material to Borrower's or any Subsidiary's business to be abandoned, forfeited, or dedicated to the public without Bank's written consent. 5. 9 Litigation Cooperation. From the date hereof and continuing through the termination of this Agreement, make available to Bank (and if no Event of Default exists, during normal business hours), without expense to Bank, Borrower and its officers, employees, and agents and Borrower's books and records, to the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with respect to any Collateral or relating to Borrower. 5. 10 Formation or Acquisition of Subsidiaries. Notwithstanding and without limiting the negative covenants contained in Sections 6. 3 and 6. 7 hereof, within 14 Business Days (or such longer period as Bank may agree in writing in its sole and absolute discretion) after the date that that Borrower or any Guarantor forms any Subsidiary or acquires any Subsidiary after the Effective Date (including, without limitation, pursuant to a Division), Borrower and such Guarantor shall (a) cause such new Subsidiary to provide to Bank a joinder to this Agreement to become a co-borrower hereunder or a guaranty to become a Guarantor hereunder (as determined by Bank in its sole discretion), together with documentation, all in form and substance satisfactory to Bank (including being sufficient to grant Bank a first priority Lien (subject to Permitted Liens) in and to the assets of such newly formed or acquired Subsidiary); (b) provide to Bank appropriate certificates and powers and financing statements, pledging all of the direct or beneficial ownership interest in such new Subsidiary, in form and substance satisfactory to Bank; and (c) provide to Bank all other documentation in form and substance satisfactory to Bank. Any document, agreement, or instrument executed or issued pursuant to this Section 5. 10 shall be a Loan Document. Notwithstanding the foregoing, as of the Effective Date and thereafter, CLSN Laboratories, Inc. shall not be a co-Borrower or Guarantor hereunder. 5. 11 Inventory; Returns. Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances between Borrower and its Account Debtors shall follow Borrower's customary practices in the ordinary course. Borrower shall promptly notify Bank of all returns, recoveries, disputes, and claims that involve more than \$ 150, 000. 00. 5. 12 Further Assurances. Execute any further instruments and take such further action as Bank reasonably requests to perfect, protect, ensure the priority of, or continue Bank's Lien on the Collateral or to effect the purposes of this Agreement. 5. 13 Sanctions. (a) Not, and not permit any of its Subsidiaries to, engage in any of the activities described in Section 4. 10 in the future; (b) not, and not permit any of its Subsidiaries to, become a Sanctioned Person; (c) ensure that the proceeds of the Obligations are not used to violate any Sanctions; and (d) deliver to Bank any certification or other evidence requested from time to time by Bank in its sole discretion, confirming each such Person's compliance with this Section 5. 13. In addition, have implemented, and will consistently apply while this Agreement is in effect, procedures to ensure that the representations and warranties in Section 4. 10 remain true and correct while this Agreement is in effect. 5. 14 Post-Closing Matters. Deliver to Bank, within thirty (30) days of the Effective Date, in form and substance acceptable to Bank, evidence that the insurance endorsements required by Section 5. 6 hereof are in full force and effect, together with additional insured clauses or endorsements in favor of Bank. NEGATIVE COVENANTS Borrower shall not do any of the following without Bank's prior written consent: 6. 1 Dispositions. Convey, sell, lease, transfer, assign, or otherwise dispose of (including, without limitation, pursuant to a Division) (collectively, "Transfer"), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn-out or obsolete Equipment that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful in the ordinary course of business of Borrower; (c) consisting of Permitted Liens and Permitted Investments; (d) consisting of the sale or issuance of any stock, partnership, membership, or other ownership interest or other equity securities of Borrower permitted under Section 6. 2 of this Agreement; (e) consisting of Borrower's or its Subsidiaries' use or transfer of money or Cash Equivalents in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents; (f) of non-exclusive licenses, sublicenses, and cross-licenses for the use of the property of Borrower or its Subsidiaries in the ordinary course of business; and (g) transfers from Borrower to another Borrower or a secured Guarantor. 6. 2 Changes in Business, Management, Control, or Business Locations. (a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or reasonably related or incidental thereto; (b) liquidate or dissolve or permit any of its Subsidiaries to liquidate or dissolve (except that a Subsidiary may liquidate or dissolve, provided that all assets of such Subsidiary are transferred to Borrower or another Subsidiary); (c) fail to provide notice to Bank of any Key Person departing from or ceasing to be employed by Borrower within 10 Business Days after such Key Person's departure from Borrower; and (d) permit, allow, or suffer to occur any Change in Control. Borrower shall not without at least 10 days' prior written notice (or such shorter notice as Bank may agree in writing in its sole and absolute discretion) to Bank, (i) add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than \$ 100, 000. 00 in Borrower's assets or property) or deliver any portion of the Collateral valued, individually or in the aggregate, in excess of \$ 100, 000. 00 to a

bailee at a location other than to a bailee and at a location already disclosed in the Perfection Certificate, (ii) change its jurisdiction of organization, (iii) change its organizational structure or type, or (iv) change its legal name. 6. 3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the stock, partnership, membership, or other ownership interest or other equity securities or property of another Person (including, without limitation, by the formation of any Subsidiary or pursuant to a Division). A Subsidiary may merge or consolidate into another Subsidiary or into Borrower. 6. 4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness. 6. 5 Encumbrance. Create, incur, allow, or suffer to exist any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens; permit any Collateral not to be subject to the first priority security interest granted herein. 6. 6 Maintenance of Collateral Accounts. Maintain any Collateral Account except pursuant to the terms of Section 5. 7 (e). 6. 7 Distributions; Investments. (a) Pay any dividends or make any distribution or payment, or redeem, retire, or purchase any stock, partnership, membership, or other ownership interest or other equity securities; or (b) directly or indirectly make any Investment (including, without limitation, by the formation of any Subsidiary) other than Permitted Investments, or permit any of its Subsidiaries to do so. 6. 8 Transactions with Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for transactions that are in the ordinary course of Borrower's business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm's-length transaction with a non-affiliated Person. 6. 9 Subordinated Debt. Except as expressly permitted under the terms of the subordination, intercreditor, or other similar agreement to which any Subordinated Debt is subject: (a) make or permit any payment on such Subordinated Debt; or (b) amend any provision in any document relating to such Subordinated Debt which would increase the principal amount thereof, provide for earlier or greater principal, interest, or other payments thereon, or adversely affect the subordination thereof to Obligations owed to Bank. 6. 10 Compliance. (a) Become an "investment company" or a company controlled by an "investment company", under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System); or use the proceeds of any Credit Extension for that purpose; (b) (i) fail to meet the minimum funding requirements of ERISA, (ii) permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur, (iii) fail to comply with the Federal Fair Labor Standards Act, or (iv) violate any other law or regulation, if the foregoing subclauses (i) through (iv), individually or in the aggregate, could reasonably be expected to have a material adverse effect on Borrower's business or operations; or permit any of its Subsidiaries to do so; or (c) withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing, and deferred compensation plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority. EVENTS OF DEFAULT Any one of the following shall constitute an event of default (an "Event of Default") under this Agreement: 7. 1 Payment Default. Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within 3 Business Days after such Obligations are due and payable (which Business Day cure period shall not apply to payments due on the Term Loan Maturity Date). During the cure period, the failure to make or pay any payment specified under clause (b) hereunder is not an Event of Default (but no Credit Extension will be made during the cure period); 7. 2 Covenant Default. (a) Borrower fails or neglects to perform any obligation in Section 5 (other than Sections 5. 2 (Government Compliance), 5. 9 (Litigation Cooperation), 5. 11 (Inventory; Returns), and 5. 12 (Further Assurances)) or violates any covenant in Section 6; or (b) Borrower fails or neglects to perform, keep, or observe any other term, provision, condition, covenant, or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 7) under such other term, provision, condition, covenant, or agreement that can be cured, has failed to cure the default within 10 Business Days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the 10-Business-Day period or cannot after diligent attempts by Borrower be cured within such 10-Business-Day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed 30 days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Cure periods provided under this section shall not apply, among other things, to financial covenants or any other covenants that are required to be satisfied, completed, or tested by a date certain or any covenants set forth in clause (a) above; 7. 3 Material Adverse Change. A Material Adverse Change occurs; 7. 4 Attachment; Levy; Restraint on Business. (a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any Subsidiary in excess of \$ 50, 000. 00, or (ii) a notice of lien or levy is filed against any of Borrower's or any of its Subsidiaries' assets by any Governmental Authority with a value in excess of \$ 50, 000. 00, and the same under subclauses (i) and (ii) hereof are not, within 10 Business Days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any 10-day cure period; or (b) (i) any material portion of Borrower's or any of its Subsidiaries' assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting all or any material part of its business; 7. 5 Insolvency. (a) Borrower is unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b) Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and is not dismissed or stayed within 45 days (but no Credit Extensions shall be made while any of the conditions described in clause (a) exist or until any Insolvency Proceeding is dismissed); 7. 6 Other Agreements. There is, under any agreement to which Borrower, any of Borrower's Subsidiaries, or any Guarantor is a party with a third party or parties: (a) any default resulting in a complete write off of the convertible right by such third party or parties, whether or not note exercised, to accelerate the maturity of any Indebtedness in an and related warrants, amount individually or in the aggregate in excess of \$ 250 - 20, 000. SUBSEQUENT EVENTS 00; or (b) any breach or default by Borrower, any of Borrower's Subsidiaries, or Guarantor, the result of which could have a material adverse effect on Borrower's, any of Borrower's Subsidiaries', or any Guarantor's business or operations; 7. 7 Judgments; Penalties. One On March 6 or more fines, penalties 2024 Dr or final judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least \$ 250, 000. 00 (not covered by independent third-party insurance Corinne Le Goff, Pharm. D., informed the Board of Directors of her resignation from her position as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries by any Governmental Authority, and the same are not, within 30 days after the entry, assessment, or issuance thereof, discharged, or after execution thereof, or stayed pending appeal, or such judgments are not discharged prior to the expiration of any such stay (provided that no Credit Extensions will be made prior to the discharge, or stay of such fine, penalty, judgment, order, or decree); 7. 8 Misrepresentations. Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document, or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made (it being agreed and acknowledged by Bank that the projections and forecasts provided by Borrower or any of its Subsidiaries in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results); 7. 9 Subordinated Debt. If: (a) any document, instrument, or agreement evidencing any Subordinated Debt shall for any reason be revoked or invalidated or otherwise cease to be in full force and effect, or any Person (other than Bank) shall be in breach thereof or contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder; (b) a default or event of default (however defined) has occurred under any document, instrument, or agreement evidencing any Subordinated Debt, which default shall not have been cured or waived within any applicable grace period; or (c) the Obligations shall for any reason be subordinated or shall not have the priority contemplated by this Agreement or any applicable subordination or intercreditor agreement; 7. 10 Lien Priority. There is a material impairment in the perfection or priority of Bank's security interest in the Collateral; 7. 11 Guaranty. (a) Any guaranty of any Obligations terminates or ceases for any reason to be in full force and effect; (b) any Guarantor does not perform any obligation or covenant under any guaranty of the Obligations; (c) any circumstance described in Sections 7. 3, 7. 4, 7. 5, 7. 6, 7. 7, or 7. 8 of this Agreement occurs with respect to any Guarantor; (d) the death, liquidation, winding up, or termination of existence of any Guarantor; or (e) (i) a material impairment in the perfection or priority of Bank's Lien in the collateral provided by Guarantor or in the value of such collateral, or (ii) a material adverse change in the general affairs, management, results of operation, condition (financial or otherwise) or the prospect of repayment of the Obligations, occurs with respect to any Guarantor; or 7. 12 Governmental Approvals. Any Governmental Approval shall have been (a) revoked, rescinded, suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions described in clause (a) above, and such decision or such revocation, rescission, suspension, modification, or non-renewal (i) causes, or could reasonably be expected to cause, a Material Adverse Change, or (ii) adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension, modification, or non-renewal could reasonably be expected to cause, a Material Adverse Change. BANK'S RIGHTS AND REMEDIES 8. 1 Rights and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, without notice or demand, do any or all of the following: (a) declare all Obligations immediately due and payable (but if an Event of Default described in Section 7. 5 occurs, all Obligations are immediately due and payable without any action by Bank); (b) stop advancing money or extending credit for Borrower's benefit under this Agreement or under any other agreement between Borrower and Bank; (c) [

reserved]; (d) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and / or its security interest in the Collateral. Borrower shall assemble the Collateral if Bank requests and make it available as Bank designates. Bank may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license to enter and occupy any of its premises, without charge, to exercise any of Bank's rights or remedies; (e) apply to the Obligations any (i) balances and deposits of Borrower it holds, or (ii) amount held by Bank owing to or for the credit or the account of Borrower; (f) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. (g) place a "hold" on any account maintained with Bank and / or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; (h) demand and receive possession of Borrower's Books; and (i) exercise all rights and remedies available to Bank under the Loan Documents or at law or equity, including all remedies provided under the Code or any Applicable Law (including disposal of the Collateral pursuant to the terms thereof).

8.2 Power of Attorney. Borrower hereby irrevocably appoints Bank as its true and lawful attorney-in-fact, (a) exercisable upon the occurrence and during the continuance of an Event of Default, to: (i) endorse Borrower's name on any checks, payment instruments, or other forms of payment or security; (ii) sign Borrower's name on any invoice or bill of lading for any Account or drafts against Account Debtors; (iii) demand, collect, sue, and give releases to any Account Debtor for monies due, settle and adjust disputes and claims about the Accounts directly with Account Debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Bank's or Borrower's name, as Bank chooses); (iv) make, settle, and adjust all claims under Borrower's insurance policies; (v) pay, contest, or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (vi) transfer the Collateral into the name of Bank or a third party as the Code permits; and (b) if and when an Event of Default has occurred and is continuing, to sign Borrower's name on any documents necessary to perfect or continue the perfection of Bank's security interest in the Collateral. Bank's foregoing appointment as Borrower's attorney in fact, and all of Bank's rights and powers, coupled with an interest, are irrevocable until such time as all Obligations (other than inchoate indemnity obligations) have been satisfied in full. Bank is under no further obligation to make Credit Extensions and the Loan Documents have been terminated. Bank shall not incur any liability in connection with or arising from the exercise of such power of attorney and shall have no obligation to exercise any of the foregoing rights and remedies.

8.3 Protective Payments. If Borrower fails to obtain the insurance called for by Section 5.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Bank may obtain such insurance or make such payment, and all amounts so paid by Bank are Bank Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Bank will make reasonable efforts to provide Borrower with notice of Bank obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No payments by Bank are deemed an agreement to make similar payments in the future or Bank's waiver of any Event of Default.

8.4 Application of Payments and Proceeds. After the occurrence and during the continuance of an Event of Default, Bank may apply any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Accounts or other disposition of the Collateral, or otherwise, to the Obligations in such order as Bank shall determine in its sole discretion. Any surplus shall be paid to Borrower or other Persons legally entitled thereto; Borrower shall remain liable to Bank for any deficiency. If Bank, in its commercially reasonable discretion, directly or indirectly, enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction of the Obligations until the actual receipt by Bank of cash therefor.

8.5 Bank's Liability for Collateral. Bank's sole duty with respect to the custody, safekeeping, and physical preservation of the Collateral in its possession or under its control, under Section 9-207 of the Code or otherwise, shall be to deal with it in the same manner as Bank deals with its own property consisting of similar instruments or interests. Borrower bears all risk of loss, damage, or destruction of the Collateral.

8.6 No Waiver; Remedies Cumulative. Bank's failure, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given. Bank's rights and remedies under this Agreement and the other Loan Documents are cumulative. Bank has all rights and remedies provided under the Code, by law, or in equity. Bank's exercise of one right or remedy is not an election and shall not preclude Bank from exercising any other remedy under this Agreement or other remedy available at law or in equity, and Bank's waiver of any Event of Default is not a continuing waiver. Bank's delay in exercising any remedy is not a waiver, election, or acquiescence.

8.7 Demand Waiver. Unless otherwise provided for herein or elsewhere in the Loan Documents, Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which Borrower is liable.

NOTICES All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and 3 Business Days after deposit in the U.S. mail, first-class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail; (c) 1 Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address or email address indicated below; provided that, for clause (b), if such notice, consent, request, approval, demand, or other communication is not sent during the normal business hours of the recipient, it shall be deemed to have been sent at the opening of business on the next Business Day of the recipient. Bank or Borrower may change its mailing or electronic mail address by giving the other party written notice thereof in accordance with the terms of this Section 9. If to Borrower: Celsion Corporation Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Attn: Jeffrey W. Church Email: jchurch@celsion.com Website URL: <https://celsion.com/leadership-team/> If to Bank: Silicon Valley Bank Grove Street, Suite 2-200 Newton, MA 02466 Attn: Ryan Gass Email: rgass@svb.com with a copy to (which Morrison & Foerster LLP shall not constitute Clarendon Street, Floor 20 notice): Boston, Massachusetts 02116 Attn: David A. Ephraim, Esquire Email: DEphraim@mofo.com **CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER; JUDICIAL REFERENCE** Except as otherwise expressly provided in any of the Loan Documents, New York law governs the Loan Documents without regard to principles of conflicts of law that would require the application of the laws of another jurisdiction. Borrower and Bank each irrevocably and unconditionally submit to the exclusive jurisdiction of the State and Federal courts in New York, New York; provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from bringing suit or taking other legal action in any other jurisdiction with respect to the Loan Documents or to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of Bank. Borrower expressly, irrevocably, and unconditionally submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby irrevocably and unconditionally waives, to the fullest extent permitted by Applicable Law, any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby irrevocably and unconditionally consents to the granting of such legal or equitable relief as is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 9 of this Agreement and that service so made shall be deemed completed upon the earlier set forth to occur of Borrower's actual receipt thereof or 3 days after deposit in the U.S. mails, proper postage prepaid. **TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER AND BANK EACH WAIVES ITS RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS, OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY, AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES HERETO TO ENTER INTO THIS AGREEMENT. EACH PARTY HERETO HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.** This Section 10 shall survive the termination of this Agreement and the repayment of all Obligations.

GENERAL PROVISIONS 11.1 Termination Prior to Maturity Date; Survival. All covenants, representations, and warranties made in this Agreement shall continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations) have been satisfied. So long as Borrower has satisfied the Obligations (other than inchoate indemnity obligations, and any other obligations which, by their terms, are to survive the termination of this Agreement and the repayment of all Obligations), this Agreement may be terminated prior to the Term Loan Maturity Date by Borrower, effective 3 Business Days after written notice of termination is given to Bank. Those obligations that are expressly specified in this Agreement as surviving this Agreement's termination and the repayment of all Obligations shall continue to survive notwithstanding this Agreement's termination and the repayment of all Obligations.

11.2 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may not assign or transfer this Agreement or any rights or obligations under it without Bank's prior written consent (which may be granted or withheld in Bank's sole discretion) and any other attempted assignment or transfer by Borrower shall be null and void. Bank has the right, without the consent of or notice to Borrower, to sell, transfer, assign, negotiate, or grant participation in all or any part of, or any interest in, Bank's obligations, rights, and benefits under this Agreement and the other Loan Documents. Unless an Event of Default has occurred and is continuing, Bank shall only assign any interest in the Loan Documents to any Eligible Assignee. For purposes hereof, an "Eligible Assignee" is (a) any bank organized under the Federal

Reserve System, or (b) any commercial bank, insurance company, investment or mutual fund or other entity that is an "accredited investor" (as defined in Regulation D under the Securities Act) and which extends credit or buys loans as one of its businesses and (i) has at least \$ 500,000,000 of Tier 1 Capital and a Credit Rating of at least A1+/P1 or equivalent or single A or equivalent, (ii) is not a vulture fund or distressed debt fund as reasonably determined by Bank, and (iii) is not a competitor of Borrower as reasonably determined by Borrower; provided that neither the Borrower nor any Subsidiary of the Borrower shall be an Eligible Assignee.

11.3 Indemnification. (a) General Indemnification. Borrower shall indemnify, defend, and hold Bank and its Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors, and representatives of Bank and its Affiliates (each, an "Indemnified Person") harmless against: all losses, claims, damages, liabilities, and related expenses (including Bank Expenses and the reasonable fees, charges, and disbursements of any counsel for any Indemnified Person) (collectively, "Claims") arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder, or the consummation of the transactions contemplated hereby or thereby, (ii) any Credit Extension or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of hazardous materials on or from any property owned or operated by Borrower or any of its Subsidiaries, or any environmental liability related in any way to Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation, or proceeding relating to any of the foregoing, whether based on contract, tort, or any other theory, whether brought by a third party or by Borrower, and regardless of whether any Indemnified Person is a party thereto; provided that such indemnity shall not, as to any Indemnified Person, be available to the extent that such losses, claims, damages, liabilities, or related expenses are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnified Person. All amounts due under this Section 11.3 shall be payable promptly after demand therefor. (b) Waiver of Consequential Damages, Etc. To the fullest extent permitted by Applicable Law, Borrower shall not assert, and hereby waives, any claim against any Indemnified Person, on any theory of liability, for special, indirect, consequential, or punitive damages (as opposed to direct or actual damages) or any loss of profits arising out of, in connection with, or as a result of, this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Credit Extension, or the use of the proceeds thereof. No Indemnified Person shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic, or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby. This Section 11.3 shall survive the termination of this Agreement and the repayment of all Obligations until all statutes of limitation with respect to the Claims, losses, and expenses for which indemnity is given shall have run.

11.4 Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement.

11.5 Severability of Provisions. Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.

11.6 Amendments in Writing; Waiver; Integration. No purported amendment or modification of any Loan Document, or waiver, discharge, or termination of any obligation under any Loan Document, shall be effective unless, and only to the extent, expressly set forth in a writing signed by each party hereto. Without limiting the generality of the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance, or course of conduct shall operate as, or evidence, an amendment, supplement, or waiver or have any other effect on any Loan Document. Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver. The Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of the Loan Documents merge into the Loan Documents.

11.7 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. Delivery of an executed signature page of this Agreement by electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof.

11.8 Confidentiality. Bank agrees to maintain the confidentiality of Information (as defined below), except that Information may be disclosed (a) to Bank's Subsidiaries and Affiliates and their respective employees, directors, agents, attorneys, accountants, and other professional advisors (collectively, "Representatives" and, together with Bank, collectively, "Bank Entities"); (b) to prospective transferees, assignees, credit providers, or purchasers of Bank's interests under or in connection with this Agreement and their Representatives (provided, however, Bank shall use commercially reasonable efforts to obtain any such prospective transferee's, assignee's, credit provider's, purchaser's, or their Representatives' agreement to the terms of this provision); (c) as required by law, regulation, subpoena, or other order; (d) to Bank's regulators or as otherwise required or requested in connection with Bank's examination or audit; (e) in connection with the exercise of remedies under the Loan Documents or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder; and (f) to third-party service providers of Bank so long as such service providers have executed a confidentiality agreement with Bank with terms no less restrictive than those contained herein. "Information" means all information received from Borrower regarding Borrower or its business, in each case other than information that is either: (i) in the public domain or in Bank's possession when disclosed to Bank, or becomes part of the public domain (other than as a result of its disclosure by Bank in violation of this Agreement) after disclosure to Bank; or (ii) disclosed to Bank by a third party, if Bank does not know that the third party is prohibited from disclosing the information.

11.9 Electronic Execution of Documents. The words "execution," "signed," "signature," and words of like import in any Loan Document shall be deemed to include electronic signatures, including any Electronic Signature as defined in the Electronic Transactions Law (2002 Revision) of the Cayman Islands (the "Cayman Islands Electronic Signature Law"), if applicable, or the keeping of records in electronic form, including any Electronic Record, as defined in Cayman Islands Electronic Signature Law, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any Applicable Law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Cayman Islands Electronic Signature Law; provided, however that sections 8 and 19(3) of the Cayman Islands Electronic Signature Law shall not apply to this Agreement or the execution or delivery thereof.

11.10 Right of Setoff. Borrower hereby grants to Bank a Lien and a right of setoff as security for all Obligations to Bank, whether now existing or hereafter arising upon and against all deposits, credits, collateral, and property, now or hereafter in the possession, custody, safekeeping or control of Bank or any entity under the control of Bank (including a subsidiary of Bank) or in transit to any of them, and other obligations owing to Bank or any such entity. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Bank may set off the same or any part thereof and apply the same to any liability or Obligation of Borrower even though unsecured and regardless of the adequacy of any other collateral securing the Obligations. **ANY AND ALL RIGHTS TO REQUIRE BANK TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS, OR OTHER PROPERTY OF BORROWER, ARE HEREBY KNOWINGLY, VOLUNTARILY, AND IRREVOCABLY WAIVED.**

11.11 Captions and Section References. The headings used in this Agreement are for convenience only and shall not affect the interpretation of this Agreement. Unless indicated otherwise, section references herein are to sections of this Agreement.

11.12 Construction of Agreement. The parties hereto mutually acknowledge that they and their attorneys have participated in the preparation and negotiation of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist.

11.13 Relationship. The relationship of the parties to this Agreement is determined solely by the provisions of this Agreement. The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary, or other relationship with duties or incidents different from those of parties to an arm's-length contract.

11.14 Third Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) confer any benefits, rights, or remedies under or by reason of this Agreement on any Persons other than the express parties to it and their respective permitted successors and assigns; (b) relieve or discharge the obligation or liability of any Person not an express party to this Agreement; or (c) give any Person not an express party to this Agreement any right of subrogation or action against any party to this Agreement.

11.15 Anti-Terrorism Law. Bank hereby notifies Borrower that, pursuant to the requirements of Anti-Terrorism Law, Bank may be required to obtain, verify, and record information that identifies Borrower, which information may include the name and address of Borrower and other information that will allow Bank to identify Borrower in accordance with Anti-Terrorism Law. Borrower hereby agrees to take any action necessary to enable Bank to comply with the requirements of Anti-Terrorism Law, accounting terms and other DEFINITIONS

12.1 Accounting and Other Terms. (a) Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP (except for with respect to unaudited financial statements for the absence of footnotes and subject to year-end audit adjustments); provided that, if at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either Borrower or Bank shall so request, Borrower and Bank shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP; provided, further, that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) Borrower shall provide Bank financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. (b) As used in the Loan Documents: (i) the words "shall" or "will" are mandatory, the word "may" is permissive, the word "or" is not exclusive, the words "includes" and "including" are not limiting, the singular includes the plural, and numbers denoting amounts that are set off in brackets are negative; (ii) the term "continuing" in the context of an Event of Default means that the Event of Default has not

been remedied (if capable of being remedied) or waived; and (iii) whenever a representation or warranty is made to Borrower's knowledge or awareness, to the "best of" Borrower's knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of any Responsible Officer. 12.2 Definitions. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in this Section 12.2. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. As used in this Agreement, the following capitalized terms have the following meanings: "Account" is, as to any Person, any "account" of such Person as "account" is defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to such Person. "Account Debtor" is any "account debtor" as defined in the Code, with such additions to such term as may hereafter be made. "Affiliate" is, with respect to any Person, each other Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person's senior executive officers, directors, partners, and, for any Person that is a limited liability company, that Person's managers and members. "Agreement" is defined in the preamble hereof. "Anti-Terrorism Law" means any law relating to terrorism or money laundering, including Executive Order No. 13224 and the USA Patriot Act. "Applicable Law" means all applicable provisions of constitutions, laws, statutes, ordinances, rules, treaties, regulations, permits, licenses, approvals, interpretations, and orders of courts or Governmental Authorities and all orders and decrees of all courts and arbitrators. "Authorized Signer" means any individual listed in Borrower's Borrowing Resolution who is authorized to execute the Loan Documents, including making (and executing if applicable) any Credit Extension request, on behalf of Borrower. "Bank" is defined in the preamble hereof. "Bank Entities" is defined in Section 11.8. "Bank Expenses" are all audit fees, costs, and reasonable expenses (including reasonable, out-of-pocket, and documented attorneys' fees and expenses) for preparing, amending, negotiating, administering, defending, and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to Borrower or any Guarantor. "Board" is Borrower's board of directors or equivalent governing body. "Borrower" is set forth on Schedule I hereto. "Borrower's Books" are all Borrower's books and records including ledgers, federal and state tax returns, records regarding Borrower's assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. "Borrowing Resolutions" are, with respect to any Person, those resolutions adopted by such Person's board of directors (and, if required under the terms of such Person's Operating Documents, stockholders) and delivered by such Person to Bank approving the Loan Documents to which such Person is a party and the transactions contemplated thereby, together with a certificate executed by its secretary on behalf of such Person certifying (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Loan Documents to which it is a party, (b) that set forth as a part of or attached as an exhibit to such certificate is a true, correct, and complete copy of the resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Loan Documents to which it is a party, (c) the name (s) of the Person (s) authorized to execute the Loan Documents, including making (and executing if applicable) any Credit Extension request, on behalf of such Person, together with a sample of the true signature (s) of such Person (s), and (d) that Bank may conclusively rely on such certificate unless and until such Person shall have delivered to Bank a further certificate canceling or amending such prior certificate. "Business Day" is a day other than a Saturday, Sunday, or other day on which commercial banks in the State of California are authorized or required by law to close. "Cash Collateral Account" is defined in Section 5.7(a) hereof. "Cash Equivalents" are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard & Poor's Ratings Group or Moody's Investors Service, Inc.; (c) Bank's certificates of deposit issued maturing no more than one (1) year after issue; and (d) money market funds at least 95.0% of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition. "Cash Pledge Agreement" is that certain Cash Pledge Agreement dated as of the Effective Date executed by Borrower in favor of Bank, as amended, modified, supplemented and/or restated from time to time. "Cayman Islands Electronic Signature Law" is defined in Section 11.9. "Change in Control" means (a) at any time, any "person" or "group" (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act), shall become, or obtain rights (whether by means of warrants, options, or otherwise) to become, the "beneficial owner" (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act), directly or indirectly, of 35.0% or more of the ordinary voting power for the election of directors, partners, managers, and members, as applicable, of Borrower (determined on a fully diluted basis) other than by the sale of Borrower's equity securities in a public offering or to venture capital or private equity investors so long as Borrower identifies to Bank the venture capital or private equity investors at least 7 Business Days prior to the closing of the transaction and provides to Bank a description of the material terms of the transaction; (b) during any period of 12 consecutive months, a majority of the members of the Board of Borrower cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (iii) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; or (c) at any time, Borrower shall cease to own and control, of record and beneficially, directly or indirectly, 100.0% of each class of outstanding stock, partnership, membership, or other ownership interest or other equity securities of each Subsidiary of Borrower free and clear of all Liens (except Permitted Liens). "Change in Law" means the occurrence, after the Effective Date, of: (a) the adoption or taking effect of any law, rule, regulation, or treaty; (b) any change in Applicable Law or in the administration, interpretation, implementation, or application thereof by any Governmental Authority; or (c) the making or issuance of any request, rule, guideline, or directive (whether or not having the force of law) by any Governmental Authority; provided that, notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines, or directives promulgated by Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority), or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a "Change in Law", regardless of the date enacted, adopted, or issued. "Claims" is defined in Section 11.3. "Collateral" consists of all of Borrower's right, title, and interest in that certain money market account (Cash Collateral Account) - Account No. xxxxxxx504 (last three digits of account only) maintained by Borrower at Bank, and all cash, Cash Equivalents and other deposits and proceeds from time to time contained therein. "Collateral Account" is any Deposit Account, Securities Account, or Commodity Account. "Commodity Account" is any "commodity account" as defined in the Code, with such additions to such term as may hereafter be made. "Compliance Statement" is that certain statement in the form attached hereto as Exhibit A. "Connection Income Taxes" means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes. "Contingent Obligation" is, for any Person, any direct or indirect liability of that Person for (a) any direct or indirect guaranty by such Person of any indebtedness, lease, dividend, letter of credit, credit card, or other obligation of another, (b) any other obligation endorsed, co-made, discounted, or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (c) any obligations for undrawn letters of credit for the account of that Person; and (d) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates, or commodity prices; but "Contingent Obligation" does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. "Control Agreement" is any control agreement entered into among the depository institution at which Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Bank pursuant to which Bank obtains control (within the meaning of the Code) over such Deposit Account, Securities Account, or Commodity Account. "Copyrights" are any and all copyright rights, copyright applications, copyright registrations, and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. "Credit Extension" is any Term Loan Advance, or any other extension of credit by Bank for Borrower's benefit. "Currency" is coined money and such other banknotes or other paper money as are authorized by law and circulate as a medium of exchange. "Default" means any event which with notice or passage of time or both, would constitute an Event of Default. "Default Rate" is defined in Section 1.2(c). "Deposit Account" is any "deposit account" as defined in the Code, with such additions to such term as may hereafter be made. "Designated Deposit Account" is the deposit account established by Borrower with Bank for purposes of receiving Credit Extensions. "Division" means, in reference to any Person which is an entity, the division of such Person into two (2) or more separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated under Section 18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, Section 17-220 of the Delaware Revised Uniform Limited Partnership Act for limited partnerships formed under Delaware law, or any analogous action taken pursuant to any other Applicable Law with respect to any corporation, limited liability company, partnership, or other entity. "Dollars," "dollars," or use of the sign "\$" means only lawful money of the United States and not any other currency, regardless of whether that currency uses the "\$" sign to denote its currency or may be readily converted into lawful money of the United States. "Dollar Equivalent" is, at any time, (a) with respect to any amount denominated in Dollars, such

amount, and (b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency. "Draw Period" is set forth on Schedule I hereto. "Effective Date" is set forth on Schedule I hereto. "Eligible Assignee" is defined in Section 11.2. "Environmental Laws" means any Applicable Law (including any permits, concessions, grants, franchises, licenses, agreements, or governmental restrictions) relating to pollution or the protection of health, safety, or the environment or the release of any materials into the environment (including those related to hazardous materials, air emissions, discharges to waste or public systems, and health and safety matters). "Equipment" is all "equipment" as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. "ERISA" is the Employee Retirement Income Security Act of 1974, as amended, and its regulations. "Event of Default" is defined in Section 7. "Exchange Act" is the Securities Exchange Act of 1934, as amended. "Excluded Taxes" means any of the following Taxes imposed on or with respect to Bank or required to be withheld or deducted from a payment to Bank, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of Bank being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U. S. federal withholding Taxes imposed on amounts payable to or for the account of Bank with respect to an applicable interest in a Credit Extension pursuant to a law in effect on the date on which (i) Bank acquires such interest in the Credit Extensions or (ii) Bank changes its lending office, except in each case to the extent that, pursuant to Section 1.6, amounts with respect to such Taxes were payable either to Bank's assignor immediately before Bank became a party hereto or to Bank immediately before it changed its lending office, (c) Taxes attributable to Bank's failure to comply with Section 1.6 (c), and (d) any withholding Taxes imposed under FATCA. "FATCA" means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471 (b) (1) of the Internal Revenue Code, and any fiscal or regulatory legislation, rules, or practices adopted pursuant to any intergovernmental agreement, treaty, or convention among Governmental Authorities and implementing such Sections of the Internal Revenue Code. "Final Payment" is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of (a) the Term Loan Maturity Date, (b) the repayment of the Term Loan Advances in full, (c) as required pursuant to Sections 1.1 (c) or 1.1 (d), or (d) the termination of this Agreement, in the amount of \$ 300,000.00. "Financial Statement Repository" is Bank's email address specified in Section 9 or such other means of collecting information approved and designated by Bank after providing notice thereof to Borrower from time to time. "Foreign Currency" is the lawful money of a country other than the United States. "Funding Date" is any date on which a Credit Extension is made to or for the account of Borrower, which shall be a Business Day. "GAAP" is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination. "General Intangibles" is all "general intangibles" as defined in the Code in effect on the date hereof, with such additions to such term as may hereafter be made, and includes, without limitation, all Intellectual Property, claims, income and other tax refunds, security and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort, or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance, and rights to payment of any kind. "Governmental Approval" is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing, or notice, of, issued by, from, or to, or other act by or in respect of, any Governmental Authority. "Governmental Authority" is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank, or other entity exercising executive, legislative, judicial, taxing, regulatory, or administrative functions of or pertaining to government, any securities exchange, and any self-regulatory organization. "Guarantor" is any Person providing a Guaranty in favor of Bank. "Guaranty" is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified, or otherwise supplemented. "Horizon Finance" is collectively, (i) Horizon Technology Finance Corporation, (ii) Horizon Funding I, LLC, and (iii) Horizon Funding Trust 2019-1, each of (ii) and (iii) is an assignee of (i). "Horizon Obligations" is set forth on Schedule I hereto. "Indebtedness" is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures, or similar instruments, (c) capital lease obligations, (d) Contingent Obligations, and (e) other short- and long-term obligations under debt agreements, lines of credit, and extensions of credit. "Indemnified Person" is defined in Section 11.3. "Indemnified Taxes" means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of Borrower under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes. "Information" is defined in Section 11.8. "Initial Term Loan Advance" is set forth on Schedule I hereto. "Insolvency Proceeding" is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, receivership, or other relief. "Intellectual Property" means, with respect to any Person, all of such Person's right, title, and interest in and to the following: (a) any Copyrights, Trademarks, and Patents; (b) any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, and operating manuals; (c) any and all source code; (d) any and all design rights which may be available to such Person; (e) any and all claims for damages by way of past, present, and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and (f) all amendments, renewals, and extensions of any of the Copyrights, Trademarks, or Patents. "Internal Revenue Code" means the U. S. Internal Revenue Code of 1986, and the rules and regulations promulgated thereunder, each as amended or modified from time to time. "Inventory" is all "inventory" as defined in the Code in effect on the date hereof, with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process, and finished products, including without limitation such inventory as is temporarily out of Borrower's custody or possession or in transit and including any returned goods and any documents of title representing any of the above. "Investment" is any beneficial ownership interest in any Person (including stock, partnership, membership, or other ownership interest or other equity securities), and any loan, advance, or capital contribution to any Person. "Key Person" is each of Borrower's (i) President and Chief Executive Officer, who is Michael H. Tardugno, (ii) Executive Vice President and Chief Scientific Officer, who is Kurshed Anwer, (iii) Executive Vice President and Chief Medical Officer, who is Nicholas Borys, and (iv) Executive Vice President, Chief Financial Officer and Corporate Secretary, who is Jeffrey W. Church. "Lien" is a claim, mortgage, deed of trust, levy, attachment charge, pledge, hypothecation, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. "Loan Documents" are, collectively, this Agreement and from any schedules, exhibits, certificates, notices, and any other the Board documents related to this Agreement, effective the Perfection Certificate, Control Agreements, the Cash Pledge Agreement, any subordination agreement, any note, or notes, or guaranties executed by Borrower or any Guarantor, landlord waivers and consents, bailce waivers and consents, and any other present or future agreement by Borrower and / or any Guarantor with or for the benefit of Bank in connection with this Agreement, all as amended, restated, or otherwise modified in accordance with the terms thereof. "Material Adverse Change" is (a) a material impairment in the perfection or priority of Bank March 15, 2024. Dr. Le Goff's Lien in resignation was not the Collateral result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company is conducting in the value of such Collateral; (b) a search material adverse change in the business, operations, or for Dr condition (financial or otherwise) of Borrower; or (c) a material impairment of the prospect of repayment of any portion of the Obligations. Le Goff Minimum Threshold Amount" defined in Section 5.7 (a) hereof. "Obligations" are Borrower's obligations to pay when due any debts, principal, interest, fees, Bank Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes Bank now or later, whether under this Agreement, the other Loan Documents, or otherwise, including, without limitation, interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Bank, and to perform Borrower's duties under the Loan Documents. "OFAC" is the Office of Foreign Assets Control of the United States Department of the Treasury and any successor thereto. "Operating Documents" are, for any Person, such Person's formation documents, as certified by the Secretary of State (or equivalent agency) of such Person's jurisdiction of organization on a date that is no earlier than 30 days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership or limited partnership, its partnership agreement or limited partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto. "Other Connection Taxes" means, with respect to Bank, Taxes imposed as a result of a present or former connection between Bank and the jurisdiction imposing such Tax (other than connections arising from Bank having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to, or enforced any Loan Document, or sold or assigned an interest in any Credit Extension or Loan Document). "Other Taxes" means all present or future stamp, court, documentary, intangible, recording, filing, or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement, or

registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment. "Patents" means all patents, patent applications, and like protections, including without limitation improvements, divisions, continuations, renewals, reissues, extensions, and continuations in part of the same. "Payment / Advance Form" is that certain form in the form attached hereto as Exhibit B. "Payment Date" is set forth on Schedule I hereto. "Perfection Certificate" is the Perfection Certificate delivered by Borrower in connection with this Agreement. "Permitted Indebtedness" is: (a) Borrower's Indebtedness to Bank under this Agreement and the other Loan Documents; (b) Indebtedness existing on the Effective Date which is shown on the Perfection Certificate; (c) Subordinated Debt; (d) unsecured Indebtedness to trade creditors incurred in the ordinary course of business; (e) Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of business; (f) Indebtedness secured by Liens permitted under clauses (a) and (c) of the definition of "Permitted Liens" hereunder; and (g) extensions, refinancings, modifications, amendments, and restatements of any items of Permitted Indebtedness (a) through (f) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. "Permitted Investments" are: (a) Investments (including, without limitation, Subsidiaries) existing on the Effective Date which are shown on the Perfection Certificate; and (b) Investments consisting of Cash Equivalents. "Permitted Liens" are: (a) Liens existing on the Effective Date which are shown on the Perfection Certificate or arising under this Agreement or the other Loan Documents; (b) Liens for taxes, fees, assessments, or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Borrower maintains adequate reserves on Borrower's Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code; (c) purchase money Liens (i) on Equipment acquired or held by Borrower incurred for financing the acquisition of the Equipment, securing no more than \$ 150,000.00 in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the Equipment; and (d) Liens incurred in the extension, renewal or refinancing of the Indebtedness secured by Liens described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase. "Person" is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity, or government agency. "Prepayment Fee" shall be an additional fee, payable to Bank, with respect to the Term Loan Advances, in an amount equal to: (a) for a prepayment of the Term Loan Advances made on or prior to the first (1st) anniversary of the Effective Date, three percent (3.0%) of the then outstanding principal amount of the Term Loan Advances immediately prior to the date of such prepayment; (b) for a prepayment of the Term Loan Advances made after the first (1st) anniversary of the Effective Date, but on or prior to the second (2nd) anniversary of the Effective Date, two percent (2.0%) of the then outstanding principal amount of the Term Loan Advances immediately prior to the date of such prepayment; (c) for a prepayment of the Term Loan Advances made after the second (2nd) anniversary of the Effective Date, but on or prior to the Third anniversary of the Effective Date, one percent (1.0%) of the then outstanding principal amount of the Term Loan Advances immediately prior to the date of such prepayment; and (d) for a prepayment of the Term Loan Advances made after the third (3rd) anniversary of the Effective Date, zero percent (0.0%) of the then outstanding principal amount of the Term Loan Advances immediately prior to the date of such prepayment. Notwithstanding the foregoing, provided no Event of Default has occurred and is continuing, the Prepayment Fee shall be waived by Bank if Bank closes on the refinance and redocumentation of the Term Loan Advances (in its sole and absolute discretion) prior to the Term Loan Maturity Date. "Prime Rate" is set forth on Schedule I hereto. "Registered Organization" is any "registered organization" as defined in the Code, with such additions to such term as may hereafter be made. "Representatives" is defined in Section 11.8. "Responsible Officer" is any of the Chief Executive Officer, President, Chief Financial Officer, and Controller of Borrower. **Michael H. Tardugno**. "Sanctioned Person" means a Person that: (a) is listed on any Sanctions list maintained by OFAC or any similar Sanctions list maintained by any other -- **the Company** Governmental Authority having jurisdiction over Borrower; (b) is located, organized, or resident in any country, territory, or region that is the subject or target of Sanctions; or (c) is 50.0% or more owned or controlled by 1 or more Persons described in clauses (a) and (b) hereof. "Sanctions" means the economic sanctions laws, regulations, embargoes, or restrictive measures administered, enacted, or enforced by the United States government and any of its agencies, including, without limitation, OFAC and the U. S. State Department, or any other Governmental Authority having jurisdiction over Borrower. "SEC" is the Securities and Exchange Commission, any successor thereto, and any analogous Governmental Authority. "Securities Account" is any "securities account" as defined in the Code, with such additions to such term as may hereafter be made. "Specified Affiliate" is any Person (a) more than 10.0% of whose aggregate issued and outstanding equity or ownership securities or interests, voting, non-voting or both, are owned or held directly or indirectly, beneficially or of record, by Borrower, and / or (b) whose equity or ownership securities or interests representing more than 10.0% of such Person's **Executive Chairman** total outstanding combined voting power are owned or held directly or indirectly, beneficially or of record, by Borrower and **Chief Executive Officer prior to Dr. Le Goff, has assumed day-to-day leadership of the Company until such successor is named and will continue** indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all of Borrower's or any of its Subsidiaries' now or hereafter indebtedness to Bank (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into between Bank and the other creditor), on terms acceptable to Bank. "Subsidiary" is, as to any Person, a corporation, partnership, limited liability company, or other entity of which shares of stock, partnership, membership, or other ownership interest or other equity securities having ordinary voting power (other than stock, partnership, membership, or other ownership interest or other equity securities having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership, or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person. Unless the context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of Borrower or Guarantor. "Taxes" means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees, or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. "Term Loan Advance" and "Term Loan Advances" are each defined in Section 1.1 of this **his** Agreement. "Term Loan Availability Amount" is set forth on Schedule I hereto. "Term Loan Maturity Date" is set forth on Schedule I hereto. "Trademarks" means, with respect to any Person, any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Person connected with and symbolized by such trademarks. "Transfer" is defined in Section 6.1. "USA Patriot Act" means the "Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001" (Public Law 107-56, signed into law on October 26, 2001), as amended from time to time. [Signature page follows] IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date. BORROWER: CELSION CORPORATION By: /s/ Jeffrey W. Church Name: Jeffrey W. Church Title: Executive Vice President, Chief Financial Officer and Corporate Secretary BANK: SILICON VALLEY BANK By: /s/ Lauren Cole **role directing Company** Name: Lauren Cole Title: Director Signature Page to Loan and Security Agreement SCHEDULE I LSA PROVISIONS LSA Section LSA Provision 1.1 (a) Term Loan Availability Each Term Loan Advance must be in an amount equal to at least \$ 2,000,000.00. After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. Subject to the terms and conditions of this Agreement, upon Borrower's request, Bank shall make an initial Term Loan Advance ("Initial Term Loan Advance") available to Borrower on or about the Effective Date in an original principal amount of \$ 6,000,000.00; provided that all or a portion of the Initial Term Loan Advance shall be used to repay in full Borrower's outstanding obligations and liabilities to Horizon Finance (the "Horizon Obligations"). Borrower hereby authorizes Bank to apply the proceeds of the Initial Term Loan Advance to the Horizon Obligations as part of the funding process without actually depositing such funds into an account of Borrower. 1.1 (b) Term Loan Repayment Commencing on July 1, 2023 and continuing on each Payment Date thereafter, Borrower shall repay each Term Loan Advance in (i) 24 equal monthly installments of principal, plus (ii) monthly payments of accrued interest at the rate set forth in Section 1.2 (b) (i). 1.2 (a) Interest Payments Term Loan Advances Interest on the principal amount of each Term Loan Advance is payable in arrears monthly (A) on each Payment Date commencing on the first Payment Date following the Funding Date of each such Term Loan Advance, (B) on the date of any prepayment, and (C) on the Term Loan Maturity Date. 1.2 (b) (i) Interest Rate Term Loan Advances The outstanding principal amount of any Term Loan Advance shall accrue interest at a floating rate per annum equal to the greater of (1) 3.25% and (2) the Prime Rate, which interest shall be payable in accordance with Section 1.2 (a). 1.2 (e) Interest Computation Interest shall be computed on the basis of the actual number of days elapsed and a 360-day year for any Credit Extension outstanding. 12.2 "Borrower" "Borrower" means Celsion Corporation, a Delaware corporation. 12.2 "Draw Period" "Draw Period" is the period commencing on the Effective Date and ending on June 30, 2022. 12.2 "Effective Date" "Effective Date" is June 18, 2021. 12.2 "Payment Date" "Payment Date" is the first (1st) calendar day of each month. 12.2 "Prime Rate" "Prime Rate" is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the "prime rate" then in effect; provided that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Bank, the "Prime Rate" shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank-announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than 0.0% per annum, such rate shall be deemed to be 0.0% per annum for purposes of this Agreement. 12.2 "Term Loan Availability Amount" "Term Loan Availability Amount" is an aggregate principal amount equal to \$ 10,000,000.00. 12.2 "Term Loan

Maturity Date "Term Loan Maturity Date" is June 1, 2025. I-1 EXHIBIT A COMPLIANCE STATEMENT TO: SILICON VALLEY BANK Date: FROM: CELSION CORPORATION Under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (as amended, modified, supplemented, and / or restated from time to time, the "Agreement"), Borrower is in complete compliance for the period ending _____ with all required covenants except as noted below. Attached are the required documents evidencing such compliance, setting forth calculations prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. Please indicate compliance status by circling Yes / No under "Complies" column. Reporting Covenants Required Complies Compliance Statement Quarterly within 45 days Yes No 10-Q Report Within 45 days of Q1, Q2, and Q3 10-K Report and Annual financial statements (CPA Audited) FYE within 90 days Yes No Filed 10-Q, 10-K and 8-K Promptly after filing with SEC Yes No Board approved projections FYE within 90 days and as amended / updated Yes No The following are the exceptions with respect to the statements above: (If no exceptions exist, state **strategy** "No exceptions to note" **F-28**) EXHIBIT B LOAN PAYMENT / ADVANCE REQUEST FORM Deadline for same day processing is Noon Eastern Time Date:

Loan Payment: CELSION CORPORATION From Account # _____ To Account # _____
(Deposit Account #) (Loan Account #) Principal \$ _____ and / or Interest \$ _____
Authorized Signature: Phone Number: _____ Print Name / Title: _____

Loan Advance: Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire. From Account # _____ To Account # _____ (Loan Account #) (Deposit Account #) Amount of Term Loan Advance \$ _____ All Borrower's representations and warranties in the Loan and Security Agreement are true, correct, and complete in all material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true and correct in all material respects as of such date. Authorized Signature: _____
Phone Number: _____ Print Name / Title: _____

Outgoing Wire Request: Complete only if all or a portion of funds from the loan advance above is to be wired. Deadline for same day processing is noon, Eastern Time Beneficiary Name: _____ Amount of Wire: \$ _____ Beneficiary Bank: _____

Account Number: _____ City and State: _____ Beneficiary Bank Transit (ABA) #: _____ Beneficiary Bank Code (Swift, Sort, Chip, etc.): _____ (For International Wire Only) Intermediary Bank: _____
Transit (ABA) #: _____ For Further Credit to: _____ Special

Instruction: _____ By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements (s) covering funds transfer service (s), which agreements (s) were previously received and executed by me (us). Authorized Signature: _____ 2nd Signature (if required): _____ Print Name / Title: _____ Print Name / Title: _____
Telephone #: _____ Telephone #: _____

Exhibit 21. 1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. **Delaware** Exhibit **Delaware** Celsion GmbH Switzerland Exhibit **23. 1** CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of Imunon, Inc. on Form S-1 (333- 221543, 333- 219414, 333- 217156, 333- 214353 and 333- 234603), Form S-3 (Nos. 333- 174960, 333- 183286, 333- 198786, 333- 193936, 333- 205608, 333- 206789 and 333- 227236) and on Form S-8 (Nos. 33 139784, 333- 145680, 333- 183288, 333- 207864) of **Imunon, Inc. of** our report dated March **30-27, 2023-2024** (which includes an explanatory paragraph relating to the **Imunon, Inc. ability to continue as a going concern**), relating to the consolidated financial statements **as of and for the years ended December 31, 2023 and 2022**, which appears- appear in this Form 10-K. We also consent to the reference to us under the caption "Experts" in these Registration Statements. / s / WithumSmith Brown, PC **Princeton East Brunswick**, New Jersey March **30-27, 2023-2024** Exhibit 31. 1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13a- 14 (a) AND 15d- 14 (a)

AS ADOPTED PURSUANT TO § 302 OF THE SARBANES- OXLEY ACT OF 2002 I, **Corrine Le Goff** **Michael H. Tardugno**, certify that: 1. I have reviewed this Annual Report of Imunon, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15 (f) and 15d- 15 (f)) for the Registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and 5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's Board of Directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting. Date: March **30-28, 2023-2024** / s / **Corrine Le Goff** **Corrine Le Goff** President and Chief Executive Officer Exhibit **Michael H. Tardugno** **Michael H. Tardugno** Chairman of the Board Exhibit **31. 2**

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO I, Jeffrey W. Church, certify that: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and 5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions): Date: March **30-28, 2023-2024** / s / Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer Exhibit 32. 1 PURSUANT TO 18 UNITED STATES CODE § 1350 § 906 OF THE SARBANES- OXLEY ACT OF 2002 In connection with the Annual Report of Imunon, Inc. (the " Company ") for the year ended December 31, **2022-2023**, as filed with the Securities and Exchange Commission on or about March **30-28, 2023-2024** (the " Report "), I, **Corrine Le Goff** **Michael H. Tardugno**, President and Chief Executive Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to my knowledge: 1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification accompanies each Report pursuant to § 906 of the Sarbanes- Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes- Oxley Act of 2002, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Exhibit 32. 2 In connection with the Annual Report of Imunon, Inc. (the " Company ") for the year ended December 31, **2022-2023**, as filed with the Securities and Exchange Commission on or about March Date: March **30-28, 2023-2024** (the " Report "), I, Jeffrey W. Church, Executive

Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to my knowledge: **Exhibit Imunon, Inc. Executive Officer Incentive Compensation Recovery Policy I. Purpose** The Board of Directors (the “ Board ”) of Imunon, Inc., a Delaware corporation (the “ Company ”), has adopted this policy (this “ Policy ”) which requires the recovery of certain executive compensation in the event that the Company is required to prepare an Accounting Restatement (as defined below). References herein to the Company also include all of its consolidated direct and indirect subsidiaries. This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), Rule 10D- 1 thereunder, and The Nasdaq Stock Market (“ Nasdaq ”) Listing Rule 5608 (“ Rule 5608 ”) and will be interpreted and applied accordingly. **II. Administration** This Policy will be administered by the Compensation Committee of the Board (the “ Committee ”). The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Any determinations made by the Committee will be final and binding on all affected individuals. **III. Covered Persons** This Policy applies to the Company’ s current and former executive officers, as determined pursuant to Rule 16a- 1 (f) promulgated under the Exchange Act and including executive officers identified under Item 401 (b) of Regulation S- K (“ Executive Officers, ” and together with any former Executive Officer, the “ Covered Persons ”). **IV. Recoupment upon an Accounting Restatement** If the Company is required to prepare an Accounting Restatement, the Company will recover reasonably promptly all Erroneously Awarded Compensation from each Covered Person, unless the Committee determines in accordance with Section VI below that such recovery is impracticable. For purposes of the foregoing: • “ Accounting Restatement ” means an accounting restatement of any of the Company’ s financial statements due to the Company’ s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or to correct an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, within the meaning of Rule 10D- 1 and Rule 5608. For the avoidance of doubt, an Accounting Restatement will not be deemed to occur in the event of a restatement of the Company’ s financial statements due to an out- of- period adjustment or due to a retrospective (i) application of a change in accounting principles; (ii) revision to reportable segment information due to a change in the structure of the Company’ s internal organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control; or (v) revision for stock splits, reverse stock splits, stock dividends, or other changes in capital structure. • “ Covered Incentive Compensation ” means Incentive Compensation Received on or after October 2, 2023 by a person: (i) after beginning service as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for that Incentive Compensation, and (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the three completed fiscal years immediately preceding the date that the Company is required to prepare the Accounting Restatement (or such longer period as required under Rule 5608 in the event the Company changes its fiscal year). The date that the Company is required to prepare the Accounting Restatement will be the earlier of (x) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes or reasonably should have concluded that the Accounting Restatement is required, and (y) the date a court, regulator or other authorized body directs the Company to prepare the Accounting Restatement. • “ Erroneously Awarded Compensation ” means the amount of Covered Incentive Compensation that was Received by each Covered Person in excess of the Covered Incentive Compensation that would have been Received by the Covered Person had such Covered Incentive Compensation been determined based on the restated Financial Reporting Measure following an Accounting Restatement, computed without regard to taxes paid. For this purpose, if the amount of Covered Incentive Compensation that is Received by a Covered Person was based on the Company’ s stock price or total shareholder return and is not subject to mathematical recalculation directly from the Accounting Restatement, the amount to be recovered as Erroneously Awarded Compensation shall be based on a reasonable estimate of the effect of the Accounting Restatement on the Financial Reporting Measure upon which the Covered Incentive Compensation was Received. The Company’ s Chief Financial Officer shall, on behalf of the Committee, obtain and maintain all documentation of the determination of any such reasonable estimate and provide such documentation to Nasdaq when required. • “ Financial Reporting Measure ” means (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’ s financial statements and any measure that is derived wholly or in part from any such measure, and (ii) the Company’ s stock price and the total stockholder return of the Company. A measure, however, need not be presented within the financial statements or included in a filing with the U. S. Securities and Exchange Commission (“ SEC ”) to constitute a Financial Reporting Measure. • “ Incentive Compensation ” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, Incentive Compensation shall also be deemed to include any amounts which were determined based on (or were otherwise calculated by reference to) Incentive Compensation (including, without limitation, any amounts under any long- term disability, life insurance or supplemental retirement plan or any notional account that is based on Incentive Compensation, as well as any earnings accrued thereon). • “ Received ”- Incentive Compensation is deemed “ Received ” in the Company’ s fiscal period during which the Financial Reporting Measure specified in such Incentive Compensation is attained, even if the payment or grant of Incentive Compensation occurs after the end of the period. **Recoupment of Erroneously Awarded Compensation pursuant to this Policy is made on a “ no fault ” basis, without regard to whether any misconduct occurred or whether any Covered Person has responsibility for the noncompliance that resulted in the Accounting Restatement.** **V. Method of Recoupment** The Committee will determine, in its sole discretion, the method for recouping Erroneously Awarded Compensation hereunder, which may include, without limitation, any of the following: • Requiring reimbursement of cash Incentive Compensation previously paid; • Seeking recovery of any gain realized on or since the vesting, exercise, settlement, sale, transfer, or other disposition of any equity- based awards; • Offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Person (including, without limitation, any severance otherwise payable by the Company to the Covered Person); • Making a deduction from the Covered Person’ s salary; • Requiring the Covered Person to transfer back to the Company any shares he or she received pursuant to an equity award; • Surrendering to the Company any shares being held pursuant to stock ownership guidelines; • Cancelling, or reducing the number of shares subject to, or the value of, outstanding vested or unvested equity awards; and / or • Taking any other remedial and recovery action permitted by law, as determined by the Committee. The Committee will consider Section 409A of the U. S. Internal Revenue Code of 1986, as amended, prior to offsetting recouped amounts against future payments of deferred compensation. In addition, the Committee may, in its sole discretion, determine whether and to what extent additional action is appropriate to address the circumstances surrounding the noncompliance so as to minimize the likelihood of any recurrence. **VI. Impracticability** The Committee will recover any Erroneously Awarded Compensation in accordance with this Policy unless the Committee determines that such recovery would be impracticable because (i) the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered, (ii) recovery would violate an applicable home country law adopted prior to November 28, 2022, or (iii) recovery would likely cause an otherwise tax- qualified, broad- based retirement plan of the Company to fail to meet the requirements of 26 U. S. C. 401 (a) (13) or 26 U. S. C. 411 (a) and regulations thereunder. Before concluding that it would be impracticable to recover any Erroneously Awarded Compensation based on the expense of enforcement, the Company shall make a reasonable attempt to recover such Erroneously Awarded Compensation, and the Company’ s Chief Financial Officer, on behalf of the Committee, shall document such reasonable attempt (s) to recover and provide that documentation to the Nasdaq when required. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of law, the Committee shall engage legal counsel experienced and qualified to practice law in the applicable jurisdiction (if such counsel is acceptable to the Nasdaq) to render an opinion that recovery would result in a violation of law and shall provide such opinion to the Nasdaq. The Company shall provide funding for the fees and expenses of such legal counsel as approved by the Committee. **VII. No Indemnification or Insurance** Neither the Company nor any of its subsidiaries or affiliates shall indemnify any Covered Person against the loss of any Erroneously Awarded Compensation. Further, neither the Company nor any of its subsidiaries or affiliates shall pay or reimburse any Covered Person for any insurance policy entered into by a Covered Person that provides for full or partial coverage of any recoupment obligation under this Policy. **VIII. Amendment; Termination** The Board or the Committee may amend this Policy from time to time in its discretion in any manner consistent with applicable law and regulation. The Board or Committee may terminate this Policy at any time when the Company does not have a class of securities listed on a national securities exchange or a national securities association. **IX. Other Recoupment Rights** The Board intends that this Policy will be applied to the fullest extent of the law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company (a) under applicable law, regulation or rule, (b) pursuant to the terms of, any similar policy or recoupment provision in any employment agreement, severance agreement, equity award agreement, bonus plan, or similar agreement or plan, and (c) any other legal remedies available to the Company. Further, the provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes- Oxley Act of 2002. **X. Successors** This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators, or

other legal representatives. XI. Disclosure The circumstances of any recoupment pursuant to this Policy will be publicly disclosed where required by Rule 10D-1, Item 402 of Regulation S-K and Rule 5608. In accordance with Rule 10D-1, the Policy shall be filed with the SEC as an exhibit to the Company's Form 10-K, as provided in Item 601 (b) of Regulation S-K. XII. Change of Listing In the event that the Company lists its securities on any national securities exchange or national securities association other than the Nasdaq, all references to Nasdaq in this Policy shall mean each national securities exchange or national securities association upon which the Company has a class of securities then listed.

v3. 23-24. 1Cover-USD (\$) \$ in Millions 12 Months EndedDec. 31, 2022-2023 Mar. 28-26, 2023-2024 Jun. 30, 2022Cover-2023Cover [Abstract] Document Type 10-K Amendment Flag false Document Annual Report true Document Transition Report false Document Period End Date Dec. 31, 2022-2023 Document Fiscal Period Focus FY Document Fiscal Year Focus Current Fiscal Year End Date-- 12-31 Entity File Number 001-15911 Entity Registrant Name IMUNON, INC. Entity Central Index Key Entity Tax Identification Number 52-1256615 Entity Incorporation, State or Country Code DE Entity Address, Address Line One LENOX DRIVE Entity Address, Address Line Two SUITE 100 Entity Address, City or Town LAWRENCEVILLE Entity Address, State or Province NJ Entity Address, Postal Zip Code City Area Code (609) Local Phone Number 896-9100 Title of 12 (b) Security Common Stock, Par Value \$ 0.01 Per Share Trading Symbol IMNN Security Exchange Name NASDAQ Entity Well-known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false Entity Shell Company false Entity Public Float \$ 13.11. Entity 9Entity Common Stock, Shares Outstanding 9,089,399. 789 Documents Incorporated by Reference None Portions of the Registrant's definitive Proxy Statement to be filed for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K-ICFR Auditor Attestation Flag false Document Financial Statement Error Correction [Flag] false Auditor Name WithumSmith Brown, PC Auditor Location Princeton East Brunswick, New Jersey Auditor Firm ID X-DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. ReferencesNo definition available. Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionPCAOB issued Audit Firm Identifier ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10-K- Number 249- Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20-F- Number 249- Section 220- Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40-F- Number 249- Section 240- Subsection fDetails Name: dei_AuditorFirmId Namespace Prefix: dei_ Data Type: dei: nonemptySequenceNumberItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10-K- Number 249- Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20-F- Number 249- Section 220- Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40-F- Number 249- Section 240- Subsection fDetails Name: dei_AuditorLocation Namespace Prefix: dei_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10-K- Number 249- Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20-F- Number 249- Section 220- Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40-F- Number 249- Section 240- Subsection fDetails Name: dei_AuditorName Namespace Prefix: dei_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- DefinitionArea code of city ReferencesNo definition available. Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionCover page. ReferencesNo definition available. Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionEnd date of current fiscal year in the format-- MM-DD. ReferencesNo definition available. Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli: gMonthDayItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true only for a form used as an annual report. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10-K- Number 249- Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20-F- Number 249- Section 220- Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40-F- Number 249- Section 240- Subsection fDetails Name: dei_DocumentAnnualReport Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S-K- Number 229- Section 402- Subsection wReference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10-K- Number 249- Section 310Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20-F- Number 249- Section 220- Subsection fReference 4: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40-F- Number 249- Section 240- Subsection fDetails Name: dei_DocumentFinStmntErrorCorrectionFlag Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. ReferencesNo definition available. Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei: fiscalPeriodItemType Balance Type: na Period Type: durationX- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. ReferencesNo definition available. Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli: gYearItemType Balance Type: na Period Type: durationX- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. ReferencesNo definition available. Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli: dateItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true only for a form used as a transition report. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Forms 10-K, 10-Q, 20-F- Number 240- Section 13- Subsection a-1 Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. ReferencesNo definition available. Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei: submissionTypeItemType Balance Type: na Period Type: durationX- DefinitionDocuments incorporated by reference. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b-23 Details Name: dei_DocumentsIncorporatedByReferenceTextBlock Namespace Prefix: dei_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 1 such as Attn, Building Name, Street Name ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 2 such as Street or Suite number ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the City or Town ReferencesNo definition available. Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei: stateOrProvinceItemType Balance Type: na Period Type: durationX- DefinitionA unique 10-digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b-2 Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei: centralIndexKeyItemType Balance Type: na Period Type: durationX- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b-2 Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8

digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen. ReferencesNo definition available. Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei: fileNumberItemType Balance Type: na Period Type: durationX- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei: filerCategoryItemType Balance Type: na Period Type: durationX- DefinitionTwo-character EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei: edgarStateCountryItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-T-Number232-Section405DetailsName:dei_EntityInteractiveDataCurrentNamespacePrefix:dei_DataType:dei:yesNoItemType Balance Type: na Period Type: durationX- DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei_EntityPublicFloat Namespace Prefix: dei_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionIndicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9- digit value assigned by the IRS. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei: employerIdItemType Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10- K, 10- Q, 8- K, 20- F, 6- K, 10- K/A, 10- Q/A, 20- F/A, 6- K/A, N- CSR, N- Q, N- 1A. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameSecuritiesAct-Number230-Section405DetailsName:dei_EntityWellKnownSeasonedIssuerNamespacePrefix:dei_DataType:dei:yesNoItemType Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310Reference2:> <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Number249-Section220-SubsectionfReference3:> <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm40-F-Number249-Section240-Subsectionf> Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb2DetailsName:dei_Security12bTitleNamespacePrefix:dei_DataType:dei:securityTitleItemType Balance Type: na Period Type: durationX- DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectiond1-1> Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei: edgarExchangeCodeItemType Balance Type: na Period Type: durationX- DefinitionTrading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei: tradingSymbolItemType Balance Type: na Period Type: durationConsolidated Balance Sheets- USD (\$) Dec. 31, 2022-2023 Dec. 31, 2021Current 2022Current assets: Cash and cash equivalents \$ 5,838,566 \$ 11,492,841 \$ 19,586,272Investment 841Investment in debt securities available for sale, at fair value 9,857,087 21,254,485 29,803,095Accrued 485Accrued interest receivable on investment securities 128,932Money 932 108,844Money-market investments, restricted cash 1,500,000Advances 000Advances and deposits on clinical programs and other current assets 2,778 545,433 051 2,447 403,413Total 433Total current assets 37 18,154 240,691 51 704 36,945 779,624Property 691Property and equipment (at cost, less accumulated depreciation and amortization) 751,906 548,301 477,011Other 301Other assets: Money market investments, restricted cash 4,500,000 6,000,000 000Deferred income tax asset 1,280,385 1,567,026 1,383,446In-process research and development, net 13,366,234Operating 026Operating lease right-of-use assets, net 1,595,074 155,876Deposits 876 690,995Deposits and other assets 50,000 483 425,489Total 000Total other assets 2,925,459 6,272 647,902 902Total assets 21,624 918,069 164Total assets 43,975,894 894X \$ 74,046,799X- liabilities: Accounts payable - trade 3,515,192 3,586,623 2,547,251Other 623Other accrued liabilities 3,390,521 4,794,936 3,173,537Notes 936Notes payable - current portion, net of deferred financing costs 1,424,774Operating 774Operating lease liability 485,421 230,749Total 749 548,870Deferred revenue - current portion 500,000Total current liabilities 7,391,134 10,037,082 6,769,658Earn-out milestone liability 5,396,000Notes 082Notes payable - non-current portion, net of deferred financing costs 4,610,946 5,854,461Operating 946Operating lease liability 1,139,293 749Total --- Total liabilities 8,530,427 14,648,028 18,250,868Commitments 028Commitments and contingencies Stockholders' equity: Preferred Stock- \$ 0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022 and 2021-) Common stock- \$ 0.01 par value (112,500,000 shares authorized; 9,399,811 and 7,436,219 and 5,770,538 shares issued at December 31, 2023 and 2022 and 2021-, respectively, and 9,399,789 and 7,436,197 and 5,770,516 shares outstanding at December 31, 2023 and 2022 and 2021-, respectively) 93,998 74,362 57,705Additional 362Additional paid-in capital 401,500,838 397,980,023 388,600,979Accumulated 023Accumulated other comprehensive income (loss) 60,796 26,494 (7,974)Accumulated 494Accumulated deficit (388,182,802) (368,667,825) (332,769,591) Total stockholders' equity before treasury stock 13,472,830 29,413,054Treasury 054 55,881,119Treasury stock, at cost (22 shares at December 31, 2023 and 2022 and 2021-) (85,188) (85,188) Total stockholders' equity 13,387,642 29,327,866Total 866 55,795,931Total liabilities and stockholders' equity \$ 21,918,069 \$ 43,975,894 894X \$ 74,046,799X- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: [http://fasb-www.xbrl.org/2003/us-gaap/role/exampleRef/ref/legacyRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-5-PublisherFASB-02-19\(a\)\)-URIhttps://asc.fasb.org/1943274/2147481372/852extlink&oid=120391452&loc=d3e13212-10-55-122682Reference10Reference2:](http://fasb-www.xbrl.org/2003/us-gaap/role/exampleRef/ref/legacyRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-55-Paragraph1-Subparagraph(SX210-10-5-PublisherFASB-02-19(a))-URIhttps://asc.fasb.org/1943274/2147481372/852extlink&oid=120391452&loc=d3e13212-10-55-122682Reference10Reference2:) [http://www.fasb.org/2003/us-gaap/role/ref/legacyRef/exampleRef-PublisherFASB-NameAccountingStandardsCodification-Topic852-210-SubTopic10-Section55-S99-Paragraph1-Subparagraph\(SX40-210-5-02.19\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210extlink&oid=84165509&loc=d3e56426-112766-10-S99-1](http://www.fasb.org/2003/us-gaap/role/ref/legacyRef/exampleRef-PublisherFASB-NameAccountingStandardsCodification-Topic852-210-SubTopic10-Section55-S99-Paragraph1-Subparagraph(SX40-210-5-02.19(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210extlink&oid=84165509&loc=d3e56426-112766-10-S99-1) Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02.20\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02.20)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAccumulated change-DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transactions- transaction and other events- event and circumstances- circumstance from non-owner nonowner sources- source, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not

that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-210-220-SubTopic-10-Section-S99-45-Paragraph-1-14A-Publisher-FASB-Subparagraph-\(SX-210-5-02-30\)-\(a\)-\(4\)-URI-https://asc.fasb.org/1943274/2147482790/220-extlink&oid=120391452&loc=d3e13212-122682Reference-2](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-210-220-SubTopic-10-Section-S99-45-Paragraph-1-14A-Publisher-FASB-Subparagraph-(SX-210-5-02-30)-(a)-(4)-URI-https://asc.fasb.org/1943274/2147482790/220-extlink&oid=120391452&loc=d3e13212-122682Reference-2): <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-220-SubTopic-10-Section-45-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-extlink&oid=126968391&loc=d3e637-10-45-108580Reference-11Reference-3>: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)-\(2\)-\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference-4](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)-(2)-(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference-4): [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-210-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-03-\(a\)-\(23\)-\(a\)-\(3\)\)-URI-https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910Reference-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-210-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03-(a)-(23)-(a)-(3))-URI-https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910Reference-4): <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-Paragraph-14-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-extlink&oid=126968391&loc=SL7669686-108580Reference-40-65-2Reference-5>: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-30\)-\(a\)-\(4\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-6](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-30)-(a)-(4))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-6): [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-40-Section-65-Paragraph-2-Subparagraph-\(h\)-\(2\)-URI-https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641Reference-6](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-40-Section-65-Paragraph-2-Subparagraph-(h)-(2)-URI-https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641Reference-6): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-40-Section-65-S99-Paragraph-2-Subparagraph-\(g\)-SX-210-7-03-\(2-a\)-\(ii-23\)-\(a\)-\(3\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-extlink&oid=124501264&loc=SL117420844-210-S99-207641Reference-7](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-40-Section-65-S99-Paragraph-2-Subparagraph-(g)-SX-210-7-03-(2-a)-(ii-23)-(a)-(3))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-extlink&oid=124501264&loc=SL117420844-210-S99-207641Reference-7): <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-Paragraph-14-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-extlink&oid=126968391&loc=d3e681-108580-10-45-14> Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Definition: Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-extlink&oid=84165509&loc=d3e56426-10-55-112766Reference-10Reference-2>: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Publisher-FASB-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04-\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference-3](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Publisher-FASB-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04-(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference-3): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-30\)-\(a\)-\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-30)-(a)-(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Definition: Sum of the carrying amounts of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-942-SubTopic-210-Section-S99-50-Paragraph-1-3-Subparagraph-\(bb\)-SX-210-9-03-\(11\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-extlink&oid=126897435&loc=d3e534808-122878Reference-10-50-3Reference-2](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-942-SubTopic-210-Section-S99-50-Paragraph-1-3-Subparagraph-(bb)-SX-210-9-03-(11))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-extlink&oid=126897435&loc=d3e534808-122878Reference-10-50-3Reference-2): [http://www.xbrl.org/2003/role/exampleRef/disclosureRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-55-45-Paragraph-10-25-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-extlink&oid=84165509&loc=d3e56426-10-45-112766Reference-25Reference-3](http://www.xbrl.org/2003/role/exampleRef/disclosureRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-55-45-Paragraph-10-25-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-extlink&oid=84165509&loc=d3e56426-10-45-112766Reference-25Reference-3): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)\)-08-\(g\)-\(1\)-\(iii\)-\(ii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126975872&loc=SL124442552-210-S99-122756Reference-11Reference-4](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210-13-02-(a)-(4))-08-(g)-(1)-(iii)-(ii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126975872&loc=SL124442552-210-S99-122756Reference-11Reference-4): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-22-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-extlink&oid=126901519&loc=d3e8736-108599Reference-10-50-3Reference-5](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-22-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-extlink&oid=126901519&loc=d3e8736-108599Reference-10-50-3Reference-5): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-28-Subparagraph-\(f\)-SX-210-13-01-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-extlink&oid=126975872&loc=SL124442526-10-50-122756Reference-28Reference-6](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-28-Subparagraph-(f)-SX-210-13-01-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-extlink&oid=126975872&loc=SL124442526-10-50-122756Reference-28Reference-6): [http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-Section-S99-55-Paragraph-1-Subparagraph-\(SX-210-10-7-Publisher-FASB-03-\(a\)-\(12\)\)-URI-https://asc.fasb.org/1943274/2147481372/852-extlink&oid=126734703&loc=d3e572229-10-55-122910Reference-10Reference-7](http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-Section-S99-55-Paragraph-1-Subparagraph-(SX-210-10-7-Publisher-FASB-03-(a)-(12))-URI-https://asc.fasb.org/1943274/2147481372/852-extlink&oid=126734703&loc=d3e572229-10-55-122910Reference-10Reference-7): [http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-50-55-Paragraph-7-12-Publisher-FASB-Subparagraph-\(a\)-URI-https://asc.fasb.org/1943274/2147480167/946-extlink&oid=124433192&loc=SL2890621-830-55-112765Reference-12Reference-8](http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-50-55-Paragraph-7-12-Publisher-FASB-Subparagraph-(a)-URI-https://asc.fasb.org/1943274/2147480167/946-extlink&oid=124433192&loc=SL2890621-830-55-112765Reference-12Reference-8): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-Paragraph-1B-1-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(12\)-\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-extlink&oid=126975872&loc=SL124442552-210-S99-122756Reference-11Reference-9](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-Paragraph-1B-1-Subparagraph-(SX-210-13-01-(a)-(4)-(12)-(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-extlink&oid=126975872&loc=SL124442552-210-S99-122756Reference-11Reference-9): [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-22-Publisher-FASB-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)\)-URI-https://asc.fasb.org/1943274/2147482810/280-extlink&oid=126975872&loc=SL124442526-10-50-122756Reference-22Reference-10](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-22-Publisher-FASB-Subparagraph-(SX-210-13-01-(a)-(4)-(iii))-URI-https://asc.fasb.org/1943274/2147482810/280-extlink&oid=126975872&loc=SL124442526-10-50-122756Reference-22Reference-10): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-12](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-12): [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)-\(A\)\)-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-12](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-12): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-13](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-13): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(i\)\)-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-13](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(i))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-13): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(08\)-\(g\)-\(1\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference-1AReference-14](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(08)-(g)-(1)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference-1AReference-14): [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-15](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-15): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-S99-Paragraph-28-1A-Subparagraph-\(f\)-SX-210-13-01-\(a\)-\(4\)-\(iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123596393&loc=d3e14064-10-S99-108612Reference-1AReference-16](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-S99-Paragraph-28-1A-Subparagraph-(f)-SX-210-13-01-(a)-(4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123596393&loc=d3e14064-10-S99-108612Reference-1AReference-16): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-17](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference-17): [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(B\)\)-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756Reference-17](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756Reference-17): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-50-S99-Paragraph-3-1A-Subparagraph-\(bb\)-SX-210-13-01-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123419778&loc=d3e5710-10-S99-111685Reference-1AReference-18](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-50-S99-Paragraph-3-1A-Subparagraph-(bb)-SX-210-13-01-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123419778&loc=d3e5710-10-S99-111685Reference-1AReference-18): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(ii\)\)-Publisher-FASB-URI-https://](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii))-Publisher-FASB-URI-https://)

asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5)))-URI <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50S99-Paragraph32-1B-Subparagraph\(dSX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50S99-Paragraph32-1B-Subparagraph(dSX210.13-02(a)(4)(iii)(A))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=126901519&loc=d3e8933-10-S99-108599>Reference 1BReference 20: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45S99-Paragraph25-1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45S99-Paragraph25-1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=116870748&loc=SL6758485-10-S99-165988>Reference 1BReference 21: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference22>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv)))-URI <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-1B-Subparagraph\(SX210.13-02\(a\)\(5-02\(18\)\)\)](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-1B-Subparagraph(SX210.13-02(a)(5-02(18))))-PublisherFASB - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120391452&loc=d3e13212-10-S99-122682>Reference 1BReference 23: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-Paragraph3-7-Subparagraph\(e-a\)-PublisherFASB](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-Paragraph3-7-Subparagraph(e-a)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147481404/852-extlink&oid=114001798&loc=d3e33918-10-50-111571>Reference 7Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(c\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(c)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147482810/280-extlink&oid=126901519&loc=d3e8906-108599-10-50-32>Reference 26: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.9-03\(11\)\)-PublisherFASB](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.9-03(11))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1>Details Name: us-gaap_Assets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section45-50-Paragraph1-3-Subparagraph\(bb\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section45-50-Paragraph1-3-Subparagraph(bb)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147481203/810-extlink&oid=124098289&loc=d3e6676-107765>Reference 10-50-3Reference 2: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic852-SubTopic10-Section55-45-Paragraph40-25-Subparagraph\(a\)-PublisherFASB](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic852-SubTopic10-Section55-45-Paragraph40-25-Subparagraph(a)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147481231/810-extlink&oid=84165509&loc=d3e56426-10-45-112766>Reference 25Reference 3: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic852-SubTopic10-Section50-S99-Paragraph7-1-Subparagraph\(aSX210.4-08\(g\)\(1\)\(ii\)\)-PublisherFASB](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic852-SubTopic10-Section50-S99-Paragraph7-1-Subparagraph(aSX210.4-08(g)(1)(ii))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480678/235-extlink&oid=124433192&loc=SL2890621-10-S99-112765>Reference 1Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-3-Subparagraph\(cSX210.13-01\(a\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-3-Subparagraph(cSX210.13-01(a))-PublisherFASB) (4)(i))-URI <https://asc.fasb.org/1943274/2147481687/323-extlink&oid=126975872&loc=SL124442526-122756>Reference 10-50-3Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-28-Subparagraph\(fSX210.13-02\(a\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-28-Subparagraph(fSX210.13-02(a))-PublisherFASB) (4)(iii)(A))-URI <https://asc.fasb.org/1943274/2147482907/825-extlink&oid=126975872&loc=SL124442552-10-50-122756>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-55-Paragraph1A-Subparagraph\(SX210.10-13-PublisherFASB01\(a\)\(4\)\(iii\)\(A\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-55-Paragraph1A-Subparagraph(SX210.10-13-PublisherFASB01(a)(4)(iii)(A))-URI) <https://asc.fasb.org/1943274/2147481372/852-extlink&oid=126975872&loc=SL124442526-10-55-122756>Reference 10Reference 7: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-45-Paragraph1A-1-PublisherFASB> Subparagraph(SX210.13-01(a)(4)(iii))-URI <https://asc.fasb.org/1943274/2147483467/210-extlink&oid=126975872&loc=SL124442526-10-45-122756>Reference 1Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph28-1-Subparagraph\(fSX210.5-02\(9\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph28-1-Subparagraph(fSX210.5-02(9))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480566/210-extlink&oid=123596393&loc=d3e14064-10-S99-108612>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(i))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference10>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5\)\)-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(ii\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(ii))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference11>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45-S99-Paragraph25-1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45-S99-Paragraph25-1A-Subparagraph(SX210.13-01(a)(4)(iii))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=116870748&loc=SL6758485-10-S99-165988>Reference 1AReference 12: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(B\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii)(B))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph3-1A-Subparagraph\(eSX210.13-01\(a\)\(4\)\(iv\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph3-1A-Subparagraph(eSX210.13-01(a)(4)(iv))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=114001798&loc=d3e33918-10-S99-111571>Reference 1AReference 14: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5\)\)-PublisherFASB](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference15>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(ii\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(ii))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(i\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(i))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference16>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section50-S99-Paragraph3-1B-Subparagraph\(bbSX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section50-S99-Paragraph3-1B-Subparagraph(bbSX210.13-02(a)(4)(iii)(A))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123419778&loc=d2e5710-10-S99-111685>Reference 1BReference 17: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference18>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv))-URI) <https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.5-13-02\(9-a\)\(4\)\(iv\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.5-13-02(9-a)(4)(iv))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120391452&loc=d3e13212-10-S99-122682>Reference 1BReference 19: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-Paragraph1B-Subparagraph\(SX210.4-13-08-02\(g-a\)\(15\)\(ii\)\)-PublisherFASB](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-Paragraph1B-Subparagraph(SX210.4-13-08-02(g-a)(15)(ii))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120395691&loc=d3e23780-10-S99-122690>Reference 1BReference 20: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-7-Subparagraph\(SX210.13-02\(a\)\)-PublisherFASB](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-7-Subparagraph(SX210.13-02(a))-PublisherFASB) (4)(i))-URI <https://asc.fasb.org/1943274/>

2147481404 / 852 extlink & oid = 126975872 & loc = SL124442552- 122756-10-50-7 Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 320- SubTopic 10** - Name Accounting Standards Codification- **Section 45- Paragraph 2- Publisher FASB- URI https://asc.fasb.org//1943274/2147481830/320-10-45-2**Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 326- SubTopic 30 -Section 45- Paragraph 1- URI https://asc.fasb.org/ extlink & oid = 124258926 & loc = SL82898722-210454Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 320- SubTopic 10- Section 45- Paragraph 2- 1- Publisher FASB - URI https://asc.fasb.org//1943274/2147479130/326** extlink & oid = 124260329 & loc = d3e26626- 111562-30-45-1 Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of,..... xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- **Publisher FASB- Topic 210- SubTopic 10** - Name Accounting Standards Codification- **Topic 230- SubTopic 10- Section 45- S99**, Paragraph 4-1- Subparagraph (SX 210. 5- 02 (1))- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 126954810 & loc = d3e3044- 10- S99- 108585Reference ----- 1Reference 2: http://www.xbrl.org/2003/role/exampleRef- **Publisher FASB- Topic 210- SubTopic 10** - Name Accounting Standards Codification- **Topic 210- SubTopic 10- Section 45- Paragraph 1- Subparagraph (a)- Publisher FASB** - URI https://asc.fasb.org//1943274/2147483467/210 extlink & oid = 124098289 & loc = d3e6676- 10- 45- 107765Reference ----- 1Reference 3: http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99 45- Paragraph 1- 4- Publisher FASB Subparagraph (SX 210. 5- 02 (1))- URI https://asc.fasb.org//1943274/2147482740/230** extlink & oid = 120391452 & loc = d3e13212- 122682-10- 45- 4 Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- **Publisher FASB- Topic 944- SubTopic 210** - Name Accounting Standards Codification- **Topic 210- SubTopic 10- Section S99**, Paragraph 1- Subparagraph (SX 210. 5- 7- 02- 25- 03 (a) (19))- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147479440/944 extlink & oid = 120391452 & loc = d3e13212- 210- S99- 122682Reference ----- 1Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- **Publisher FASB- Topic 946- SubTopic 210** - Name Accounting Standards Codification- **Topic 944- SubTopic 210- Section S99**, Paragraph 1- Subparagraph (SX 210. 7- 6- 04 03- (a- 15)- 19)- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147479617/946 extlink & oid = 126734703 & loc = d3e572229- 210- S99- 122910Reference ----- 1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 942- SubTopic 210- Section S99**, Paragraph 1- Subparagraph (SX 210. 9- 03. 17)- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147479853/942 extlink & oid = 126897435 & loc = d3e534808- 122878- 210- S99- 1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef- **Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99**, Paragraph 1- Subparagraph (SX 210. 5- 02. 25)- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147480566/210-10- S99- 1 Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef- **Publisher FASB- Topic 852- SubTopic 10** - Name Accounting Standards Codification- **Topic 852- SubTopic 10- Section 55**, Paragraph 10- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147481372/852 extlink & oid = 84165509 & loc = d3e56426- 10- 55- 112766Reference ----- 10Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- **Publisher FASB- Topic 944- SubTopic 210** - Name Accounting Standards Codification- **Section S99**, Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (22))- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147479440/944-210- S99- 1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- **Topic 210- SubTopic 10** - **Section S99**, Paragraph 1-..... /role/disclosureRef- **Publisher FASB** - Name Accounting Standards Codification- **Topic 606- SubTopic 10- Section 45- S99**, Paragraph 1- **Subparagraph (SX 210. 5- 02 (29))- Publisher FASB** - URI https://asc.fasb.org/ extlink & oid = 126919976 & loc = SL49130531- 203044Reference 2: http://1943274/2147480566 www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Name Accounting Standards Codification- Topic 606- SubTopic 10** - **Section 45- Paragraph 2- URI https://asc.fasb.org/ extlink & oid = 126919976 & loc = SL49130532- 203044**Reference 3: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Name Accounting Standards Codification- Topic 606- SubTopic 10- S99** Section 50- 1 Paragraph 8- Subparagraph (a)- URI https://asc.fasb.org/ extlink & oid = 126920106 & loc = SL49130549- 203045- Details Name: us-gaap_ContractWithCustomerLiabilityCurrent **gaap_CommonStockValue** Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount, after allowance for credit loss, of accrued interest on investment in debt security measured at amortized cost (held- to- maturity). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 320- SubTopic 10** - Name Accounting Standards Codification- **Topic 320- SubTopic 10- Section 50- Paragraph 5C- Publisher FASB** - URI https://asc.fasb.org//1943274/2147481800/320 extlink & oid = 126970911 & loc = SL121698325- 10- 50- 111563Reference --- 5CReference 2: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 326- SubTopic 20** - Name Accounting Standards Codification- **Section 45- Paragraph 5- Publisher FASB** - URI https://asc.fasb.org//1943274/2147479344/326-20-45-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef- **Topic 326- SubTopic 20** -Section 45- Paragraph 5- URI https://asc.fasb.org/ extlink & oid = 124255206 & loc = SL120267845- 210446Reference 3: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Name Accounting Standards Codification- Topic 326- SubTopic 20- Section 50- Paragraph 3A- Publisher FASB** - URI https://asc.fasb.org//1943274/2147479319/326 extlink & oid = 124255953 & loc = SL120267960- 210447-20- 50- 3A Details Name: us-gaap_DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 740- SubTopic 10** - Name Accounting Standards Codification- **Section 45- Paragraph 4- Publisher FASB** - URI https://asc.fasb.org//1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Topic 740- SubTopic 10** - **Section 45- Paragraph 6- URI https://asc.fasb.org/ extlink & oid = 123427490 & loc = d3e31931- 109318**Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 45- Paragraph 4- 6- Publisher FASB** - URI https://asc.fasb.org//1943274/2147482525/740 extlink & oid = 123427490 & loc = d3e31917- 109318-10- 45- 6 Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Topic 210- SubTopic 10** - Name Accounting Standards Codification- **Topic 210- SubTopic 10- Section S99**, Paragraph 1- Subparagraph (SX 210. 5- 02 (17))- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 120391452 & loc = d3e13212- 122682-10- S99- 1 Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Topic 210- SubTopic 10** - Name Accounting Standards Codification- **Topic 210- SubTopic 10- Section S99**, Paragraph 1- Subparagraph (SX 210. 5- 02 (3) (a) (4))- **Publisher FASB** - URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 120391452 & loc = d3e13212- 122682-10- S99- 1 Details Name: us-gaap_GrantsReceivableCurrent Namespace Prefix: us-gaap_Data..... Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. ReferencesReference 1: http://

fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-599-50-Paragraph-1-3-Subparagraph-(c)-SX-210-5-02-19-26-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-extlink&oid=120391452&loc=d3e13212-122682Reference-10-50-3Reference-2: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-50-45-Paragraph-7-25-Subparagraph-(a-b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-extlink&oid=124433192&loc=SL2890621-10-45-112765Reference-25Reference-3: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Publisher-FASB-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-30-3-Subparagraph-(d-bb)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-extlink&oid=126901519&loc=d3e8906-108599Reference-10-50-3Reference-4: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-50-599-Paragraph-7-1-Subparagraph-(b)-SX-210-4-08-(g)-(1)-(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=124433192&loc=SL2890621-10-599-112765Reference-1Reference-5: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-45-50-Paragraph-25-3-Subparagraph-(b-c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-extlink&oid=116870748&loc=SL6758485-165988Reference-10-50-3Reference-6: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-50-Paragraph-1B-28-Subparagraph-(f)-SX-210-13-02-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-extlink&oid=126975872&loc=SL124442552-10-50-122756Reference-28Reference-7: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-55-Paragraph-28-12-Publisher-FASB-Subparagraph-(f)-URI-https://asc.fasb.org/1943274/2147480167/946-extlink&oid=123596393&loc=d3e14064-830-55-108612Reference-12Reference-8: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-6-04-(14))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-599-1Reference-9: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756Reference-9: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-(bb)-SX-210-13-01-(a)-(4)-(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123419778&loc=d3e5710-10-599-11685Reference-1AReference-10: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference-11: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756Reference-11: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference-12: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-12: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-(e)-SX-210-13-01-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=123419778&loc=d3e5710-10-599-11685Reference-1AReference-13: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-323-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-(e)-SX-210-13-01-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=114001798&loc=d3e33918-10-599-11571Reference-1AReference-14: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference-15: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-15: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference-16: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-16: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference-17: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-599-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference-18: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-URI-https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756Reference-18: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-599-Paragraph-1B-Subparagraph-(SX-210-4-13-08-02-(g-a)-(1)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-extlink&oid=120395691&loc=d3e23780-10-599-122690Reference-1BReference-19: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-50-Paragraph-1B-7-Subparagraph-(a)-Publisher-FASB-(4)-(iii)-(A))-URI-https://asc.fasb.org/1943274/2147481404/852-extlink&oid=126975872&loc=SL124442552-10-50-122756Reference-7Reference-20: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference-21: http://www.xbrl.org/2003/role/exampleRef-Topic-470-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference-22: http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-599-Paragraph-1A-1-Subparagraph-(SX-210-13-5-01-(a)-02-19-26)-Publisher-FASB-(4)-(iii))-URI-https://asc.fasb.org/1943274/2147480566/210-extlink&oid=126975872&loc=SL124442526-122756-10-599-1-Details-Name: us-gaap_Liabilities-namespace-Prefix: us-gaap_Data-Type: xbrl:monetaryItemType-Balance-Type: credit-Period-Type: instantX-Definition: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. References: Reference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Publisher-FASB-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Topic-323-SubTopic-10-Section-50-55-Paragraph-3-10-Publisher-FASB-Subparagraph-(e)-URI-https://asc.fasb.org/1943274/2147481372/852-extlink&oid=114001798&loc=d3e33918-10-55-11571Reference-10Reference-2: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Publisher-FASB-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Topic-852-SubTopic-10-Section-55-599-Paragraph-1-Subparagraph-(SX-10-210-7-03-(a)-(25))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-extlink&oid=84165509&loc=d3e56426-210-599-112766Reference-1Reference-3: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-942-SubTopic-210-Section-599-Paragraph-1-Subparagraph-(SX-210-9-4-03-08-(23-g)-(1)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126897435&loc=d3e534808-10-599-122878Reference-1Reference-4: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Publisher-FASB-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-Section-599-50-Paragraph-1-3-Subparagraph-(c)-SX-210-7-03-(a)-Publisher-FASB-(25))-URI-https://asc.fasb.org/1943274/2147481687/323-extlink&oid=126734703&loc=d3e572229-122910Reference-10-50-3Reference-5: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-599-50-Paragraph-1-28-Subparagraph-(f)-SX-210-4-08-(g)-(1)-(ii))-URI-https://asc.fasb.org/1943274/2147482907/825-extlink&oid=120395691&loc=d3e23780-10-50-122690Reference-28Reference-6: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-9-03-(23))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-210-599-1Reference-7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Section-599-Paragraph-1-Subparagraph-(SX-210-5-02-(23))-URI-https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682Reference-7: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-599-Paragraph-28-1-Subparagraph-

SL77918627- 209977-20-45-1 Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of lessee's right to use underlying asset under operating lease. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-Topic 842- SubTopic 20- Name Accounting Standards Codification- Topic 842- SubTopic 20- Section 45- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147479041/842 extlink & oid=123391704 & loc=SL77918627-209977-20-45-1 Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us-gaap_OtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of noncurrent assets classified as other. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-Topic 210- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (17))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210 extlink & oid=120391452 & loc=d3e13212- 122682-10- S99- 1 Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of long- term investments classified as other. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef ref/legacyRef- Publisher FASB-Topic 944- SubTopic 210- Name Accounting Standards Codification- Topic 944- SubTopic 210- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (1) (f))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/944 extlink & oid=126734703 & loc=d3e572229- 210- S99- 122910Reference----- 1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Publisher FASB-Topic 210- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (12))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210 extlink & oid=120391452 & loc=d3e13212- 122682-10- S99- 1 Details Name: us-gaap_OtherLongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of short- term investments classified as other. ReferencesReference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Publisher FASB-Topic 944- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (1) (g))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/944- 210- S99- 1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (8))- URI https://asc.fasb.org/extlink & oid=120391452 & loc=d3e13212- 122682Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 944- SubTopic 210- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 5- 02 03- 1 (g 8))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210 extlink & oid=126734703 & loc=d3e572229- 10- S99- 122910Reference----- 1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 942- SubTopic 210- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03. 5)- Publisher FASB- URI https://asc.fasb.org/1943274/2147479853/942 extlink & oid=126897435 & loc=d3e534808- 122878- 210- S99- 1 Details Name: us-gaap_OtherShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef ref/legacyRef- Publisher FASB-Topic 852- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- 55- Paragraph 1- Subparagraph (SX 210- 10- 5- 5- Publisher FASB 02 (28))- URI https://asc.fasb.org/1943274/2147481372/852 extlink & oid=120391452 & loc=d3e13212- 10- 55- 122682Reference 10Reference 2: http://www.xbrl.org/2003/role/exampleRef disclosureRef- Publisher FASB-Topic 944- SubTopic 210- Name Accounting Standards Codification- Topic 852- SubTopic 10- Section 55- S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (21))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/944 extlink & oid=84165509 & loc=d3e56426- 112766- 210- S99- 1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210- 10- S99- 1 Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 1- SubTopic 10- Topic 360- Publisher FASB SubTopic 10- Section 50- Paragraph 1- URI https://asc.fasb.org/1943274/2147482099/360 extlink & oid=6391035 & loc=d3e2868- 10- 50- 110229Reference----- 1Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef ref/legacyRef- Publisher FASB-Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https://asc.fasb.org/1943274/2147481372/852- 10- 55- 10Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 944- SubTopic 210- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (8))- URI https://asc.fasb.org/extlink & oid=126734703 & loc=d3e572229- 122910Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (8))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/944- 210- S99- 1Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Topic 942- SubTopic 360- Section 50- Paragraph 1- URI https://asc.fasb.org/extlink & oid=124429447 & loc=SL124453093- 239630Reference 4: http://www.xbrl.org/2003/role/exampleRef- Publisher FASB- Name Accounting Standards Codification- Topic 852- SubTopic 10- Section 55- 50- Paragraph 10- 1- Publisher FASB- URI https://asc.fasb.org/1943274/2147480842/942 extlink & oid=84165509 & loc=d3e56426- 112766- 360- 50- 1 Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionThe DefinitionAmount of cumulative-- accumulated amount of the reporting entity's undistributed earnings or (deficit). ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef ref/legacyRef- Publisher FASB-Topic 852- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- 55- Paragraph 1- Subparagraph (SX 210- 10- 5- 5- Publisher FASB 02 (30) (a) (3))- URI https://asc.fasb.org/1943274/2147481372/852 extlink & oid=120391452 & loc=d3e13212- 10- 55- 122682Reference 10Reference 2: http://www.xbrl.org/2003/role/exampleRef disclosureRef- Publisher FASB-Topic 944- SubTopic 40- Name Accounting Standards Codification- Topic 852- SubTopic 10- Section 55- 65- Paragraph 10- 2- Subparagraph (g) (2) (i)- Publisher FASB- URI https://asc.fasb.org/1943274/2147480016/944 extlink & oid=84165509 & loc=d3e56426- 40- 65- 112766Reference----- 2Reference 3: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef ref/legacyRef- Publisher FASB-Topic 944- SubTopic 40- Name Accounting Standards Codification- Topic 944- SubTopic 210- Section S99- 65- Paragraph 1- 2- Subparagraph (h) (2) (i) (23 2)- Publisher FASB (a) (4))- URI https://asc.fasb.org/1943274/2147480016/944 extlink & oid=126734703 & loc=d3e572229- 40- 65- 122910Reference----- 2Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-Topic 946- SubTopic 20- Name Accounting Standards Codification- Section 50- Paragraph 11- Publisher FASB- URI https://asc.fasb.org/1943274/2147480990/946- 20- 50- 11Reference 5: http://www.xbrl.org/2003/role/disclosureRef- Topic 944- SubTopic 210 40- Section 65- Paragraph 2- Subparagraph (h) (2)- URI https://asc.fasb.org/extlink & oid=124501264 & loc=SL117420844- 207641Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 3- 7- 04 03 (a) (23) (a) (4))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/944 extlink & oid=120391783 & loc=d3e187085- 210- S99- 122770Reference----- 1Reference 6: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-Topic 946- SubTopic 210- Name Accounting Standards Codification- Topic 944- SubTopic 40- Section 65- S99- Paragraph 2- 1- Subparagraph (g) (2) (i) (23 2)- Publisher FASB- URI https://asc.fasb.org/1943274/2147479617/946 extlink & oid=124501264 & loc=SL117420844- 207641 Details Name: 210- S99- 1Reference 7: http://fasb.org/us-gaap-RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap- Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef ref/legacyRef- Publisher FASB-Topic 505- SubTopic 10- Name Accounting Standards Codification- Topic 235- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 3- 04 08 (g))- Publisher FASB (1) (iii))- URI https://asc.fasb.org/1943274/2147480008/505 extlink & oid=120395691 & loc=d3e23780- 10- S99- 122690Reference----- 1Reference 2 8: http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef ref/legacyRef- Publisher FASB-Topic 210- SubTopic 10- Name Accounting Standards Codification- exampleRef- Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50 S99- Paragraph 2- 1- Subparagraph (SX 210. 5- 02 (30) (a) (1 3))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210 extlink & oid=128089324 & loc=d3e5070- 113901- 10- S99- 1 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli: durationItemType monetaryItemType Balance Type: na- credit Period Type: durationX- instantX- DefinitionAmount

DefinitionPer share decrease in exercise price of warrant equity (deficit) attributable to parent. Excludes change due temporary equity and equity attributable to noncontrolling interest standard antidilution provision. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef/exampleRef-PublisherFASB-Topic852-SubTopic10-Section55-Paragraph10-URIhttps://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766Reference3:http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic310-SubTopic10-SectionS99-55-Paragraph2-10-PublisherFASB-Subparagraph\(SAB-Topic4-E\)-URIhttps://asc.fasb.org/1943274/2147481372/852-extlink&oid=122038336&loc=d3e74512-10-55-122707Reference-----10Reference4-2](http://www.xbrl.org/2003/role/disclosureRef/exampleRef-PublisherFASB-Topic852-SubTopic10-Section55-Paragraph10-URIhttps://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766Reference3:http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic310-SubTopic10-SectionS99-55-Paragraph2-10-PublisherFASB-Subparagraph(SAB-Topic4-E)-URIhttps://asc.fasb.org/1943274/2147481372/852-extlink&oid=122038336&loc=d3e74512-10-55-122707Reference-----10Reference4-2); [http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic830-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-55-Paragraph1-12-PublisherFASB-Subparagraph\(SX210.5-02\(31\)\)-URIhttps://asc.fasb.org/1943274/2147480167/946-extlink&oid=120391452&loc=d3e13212-210-S99-122682Reference-----12Reference5-3](http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic830-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-55-Paragraph1-12-PublisherFASB-Subparagraph(SX210.5-02(31))-URIhttps://asc.fasb.org/1943274/2147480167/946-extlink&oid=120391452&loc=d3e13212-210-S99-122682Reference-----12Reference5-3); [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-6-02-04\(29-19\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-extlink&oid=120391452&loc=d3e13212-210-S99-122682Reference-----1Reference6-4](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-6-02-04(29-19))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-extlink&oid=120391452&loc=d3e13212-210-S99-122682Reference-----1Reference6-4); [http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50S99-Paragraph28-3-Subparagraph\(fSX210.6-09\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=122596393&loc=d3e14064-108612Reference8-220-S99-3Reference6](http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50S99-Paragraph28-3-Subparagraph(fSX210.6-09(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=122596393&loc=d3e14064-108612Reference8-220-S99-3Reference6); [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic210-SectionS99-Paragraph1-Subparagraph\(SX210.7-6-03-09\(a-6\)\(23\)\)-PublisherFASB\(a\)\(4\)\)-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=126734703&loc=d3e572229-122910Reference4-220-S99-3Reference7](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic210-SectionS99-Paragraph1-Subparagraph(SX210.7-6-03-09(a-6)(23))-PublisherFASB(a)(4))-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=126734703&loc=d3e572229-122910Reference4-220-S99-3Reference7); [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic40-Section65S99-Paragraph2-3-Subparagraph\(h\)SX210.6-09\(2-7\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=124501264&loc=SL117420844-207641Reference5-220-S99-3Reference8](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic40-Section65S99-Paragraph2-3-Subparagraph(h)SX210.6-09(2-7))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-extlink&oid=124501264&loc=SL117420844-207641Reference5-220-S99-3Reference8); [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.3-4-04-08\(g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-extlink&oid=120397183&loc=d3e187085-10-S99-122770Reference-----1Reference6-9](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.3-4-04-08(g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-extlink&oid=120397183&loc=d3e187085-10-S99-122770Reference-----1Reference6-9); [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-extlink&oid=114001798&loc=d3e33918-1157110-PeriodType:instantX-50-3Reference10-DefinitionContractualinterestrateforfundsborrowed,underthedebtagreement.ReferencesReference1](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-extlink&oid=114001798&loc=d3e33918-1157110-PeriodType:instantX-50-3Reference10-DefinitionContractualinterestrateforfundsborrowed,underthedebtagreement.ReferencesReference1); [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph28-1B-Subparagraph\(fb\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-extlink&oid=123466505&loc=SL123495323-10-50-28Reference112611Reference1-2](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph28-1B-Subparagraph(fb)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-extlink&oid=123466505&loc=SL123495323-10-50-28Reference112611Reference1-2); [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02-122\(29-a\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-DetailsName10-S99-1Reference12](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02-122(29-a)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-DetailsName10-S99-1Reference12); [http://fasb.org/us-gaap/DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap/role/ref/legacyRef-Topic210-gaap_DataType:dtr-types:percentItemBalanceType:naSubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-DetailsName:us-gaap_StockholdersEquityNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-ReferencesNo](http://fasb.org/us-gaap/DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap/role/ref/legacyRef-Topic210-gaap_DataType:dtr-types:percentItemBalanceType:naSubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-DetailsName:us-gaap_StockholdersEquityNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-ReferencesNo) definition available. Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTotal amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock. ReferencesNo definition available. Details Name: us-gaap_StockholdersEquityBeforeTreasuryStock Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic30-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481520/505-extlink&oid=6405834&loc=d3e23315-112656Reference30-50-4Reference2>; [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-505-SubTopic10-30-SectionS99-45-Paragraph1-PublisherFASB-Subparagraph\(SX210.5-02-29-30\)-URIhttps://asc.fasb.org/1943274/2147481549/505-extlink&oid=120391452&loc=d3e13212-30-45-122682Reference-----1Reference3](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-505-SubTopic10-30-SectionS99-45-Paragraph1-PublisherFASB-Subparagraph(SX210.5-02-29-30)-URIhttps://asc.fasb.org/1943274/2147481549/505-extlink&oid=120391452&loc=d3e13212-30-45-122682Reference-----1Reference3); [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-210-SubTopic30-10-Section45S99-Paragraph1-Subparagraph\(SX210.5-02-29-30\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-210-SubTopic30-10-Section45S99-Paragraph1-Subparagraph(SX210.5-02-29-30)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantConsolidated Balance Sheets (Parenthetical)- \$ / shares Dec. 31, 2022-2023 Dec. 31, 2021Statement 2022Statement of Financial Position [Abstract] Preferred stock, par value \$ 0. 01 \$ 0. 01Preferred stock, shares authorized 100, 000 100, 000Preferred stock, shares issuedPreferred stock, shares outstandingCommon stock, par value \$ 0. 01 \$ 0. 01Common stock, shares authorized 112, 500, 000 112, 500, 000Common stock, shares issued 9, 399, 811 7, 436, 219Common 219 5, 770, 538Common stock, shares outstanding 9, 399, 789 7, 436, 497 5, 770, 516Treasury- 197Treasury stock, sharesX- DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-04\(16\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference2](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-04(16)(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference2); [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-SubTopic10-Section50-Paragraph2-URIhttps://asc.fasb.org/1943274/2147481112/505-extlink&oid=126973232&loc=d3e21463-10-50-112644Reference-----2Reference2>; [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.6-05\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference3](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.6-05(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference3); [http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-09\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference4); [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-04\(16\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference5](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-04(16)(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference5); [http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-09\(7\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(7))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference6); [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB-URIhttps://asc](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-PublisherFASB-URIhttps://asc)

fasb.org / 1943274 / 2147480566 / 210 extlink & oid = 120391452 & loc = d3e13212-122682-10-S99-1 Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. ReferencesReference 1: http://fasb-www.xbrl.org / 2003 us-gaap / role / disclosureRef ref/legacyRef- Publisher FASB- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147481112 / 505-10-50-13Reference 2: http://fasb.org / us-gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210.5-02(28))- URI https://asc.fasb.org / extlink & oid = 120391452 & loc = d3e13212-122682Reference 2: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section 50-S99- Paragraph 13-1- Subparagraph (a-SX 210.5-02(28))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480566 / 210 extlink & oid = 126973232 & loc = SL123496158-112644-10-S99-1 Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: http://fasb-www.xbrl.org / 2003 us-gaap / role / disclosureRef ref/legacyRef- Publisher FASB- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.6-04(16)(a))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147479617 / 946-210-S99-1Reference 2: http://fasb.org / us-gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.5-02(28))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480566 / 210 extlink & oid = 120391452 & loc = d3e13212-122682-10-S99-1 Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. ReferencesReference 1: http://fasb-www.xbrl.org / 2003 us-gaap / role / disclosureRef ref/legacyRef- Publisher FASB- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147481112 / 505-10-50-13Reference 2: http://fasb.org / us-gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210.5-02(28))- URI https://asc.fasb.org / extlink & oid = 120391452 & loc = d3e13212-122682Reference 2: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section 50-S99- Paragraph 13-1- Subparagraph (a-SX 210.5-02(28))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480566 / 210 extlink & oid = 126973232 & loc = SL123496158-112644-10-S99-1 Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. ReferencesReference 1: http://fasb-www.xbrl.org / 2003 us-gaap / role / disclosureRef ref/legacyRef- Publisher FASB- Topic 946- SubTopic 210- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1-2- Subparagraph (SX 210.5-6-02(28.4))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147479617 / 946 extlink & oid = 120391452 & loc = d3e13212-210-122682 Details Name: us-S99-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- ReferencesNo-2Reference 2 definition available. Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- Definition Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends. ReferencesReference 1: http://fasb-www.xbrl.org / 2009 us-gaap / role / commonPracticeRef ref/legacyRef- Publisher FASB- Topic 946- SubTopic 220- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1-3- Subparagraph (SX 210.5-6-09(4.02-29,30)(b))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147483575 / 946 extlink & oid = 120391452 & loc = d3e13212-122682Reference 2-220-S99-3Reference 3: http://fasb-www.xbrl.org / 2003 us-gaap / role / disclosureRef ref/legacyRef- Publisher FASB- Topic 946- SubTopic 210- Name Accounting Standards Codification- Topic 505- SubTopic 30- Section 45-S99- Paragraph 1- Subparagraph (SX 210.6-04(16)(a))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147479617 / 946 extlink & oid = 6405813 & loc = d3e22329-112655 agreement. ReferencesReference 1-210-S99-1Reference 4: http://www.xbrl.org / 2003-2009 / role / disclosureRef- Publisher FASB- Topic 946- SubTopic 220- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50-S99- Paragraph 1-3- Subparagraph (b-SX 210.6-09(7))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147483575 / 946 extlink & oid = 123466505 & loc = SL123495323-112611Reference 2-220-S99-3Reference 5: http://fasb.org / us-gaap / role / ref / legacyRef- Publisher FASB- Topic 210- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210.5-02-22(28 a)(1))- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480566 / 210 extlink & oid = 120391452 & loc = d3e13212-10-122682 Details Name: us-gaap-TreasuryStockShares-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: 112644 instantX- ReferencesNo definition available. Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-durationX- Definition The Definition Number number of warrants or rights which entitle previously issued common shares repurchased by the issuing entity and held to receive future services in treasury exchange for the unvested, forfeitable warrants or rights. ReferencesReference 1: http://fasb.org / us-gaap / role / ref / legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 50-30- Section S99-45- Paragraph 1- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147481549 / 505 extlink & oid = 6784392 & loc = d3e188667-122775-30-45-1 Details Name: us-gaap-ClassOfWarrantOrRightUnissued-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantConsolidated Statements of Operations- USD (\$) 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021Income 2022Income Statement [Abstract] Technology development and licensing-Licensing revenue \$ 500,000-\$500,000Operating expenses: Research and development 11,287,691 11,733,666General 666,610,619,287General and administrative 9,742,739 13,687,899-10,887,903Total 899Total operating expenses 21,030,430 25,421,565Loss 565-21,507,190Loss from operations (21,030,430) (24,921,565) (21,007,190) Other income (expense): Gain from change in earn-out milestone liability 5,396,000 1,622,000Impairment of goodwill and in-process research and development (13,366,234) (1,976,101) Loss on debt extinguishment (234,329) 419-158 Investment income, net 1,157,625 453,356-10,996Interest 356Interest expense (197,080) (5,028,618) (569,881) Other (loss) income (396,319) 1,801-1,899Total 801Total other income (expense), net 235,068 (12,543,695) (1,145,506) Loss before income tax benefit (20,795,362) (37,465,260) (22,152,696) Income tax benefit 1,280,385 1,567,026Net 026-1,383,446Net loss \$ (19,514,977) \$ (35,898,234) \$ (20,769,250) Net loss per common share- basic-Basic and diluted \$ (2.16) \$ (5.03) Net loss per common share- Diluted \$ (3.2-83-16) \$ (5.03) Weighted average common shares outstanding- basic-Basic and diluted 9,045,320 7,142,970Weighted average common shares outstanding- Diluted 9,045,320 7,142,970-970X 5,426,953X- Definition Gain loss from change in earnout milestone liability. ReferencesNo definition available. Details Name: IMNN_GainLossFromChangeInEarnoutMilestoneLiability Namespace Prefix: IMNN_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX- Definition Impairment of in-process research and development. ReferencesNo definition available. Details Name: IMNN_ImpairmentOfGoodwillAndInprocessResearchAndDevelopment Namespace Prefix: IMNN_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. ReferencesReference 1: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 250- SubTopic 10- Name Accounting Standards Codification- Topic 815- SubTopic 40- Section 65-50- Paragraph 1-3- Publisher FASB Subparagraph (e)(4)- URI https://asc.fasb.org / 1943274 / 2147483443 / 250 extlink & oid = 126732423 & loc = SL123482106-10-50-238011Reference 2: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 260- SubTopic 10- Name Accounting Standards Codification- Topic 250- SubTopic 10- Section 50-55- Paragraph 3-15- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147482635 / 260 extlink & oid = 124431687 & loc = d3e22583-10-55-107794Reference 15Reference 3: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 815- SubTopic 40- Name Accounting Standards Codification- Topic 250- SubTopic 10- Section 50-65- Paragraph 1-1- Subparagraph (b-e)(4)- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480175 / 815 extlink & oid = 124431687 & loc = d3e22694-40-65-107794Reference 1-1Reference 4: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 815- SubTopic 40- Name Accounting Standards Codification- Topic 260- SubTopic 10- Section 45-65- Paragraph 1-1- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147480175 / 815 extlink & oid = 126958026 & loc = d3e1448-40-65-109256Reference 1Reference 5: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 11- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org / 1943274 / 2147483443 / 250-10-50-11Reference 6: http://www.xbrl.org / 2003 / role / disclosureRef- Topic 250- SubTopic 10- Section 50- Paragraph 4- URI https://asc.fasb.org / extlink & oid = 124431687 & loc = d3e22595-107794Reference 6: http://www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 11- Subparagraph (b)-

Publisher FASB- URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-Section50-Paragraph11-Subparagraph\(a\)-URIhttps://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-Section50-Paragraph11-Subparagraph(a)-URIhttps://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(a\)-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(a)-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-7)**Reference 8:** <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-Section45-Paragraph7-URIhttps://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-45-Paragraph1-2-PublisherFASBSubparagraph\(f\)-URIhttps://asc.fasb.org//1943274/2147482689/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-45-Paragraph1-2-PublisherFASBSubparagraph(f)-URIhttps://asc.fasb.org//1943274/2147482689/260) **extlink & oid = 126732423 & loc = SL123482106-10-45-238011****Reference 9:** [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section55-45-Paragraph52-60B-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482689/260](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section55-45-Paragraph52-60B-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482689/260) **extlink & oid = 128363288 & loc = d3e4984-109258****Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-Section50-Paragraph2-1-Subparagraph\(SX210-7-04\(23\)\)-URIhttps://asc.fasb.org//1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-Section50-Paragraph2-1-Subparagraph(SX210-7-04(23))-URIhttps://asc.fasb.org//1943274/2147483443/250) **extlink & oid = 120400993 & loc = SL114874131-10-50-224263****Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1)**Reference 12:** <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-Section55-Paragraph15-URIhttps://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258>**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-45-Paragraph7-10-PublisherFASBSubparagraph\(a\)-URIhttps://asc.fasb.org//1943274/2147482689/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-45-Paragraph7-10-PublisherFASBSubparagraph(a)-URIhttps://asc.fasb.org//1943274/2147482689/260) **extlink & oid = 124431687 & loc = d3e22644-10-45-107794****Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-S99-Paragraph1-2-Subparagraph\(aSX210-5-03\(25\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-S99-Paragraph1-2-Subparagraph(aSX210-5-03(25))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220) **extlink & oid = 124432515 & loc = d3e3550-10-S99-109257****Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic942-SubTopic220-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210-5-9-03-04\(25-27\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483589/942](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic942-SubTopic220-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210-5-9-03-04(25-27))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483589/942) **extlink & oid = 126953954 & loc = SL114868664-224227****Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-7-04\(23\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-7-04(23))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1)**Reference 16:** <http://www.xbrl.org/2003/role/exampleRef-Topic260-SubTopic10-Section45-Paragraph2-URIhttps://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256>**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section55-Paragraph52-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482635/260-10-55-52>**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-Section45-Paragraph60B-Subparagraph\(d\)-URIhttps://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256](http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-Section45-Paragraph60B-Subparagraph(d)-URIhttps://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-45-Paragraph1-7-PublisherFASBSubparagraph\(SX210-9-04\(27\)\)-URIhttps://asc.fasb.org//1943274/2147482689/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-45-Paragraph1-7-PublisherFASBSubparagraph(SX210-9-04(27))-URIhttps://asc.fasb.org//1943274/2147482689/260) **extlink & oid = 120399700 & loc = SL114874048-224260-10-45-7****Details Name:** us-gaap_EarningsPerShareBasic **250-Period Type:** instantX **-Definition:** Contractual interest rate for funds borrowed, under the debt agreement **SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-4****Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph\(a-b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph(a-b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260) **extlink & oid = 123466505 & loc = SL123495323-10-50-1****Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210-5-03-02-22\(25-a\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220](http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210-5-03-02-22(25-a)(1))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220) **extlink & oid = 120391452 & loc = d3e13212-10-122682****Details Name:** us-S99-gaap_DebtInstrumentInterestRateStatedPercentage **Namespace Prefix:** us-2**Reference 13-gaap_Data Type:** <http://dtr-types://www.percentItemBalanceType> **Balance Type:** na **Namespace Prefix:** us-gaap **Data Type:** dtr-types:perShareItemBalanceType **na** **Period Type:** durationX **-Definition:** Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. **References:** [http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic470-230-PublisherFASB-SubTopic50-Section40-Paragraph4-URIhttps://asc.fasb.org//1943274/2147482740/230](http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic470-230-PublisherFASB-SubTopic50-Section40-Paragraph4-URIhttps://asc.fasb.org//1943274/2147482740/230) **extlink & oid = 126972273 & loc = d3e12355-10-45-112629****Reference 2:** <http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic470-SubTopic50-Section40-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481303/470> **extlink & oid = 126972273 & loc = d3e12317-50-40-112629****Reference 3:** [http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-470-SubTopic10-Section45-40-Paragraph28-4-PublisherFASBSubparagraph\(b\)-URIhttps://asc.fasb.org//1943274/2147481303/470](http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-470-SubTopic10-Section45-40-Paragraph28-4-PublisherFASBSubparagraph(b)-URIhttps://asc.fasb.org//1943274/2147481303/470) **extlink & oid = 126954810 & loc = d3e3602-108585-50-40-4****Details Name:** us-gaap_GainsLossesOnExtinguishmentOfDebt **Namespace Prefix:** us-gaap **Data Type:** xbrli:monetaryItemBalanceType **Balance Type:** credit **Period Type:** durationX **-Definition:** The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. **References:** [http://www.fasb.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-6-07\(2\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-1](http://www.fasb.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-6-07(2)(a))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-1)**Reference 2:** [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210-5-03-4\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210-5-03-4)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220) **extlink & oid = 126953954 & loc = SL114868664-224227-10-S99-2****Details Name:** us-gaap_GeneralAndAdministrativeExpense **Namespace Prefix:** us-gaap **Data Type:** xbrli:monetaryItemBalanceType **Balance Type:** na **debit** **Period Type:** durationX **-Definition:** Number of share options (or share units) exercised during the current impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. **References:** [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-45-Paragraph2-28-Subparagraph\(e-b\)-PublisherFASB-\(1\)\(iv\)\(02\)-URIhttps://asc.fasb.org//1943274/2147482740/230](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-45-Paragraph2-28-Subparagraph(e-b)-PublisherFASB-(1)(iv)(02)-URIhttps://asc.fasb.org//1943274/2147482740/230) **extlink & oid = 128089324 & loc = d3e5070-113901****Reference 2:** [http://www.fasb.org/us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic350-SubTopic30-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-50-Paragraph1-3-Subparagraph\(b\)SX210-3-04\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482665/350](http://www.fasb.org/us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic350-SubTopic30-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-50-Paragraph1-3-Subparagraph(b)SX210-3-04)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482665/350) **extlink & oid = 120397183 & loc = d3e187085-122770****Reference 30-50-3****Details Name:** <http://www.fasb.org/us-gaap/ImpairmentOfIntangibleAssetsIndefinitelyLivedExcludingGoodwill> **gaap/role/ref/legacyRef-PublisherFASB-Namespace Prefix:** us-gaap **Data Type:** xbrli:monetaryItemBalanceType **Balance Type:** debit **Period Type:** durationX **-Definition:** Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. **References:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-7-04\(11\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-7-04(11))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph\(c\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(c)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph\(f\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(f)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599)**Reference 4:** [http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic940-SubTopic20-Section25-50-Paragraph1-32-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280](http://www.fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic940-SubTopic20-Section25-50-Paragraph1-32-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280) **extlink & oid = 126941158 & loc = d3e41242-10-50-110953****Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-31>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-URIhttps://asc.fasb.org>

/extlink & oid=126901519 & loc=d3e8736-108599Reference 6:

126732423 & loc=SL123482106- 10-50-238011Reference----- 3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 250-SubTopic 10- Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 50- Paragraph 6-1-Subparagraph (b) (2)- Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250 extlink & oid=124431353 & loc=SL124452729-227067Reference 10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 815-SubTopic 40- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-65- Paragraph 1B-1- Subparagraph (f) (SX 210.13-02(a)- Publisher FASB (5))- URI https://asc.fasb.org/1943274/2147480175/815 extlink & oid=126975872 & loc=SL124442552-40-65-122756Reference----- 1Reference 8: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic 250-SubTopic 10- Name Accounting Standards Codification-Topic 220-SubTopic 10-Section S99-50- Paragraph 2-8- Publisher FASB Subparagraph (SX 210.5-03(20))- URI https://asc.fasb.org/1943274/2147483443/250 extlink & oid=126953954 & loc=SL114868664-224227Reference 10-50-8Reference 9: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic 250-SubTopic 10- Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-50- Paragraph 28-9- Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250 extlink & oid=126954810 & loc=d3e3602-108585Reference 10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 250-SubTopic 10- Name Accounting Standards Codification-Section 50- Paragraph 11- Subparagraph (a)- Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Section 50- Paragraph 1- Subparagraph (b) (2)- URI https://asc.fasb.org/extlink & oid=124431687 & loc=d3e22499-107794Reference 11: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-50- Paragraph 1A-11- Subparagraph (b) (SX 210.13-01(a)- Publisher FASB (4)(iv))- URI https://asc.fasb.org/1943274/2147483443/250 extlink & oid=126975872 & loc=SL124442526-10-50-122756Reference 11Reference 12: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 250-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-50- Paragraph 1A-Subparagraph (SX 210.13-01(a)- Publisher FASB (iii)(A))- URI https://asc.fasb.org/1943274/2147483443/250 extlink & oid=126975872 & loc=SL124442526-122756Reference 10-50-4Reference 13: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic 946-SubTopic 830- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-55- Paragraph 1B-Subparagraph (SX 210-13-13- Publisher FASB 02(a)(4)(i))- URI https://asc.fasb.org/1943274/2147480167/946 extlink & oid=126975872 & loc=SL124442552-830-55-122756Reference 10Reference 14: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 946-SubTopic 220- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-45- Paragraph 1A-7- Publisher FASB Subparagraph (SX 210.13-01(a)(4)(i))- URI https://asc.fasb.org/1943274/2147483581/946 extlink & oid=126975872 & loc=SL124442526-220-45-122756Reference----- 7Reference 15: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 944-SubTopic 220- Name Accounting Standards Codification-Topic 250-SubTopic 10-Section 50-S99- Paragraph 9-1-Subparagraph (SX 210.7-04(18)- Publisher FASB - URI https://asc.fasb.org/1943274/2147483586/944 extlink & oid=124431687 & loc=d3e22663-220-S99-107794Reference----- 1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 280-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-50- Paragraph 1B-22- Publisher FASB Subparagraph (SX 210.13-02(a)(4)(iv))- URI https://asc.fasb.org/1943274/2147482810/280 extlink & oid=126975872 & loc=SL124442552-10-50-122756Reference----- 22Reference 17: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic 946-SubTopic 220- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99- Paragraph 1A-1- Subparagraph (SX 210.13-6-01-07(a) (9) (4)- Publisher FASB (iii))- URI https://asc.fasb.org/1943274/2147483575/946 extlink & oid=126975872 & loc=SL124442526-220-S99-122756Reference----- 1Reference 18: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 946-SubTopic 220- Name Accounting Standards Codification-Topic 825-SubTopic 10-Section 50-S99- Paragraph 28-3- Subparagraph (SX 210.6-09(1)(d))- Publisher FASB - URI https://asc.fasb.org/1943274/2147483575/946 extlink & oid=123596393 & loc=d3e14064-108612Reference 220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 250-SubTopic 10-Section 50-S99- Paragraph 3-1A- Subparagraph (SX 210.13-01(a)(4)(i))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=124431687 & loc=d3e22583-10-S99-107794Reference-1AReference 20: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 235-SubTopic 10-Section S99- Paragraph 1-1A- Subparagraph (SX 210.13-01(a)(4-08(e)(1)(iii))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=120395691 & loc=d3e23780-10-S99-122690Reference-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 45-S99- Paragraph 60B-1A- Subparagraph (SX 210.13-01(a)(4)(iii)(A))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=126958026 & loc=SL5780133-10-S99-109256Reference-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 323-SubTopic 10-Section 50-S99- Paragraph 3-1A- Subparagraph (e-SX 210.13-01(a)(4)(iv))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=114001798 & loc=d3e33918-10-S99-111571Reference-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 250-SubTopic 10-Section 50-S99- Paragraph 8-1A- Subparagraph (SX 210.13-01(a)(5))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=124431687 & loc=d3e22658-10-S99-107794Reference-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-S99- Paragraph 1A-1B- Subparagraph (SX 210.13-02(a)(4)(i))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=126968391 & loc=SL7669619-10-S99-108580Reference-1BReference 25: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 280-SubTopic 10-Section 50-S99- Paragraph 31-1B- Subparagraph (SX 210.13-02(a)(4)(iii)(A))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=126901519 & loc=d3e8924-10-S99-108599Reference-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 250-SubTopic 10-Section 50-S99- Paragraph 11-1B- Subparagraph (b-SX 210.13-02(a)(4)(iii)(B))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=124431687 & loc=d3e22694-10-S99-107794Reference-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 470-SubTopic 10- Name Accounting Standards Codification-Topic 250-SubTopic 10-Section 50-S99- Paragraph 7-1B- Subparagraph (SX 210.13-02(a)(5))- Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470 extlink & oid=109222650 & loc=SL51721683-10-S99-107760Reference-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 280-SubTopic 10- Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-50- Paragraph 1B-30- Subparagraph (a-b)- Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280 extlink & oid=126968391 & loc=SL7669625-10-50-108580Reference-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 280-SubTopic 10- Name Accounting Standards Codification-Topic 280-SubTopic 10-Section 50- Paragraph 22-32- Subparagraph (f)- Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280 extlink & oid=126901519 & loc=d3e8736-108599Reference 10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 260-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-45- Paragraph 1A-60B- Subparagraph (SX 210.13-01(a)- Publisher FASB (5))- URI https://asc.fasb.org/1943274/2147482689/260 extlink & oid=126975872 & loc=SL124442526-122756Reference 10-45-60BReference 32: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic 280-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-50- Paragraph 1B-31- Publisher FASB Subparagraph (SX 210.13-02(a)(4)(iii)(B))- URI https://asc.fasb.org/1943274/2147482810/280 extlink & oid=126975872 & loc=SL124442552-10-50-122756Reference----- 31Reference 33: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 280-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 10-Section S99-50- Paragraph 1B-32- Subparagraph (c) (SX 210.13-02(a)- Publisher FASB (4)(iii)(A))- URI https://asc.fasb.org/1943274/2147482810/280 extlink & oid=126975872 & loc=SL124442552-10-50-122756Reference----- 32Reference 34: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 205-SubTopic 20- Name Accounting Standards Codification-Topic 280-SubTopic 10-Section 50- Paragraph 30-7- Publisher FASB Subparagraph (b)- URI https://asc.fasb.org/1943274/2147483499/205 extlink & oid=126901519 & loc=d3e8906-108599Reference 20-50-7Reference 35: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic 230-SubTopic 10- Name Accounting Standards Codification-Topic 280-SubTopic 10-Section 50-45- Paragraph 32-28- Publisher FASB Subparagraph (e)- URI https://asc.fasb.org/1943274/2147482740/230 extlink & oid=126901519 & loc=d3e8933-108599-Period Type://asc instantX- DefinitionContractual interest rate for funds borrowed,under the debt agreement, ReferencesReference 1 fasb.org/1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB Topic 220-SubTopic 10- Name Accounting Standards Codification-Topic 470-SubTopic 20- Section

45-50 - Paragraph 1B- Subparagraph (a-b) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482790/220-extlink&oid=123466505&loc=SL123495323> - 10-45-1BReference-112611Reference-38-2 : [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210.5-03-02.22\(20a\)\(1\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210.5-03-02.22(20a)(1))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483621/220-extlink&oid=120391452&loc=d3e13212> - 122682 Details Name: us- S99- 2Reference 39: http://fasb.org/us-gaap/DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap/role/ref/legacyRef-Topic942-gaap_DataType:dr-SubTopic220-types:percentItemBalanceType:na Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition The aggregate amount of income or expense from ancillary business- related activities (that is to say, excluding major activities considered part of the normal operations of the business). ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph\(SX210.5-03.7\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=126953954&loc=SL114868664-224227-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph(SX210.5-03.7)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=126953954&loc=SL114868664-224227-10-S99-2) Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. ReferencesNo definition available. Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItem Balance Type: na Period Type: durationX- Definition The net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-22Reference2:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph31-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599Reference2:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-30Reference3:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599Reference3:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-32Reference4:https://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph\(e\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference4:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-31Reference5:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph\(f\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference5:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-extlink&oid=126901519&loc=d3e8736-108599-10-50-32](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-22Reference2:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph31-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599Reference2:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-30Reference3:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599Reference3:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-32Reference4:https://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(e)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference4:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-31Reference5:https://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(f)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference5:https://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-extlink&oid=126901519&loc=d3e8736-108599-10-50-32) Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount of revenue and income classified as other. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Section50-S99-Paragraph4F-6-Subparagraph\(b-SX210.12-14\(ColumnE\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=123466505&loc=SL123495355-320-S99-112611Reference-----6Reference4-2](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Section50-S99-Paragraph4F-6-Subparagraph(b-SX210.12-14(ColumnE)(2))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=123466505&loc=SL123495355-320-S99-112611Reference-----6Reference4-2) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Topic835-SubTopic30-Section45-S99-Paragraph3-6-Subparagraph\(SX210.12-14\(ColumnE\)\(Footnote4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=124435984&loc=d3e28555-320-108399](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Topic835-SubTopic30-Section45-S99-Paragraph3-6-Subparagraph(SX210.12-14(ColumnE)(Footnote4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=124435984&loc=d3e28555-320-108399) Details Name: us- S99-gaap_AmortizationOffinancingCosts Namespace Prefix: us- S99-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of amortization expense attributable to debt discount (premium) and debt issuance costs. ReferencesReference 1: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-S99-Paragraph28-6-Subparagraph\(SX210.12-14\(ColumnE\)\(Footnote6\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=126954810&loc=d3e3602-108585Reference2-320-S99-6Reference4:https://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-04-\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944-extlink&oid=120400993&loc=SL114874131-224263-220-S99-1Reference5:https://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-07\(1\)\(c\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic320-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-S99-Paragraph28-6-Subparagraph(SX210.12-14(ColumnE)(Footnote6)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480032/946-extlink&oid=126954810&loc=d3e3602-108585Reference2-320-S99-6Reference4:https://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-04-(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944-extlink&oid=120400993&loc=SL114874131-224263-220-S99-1Reference5:https://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-07(1)(c))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946-220-S99-1) Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItem Balance Type: na Period Type: durationX- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. ReferencesReference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic730-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482916/730-10-50-1Reference2:https://www.xbrl.org/2009/role/commonPracticeRef-Topic912-SubTopic730-Section25-Paragraph1-URIhttps://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433Reference2:https://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic985-SubTopic20-Section50-25-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482517/912-extlink&oid=6501960&loc=d3e128462-730-25-11756Reference-----1Reference3:https://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic730-985-SubTopic40-20-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481283/985-extlink&oid=6420194&loc=d3e21568-108373-20-50-1> Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. ReferencesReference 1:

32Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10> - Name Accounting Standards Codification- Section 50- Paragraph 40- Publisher FASB- URI <https://asc.fasb.org//1943274/2147482810/280-10-50-40>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-Subparagraph\(a\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-Subparagraph(a)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32)**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph42-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph41-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph41-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-41)**Reference 11:** <http://www.xbrl.org/2003/role/disclosureRef-Topic606-SubTopic10-Section50-Paragraph5-URIhttps://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic924-SubTopic10-SectionS9950-Paragraph4-Subparagraph\(a\)SAB-Topic11-L-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479806/606](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic924-SubTopic10-SectionS9950-Paragraph4-Subparagraph(a)SAB-Topic11-L-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479806/606) extlink & oid = 6472922 & loc = d3e499488-122856 **10-50-4** Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-InstantX-DefinitionContractual interest rate DefinitionThe average number of shares or for funds borrowed units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), under determined based on the debt agreement timing of issuance of shares or units in the period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph1-Subparagraph\(a-b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph1-Subparagraph(a-b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260) extlink & oid = 123466505 & loc = SL123495323-10-50-1**Reference 112611Reference 2:** [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section45-S99-Paragraph16-1-PublisherFASB-Subparagraph\(SX210.5-02.22\(a\)\(1\)\)-URIhttps://asc.fasb.org//1943274/2147482689/260](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section45-S99-Paragraph16-1-PublisherFASB-Subparagraph(SX210.5-02.22(a)(1))-URIhttps://asc.fasb.org//1943274/2147482689/260) extlink & oid = 120391452 & loc = d3c13212-122682 **10-45-16** Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: xdt-types:percentItemType Balance Type: na Period Type: durationX-DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-Section45-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482689/260> extlink & oid = 126958026 & loc = d3e1448-109256 **10-45-10** Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationConsolidated Statements of Comprehensive loss-Loss-USD (\$) 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021 **Income Statement [Abstract] Net loss \$ (35,898,234) \$ (20,769,250) Changes 2022 Changes in:** Realized loss-gains on investment securities recognized in investment income, net \$ 43,431, 508 7,801 \$ 49, 149 Unrealized 222 Unrealized loss-losses (gain) on investment securities (17, net (397,499) (014- 14, 754) Other Change in realized and unrealized gains on available for sale securities, net 34, 302 34, 468 Net loss (19, 514, 977) (35, 898, 234) Total comprehensive income, net 26, 494 7, 974 Comprehensive loss \$ (19, 480, 675) \$ (35, 871-863, 766 740) \$ (20, 761, 276) X- DefinitionAmount after tax of increase (decrease) in equity from transactions from other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-24\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-24))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483621/220-10-S99-2)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic944-942-SubTopic220-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(22\)\)-URIhttps://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224262](http://www.xbrl.org/2003/role/disclosureRef-Topic944-942-SubTopic220-SectionS99-Paragraph1-Subparagraph(SX210.7-04(22))-URIhttps://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224262)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210.5-9-03-04\(24-26\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483589/942](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210.5-9-03-04(24-26))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483589/942) extlink & oid = 126953954 & loc = SL114868664-224227**Reference 220-S99-1Reference 3:** [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(22\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-04(22))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1)**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-Section45-Paragraph5-URIhttps://asc.fasb.org/extlink&oid=126968391&loc=126968391>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-45-Paragraph1A-Subparagraph\(c\)SX210.9-04\(26\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482790/220](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-45-Paragraph1A-Subparagraph(c)SX210.9-04(26))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482790/220) extlink & oid = 120399700 & loc = SL114874048-224260**Reference 10-45-1AReference 5:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1B-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482790/220](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1B-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482790/220) extlink & oid = 126968391 & loc = SL7669625-10-45-108580**Reference 1BReference 6:** [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1A-5-1-PublisherFASB-Subparagraph\(c\)-URIhttps://asc.fasb.org//1943274/2147482790/220](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1A-5-1-PublisherFASB-Subparagraph(c)-URIhttps://asc.fasb.org//1943274/2147482790/220) extlink & oid = 126968391 & loc = SL7669619-108580 **10-45-5** Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-Paragraph1-Subparagraph\(SX210.9-4-04-08\(22-g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480678/235](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-Paragraph1-Subparagraph(SX210.9-4-04-08(22-g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480678/235) extlink & oid = 120399700 & loc = SL114874048-224260**Reference 10-S99-1Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph32-3-Subparagraph\(fc\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481687/323](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph32-3-Subparagraph(fc)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481687/323) extlink & oid = 126901519 & loc = d3e8933-108599**Reference 10-50-3Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-Paragraph4-28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482907/825](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-Paragraph4-28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482907/825) extlink & oid = 124431687 & loc = d3e22595-107794**Reference 10-50-28Reference 4:** [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS9950-Paragraph1-6-1-PublisherFASB-Subparagraph\(SX210.7-04\(18\)\)-URIhttps://asc.fasb.org//1943274/2147482765/220](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS9950-Paragraph1-6-1-PublisherFASB-Subparagraph(SX210.7-04(18))-URIhttps://asc.fasb.org//1943274/2147482765/220) extlink & oid = 120400993 & loc = SL114874131-224262**Reference 6Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-50-Paragraph1-3-PublisherFASB-Subparagraph\(f\)-URIhttps://asc.fasb.org//1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-50-Paragraph1-3-PublisherFASB-Subparagraph(f)-URIhttps://asc.fasb.org//1943274/2147483443/250) extlink & oid = 126732423 & loc = SL123482106-10-50-23801**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section50-Paragraph6-1-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section50-Paragraph6-1-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250) extlink & oid = 124431353 & loc = SL124452729-227067**Reference 10-50-1Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS9965-Paragraph1B-1-Subparagraph\(f\)SX210.13-02\(a\)-PublisherFASB\(5\)\)-URIhttps://asc.fasb.org//1943274/2147480175/815](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS9965-Paragraph1B-1-Subparagraph(f)SX210.13-02(a)-PublisherFASB(5))-URIhttps://asc.fasb.org//1943274/2147480175/815) extlink & oid = 126975872 & loc = SL124442552-40-65-122756**Reference 1Reference 8:** [http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS9950-Paragraph2-8-PublisherFASB-Subparagraph\(SX210.5-03\(20\)\)-URIhttps://asc.fasb.org//1943274/2147483443/250](http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS9950-Paragraph2-8-PublisherFASB-Subparagraph(SX210.5-03(20))-URIhttps://asc.fasb.org//1943274/2147483443/250) extlink & oid = 126953954 & loc = SL114868664-224227**Reference 10-50-8Reference 9:** <http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-50-Paragraph28-9-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250> extlink & oid = 126954810 & loc = d3e3602-108585**Reference 10-50-9Reference**

10: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-NameAccountingStandardsCodification-Section-50-Paragraph-11-Subparagraph\(a\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11Reference11](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-NameAccountingStandardsCodification-Section-50-Paragraph-11-Subparagraph(a)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11Reference11): [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Section-50-Paragraph-1-Subparagraph\(b\)\(2\)-URIhttps://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794Reference11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Section-50-Paragraph-1-Subparagraph(b)(2)-URIhttps://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794Reference11): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-Subparagraph\(SX210-13-01\(a\)-1-Publisher-FASB\)\(iii\)\(A\)\)-URIhttps://asc.fasb.org/1943274/2147483443/250extlink&oid=126975872&loc=SL124442526-122756Reference10-50-4Reference13](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-11-Subparagraph(b)SX210-13-01(a)-Publisher-FASB(4)(iv)-URIhttps://asc.fasb.org/1943274/2147483443/250extlink&oid=126975872&loc=SL124442526-10-50-122756Reference11Reference12): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-45-Paragraph-1A-7-Publisher-FASBSubparagraph\(SX210-13-01\(a\)\(4\)\(i\)\)-URIhttps://asc.fasb.org/1943274/2147483581/946extlink&oid=126975872&loc=SL124442526-220-45-122756Reference7Reference15](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-55-Paragraph-1B-Subparagraph(SX210-10-13-Publisher-FASB02(a)(4)(i))-URIhttps://asc.fasb.org/1943274/2147480167/946extlink&oid=126975872&loc=SL124442552-830-55-122756Reference10Reference14): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-Paragraph-9-1-Subparagraph\(SX210-7-04\(18\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483586/944extlink&oid=124431687&loc=d3e22663-220-S99-107794Reference16](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-220-NameAccountingStandardsCodification-Topic-250-SubTopic-10-Section-S99-Paragraph-9-1-Subparagraph(SX210-7-04(18))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483586/944extlink&oid=124431687&loc=d3e22663-220-S99-107794Reference16): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-NameAccountingStandardsCodification-Topic-825-SubTopic-10-Section-S99-Paragraph-28-3-Subparagraph\(SX210-6-09\(1\)\(d\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483575/946extlink&oid=123596393&loc=d3e14064-108612Reference220-S99-3Reference19](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-Paragraph-1A-1-Subparagraph(SX210-13-6-01-07(a-9)(+)-Publisher-FASB(iii))-URIhttps://asc.fasb.org/1943274/2147483575/946extlink&oid=126975872&loc=SL124442526-220-S99-122756Reference17): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-235-SubTopic-10-Section-S99-Paragraph-1A-Subparagraph\(SX210-13-01\(a\)\(4\)-08\(g\)\(+\)\(ii\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference1AReference21](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-250-SubTopic-10-Section-S99-Paragraph-3-1A-Subparagraph(SX210-13-01(a)(4)(i))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=124431687&loc=d3e22583-10-S99-107794Reference1AReference20): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-323-SubTopic-10-Section-S99-Paragraph-3-1A-Subparagraph\(e-SX210-13-01\(a\)\(4\)\(iv\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=114001798&loc=d3e33918-10-S99-111571Reference1AReference23](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-260-SubTopic-10-Section-45-S99-Paragraph-60B-1A-Subparagraph(SX210-13-01(a)(4)(iii)(A))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=126958026&loc=SL5780133-10-S99-109256Reference1AReference22): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-220-SubTopic-10-Section-45-S99-Paragraph-1A-1B-Subparagraph\(SX210-13-02\(a\)\(4\)\(i\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=126968391&loc=SL7669619-10-S99-108580Reference1BReference25](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-250-SubTopic-10-Section-S99-Paragraph-8-1A-Subparagraph(SX210-13-01(a)(5))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=124431687&loc=d3e22658-10-S99-107794Reference1AReference24): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-250-SubTopic-10-Section-S99-Paragraph-11-1B-Subparagraph\(b-SX210-13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=124431687&loc=d3e22694-10-S99-107794Reference1BReference27](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-280-SubTopic-10-Section-S99-Paragraph-3-1B-Subparagraph(SX210-13-02(a)(4)(iii)(A))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=126901519&loc=d3e8924-10-S99-108599Reference1BReference26): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-205-SubTopic-20-Section-S99-Paragraph-7-1B-Subparagraph\(SX210-13-02\(a\)\(5\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=109222650&loc=SL51721683-10-S99-107760Reference1BReference29](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-NameAccountingStandardsCodification-Topic-250-SubTopic-10-Section-S99-Paragraph-11-1B-Subparagraph(SX210-13-02(a)(4)(iv))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480097/470extlink&oid=124431687&loc=d3e22694-10-S99-107794Reference1BReference28): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-NameAccountingStandardsCodification-Topic-280-SubTopic-10-Section-50-Paragraph-22-32-Subparagraph\(f\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482810/280extlink&oid=126901519&loc=d3e8736-108599Reference10-50-32Reference31](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-NameAccountingStandardsCodification-Topic-220-SubTopic-10-Section-45-50-Paragraph-1B-30-Subparagraph(a-b)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482810/280extlink&oid=126968391&loc=SL7669625-10-50-108580Reference30Reference30): [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-280-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1B-31-Publisher-FASBSubparagraph\(SX210-13-02\(a\)\(4\)\(iii\)\(B\)\)-URIhttps://asc.fasb.org/1943274/2147482810/280extlink&oid=126975872&loc=SL124442552-10-50-122756Reference31Reference33](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-260-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-45-Paragraph-1A-60B-Subparagraph(SX210-13-01(a)-Publisher-FASB(5))-URIhttps://asc.fasb.org/1943274/2147482689/260extlink&oid=126975872&loc=SL124442526-122756Reference10-45-60BReference32): [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-205-SubTopic-20-NameAccountingStandardsCodification-Topic-280-SubTopic-10-Section-50-Paragraph-30-7-Publisher-FASBSubparagraph\(b\)-URIhttps://asc.fasb.org/1943274/2147483499/205extlink&oid=126901519&loc=d3e8906-108599Reference20-50-7Reference35](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1B-32-Subparagraph(c)SX210-13-02(a)-Publisher-FASB(4)(iii)(A))-URIhttps://asc.fasb.org/1943274/2147482810/280extlink&oid=126975872&loc=SL124442552-10-50-122756Reference32Reference34): [http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic-230-SubTopic-10-NameAccountingStandardsCodification-Topic-280-SubTopic-10-Section-50-45-Paragraph-32-28-Publisher-FASBSubparagraph\(e\)-URIhttps://asc.fasb.org/1943274/2147482740/230extlink&oid=126901519&loc=d3e8933-108599Reference1-#as-InstantX-DefinitionContractualInterestRateforFundsBorrowedUndertheDebtAgreement-ReferencesReference1](http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic-230-SubTopic-10-NameAccountingStandardsCodification-Topic-280-SubTopic-10-Section-50-45-Paragraph-32-28-Publisher-FASBSubparagraph(e)-URIhttps://asc.fasb.org/1943274/2147482740/230extlink&oid=126901519&loc=d3e8933-108599Reference1-#as-InstantX-DefinitionContractualInterestRateforFundsBorrowedUndertheDebtAgreement-ReferencesReference1): [http://www.fasb.org/2003-us-gaap/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-NameAccountingStandardsCodification-Topic-210-SubTopic-10-Section-S99-Paragraph-2-1-Subparagraph\(SX210-5-03-02.22\(20-a\)\(1\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483621/220extlink&oid=120391452&loc=d3e13212-122682-DetailsName10-S99-2Reference39](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-NameAccountingStandardsCodification-Topic-470-SubTopic-20-Section-45-50-Paragraph-1B-Subparagraph(a-b)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482790/220extlink&oid=123466505&loc=SL123495323-10-45-1BReference112611Reference38-2): [http://www.fasb.org/us-gaap-DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap-Role/ref/legacyRef-Topic-942-gaap-Data Type:dttr-SubTopic-220-types:percentItemTypeBalanceType:na-DetailsName:us-gaap_NetIncomeLossNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-ReferencesNo definition available. Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstractNamespacePrefix:us-gaap_DataType:xbrli:stringItemTypeBalanceType:naPeriodType:durationX-DefinitionAmount, after tax and adjustment, of unrealized gain \(loss\) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available- for- sale\) and unrealized gain \(loss\) on investment in debt security measured at amortized cost \(held- to- maturity\) from transfer to available- for- sale. ReferencesReference 1: <http://www.xbrl.org/2003/role/>](http://www.fasb.org/us-gaap-DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap-Role/ref/legacyRef-Topic-942-gaap-Data Type:dttr-SubTopic-220-types:percentItemTypeBalanceType:na-DetailsName:us-gaap_NetIncomeLossNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-ReferencesNo definition available. Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstractNamespacePrefix:us-gaap_DataType:xbrli:stringItemTypeBalanceType:naPeriodType:durationX-DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held- to- maturity) from transfer to available- for- sale. ReferencesReference 1: http://www.xbrl.org/2003/role/)

disclosureRef- Publisher FASB- Topic 220- SubTopic 10 - Name Accounting Standards Codification- Section 45- Paragraph 10A- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10 -Section 45- Paragraph 10A- Subparagraph (f)- URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 10A- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10 -Section 45- Paragraph 11- URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 220- SubTopic 10 -Section 45- Paragraph 10A- 11 - Publisher FASB Subparagraph (e)- URI https://asc.fasb.org//1943274/2147482790/220 extlink&oid=126968391&loc=SL7669646-108580-10-45-11 Details Name: us- gaap_ OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available- for- sale securities. ReferencesReference 1: http://fasb.org/us- gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 15- SubTopic 10 - Topic 220- Publisher FASB SubTopic 10 -Section 45- Paragraph 15- URI https://asc.fasb.org//1943274/2147482790/220 extlink&oid=126968391&loc=d3e689-10-45-108580Reference 15Reference 2: http://fasb.org/us- gaap/role/ref/legacyRef- Publisher FASB- Topic 220- SubTopic 10 - Name Accounting Standards Codification- Topic 220- SubTopic 10- Section 45- Paragraph 11- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220 extlink&oid=126968391&loc=d3e637-10-45-108580Reference 11Reference 3: http://fasb-www.xbrl.org/2003 us- gaap/ role / disclosureRef ref/legacyRef- Publisher FASB- Topic 320- SubTopic 10 - Name Accounting Standards Codification- Topic 320- SubTopic 10 -Section 50- Paragraph 9- Subparagraph (d)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481800/320 extlink&oid=126970911&loc=d3e27357-111563Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 220- SubTopic 10 - Name Accounting Standards Codification- Topic 220- SubTopic 10 -Section 45- Paragraph 17A- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220 extlink&oid=126968391&loc=SL34724391-108580-10-45-17A Details Name: us- gaap_ OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held- to- maturity) from transfer to available- for- sale. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 320- SubTopic 10 - Name Accounting Standards Codification- Section 50- Paragraph 9- Subparagraph (d)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10 -Section 45- Paragraph 10A- Subparagraph (e)- URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 10A- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10 - Name Accounting Standards Codification- Section 45- Paragraph 11- Publisher FASB- URI https://asc.fasb.org//1943274/2147482790/220 extlink&oid=126968391&loc=d3e637-108580-10-45-11 Details Name: us- gaap_ OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationConsolidated Statements of Cash Flows- USD (\$) 12 Months EndedDec. 31, 2022-2023 Dec. 31, 2021Cash-2022Cash flows from operating activities: Net loss \$ (19,514,977) \$ (35,898,234) \$ (20,769,250) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and 248,154 196, amortization-510 Amortization 731 of right- of- use assets 471, 629-702-851 535, 119 Recognition of deferred revenue (500,000) Realized and unrealized losses, net, on investment securities 34,302 34,918 Change-468 Change in fair value of earn- out milestone liability (5,396,000) (1,622,000) Stock- based compensation 759,013 2,673,034 3,759,737 Change-047 Change in of deferred income tax asset 462-286 641 (183,580) Loss on extinguishment of debt 329,158 Write- off of note receivable (Transomic) 375,000 377 Impairment--- Impairment of goodwill and in- process research and development 13,366,234 1,976,101 Amortization-234 Amortization of deferred finance charges and debt discount associated with note payable 55,122 181,259-237,258 Net 259 Net changes in: Accrued interest receivable on investment securities 68,136 (20,088) (108,844) Advances and, deposits , on clinical programs and other current assets (514-141, 600-619) 43 (786, 718) Other 980 Other assets 133,489 (124-241, 728-511) Accounts payable and - trade 1,039,372 302,404 Other accrued liabilities (1,072-992, 929 529-247, 142 Deferred revenue (500,000) 2 (500, 000) Net 111,901 Net cash used in operating activities (19,022,148) (23,131-096, 895 376) (16,223,603) Cash flows from investing activities: Purchases of investment in debt securities (13,541,806) (48,191-226, 390 922) (53,811,069) Proceeds from sale and maturity of investment in debt securities 25,000,000 56,775,000 24,000-000 Purchases of property and equipment (451,759) (267,800) (311,613) Net cash used in provided by investing activities 11,006,435 8,315-280, 810 Cash 278 (30,122,682) Cash flows from financing activities: Proceeds from redeemable convertible preferred stock offering 28,500,000 Payment-000 Payment upon redemption of redeemable convertible preferred stock (28,500,000) Proceeds from issuance sale of common stock equity, net of issuance costs 2,781,438 6,722,654 Payoff 667-52,688, 946 Proceeds from issuance of the SVB loan and accrued common stock upon exercise of warrants 1,508,666 Proceeds from issuance of common stock upon exercise of stock options 4,725 Proceeds from notes payable 5,756,630 Payments on notes payable including end- of- term fees (5-6, 190-420, 587-000) Net cash (used in) provided by financing activities (3,638,562) 6,722,654 Net change 667-54,768,380 Change in cash, cash equivalents and restricted cash (11,654,275) (8,093,431) Cash 8,422,095 Cash, cash equivalents and restricted cash at beginning of year 17,492,841 25,586,272 Cash 272-17,164,177 Cash, cash equivalents and restricted cash at end of year 5,838,566 17,492,841 25,586,272 Supplemental 841 Supplemental disclosure of cash flow information: Income taxes paid 2,500 2, Interest 000 Interest (179,542 4,847, 359 Non- 359) (357,277) Cash Investing and Financing Activities Recognition paid for amounts included in measurement of lease right of use asset and liabilities liability : Operating cash flows from lease payments 601,495-568, 269 Realized and unrealized gains, net, on investment in debt securities \$ 26-1, 911 494 \$ 7, 974 X-049 X- Definition Amortization of deferred finance charges and debt discount associated with notes payable. ReferencesNo definition available. Details Name: IMNN_ AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionGain loss from change in earnout milestone liability. ReferencesNo definition available. Details Name: IMNN_ GainLossFromChangeInEarnoutMilestoneLiability Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionImpairment Definition Payoff of the SVB loan in- process research and development accrued end- of- term fees ReferencesNo definition available. Details Name: IMNN_ ImpairmentOfGoodwillAndInProcessResearchAndDevelopment IMNN_ PaymentOffOfLoanAndAccruedEndofTermFees Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: debit-credit Period Type: durationX- DefinitionPayments on notes payable including endof term fees- Definition Recognition of right of use asset and liability ReferencesNo definition available. Details Name: IMNN_ PaymentsOnNotesPayableIncludingEndofTermFees- IMNN_ RecognitionOfRightUseAssetAndLiability Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionProceeds from issuance of common stock upon exercise of stock options- ReferencesNo definition available. Details Name: IMNN_ ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions- us- gaap_ AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: IMNN- us- gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: instantX- durationX- DefinitionContractual interest rate for funds borrowed, under DefinitionAmount of direct write- downs of accounts receivable charged against the allowance debt agreement. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 326- SubTopic 20 - Name Accounting Standards Codification- Topic 470- SubTopic 20 -Section 50- Paragraph 1B-13- Subparagraph (b-d) - Publisher FASB- URI https://asc.fasb.org//1943274/2147479319/326 extlink&oid=123466505&loc=SL123495323-112611Reference 2-20-50-13 Details Name : http://fasb.org/us- gaap AllowanceForDoubtfulAccountsReceivableWriteOffs Namespace Prefix: us gaap /role /ref/legacyRef- gaap_ Publisher FASB- Name Accounting Standards Codification- Topic Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRealized and unrealized gains and losses net on investment in debt securities. ReferencesNo definition available. Details Name: IMNN_ RealizedAndUnrealizedGainsAndLossesNetOnInvestmentInDebtSecurities Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_ AdjustmentsNoneashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us- gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: http://fasb-www.xbrl.org/2003 us- gaap/ role / disclosureRef ref/legacyRef- Publisher FASB- Topic 230-

SubTopic 10 - Name Accounting Standards Codification- **Section 50- Paragraph 8- Publisher FASB- URI https://asc.fasb.org//1943274/2147482913/230-10-50-8**Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10 -Section 50- Paragraph 8- URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10 -Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org//1943274/2147482740/230> extlink&oid=126954810&loc=d3e3521-108585**Reference 10- 45- 24**Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 4- Publisher FASB- URI https://asc.fasb.org//1943274/2147482740/230> extlink&oid=126954810&loc=d3e3044-108585**10- 45- 4** Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10 -Section 45- Paragraph 4- Publisher FASB- URI https://asc.fasb.org//1943274/2147482740/230> extlink&oid=123444420&loc=d3e33268-110906**Reference 10- 45- 24**Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 24-1- SubTopic 230- Topic 830- Publisher FASB- URI https://asc.fasb.org//1943274/2147481877/830> extlink&oid=126954810&loc=d3e3521-108585**230- 45- 1** Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Subparagraph \(b\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479806/606-10-50-8) Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType monetaryItemType Balance Type: na-credit Period Type: durationX- DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 99- Paragraph 1- Subparagraph \(SAB Topic 6. I. 7\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 99- Paragraph 1- Subparagraph (SAB Topic 6. I. 7)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=122134291&loc=d3e330036-10-45-122817**Reference 28**Reference 2: [http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 4- 08 \(h\) \(1\) \(Note 1\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4- 08 (h) (1) (Note 1))- Publisher FASB- URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section S99- Paragraph 1- Subparagraph \(SAB Topic 6. I. Fact. 1\)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817](http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 1)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235- SubTopic 10- Section S99- Paragraph 1- Subparagraph \(SX 210 SAB Topic 6. I. 7\)- URI https://asc.fasb.org//1943274/2147479360/740](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210 SAB Topic 6. I. 7)- URI https://asc.fasb.org//1943274/2147479360/740) extlink&oid=120395691&loc=d3e23780-10-S99-122690**Reference 1**Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section S99- Paragraph 1- Subparagraph \(SAB Topic 6. I. Fact. 2\)- Publisher FASB \(1\) \(Note 1\)\)- URI https://asc.fasb.org//1943274/2147479360/740](http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 2)- Publisher FASB (1) (Note 1))- URI https://asc.fasb.org//1943274/2147479360/740) extlink&oid=122134291&loc=d3e330036-10-S99-122817**Reference 1**Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SAB Topic 6. I. 7\)- URI https://asc.fasb.org//1943274/2147479360/740](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 6. I. 7)- URI https://asc.fasb.org//1943274/2147479360/740) extlink&oid=126954810&loc=d3e3602-10-S99-108585**Reference 1**Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section 50- Paragraph 9- Subparagraph \(b\)- URI https://asc.fasb.org//1943274/2147482685/740](http://www.xbrl.org/2003/role/disclosureRef-Topic 740- SubTopic 10- Section 50- Paragraph 9- Subparagraph (b)- URI https://asc.fasb.org//1943274/2147482685/740) extlink&oid=121826272&loc=d3e32639-109319**10- 50- 9** Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe aggregate amount of expense recognized in the current period that allocates reflects the allocation of the cost of tangible assets - intangible over the assets useful lives. Includes production and non- production related depreciation or depleting assets to periods that benefit from use of the assets. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 280-230- Publisher FASB SubTopic 10- Section 50- Paragraph 22- Subparagraph \(c\)- URI https://asc.fasb.org//1943274/2147482740/230](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 280-230- Publisher FASB SubTopic 10- Section 50- Paragraph 22- Subparagraph (c)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126901519&loc=d3e8736-10-45-108599**Reference 28**Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(b\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479360/740](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479360/740) extlink&oid=126954810&loc=d3e3602-108585**10- 50- 1** Details Name: us-gaap_DepreciationDepletionAndAmortization-gaap_Depreciation Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit xbrli: monetaryItemType Balance Type: debit Period Type: durationX instantX- DefinitionThe amount of cash paid during DefinitionContractual interest rate for funds borrowed, under the debt agreement current period to foreign, federal, state, and local authorities as taxes on income. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 230-470- SubTopic 10- Section 50- Paragraph 2-1B- Publisher FASB Subparagraph \(b\)- URI https://asc.fasb.org//1943274/2147482913/230](http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 230-470- SubTopic 10- Section 50- Paragraph 2-1B- Publisher FASB Subparagraph (b)- URI https://asc.fasb.org//1943274/2147482913/230) extlink&oid=123466505&loc=SL123495323-10-50-2**Reference 112611**Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-210- SubTopic 10- Section 45- S99- Paragraph 25-1- Subparagraph \(f\) SX 210.5- 02.22 \(a\) -Publisher FASB \(1\)\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-210- SubTopic 10- Section 45- S99- Paragraph 25-1- Subparagraph (f) SX 210.5- 02.22 (a) -Publisher FASB (1))- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=120391452&loc=d3e13212-122682**10- 45- 25** Details Name: us-gaap_IncomeTaxesPaid-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: xbrli: dtr- types- monetaryItemType percentItemType Balance Type: na Period Type: durationX- DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://www.xbrl.org/2003/role/exampleRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe increase..... xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase (decrease) in operating assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230- SubTopic 10- Section 45- Paragraph 28- Subparagraph (a)- URI https://asc.fasb.org//1943274/2147482740/230) extlink&oid=126954810&loc=d3e3602-108585**10- 45- 28** Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1:

SubTopic 10-Section 45-Paragraph 28-Subparagraph (a)- URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3602-108585-10-45-28 Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-230-SubTopic-10>. Name Accounting Standards Codification-Section 45-Paragraph 17-Subparagraph (d)- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482740/230-10-45-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Section-50-Paragraph-2> URI <https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-\(e\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-(e)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-25>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Section-45-Paragraph-17-Subparagraph-\(d\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Section-45-Paragraph-17-Subparagraph-(d)-URI) <https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-50-Paragraph-25-2-Publisher-FASB-Subparagraph-\(e\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-50-Paragraph-25-2-Publisher-FASB-Subparagraph-(e)-URI) <https://asc.fasb.org/1943274/2147482913/230> extlink & oid=126954810 & loc=d3e3536-108585-10-50-2 Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-230-SubTopic-10-Section-45-Paragraph-17-Subparagraph-\(d\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-230-SubTopic-10-Section-45-Paragraph-17-Subparagraph-(d)-URI) <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3521-108585-10-45-24 Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-230-SubTopic-10-Section-45-Paragraph-24-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3521-108585-10-45-24 Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-230-SubTopic-10-Section-45-Paragraph-28-25-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3602-108585-10-45-25 Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Section-942-SubTopic-220-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-4-04-08-\(22-g\)-\(I\)-\(ii\)\)-Publisher-FASB-URI](http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Section-942-SubTopic-220-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-4-04-08-(22-g)-(I)-(ii))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480678/235> extlink & oid=120399700 & loc=SL114874048-224260Reference 10- S99-1Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-323-SubTopic-10-Section-50-Paragraph-32-3-Subparagraph-\(f\)-\(c\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-323-SubTopic-10-Section-50-Paragraph-32-3-Subparagraph-(f)-(c))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147481687/323> extlink & oid=126901519 & loc=d3e8933-108599Reference 10- 50-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-825-SubTopic-10-Section-50-Paragraph-1-6-Publisher-FASB-Subparagraph-\(SX-210-7-04-\(18\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-825-SubTopic-10-Section-50-Paragraph-1-6-Publisher-FASB-Subparagraph-(SX-210-7-04-(18))-URI) <https://asc.fasb.org/1943274/2147482765/220> extlink & oid=120400993 & loc=SL114874131-10-50-224263Reference 6Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1-3-Publisher-FASB-Subparagraph-\(f\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1-3-Publisher-FASB-Subparagraph-(f))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=126732423 & loc=SL123482106-10-50-238011Reference 3Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1-3-Publisher-FASB-Subparagraph-\(f\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1-3-Publisher-FASB-Subparagraph-(f))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=124431353 & loc=SL124452729-227067Reference 10- 50-1Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-815-SubTopic-40-Paragraph-1B-1-Subparagraph-\(f\)\(SX-210-13-02\(a\)\)-Publisher-FASB-\(5\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-815-SubTopic-40-Paragraph-1B-1-Subparagraph-(f)(SX-210-13-02(a))-Publisher-FASB-(5))-URI) <https://asc.fasb.org/1943274/2147480175/815> extlink & oid=126975872 & loc=SL124442552-40-65-122756Reference 1Reference 8: [http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-\(f\)\(SX-210-13-02\(a\)\)-Publisher-FASB-\(5\)\)-URI](http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-(f)(SX-210-13-02(a))-Publisher-FASB-(5))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=126953954 & loc=SL114868664-224227Reference 10- 50-8Reference 9: [http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-\(f\)\(SX-210-13-02\(a\)\)-Publisher-FASB-\(5\)\)-URI](http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-(f)(SX-210-13-02(a))-Publisher-FASB-(5))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=126954810 & loc=d3e3602-108585Reference 10- 50-9Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-45-50-Paragraph-11-Subparagraph-\(a\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-45-50-Paragraph-11-Subparagraph-(a))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Section-50-Paragraph-1-Subparagraph-\(b\)\(2\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Section-50-Paragraph-1-Subparagraph-(b)(2)-URI) <https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)-\(4\)\)-Publisher-FASB-\(iii\)-\(A\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-50-Paragraph-1A-Subparagraph-(SX-210-13-01(a)-(4))-Publisher-FASB-(iii)-(A))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=126975872 & loc=SL124442526-122756Reference 11Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-\(f\)\(SX-210-13-02\(a\)\)-Publisher-FASB-\(5\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-250-SubTopic-10-Section-815-SubTopic-40-Paragraph-1B-1-Subparagraph-(f)(SX-210-13-02(a))-Publisher-FASB-(5))-URI) <https://asc.fasb.org/1943274/2147483443/250> extlink & oid=126975872 & loc=SL124442526-122756Reference 10Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-55-Paragraph-1B-Subparagraph-\(SX-210-10-13-Publisher-FASB-92\(a\)\(4\)\(i\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-55-Paragraph-1B-Subparagraph-(SX-210-10-13-Publisher-FASB-92(a)(4)(i))-URI) <https://asc.fasb.org/1943274/2147480167/946> extlink & oid=126975872 & loc=SL124442552-830-55-122756Reference 10Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-45-Paragraph-1A-7-Publisher-FASB-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(i\)\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99-45-Paragraph-1A-7-Publisher-FASB-Subparagraph-(SX-210-13-01(a)(4)(i))-URI) <https://asc.fasb.org/1943274/2147483581/946> extlink & oid=126975872 & loc=SL124442526-220-45-122756Reference 7Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-S99-Paragraph-9-1-Subparagraph-\(SX-210-7-04\(18\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-S99-Paragraph-9-1-Subparagraph-(SX-210-7-04(18))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483586/944> extlink & oid=124431687 & loc=d3e22663-220-S99-107794Reference 1Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-S99>

50 - Paragraph 4B-22. **Publisher FASB** Subparagraph (SX 210.13-02(a)(4)(iv)) - URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126975872 & loc = SL124442552 - 10-50-122756Reference - 22Reference 17: <http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220> - Name Accounting Standards Codification-Topic 470-SubTopic 10-Section 599-Paragraph 1A-1-Subparagraph (SX 210.13-01(a)(4)(i)) - **Publisher FASB** (ii) - URI <https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 126975872 & loc = SL124442526-220-599-122756Reference - 1Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-599-Paragraph-28-3-Subparagraph-\(SX-210.6-09\(1\)\(d\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Topic-825-SubTopic-10-Section-50-599-Paragraph-28-3-Subparagraph-(SX-210.6-09(1)(d))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 123596393 & loc = d3e14064 - 108612Reference 220-599-3Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(i\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-(SX-210.13-01(a)(4)(i))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 124431687 & loc = d3e22583 - 10-599-107794Reference-1AReference 20: [http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(ii\)\)-Publisher-FASB](http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-599-Paragraph-1A-Subparagraph-(SX-210.13-01(a)(4)(ii))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 120395691 & loc = d3e23780-10-599-122690Reference-1AReference 21: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-260-SubTopic-10-Section-45-599-Paragraph-60B-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-260-SubTopic-10-Section-45-599-Paragraph-60B-1A-Subparagraph-(SX-210.13-01(a)(4)(iii)(A))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 126958026 & loc = SL5780133 - 10-599-109256Reference-1AReference 22: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-323-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-\(SX-210.13-01\(a\)\(4\)\(iv\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-323-SubTopic-10-Section-50-599-Paragraph-3-1A-Subparagraph-(SX-210.13-01(a)(4)(iv))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 114001798 & loc = d3e33918 - 10-599-111571Reference-1AReference 23: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-8-1A-Subparagraph-\(SX-210.13-01\(a\)\(5\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-8-1A-Subparagraph-(SX-210.13-01(a)(5))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 124431687 & loc = d3e22658 - 10-599-107794Reference-1AReference 24: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-599-Paragraph-1A-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(i\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-599-Paragraph-1A-1B-Subparagraph-(SX-210.13-02(a)(4)(i))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 126968291 & loc = SL7669619 - 10-599-108580Reference-1BReference 25: [http://www.xbrl.org/2003/role/exampleRef/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-599-Paragraph-3-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/exampleRef/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-599-Paragraph-3-1B-Subparagraph-(SX-210.13-02(a)(4)(iii)(A))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 126901519 & loc = d3e8924 - 10-599-108599Reference-1BReference 26: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-11-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-11-1B-Subparagraph-(SX-210.13-02(a)(4)(iii)(B))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 124431687 & loc = d3e22694 - 10-599-107794Reference-1BReference 27: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-11-1B-Subparagraph-\(SX-210.13-02\(a\)\(4\)\(iv\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-250-SubTopic-10-Section-50-599-Paragraph-11-1B-Subparagraph-(SX-210.13-02(a)(4)(iv))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 124431687 & loc = d3e22694 - 10-599-107794Reference-1BReference 28: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-205-SubTopic-20-Section-50-599-Paragraph-7-1B-Subparagraph-\(SX-210.13-02\(a\)\(5\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-205-SubTopic-20-Section-50-599-Paragraph-7-1B-Subparagraph-(SX-210.13-02(a)(5))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147480097/470> extlink & oid = 109222650 & loc = SL51721683 - 10-599-107760Reference-1BReference 29: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-50-Paragraph-1B-30-Subparagraph-\(a-b\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-50-Paragraph-1B-30-Subparagraph-(a-b)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126968391 & loc = SL7669625 - 10-50-108580Reference-30Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-22-32-Subparagraph-\(f\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-22-32-Subparagraph-(f)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126901519 & loc = d3e8736 - 108599Reference-10-50-32Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-45-Paragraph-1A-60B-Subparagraph-\(SX-210.13-01\(a\)\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-45-Paragraph-1A-60B-Subparagraph-(SX-210.13-01(a))-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482689/260> extlink & oid = 126975872 & loc = SL124442526 - 122756Reference-10-45-60BReference 32: <http://www.xbrl.org/2003/role/disclosureRef/exampleRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-50-Paragraph-1B-31-Publisher-FASB> Subparagraph (SX 210.13-02(a)(4)(iii)(B)) - URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126975872 & loc = SL124442552 - 10-50-122756Reference - 31Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-50-Paragraph-1B-32-Subparagraph-\(c\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-470-SubTopic-10-Section-599-50-Paragraph-1B-32-Subparagraph-(c)-Publisher-FASB) (c SX 210.13-02(a)) - **Publisher FASB** (4)(iii)(A)) - URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126975872 & loc = SL124442552 - 10-50-122756Reference - 32Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-Paragraph-30-7-Publisher-FASB> Subparagraph (b) - URI <https://asc.fasb.org/1943274/2147483499/205> extlink & oid = 126901519 & loc = d3e8906 - 108599Reference-20-50-7Reference 35: <http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Topic-280-SubTopic-10-Section-50-45-Paragraph-32-28-Publisher-FASB> Subparagraph (e) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid = 126901519 & loc = d3e8933 - 108599-Details Name: us-45-gaap_NetIncomeLoss Namespace Prefix: us-28Reference 36 gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-45-Paragraph-5-1A-Subparagraph-\(e-a\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-45-Paragraph-5-1A-Subparagraph-(e-a)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482790/220> extlink & oid = 123391704 & loc = SL77918643 - 209977Reference-2-10-45-1AReference 37: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-50-45-Paragraph-4-1B-Subparagraph-\(g-a\)\(1\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-50-45-Paragraph-4-1B-Subparagraph-(g-a)(1)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482790/220> extlink & oid = 128292326 & loc = SL77918686 - 209980-lives-ReferencesReference 1-10-45-1BReference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-350-SubTopic-30-Section-50-599-Paragraph-2-Subparagraph-\(a\)-SX-210.5-03\(2\)-\(2\)-Publisher-FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Topic-350-SubTopic-30-Section-50-599-Paragraph-2-Subparagraph-(a)-SX-210.5-03(2)-(2)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147483621/220> extlink & oid = 66006027 & loc = d3e16323 - 10-599-109275Reference - 2Reference 2-39: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-599-Paragraph-28-1-Subparagraph-\(b\)-SX-210.9-04\(22\)-Publisher-FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-599-Paragraph-28-1-Subparagraph-(b)-SX-210.9-04(22)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147483589/942> extlink & oid = 126954810 & loc = d3e3602 - 220-108585-Details Name: us-599-gaap_AdjustmentForAmortization Namespace Prefix: us-1-gaap-Data Type: Details Name: us-gaap-OperatingLeasePayments-gaap_NetIncomeLoss Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-warrants or rights 4,059,213,333 Warrants, exercise price \$ 31.05 X-ReferencesNo definition available. Details Name: IMNN-DisclosureWarrantsAbstract-us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: IMNN-us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Amount Definition Exercise price per share or per unit of warrants or periodic reduction over lease term of carrying amount of rights - right outstanding - of us asset from operating lease. ReferencesReference 1: [http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef-Publisher-FASB-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-45-Paragraph-3-28-Subparagraph-\(b\)-Publisher-FASB](http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef-Publisher-FASB-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-45-Paragraph-3-28-Subparagraph-(b)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid = 126973232 & loc = d3e21475 - 112644-10-45-28-Details Name: us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap-Data Type: xbrli:dtr-types: perShareItemType-monetaryItemType Balance Type: debit na-Period Type: Period Type: durationX-Definition The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-15-Subparagraph-\(a\)-Publisher-FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-15-Subparagraph-(a)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid = 126954810 & loc = d3e3291 - 108585-10-45-15-Details Name: us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-13-11-Publisher-FASB> Subparagraph (a) - URI <https://asc.fasb.org/1943274/2147481830/320> extlink & oid = 126954810 & loc = d3e3213 - 10-45-108585Reference-11Reference

2: [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph11-13-Subparagraph\(a\)-Publisher-FASB](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph11-13-Subparagraph(a)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3151-10-45-108585Reference 3: <http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic320-SubTopic10-Section45-Paragraph11-Publisher-FASB> - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=124260329 & loc=d3e26853-111562-10-45-11 Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph13-Subparagraph\(c\)-Publisher-FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph13-Subparagraph(c)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3213-108585-10-45-13 Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe cash inflow from the additional capital contribution to the entity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph\(a\)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph\(a\)-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URI) <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3255-108585-10-45-14 Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph\(a\)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph\(a\)-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URI) <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3255-108585-10-45-14 Details Name: us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-1943274/2147481830/320-10-45-11Reference2>: <http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-Section45-Paragraph11-URI> <https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585Reference2>: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph11-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-Section45-Paragraph12-Subparagraph\(a\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-Section45-Paragraph12-Subparagraph(a)-URI) <https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585Reference3>: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic320-SubTopic10-Section45-Paragraph11-12-Subparagraph\(a\)-Publisher-FASB](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic320-SubTopic10-Section45-Paragraph11-12-Subparagraph(a)-Publisher-FASB) - URI <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=124260329 & loc=d3e26853-111562-10-45-12 Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of noncash expense for share-based payment arrangement DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. ReferencesReference 1: [http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph\(a\)-URI](http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URI) <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3255-108585-10-45-28 Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of unrealized gain (loss) on investment noncash expense for share-based payment arrangement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph28-Subparagraph\(a\)-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-Publisher-FASB-SubTopic10-Section45-Paragraph28-Subparagraph(a)-URI) <https://asc.fasb.org/1943274/2147482740/230> extlink & oid=126954810 & loc=d3e3662-108585-10-45-28 Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationConsolidated Statements of Changes in Stockholders' Equity- USD (\$) Series A and B Preferred Stock [Member] Series A and B-Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock [Common] AOCI Attributable to Parent [Member] Retained Earnings [Member] TotalBalance TotalBeginning balance, value at Dec. 31, 2020 2021 \$ 27-57, 134-705 \$ 330-388, 669-600, 476-979 \$ (85, 188) \$ (312-7, 974 000, 341) \$ 18-(332, 611-769, 081Beginning balance 591) \$ 55, 795, 931Balance, shares at Dec. 31, 2020 2, 713, 402 Net loss (20, 769, 250) (20, 769, 250) Sale of equity through equity financing facilities \$ 29, 755-52, 659, 191-52, 688, 946Sale of equity through equity financing facilities, shares 2, 975, 503 Realized and unrealized gains and losses, net, on investment securities (7, 974) (7, 974) Stock-based compensation expense 3, 759, 737-3, 759, 737Issuance of common stock upon exercise of options \$ 5-4, 720-4, 725Issuance of common stock upon exercise of options, shares Shares issued pursuant to warrant exercises \$ 811-1, 507, 855-1, 508, 666Shares issued pursuant to warrant exercises, shares 81, 111 Ending balance, value at Dec. 31, 2021 \$ 57, 705-388, 600, 979 \$ (85, 188) (7, 974) (332, 769, 591) 55, 795, 931Ending balance, shares at Dec. 31, 2021 5, 770, 516 Net loss (35, 898, 234) (35, 898, 234) Effect of reverse stock split Effect of reverse stock split, shares (27) Issuance of preferred stock upon financing \$ 28, 500, 000 Issuance of preferred stock upon financing, shares 100, 000 Redemption of preferred stock \$ (28, 500, 000) Redemption of preferred stock, shares (100, 000) Sale of equity through equity financing facilities \$ 16, 644-6, 706, 010-6, 722, 654Sale of equity through equity financing facilities, shares 1, 664, 349 Realized and unrealized gains, net, on investment securities 34, 468-302-34, 468Stock-based compensation expense 2-758, 673-418 \$ 758, 034-2-418Effect of reverse stock split, 673 shares (5, 034) Ending 770, 516) balance Balance, value at Dec. 31, 2022 2023 \$ 74-93, 362-998 \$ 397-401, 980-500, 023-838 \$ (85, 188) \$ 26-60, 494-796 \$ (368-388, 667-182, 825-802) \$ 29-13, 327-387, 642Balance 866Ending balance, shares at Dec. 31, 2022 2023 7-9, 436-399, 219-811 X- DefinitionIssuance of preferred stock upon financing, shares. ReferencesNo definition available. Details Name: IMNN_StockIssuedDuringPeriodIssuanceOfPreferredStockUponFinancingShares Namespace Prefix: IMNN_Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionIssuance of preferred stock upon financing. ReferencesNo definition available. Details Name: IMNN_StockIssuedDuringPeriodValueIssuanceOfPreferredStockUponFinancing Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionStock issued during period value reverse stock splits. ReferencesNo definition available. Details Name: IMNN_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. ReferencesReference 1: <http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic718-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic20-Section55-Paragraph13-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147480483/718> extlink & oid=126964447 & loc=d3e11149-113907Reference 10-35-2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic718-SubTopic20-Section55-Paragraph13-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481089/718> extlink & oid=126964447 & loc=d3e11178-20-55-113907Reference 3: <http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Topic718-SubTopic10-Section35-55-Paragraph2-12-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481089/718> extlink & oid=126961718 & loc=d3e4534-113899-20-55-12 Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_Data Type: xbrli:

monetaryItem Type Balance Type: credit Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-Paragraph1-Subparagraph\(SX210.94-0408\(22g\)\(I\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Topic942-SubTopic220-SectionS99-Paragraph1-Subparagraph(SX210.94-0408(22g)(I)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235) extlink & oid=120399700 & loc=SL114874048-224260Reference 10- S99-1Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph323-Subparagraph\(fc\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic323-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph323-Subparagraph(fc)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323) extlink & oid=126901519 & loc=d3e8933-108599Reference 10- 50-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-Paragraph428-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic825-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-Paragraph428-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825) extlink & oid=124431687 & loc=d3e22595-107794Reference 10- 50-28Reference 4: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph16-PublisherFASB-Subparagraph\(SX210.7-04\(18\)\)-URIhttps://asc.fasb.org/1943274/2147482765/220](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph16-PublisherFASB-Subparagraph(SX210.7-04(18))-URIhttps://asc.fasb.org/1943274/2147482765/220) extlink & oid=120400993 & loc=SL114874131-10-50-224263Reference 6Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-50-Paragraph13-PublisherFASB-Subparagraph\(f\)-URIhttps://asc.fasb.org/1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic815-SubTopic40-Section65-50-Paragraph13-PublisherFASB-Subparagraph(f)-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=126732423 & loc=SL123482106-10-50-238011Reference 6Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section50-Paragraph61-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section50-Paragraph61-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=124431353 & loc=SL124452729-227067Reference 10- 50-1Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-65-Paragraph1B-1-Subparagraph\(fSX210.13-02\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-65-Paragraph1B-1-Subparagraph(fSX210.13-02(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815) extlink & oid=126975872 & loc=SL124442552-40-65-122756Reference 1Reference 8: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-50-Paragraph28-PublisherFASB-Subparagraph\(SX210.5-03\(20\)\)-URIhttps://asc.fasb.org/1943274/2147483443/250](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-50-Paragraph28-PublisherFASB-Subparagraph(SX210.5-03(20))-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=126953954 & loc=SL114868664-224227Reference 10- 50-8Reference 9: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-50-Paragraph28-9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250> extlink & oid=126954810 & loc=d3e3602-108585Reference 10- 50-9Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=124431687 & loc=d3e22499-107794Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-11-Subparagraph\(bSX210.13-01\(a\)\)-PublisherFASB\(4\)\(iv\)\)-URIhttps://asc.fasb.org/1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-11-Subparagraph(bSX210.13-01(a))-PublisherFASB(4)(iv))-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=126975872 & loc=SL124442526-10-50-122756Reference 11Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)-PublisherFASB\)\(iii\)\(A\)\)-URIhttps://asc.fasb.org/1943274/2147483443/250](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic250-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1A-Subparagraph(SX210.13-01(a)(4)-PublisherFASB)(iii)(A))-URIhttps://asc.fasb.org/1943274/2147483443/250) extlink & oid=126975872 & loc=SL124442526-122756Reference 10- 50-4Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic946-SubTopic830-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-55-Paragraph1B-Subparagraph\(SX210-10-13-PublisherFASB02\(a\)\(4\)\(i\)\)-URIhttps://asc.fasb.org/1943274/2147480167/946](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-PublisherFASB-Topic946-SubTopic830-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-55-Paragraph1B-Subparagraph(SX210-10-13-PublisherFASB02(a)(4)(i))-URIhttps://asc.fasb.org/1943274/2147480167/946) extlink & oid=126975872 & loc=SL124442552-830-55-122756Reference 10Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-45-Paragraph1A-7-PublisherFASB-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-URIhttps://asc.fasb.org/1943274/2147483581/946](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-45-Paragraph1A-7-PublisherFASB-Subparagraph(SX210.13-01(a)(4)(i))-URIhttps://asc.fasb.org/1943274/2147483581/946) extlink & oid=126975872 & loc=SL124442526-220-45-122756Reference 10Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph91-Subparagraph\(SX210.7-04\(18\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph91-Subparagraph(SX210.7-04(18))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944) extlink & oid=124431687 & loc=d3e22663-220-S99-107794Reference 10Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-22-PublisherFASB-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-URIhttps://asc.fasb.org/1943274/2147482810/280](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-22-PublisherFASB-Subparagraph(SX210.13-02(a)(4)(iv))-URIhttps://asc.fasb.org/1943274/2147482810/280) extlink & oid=126975872 & loc=SL124442552-10-50-122756Reference 10Reference 17: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-Paragraph1A-1-Subparagraph\(SX210.13-01\(a\)\(9\)-\(a-9\)-\(4\)-PublisherFASB\(iii\)\)-URIhttps://asc.fasb.org/1943274/2147483575/946](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-Paragraph1A-1-Subparagraph(SX210.13-01(a)(9)-(a-9)-(4)-PublisherFASB(iii))-URIhttps://asc.fasb.org/1943274/2147483575/946) extlink & oid=126975872 & loc=SL124442526-220-S99-122756Reference 10Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph283-Subparagraph\(fSX210.6-09\(1\)\(d\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph283-Subparagraph(fSX210.6-09(1)(d))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946) extlink & oid=123596393 & loc=d3e14064-108612Reference 220-S99-3Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph31A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph31A-Subparagraph(SX210.13-01(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=124431687 & loc=d3e22583-10-S99-107794Reference 1AReference 20: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4-08\(g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4-08(g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=120395691 & loc=d3e23780-10-S99-122690Reference 1AReference 21: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section45-S99-Paragraph60B-1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section45-S99-Paragraph60B-1A-Subparagraph(SX210.13-01(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=126958026 & loc=SL5780133-10-S99-109256Reference 1AReference 22: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph31A-Subparagraph\(eSX210.13-01\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph31A-Subparagraph(eSX210.13-01(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=114001798 & loc=d3e33918-10-S99-111571Reference 1AReference 23: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph81A-Subparagraph\(SX210.13-01\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph81A-Subparagraph(SX210.13-01(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=124431687 & loc=d3e22658-10-S99-107794Reference 1AReference 24: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-S99-Paragraph1A-1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-S99-Paragraph1A-1B-Subparagraph(SX210.13-02(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=126968391 & loc=SL7669619-10-S99-108580Reference 1BReference 25: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-S99-Paragraph31B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-S99-Paragraph31B-Subparagraph(SX210.13-02(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=126901519 & loc=d3e8924-10-S99-108599Reference 1BReference 26: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph11B-Subparagraph\(bSX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph11B-Subparagraph(bSX210.13-02(a)(4)(iii)(B))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=124431687 & loc=d3e22694-10-S99-107794Reference 1BReference 27: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph11B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic250-SubTopic10-Section50-S99-Paragraph11B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=124431687 & loc=d3e22694-10-S99-107794Reference 1BReference 28: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic205-SubTopic20-Section50-S99-Paragraph71B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic10-NameAccountingStandardsCodification-Topic205-SubTopic20-Section50-S99-Paragraph71B-Subparagraph(SX210.13-02(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470) extlink & oid=109222650 & loc=SL51721683-10-S99-107760Reference 1BReference 29: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-50-Paragraph1B-30-Subparagraph\(a-b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-50-Paragraph1B-30-Subparagraph(a-b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280) extlink & oid=126968391 & loc=SL7669625-10-50-108580Reference 30Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280) extlink & oid=126901519 & loc=d3e8736-108599Reference 10- 50-32Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-45-Paragraph1A-60B-Subparagraph\(SX210.13-01\(a\)-PublisherFASB\(5\)\)-URIhttps://asc.fasb.org/1943274/2147482689/260](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-45-Paragraph1A-60B-Subparagraph(SX210.13-01(a)-PublisherFASB(5))-URIhttps://asc.fasb.org/1943274/2147482689/260)

extlink & oid = 126975872 & loc = SL124442526 - 122756Reference - 10-45-60BReference 32: [http://www.xbrl.org/2003/role/disclosureRef/exampleRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-31-PublisherFASBSubparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef/exampleRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-31-PublisherFASBSubparagraph(SX210.13-02(a)(4)(iii)(B))) URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126975872 & loc = SL124442552 - 10-50-122756Reference - 31Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-32-Subparagraph\(c\)\(SX210.13-02\(a\)-PublisherFASB\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-SectionS99-50-Paragraph1B-32-Subparagraph(c)(SX210.13-02(a)-PublisherFASB(4)(iii)(A))) URI <https://asc.fasb.org/1943274/2147482810/280> extlink & oid = 126975872 & loc = SL124442552 - 10-50-122756Reference - 32Reference 34: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic205-SubTopic20-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph30-7-PublisherFASBSubparagraph\(b\)-URIhttps://asc.fasb.org/1943274/2147483499/205](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic205-SubTopic20-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph30-7-PublisherFASBSubparagraph(b)-URIhttps://asc.fasb.org/1943274/2147483499/205) extlink & oid = 126901519 & loc = d3e8906-108599Reference - 20-50-7Reference 35: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-45-Paragraph32-28-PublisherFASBSubparagraph\(e\)-URIhttps://asc.fasb.org/1943274/2147482740/230](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-45-Paragraph32-28-PublisherFASBSubparagraph(e)-URIhttps://asc.fasb.org/1943274/2147482740/230) extlink & oid = 126901519 & loc = d3e8933-108599-PeriodType://aseInstantX-DefinitionContractualInterestRateForFundsBorrowedUnderTheDebtAgreement-ReferencesReference1 asc.fasb.org/1943274/2147482790/220 - 10-45-1AReference 37: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-Section45-50-Paragraph1B-Subparagraph\(a-b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482790/220](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic10-Section45-50-Paragraph1B-Subparagraph(a-b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482790/220) extlink & oid = 123466505 & loc = SL123495323 - 10-45-1BReference - 112611Reference 38-2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210.5-03-02.22\(20a\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210.5-03-02.22(20a)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220) extlink & oid = 120391452 & loc = d3e13212 - 122682-DetailsName:10-S99-2Reference 39: <http://fasb.org/us-gaap/DebtInstrumentInterestRateStatedPercentageNamespacePrefix:us-gaap/role/ref/legacyRef-Topic942-gaap-Data Type:dtr-SubTopic220-types:percentItem Type:Balance Type:na> Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: durationX-DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. ReferencesReference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1B-19-PublisherFASBSubparagraph\(b\)-URIhttps://asc.fasb.org/1943274/2147481231/810](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic810-SubTopic10-NameAccountingStandardsCodification-Topic220-SubTopic10-Section45-Paragraph1B-19-PublisherFASBSubparagraph(b)-URIhttps://asc.fasb.org/1943274/2147481231/810) extlink & oid = 126968391 & loc = SL7669625 - 10-45-108580Reference - 19Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph20-SubTopic10-Topic810-PublisherFASBSubTopic10-Section50-Paragraph1A-Subparagraph\(e\)\(3\)-URIhttps://asc.fasb.org/1943274/2147481231/810](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph20-SubTopic10-Topic810-PublisherFASBSubTopic10-Section50-Paragraph1A-Subparagraph(e)(3)-URIhttps://asc.fasb.org/1943274/2147481231/810) extlink & oid = 109239629 & loc = SL4573702 - 11684Reference - 10-45-20Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1A-Subparagraph\(c\)\(3\)-SubTopic10-Topic810-PublisherFASBSubTopic10-Section45-Paragraph20-URIhttps://asc.fasb.org/1943274/2147481203/810](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1A-Subparagraph(c)(3)-SubTopic10-Topic810-PublisherFASBSubTopic10-Section45-Paragraph20-URIhttps://asc.fasb.org/1943274/2147481203/810) extlink & oid = 126929396 & loc = SL4569643 - 10-50-11683Reference - 1AReference 4: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-Section45-Paragraph1A-Subparagraph\(b\)-URIhttps://asc.fasb.org/1943274/2147482790/220](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic220-SubTopic10-Section45-Paragraph1A-Subparagraph(b)-URIhttps://asc.fasb.org/1943274/2147482790/220) extlink & oid = 126968391 & loc = SL7669619 - 108580Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45-Paragraph19-1A-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482790/220](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic810-SubTopic10-Section45-Paragraph19-1A-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482790/220) extlink & oid = 126929396 & loc = SL4569616 - 11683-10-45-1A-DetailsName:us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: durationX-DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. ReferencesNo definition available. Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX-DefinitionNumber of new stock issued during the period. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic210-505-PublisherFASBSubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-URIhttps://asc.fasb.org/1943274/2147481112/505](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic210-505-PublisherFASBSubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-URIhttps://asc.fasb.org/1943274/2147481112/505) extlink & oid = 120391452 & loc = d3e13212 - 10-50-122682Reference - 2Reference 2: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic505-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481004/946](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic505-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481004/946) extlink & oid = 126973232 & loc = d3e21463 - 505-50-112644Reference - 2Reference 3: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-3-Subparagraph\(SX210.3-04\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-3-Subparagraph(SX210.3-04(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575/946) extlink & oid = 120397183 & loc = d3e187085 - 122770Reference - 20-S99-3Reference 4: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(i\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886/946](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(i)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886/946) - 10-S99-3Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph1-Subparagraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph1-Subparagraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210) - 10-S99-1Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-Section50-Paragraph2-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644Reference2:> [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-PeriodType:instantX-DefinitionContractualInterestRateForFundsBorrowedUnderTheDebtAgreement-ReferencesReference1:](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-PeriodType:instantX-DefinitionContractualInterestRateForFundsBorrowedUnderTheDebtAgreement-ReferencesReference1:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph1B-Subparagraph\(b\)\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph1B-Subparagraph(b)(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505) extlink & oid = 123466505 & loc = SL123495323 - 10-S99-1Reference - 112611Reference - 7-2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02.22\(29a\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02.22(29a)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210) extlink & oid = 120391452 & loc = d3e13212 - 122682-10-S99-1-DetailsName:us-gaap_StockIssuedDuringPeriodSharesNewIssues gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: xbrli:dtr-types: sharesItem Type: percentItem Type Balance Type: na Period Type: durationX-DefinitionTotal number of shares issued during the period, including shares forfeited as a result of Restricted Stock Awards. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-2Reference2:> [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505) extlink & oid = 120397183 & loc = d3e187085 - 122770-10-S99-1-DetailsName:us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX-DefinitionReduction in the number of shares during the period as a result of a reverse stock split. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505> extlink & oid = 126973232 & loc = d3e21463 - 112644 - 10-50-2-DetailsName:us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX-DefinitionNumber of share options (or share units) exercised during the current period. ReferencesReference 1: <http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-2Reference2:> [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Section718-SubTopic10-Section50-Paragraph2-Subparagraph\(c\)\(1\)\(iv\)\(02\)-URIhttps://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901Reference2:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Section718-SubTopic10-Section50-Paragraph2-Subparagraph(c)(1)(iv)(02)-URIhttps://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901Reference2:) [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-50-Paragraph2-Subparagraph\(c\)\(1\)-Subparagraph\(SX210.3-04\)\(iv\)\(02\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-50-Paragraph2-Subparagraph(c)(1)-Subparagraph(SX210.3-04)(iv)(02)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718) extlink & oid = 120397183 & loc = d3e187085 - 10-50-122770Reference - 2Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210) extlink & oid = 120391452 & loc = d3e13212 - 10-S99-122682Reference - 1Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference5:](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference5:) [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-URIhttps://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682Reference5:](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-URIhttps://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682Reference5:) [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-S99-Paragraph2-1-Subparagraph\(SX](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-S99-Paragraph2-1-Subparagraph(SX)

210.5-02 (29)- Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 126973232 & loc = d3e21463-112644-10-S99-1
Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na
Period Type: durationX- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a
secondary public offering. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10> Topic 505- **Publisher FASB SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)** - URI <https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 120397183 & loc = d3e187085-10-50-122770Reference----- **2Reference** 2: <http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic830> - Name Accounting Standards Codification- Topic 505-SubTopic
10-Section 50-55- Paragraph 2-11- **Publisher FASB** - URI <https://asc.fasb.org/1943274/2147480167/946> extlink & oid = 126973232 & loc = d3e21463-
830-55-112644Reference----- 11Reference 3: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic205> - Name Accounting Standards Codification- Topic 210-SubTopic 10-Section S99-45- Paragraph 1-4- Subparagraph (a SX 210.5-02 (29)) -
Publisher FASB - URI <https://asc.fasb.org/1943274/2147480767/946> extlink & oid = 120391452 & loc = d3e13212-122682Reference-205-45-
4Reference 4: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic505> - Name Accounting
Standards Codification- legacyRef-Section 50- Paragraph 2- Subparagraph (a) - **Publisher FASB -Name Accounting Standards Codification-Topic 805-
SubTopic 30-Section 25-Paragraph 5-** URI <https://asc.fasb.org/1943274/2147481004/946> extlink & oid = 6911189 & loc = d3e6405-505-50-
128476Reference----- **2Reference** 3-5: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic220> - Name Accounting Standards
Codification- Topic 805-SubTopic 30-Section 50-S99- Paragraph 1-3- Subparagraph (SX 210.6-09 (4) (b) (2) - **Publisher FASB** - URI <https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 126975305 & loc = d3e6927-128479Reference-4-220-S99-3Reference **6**: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28)))-
Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 120391452 & loc = d3e13212-122682-lives-ReferencesReference-1
10-S99-1Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic350-SubTopic30-Section50-S99-Paragraph2-1-Subparagraph\(a-SX210.3-04\)\(2\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic350-SubTopic30-Section50-S99-Paragraph2-1-Subparagraph(a-SX210.3-04)(2)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480008/505> extlink & oid = 66006027 & loc = d3e16323-10-S99-109275Reference----- **1Reference** 2-8: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-S99-Paragraph28-1-Subparagraph\(b-SX210.5-02\(29\)\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-S99-Paragraph28-1-Subparagraph(b-SX210.5-02(29))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 126954810 & loc = d3e3602-10108585-Details
Name:us-S99-gaap-AdjustmentForAmortizationNamespacePrefix:us-gaap-1-Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace
Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionValue of shares of stock issued attributable to
transactions classified as other. ReferencesNo definition available. Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_Data
Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAggregate value of stock related to Restricted Stock Awards issued during
the period. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10> Topic 505- **Publisher FASB SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)** - URI <https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 120397183 & loc = d3e187085-10-50-122770Reference----- **2Reference** 2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 120391452 & loc = d3e13212-10-S99-
122682Reference----- **1Reference** 3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference4>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))) - URI
<https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 120391452 & loc = d3e13212-122682Reference-4: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-S99-Paragraph2-1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-S99-Paragraph2-1-Subparagraph(SX210.5-02(29))-PublisherFASB) - URI
<https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 126973232 & loc = d3e21463-112644-10-S99-1-Details Name: us-
gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period
Type: durationX- DefinitionValue of stock issued as a result of the exercise of stock options. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10> Topic 505- **Publisher FASB SubTopic 10-
Section 50-Paragraph 2** - URI <https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 126973232 & loc = d3e21463-10-50-112644Reference----- **2Reference** 2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480008/505> extlink & oid =
120397183 & loc = d3e187085-10-S99-122770Reference----- **1Reference** 3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29-31\)\)-PublisherFASB](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29-31))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 120391452 & loc = d3e13212-122682-10-S99-1-Details Name: us-
gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:
durationX- DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10> Topic 505- **Publisher FASB SubTopic 10-
Section 50-Paragraph 2** - URI <https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 126973232 & loc = d3e21463-112644-10-50-2-Details Name:
us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-
DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10> Topic 505- **Publisher FASB SubTopic 10-
Section 50-Paragraph 2** - URI <https://asc.fasb.org/1943274/2147481112/505> extlink & oid = 126973232 & loc = d3e21463-112644-10-50-2-Details Name:
us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type:
durationX- DefinitionTotal- **DefinitionAmount** of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the
entity which are attributable to the parent. **Excludes temporary equity** and the amount of the economic entity's stockholders' equity attributable to the parent
excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling
interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. - ReferencesReference 1: [http://www.xbrl.org/2009/2003/role/commonPracticeRef-exampleRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-4\)-PublisherFASB08\(g\)\(1\)\(ii\)](http://www.xbrl.org/2009/2003/role/commonPracticeRef-exampleRef-PublisherFASB-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic235-SubTopic10-SectionS99-55-Paragraph1-Subparagraph(SX210-10-4)-PublisherFASB08(g)(1)(ii)) - URI <https://asc.fasb.org/1943274/2147481372/852> extlink & oid =
120395691 & loc = d3e23780-10-55-122690Reference----- **10Reference** 2: <http://www.xbrl.org/2003/role/exampleRef-PublisherFASB-Topic946-SubTopic830> - Name Accounting Standards Codification- Topic 852-SubTopic 10-Section 55- Paragraph 10-12- **Publisher FASB** - URI <https://asc.fasb.org/1943274/2147480167/946> extlink & oid = 84165509 & loc = d3e56426-830-55-112766Reference----- **12Reference** 3: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic310-SubTopic10-SectionS99-Paragraph2-1-Subparagraph\(SX210-E-6-04\(19\)\)-PublisherFASB](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic310-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(SX210-E-6-04(19))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147479617/946> extlink & oid = 122038336 & loc = d3e74512-210-S99-122707Reference----- **1Reference** 4: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-2-Subparagraph\(SX210.5-6-02-05\(31-4\)\)-PublisherFASB](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-2-Subparagraph(SX210.5-6-02-05(31-4))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147479617/946> extlink & oid = 120391452 & loc =
d3e13212-210-S99-122682Reference----- **2Reference** 5: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-3-Subparagraph\(SX210.5-6-02-09\(29-4\)\(b\)\)-PublisherFASB](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-3-Subparagraph(SX210.5-6-02-09(29-4)(b))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 120391452 & loc = d3e13212-122682Reference-220-S99-3Reference **6**: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-3-Subparagraph\(SX210.5-6-02-09\(30-6\)\)-PublisherFASB](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-3-Subparagraph(SX210.5-6-02-09(30-6))-PublisherFASB) - URI
<https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 120391452 & loc = d3e13212-122682Reference-220-S99-3Reference **7**: [http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph28-3-Subparagraph\(SX210.6-09\(7\)\)-PublisherFASB](http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic825-SubTopic10-Section50-S99-Paragraph28-3-Subparagraph(SX210.6-09(7))-PublisherFASB) - URI <https://asc.fasb.org/1943274/2147483575/946> extlink & oid = 123596393 & loc = d3e14064-108612Reference-220-S99-3Reference **8**: [http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(g\)\(1\)\(ii\)\)-Publisher](http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(g)(1)(ii))-Publisher)

and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in-process research and development. Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per **Share of Common Share Stock** Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, **2023 and 2022 and 2021**, the total number of shares of common stock issuable upon exercise of warrants and equity awards **is was 1, 255, 642 and 988, 389 and 618, 800**, respectively. For the years ended December 31, **2023 and 2022 and 2021**, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive. Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category. As more fully discussed in Note 10, on **September 19 November 28, 2022-2023**, the Company received approval from the New Jersey Economic Development Authority to sell \$ **1. 6-3** million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, **2022-2023** for the net proceeds (approximately \$ **1. 6-3** million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on **October 31 November 28, 2022-2023**, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On **January 10 March 22, 2023-2024**, the Company received approximately \$ **1. 6-3** million upon completion of the sale of the **2023 NOLs. During 2022 NOLs. During 2021**, the Company received approval to sell \$ **1. 5-6** million of its New Jersey NOLs, receiving net proceeds of approximately \$ **1. 4-6** million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ **15** million to \$ **20** million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ **+0. 9-4** million in net operating losses under this maximum lifetime benefit (see Note 2). Stock-Based Compensation In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation- Stock Compensation, which simplifies various aspects of accounting for share-based payments. The areas for simplification involve several aspects of the accounting for share-based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures in compensation cost when they occur. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In **June 2016 December 2023**, the FASB issued ASU No. **2016-2023- 43-09. Improvements to Income Tax Disclosures Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments**, which **requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies the other income tax measurement of expected credit losses on certain financial instruments.** The Company adopted ASU 2016-13 in its first quarter of 2021 utilizing the modified retrospective transition method. Based on the composition of the Company's investment portfolio and current market conditions, the adoption of ASU 2016-13 did not have a material impact on its Financial Statements. In May 2021, the FASB issued ASU No. **2021-2023- 09-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).** This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity-classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder's accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, **2021 2024 and allows**, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or for adoption exchanges occurring on or after the effective date of the amendments **a prospective basis, with a retrospective option**. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted **is currently evaluating the impact of the ASU 2021-04 on its income tax disclosures within the consolidated Financial financial Statements statements**. X-ReferencesNo definition available. Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrl:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference-2:https://fasb.org/us-gaap/role/ref/legacyRef-Topic-235-SubTopic-10-Section-50-Paragraph-1-URI-https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790Reference-2:https://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-Publisher-FASB-URI-https://asc.fasb.org/235/tableOfContent-topic&trid=2122269> Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationFINANCIAL CONDITION AND LIQUIDITY **GOING CONCERN UNCERTAINTY** 12 Months Ended Dec. 31, **2022-2023** Organization, Consolidation and Presentation of Financial Statements [Abstract] FINANCIAL CONDITION AND **LIQUIDITY-GOING CONCERN UNCERTAINTY** 2. FINANCIAL CONDITION AND **LIQUIDITY-GOING CONCERN UNCERTAINTY** Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the **FDA U. S. Food and Drug Administration**. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. **As of For the year ended** December 31, **2022-2023**, **the Company had a net loss of \$ 19. 5 million and used \$ 19. 0 million to fund operations. As of December 31, 2023**, the Company has incurred approximately \$ **369-388** million of cumulative net losses. As of December 31, **2022-2023**, the Company had \$ **32-15. 8-7** million in cash and cash equivalents, short-term investments, and interest receivable **and \$ 1. 6-3 million** net proceeds **on from the sale of its New Jersey** net operating losses **and \$ 6. 0 million in restricted cash required to maintain on deposit with SVB as cash collateral for the SVB debt**. The Company has substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its **drug candidates and** technologies. **The Company believes it has sufficient capital resources to fund its operations into 2025.** The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company's ability to achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. **The Company expects that its operating results will of the Company have fluctuated—fluctuate significantly in the past future and will depend on a number of factors, many of which are outside the Company's control.** The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the **ongoing COVID- 19 pandemic**. **The disruptions caused by COVID-19 may also**

disrupt the Russian invasion clinical trials process and enrollment of patients. This may delay commercialization efforts. Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is reasonably possible that the these virus events could have result in a variety negative effect on the Company's financial condition and results of operations risks to the business. The specific impact, if any, is not readily determinable as of the date of these consolidated Financial Statements. The actual amount of funds the..... and interest through the scheduled maturity date. The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company's shares or debt, the sale of the Company's New Jersey NOLs and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted. The actual amount See Note 11 for a discussion of funds the Company will need to operate is subject to many factors, some of which are beyond the Company's control. These factors include the following:

- the progress of research activities;
- the number and scope of research programs;
- the progress of preclinical and clinical development activities;
- the progress of the development efforts of parties with whom the Company has entered into research and development agreements;
- the costs associated with additional clinical trials of drug candidates;
- the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;
- the ability to achieve milestones under licensing arrangements;
- the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and
- the costs and timing of regulatory approvals.

On July 13 The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company's business plan including, but not limited to:

- the Company's financial position for the year ended December 31, 2020-2023;
- significant events and transaction the Company announced that it has received a recommendation entered into since December 31, 2023;
- the Company's cash flow and cash usage forecasts for the period one year from the independent DMC to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation issuance date of this Annual Report on Form 10-K;
- the Company's capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and
- continued support of the Company's stockholders.

As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has and an redemption accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of Series this Annual Report on Form 10-K. The report of our independent registered public accounting firm for the year ended December 31, 2023 includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. A Preferred Stock fundamental component of the ability to continue as a going concern is the Company's ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives:

- it has assessed its current expenditures and Series B Preferred Stock will be reducing the current spending requirements where necessary;
- it will pursue additional capital funding in the public and private markets through equity sales and / or debt facilities;
- it will pursue possible partnerships and collaborations; and
- it will pursue potential out licensing for its drug candidates.

Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months.
X- ReferencesNo definition available. Details Name: us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-205-SubTopic-40- Name Accounting Standards Codification- Publisher FASB-Topic-205-SubTopic-40- URI https://asc.fasb.org/subtopic&trid=51888271/205-40/tableOfContent Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationINVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE 12 Months Ended Dec. 31, 2022 2023 Investments, Debt and Equity Securities [Abstract] INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE 3. INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE Investments in debt securities available for sale with a fair value of \$ 9, 857, 087 and \$ 21, 254, 485 and \$ 29, 803, 095 as of December 31, 2023 and 2022 and 2021, respectively, consisted of U. S. Treasury securities and corporate debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive loss. Investments in The Company reviews its debt securities available classified as short-term investments on a regular basis for sale are evaluated periodically to impairment. For debt securities in unrealized loss positions, the Company determine determines whether a any portion of the decline in their fair value below the amortized cost basis is other due to credit-related factors if it neither intends to sell nor anticipates that it is more likely than temporary not that it will be required to sell prior to recovery of the amortized cost basis. The Company considers factors term "other than temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the extent to which magnitude and duration of the decline, market value as has well as been less than the cost, any noted failure of the issuer to make scheduled payments, changes to the rating of the security and the other reasons relevant credit-related factors in determining whether or not a credit loss exists. During fiscal 2023 and 2022, the Company did not recognize an allowance for the decline, to predict credit whether the related loss losses on any in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of our investments the security is reduced and a corresponding charge to earnings is recognized. A summary of the cost, fair value and maturities of the Company's short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short-term investments U. S. Treasury securities \$ -9, 796, 291 \$ -9, 857, 087 \$ -14, 786, 982 \$ -14, 778, 705 Corporate debt securities \$ 21, 227, 991 \$ 21, 254, 485 \$ 15, 024, 796, 291 \$ 9, 857, 087 \$ 15, 024, 390 Total \$ 21, 227, 991 \$ 21, 254, 485 \$ 29, 811, 069 \$ 29, 803, 095 December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months \$ 2, 467, 518 \$ 2, 490, 775 \$ 4, 005, 559 \$ 3, 994, 590 \$ 19, 798, 177 \$ 19, 799, 835 Between 3- 12 months \$ 7, 328, 773 \$ 7, 366, 312 \$ 17, 222, 432 \$ 17, 259, 895 \$ 10, 012, 892 \$ 10, 003, 260 Total \$ 9, 796, 291 \$ 9, 857, 087 \$ 21, 227, 991 \$ 21, 254, 485 \$ 29, 811, 069 \$ 29, 803, 095 The following table shows the Company's investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022 and 2021. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2022-2023 December 31, 2021-2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains \$ 9, 857, 087 \$ 60, 796 \$ 13, 278, 505 \$ 43, 508 \$ 8, 999, 580 \$ 3, 499 Investments in debt securities with unrealized losses \$ -7, 975, 980 \$ (17, 014) Total \$ 9 (17, 857 014) 20, 803 087 \$ 60, 796 515 (11, 473) Total \$ 21, 254, 485 \$ 26, 494 \$ 29, 803, 095 \$ (7, 974) Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023 2022 2021 Interest and dividends accrued and paid \$ 725, 824 \$ 502, 578 \$ 18, 145 Realized losses \$ 431, 801 (49, 222) Realized gains (7 losses) \$ 431, 801 (149, 49, 222) Investment income, net \$ 1, 157, 625 \$ 453, 356 \$ 10, 996 X- ReferencesNo definition available. Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for investments in certain debt and equity securities. ReferencesReference 1: http://fasb-www.xbrli.org/2003-us-gaap/role/

disclosureRef ref/legacyRef- **Publisher FASB Topic 320** - Name Accounting Standards Codification- **Publisher FASB Topic 942-SubTopic 320** - URI https://asc.fasb.org//320/tableOfContentReference **subtopic & trid=2209399**Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/**disclosureRef** ref/legacyRef- **Publisher FASB Topic 320-SubTopic 10** - Name Accounting Standards Codification- **Topic 946 Section 50 - SubTopic 320- Paragraph 10- Subparagraph (d)- Publisher FASB** - URI https://asc.fasb.org/subtopic & trid=2324412Reference- **1943274 / 2147481800 / 320- 10- 50- 10Reference 3**: http://fasb-www.xbrl.org/2003-us-gaap/role/**disclosureRef** ref/legacyRef- **Publisher FASB Topic 820- SubTopic 10** - Name Accounting Standards Codification- **Topic 320 Section 50- Paragraph 6B- Subparagraph (b)- Publisher FASB** - URI https://asc.fasb.org/topic & trid=2196928Reference- **1943274 / 2147482106 / 820- 10- 50- 6BReference 4**: http://fasb-www.xbrl.org/2003-us-gaap/role/**disclosureRef** ref/legacyRef- **Publisher FASB Topic 820- SubTopic 10** - Name Accounting Standards Codification- **Topic 940 Section 50 - SubTopic 320 Paragraph 6B- Subparagraph (c)- Publisher FASB** - URI https://asc.fasb.org/subtopic & trid=2176304Reference- **1943274 / 2147482106 / 820- 10- 50- 6BReference 5**: http://www.xbrl.org/2003/role/disclosureRef- **Publisher SEC- Name Regulation S- K (SK)- Number 229- Section 1403- Paragraph (b) - Publisher SECReference 6**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB Topic 946- SubTopic 320** - Name Accounting Standards Codification- **Publisher FASB Topic 805- SubTopic 30- Section 30- Paragraph 7** - URI https://asc.fasb.org//946 extlink & oid=126966197 & loc=d3e6578-128477Reference 2 **320 / tableOfContentReference 7**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB Topic 940- SubTopic 320** - Name Accounting Standards Codification- **Publisher FASB Topic 805- SubTopic 30- Section 25- Paragraph 5** - URI https://asc.fasb.org//940 extlink & oid=6911189 & loc=d3e6405-128476Reference 3 **320 / tableOfContentReference 8**: http://fasb-www.xbrl.org/2003-us-gaap/role/**disclosureRef** ref/legacyRef- **Publisher FASB Topic 942- SubTopic 320** - Name Accounting Standards Codification- **Topic 805- Publisher FASB - SubTopic 30- URI https://asc.fasb.org//942 - Section 320 / tableOfContent** Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItem Type Balance Type: na Period Type: durationRESTRICTED CASH 12 Months Ended Dec. 31, 2022-2023 Receivables [Abstract] RESTRICTED CASH 4. RESTRICTED CASH As a condition of the SVB Loan Facility entered into on June 18, 2021, as further discussed in Note 11-9, the Company is was required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100 % of the aggregate outstanding amount of the SVB loan facility. SVB may could restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The loan was repaid in full during the quarter ended June 30, 2023, thus removing this requirement. The required reserve totaled \$ 6. 0 million as of December 31, 2022 and 2021. This amount is presented in part as restricted cash for \$ 1. 5 million in current assets and \$ 4. 5 million in other non- current assets on the accompanying condensed consolidated balance sheets. On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. Although the Department of the Treasury, the Federal Reserve and the FDIC stated all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, or any other financial institution that is placed into receivership by the FDIC may be impacted by other disruptions to the U. S. banking system caused by the recent developments involving SVB. The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2022-2023 December 31, 2021-2022 Cash and cash equivalents \$ 5, 838, 566 \$ 11, 492, 841 \$ 19, 586, 272 Money market investments, restricted 6, 000, 000 6, 000, 000 Total \$ 5, 838, 566 \$ 17, 492, 841 \$ 25, 586, 272 X- References No definition available. Details Name: us-gaap_Receivables Abstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- Definition The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction. References No definition available. Details Name: us-gaap_RestrictedAssets DisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItem Type Balance Type: na Period Type: duration FAIR VALUES OF FINANCIAL INSTRUMENTS 12 Months Ended Dec. 31, 2022-2023 Fair Values Of Financial Instruments FAIR VALUES OF FINANCIAL INSTRUMENTS 5. FAIR VALUES OF FINANCIAL INSTRUMENTS FASB ASC Section 820, Fair Value Measurements and Disclosures, establishes a three- level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability. Cash and cash equivalents and other current assets, accounts payable and other accrued liabilities are reflected in the consolidated balance sheets at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for sale are determined by relying on the securities’ relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2023 and 2022 and 2021. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the years ended December 31, 2023 and 2022 and 2021. The changes in Level 3 liabilities were the result of changes in the fair value of the earn- out milestone liability included in earnings and in- process R & D. The earnout milestone liability at December 31, 2021 is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets / Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2023 Corporate debt securities, available for sale \$ 9, 857, 087 \$ 9, 857, 087 \$ - \$ - Recurring items as of December 31, 2022 Corporate debt securities and U. S. treasury obligations available for sale \$ 21, 254, 485 \$ 21, 254, 485 \$ - \$ - 254, 485 Non- recurring items as of December 31, 2022 In- process R & D (Note 6) \$ - \$ - \$ - \$ - Liabilities: Recurring items as of December 31, 2021 Corporate debt securities and U. S. treasury obligations, available for sale \$ 29, 803, 095 \$ - \$ 29, 803, 095 \$ - \$ - 29, 803, 095 Non- recurring items as of December 31, 2021 In- process R & D (Note 6) \$ 13, 366, 234 \$ - \$ 13, 366, 234 \$ - \$ - 13, 366, 234 Liabilities: Recurring items as of December 31, 2022 Earn- out milestone liability (Note 13) \$ - \$ - \$ - \$ - \$ - Recurring items as of December 31, 2021 Earn- out milestone liability (Note 13) \$ 5, 396, 000 \$ - \$ 5, 396, 000 \$ - \$ - 5, 396, 000 X- References No definition available. Details Name: IMNN_DisclosureFairValuesOfFinancialInstruments Abstract Namespace Prefix: IMNN_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- Definition The entire disclosure for derivatives and fair value of assets and liabilities. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB Topic 815** - Name Accounting Standards Codification- **Publisher FASB- URI https://asc.fasb.org//815/ tableOfContentReference 2**: http://fasb.org/us-gaap/role/ref/legacyRef- **Topic 820 - URI https://asc.fasb.org/topic & trid=2155941**Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 815- Publisher FASB** - URI https://asc.fasb.org//820/tableOfContent **topic & trid=2229140** Details Name: us-gaap_DerivativesAndFairValueTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItem Type Balance Type: na Period Type: duration INTANGIBLE ASSETS 12 Months Ended Dec. 31, 2022-2023 Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS 6. INTANGIBLE ASSETS In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation (“EGEN”), which changed its company name to EGWU, Inc. after the closing of the acquisition (the “EGEN Acquisition”). The Company acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. Acquired In- process Research and Development. Acquired in- process research and development (“IPR & D”) consists of EGEN’s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR & D drug technology platforms was estimated to be \$ 24. 2 million as of the acquisition date. As of the closing of the acquisition, the IPR & D was considered indefinite lived intangible assets and will not be amortized. IPR & D is was reviewed for impairment at least annually as of the third quarter ended September 30, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. The Company’s IPR & D consisted of three core elements, its RNA delivery system, its glioblastoma multiforme cancer (“GBM”) drug candidate and its ovarian cancer indication. As of December 31, 2022, the Company assessed whether there were indicators of impairment for the Company’s IPR & D and determined that the IPR & D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2022 and 2021 and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company’s IPR & D assets, the Company concluded the IPR & D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the \$ 13. 4 million carrying value of this asset, thereby recognizing a non- cash charge of \$ 13. 4 million in the fourth quarter of 2022. As of September 30, 2021, the Company assessed whether there were indicators of impairment for the Company’s IPR & D and determined that no IPR & D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2021

and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company's IPR & D assets, the Company concluded no IPR & D asset was impaired during that period. Due to the continuing slowdown in investment by public capital markets in the biotech industry and its impact on market capitalization rates in this sector, the Company conducted a valuation analysis of its IPR & D for the ovarian cancer indication as of December 31, 2021. Based on this valuation analysis, the Company has concluded that it is not more likely than not that the asset is impaired as of December 31, 2021. As such, no impairment charges for IPR & D related to the ovarian cancer indication were recorded during 2021. Covenants Not to Compete Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants ("Covenant Not To Compete") to the Company whereby EGEN agreed, during the period ending on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not to enter into any business, directly or indirectly, which competes with the business of the Company nor would it contact, solicit or approach any of the employees of the Company for purposes of offering employment. The Covenant Not to Compete which was valued at approximately \$ 1.6 million at the date of the EGEN Acquisition has a definitive life and is amortized on a straight-line basis over its life of 7 years. The Company recognized amortization expense of \$ 113, 660 in 2021. The Covenant Not to Compete was fully amortized by the end of 2021. Goodwill The purchase price exceeded the estimated fair value of the net assets acquired by approximately \$ 2.0 million which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least annually as of the Company's third quarter ended September 30 or sooner if the Company believes indicators of impairment exist. As of September 30, 2021, the Company's fair value exceeded its carrying value and as such no impairment was recognized for Goodwill through the third quarter of 2021. Due to the continuing slowdown in investment in 2021 by public capital markets in the biotech industry and its impact on market capitalization rates in this sector, Goodwill was reviewed for impairment as of December 31, 2021. Based on this assessment, Company concluded that Goodwill was impaired. As of December 31, 2021, the Company wrote off the \$ 2.0 million carrying value of this asset, thereby recognizing a non-cash charge of \$ 2.0 million in the fourth quarter of 2021. The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the two years year ended December 31, 2022: SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR & D Goodwill Covenant Not to Compete Balance at January 1, 2021 2022, net \$ 13, 366, 234 Balance \$ 1, 976, 101 \$ 113- 13, 366 660 Amortization (113, 234 660) Impairment charge (1 13, 976 366, 401 234) -Balance at December 31, 2021, net 13, 366, 234 -Balance 13, 366, 234 -Impairment charge (13, 366, 234) -Balance at December 31, 2022, net \$- \$- Balance \$- \$- X- References No definition available. Details Name: us- gaap- GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrl: stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for all or part of the information related to intangible assets. References Reference 1: http://www. xbrl. org / 2003 / role / disclosureRef- Publisher FASB- Topic 350- SubTopic 30- Name Accounting Standards Codification- Publisher FASB- Topic 350- SubTopic 30- URI https://asc. fasb. org / subtopic & trid=2144471-350-30 / tableOfContent Details Name: us- gaap_ IntangibleAssetsDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: duration PROPERTY AND EQUIPMENT 12 Months Ended Dec. 31, 2022 2023 Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT 7. PROPERTY AND EQUIPMENT Property and equipment at December 31, 2023 and 2022 and 2021 consist of the following: SUMMARY OF PROPERTY AND EQUIPMENT 2023 2022 2021 December 31, 2023 2022 2021 Machinery and equipment (5- 7 year life) \$ 2, 055, 192 \$ 2, 468, 388 Machinery and equipment (5- 7 year life) \$ 3- 2, 406 055, 069 192 \$ 2, 468, 388 Furniture and fixtures (3- 5 year life) 191, 932 350, 481 383, 477 Leasehold improvements (5- 7 year life) 607, 054 373, 194 343, 203 Property and equipment gross 2, 854, 178 3, 192, 063 3, 832, 749 Less accumulated depreciation and amortization (2, 102, 272) (2, 643, 762) (3, 355, 738) Total \$ 751, 906 \$ 548, 301 \$ 477, 011 X- References No definition available. Details Name: us- gaap_ PropertyPlantAndEquipmentAbstract Namespace Prefix: us- gaap_ Data Type: xbrl: stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. References Reference 1: http://www. fasb. org / 2003- us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 360- Name Accounting Standards Codification- Publisher FASB- Topic 958- SubTopic 360- Section 50- Paragraph 6- URI https://asc. fasb. org / / 360 / tableOfContentReference extlink & oid=126982197 & loc=d3e99893-112916 Reference 2: http://fasb. www. xbrl. org / 2003- us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 6- SubTopic 360- Topic 360- 958- Publisher FASB- URI https://asc. fasb. org / topic & trid=2155823 Reference / 1943274 / 2147480321 / 958- 360- 50- 6 Reference 3: http://www. xbrl. org / 2003 / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (d)- SubTopic 360- Topic 958- Publisher FASB SubTopic 360- Section 50- Paragraph 7- URI https://asc. fasb. org / / 1943274 / 2147480321 / 958 extlink & oid=126982197 & loc=SL120174063- 360- 50- 112916 Reference ----- 1 Reference 4: http://www. xbrl. org / 2003 / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 7- SubTopic 360- Topic 958- Publisher FASB SubTopic 360- Section 50- Paragraph 1- Subparagraph (d)- URI https://asc. fasb. org / / 1943274 / 2147480321 / 958 extlink & oid=126982197 & loc=d3e99779- 112916 360- 50- 7 Details Name: us- gaap_ PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: duration OTHER ACCRUED LIABILITIES 12 Months Ended Dec. 31, 2022 2023 Payables and Accruals [Abstract] OTHER ACCRUED LIABILITIES 8. OTHER ACCRUED LIABILITIES Other accrued liabilities at December 31, 2023 and 2022 and 2021 include the following: SCHEDULE OF OTHER ACCRUED LIABILITIES 2023 2022 2021 December 31, 2023 2022 2021 Amounts due to contract research organizations and other contractual agreements \$ 1, 442, 659 \$ 2, 196, 711 \$ 1, 401, 356 Accrued payroll and related benefits 1, 693, 383 2, 139, 927 1, 636, 727 Accrued interest 37, 583 16, 792 Accrued professional fees 234, 479 215, 402 87, 250 Other 20, 000 205, 313 31, 412 Total \$ 3, 390, 521 \$ 4, 794, 936 \$ 3, 173, 537 X- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. References Reference 1: http://fasb. org / us- gaap / role / disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02. 19 (a), 20, 24)- Publisher FASB- URI https://asc. fasb. org / / 1943274 / 2147480566 / 210 extlink & oid=120391452 & loc=d3e13212- 122682- 10- S99- 1 Details Name: us- gaap_ AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: duration NOTES PAYABLE 12 Months Ended Dec. 31, 2022 2023 Debt Disclosure [Abstract] NOTES PAYABLE 9. NOTES PAYABLE The SVB Loan Facility On June 18, 2021, the Company entered into a \$ 10 million loan facility (the "SVB Loan Facility") with Silicon Valley Bank ("SVB"). Imunon immediately drew down \$ 6 million from the SVB Loan Facility and used the funds to retire all outstanding indebtedness with Horizon as further discussed below. Technology Finance Corporation pursuant to a loan agreement entered into on June 27, 2018, under which the Company had drawn down \$ 10 million and repaid \$ 5 million in August 2020. Concurrently with this transaction, the Company used \$ 6. 0 million of other available funds to establish a restricted cash account which serves served as security for the SVB Loan Facility. The SVB Loan Facility is was in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime- based variable rate (currently 7. 75 %). A final payment equal to 3 % of the total \$ 10 million commitment amount is was due upon maturity or prepayment of the SVB Loan Facility. There was no facility commitment fee, and no stock or warrants were issued to SVB. Payments under the loan agreement are were interest only for the first 24 months after loan closing, followed by a 24- month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling \$ 243, 370 which is was recorded and classified as debt discount and was are being amortized as interest expense using the effective interest method over the life of the loan. Also, in connection with the SVB Loan Facility, the Company is required to pay an end- of- term fee equal to 3. 0 % of the original loan amount at time of maturity. Therefore, these amounts totaling \$ 300, 000 are being amortized as interest expense using the effective interest method over the life of the loan. During the years ended December 31, 2022 and 2021, the Company incurred interest expense of \$ 295, 792 and \$ 106, 709 and amortized \$ 181, 259 and \$ 97, 831, respectively, as interest expense for debt discounts and end- of- term fee in connection with the SVB Loan Facility. The following is a schedule of future principal payments, net of unamortized debt discounts and amortized end- of- term fee, due on the SVB Loan Facility: SCHEDULE OF FUTURE PRINCIPAL PAYMENTS, NET OF UNAMORTIZED DEBT DISCOUNTS As of December 31, 2023 \$ 1, 500, 000 2024 3, 000, 000 2025 and thereafter 1, 500, 000 Subtotal of future principal payments 6, 000, 000 Amortized end- of- term fee, net (35, 720) Total \$ 5, 964, 280 Horizon Credit Agreement On June 27, 2018, the Company entered into a loan agreement with Horizon Technology Finance Corporation ("Horizon") that provided \$ 10 million in new capital (the "Horizon Credit Agreement"). The Company drew down \$ 10 million upon closing of the Horizon Credit Agreement on June 27, 2018. On August 28, 2020, Horizon and the Company amended the Horizon Credit Agreement (the "Amendment") whereby Imunon repaid \$ 5 million of the \$ 10 million loan and \$ 0. 2 million in related end- of- term charges, and the remaining \$ 5 million in obligations were restructured as set forth below. Pursuant to the Amendment, the remaining \$ 5 million in obligations of Imunon under the Horizon Credit Agreement was secured by a first- priority security interest in substantially all assets of Imunon other than intellectual property assets. The obligations bore interest at a rate calculated based on an amount by which the one- month LIBOR exceeds 2 % plus 7. 625 %. In no event could the interest rate be less than 9. 625 %. Payments pursuant to the Amendment were interest only for the first 12 months after August 1, 2020, followed by a 21- month amortization period of principal and interest through the scheduled maturity date on April 1, 2023. In addition, the remaining \$ 5 million in obligations was subject to an end- of- term fee equal, in the aggregate, to \$ 275, 000, which amount was payable upon the maturity of the

obligations or upon the date of final payment or default, as applicable. In connection with the Amendment, Imunon agreed to a liquidity covenant which provided that, at all times, Imunon maintain unrestricted cash and /or cash equivalents on deposit in accounts over which the applicable lenders maintained an account control agreement in an amount not less than \$ 2.5 million. In addition, pursuant to the Amendment, Imunon agreed to provide evidence to Horizon on or before March 31, 2021, that it received aggregate cash proceeds of not less than \$ 5 million from the sale of equity, debt, its New Jersey NOLs, or a combination thereof, subsequent to the date of the Amendment. The Company met this requirement during the fourth quarter of 2020. In connection with the Horizon Credit Agreement, the Company incurred financing fees and expenses totaling \$ 175,000 which were recorded and classified as debt discount. In addition, the Company paid loan origination fees of \$ 100,000 which were recorded and classified as debt discount. These debt discount amounts totaling \$ 782,116 were being amortized as interest expense using the effective interest method over the life of the loan. Also, in connection with each of the Horizon Credit Agreement, the Company was required to pay an end of term charge fee equal to 4.30% of the original loan amount at time of maturity. Therefore, those these amounts totaling \$ 400,300,000 were being amortized as interest expense using the effective interest method over the life of the loan. During As a fee in connection with the Horizon Credit Agreement, Imunon issued Horizon warrants exercisable for a total of 12,674 shares of Imunon's common stock (the "Existing Warrants") at a per share exercise price of \$ 39.45. The Existing Warrants were immediately exercisable for cash or by net exercise from the date of grant and will expire after ten years from the date of grant. The Company valued the Existing Warrants issued using the Black-Scholes option pricing model and recorded a total of \$ 507,116 as a direct deduction from the debt liability, consistent with the presentation of debt discounts, and are being amortized as interest expense using the effective interest method over the life of the loan. Pursuant to the Amendment, one-half of the aggregate Existing Warrants, exercisable for a total of 6,337 shares of Imunon's common stock, have been canceled, and, in connection with the Amendment, Imunon issued Horizon new warrants exercisable at a per share exercise price equal to \$ 15.15 for a total of 16,501 shares of Imunon's common stock (the "New Warrants" and, together with the Existing Warrants, the "Warrants"). The remaining 6,337 Existing Warrants issued in connection with the Horizon Credit Agreement remain outstanding at the exercise price of \$ 39.45 per share. The New Warrants were immediately exercisable for cash or by net exercise from the date of grant and will expire after ten years from the date of grant. The Horizon Credit Agreement contains customary representations, warranties and affirmative and negative covenants including, among other things, covenants that limit or restrict Imunon's ability to grant liens, incur indebtedness, make certain restricted payments, merge, or consolidate and make dispositions of assets. The Amendment was evaluated in accordance with FASB ASC 470-50, Debt-Modifications and Extinguishments, for debt modification and extinguishment accounting. The Company accounted for the \$ 5 million it repaid as a debt extinguishment thereby reducing the principal obligations accordingly. The Company accounted for the remaining \$ 5 million of obligation under the Amendment as a debt modification to the initial agreement with respect to the minor changes in cash flows. Also, in connection with the \$ 5 million remaining obligations, the Company recorded \$ 5,000 of financing fees and the New Warrant fair value of \$ 247,548 as additional debt discount on the \$ 5 million remaining obligation. Therefore, approximately \$ 109,706 of unamortized debt discount will be amortized over the remaining life of the new obligations. The \$ 275,000 of end of term fees, net of previously amortized end of term fees totaling \$ 142,605 previously accrued on the original note associated with the \$ 5 million remaining obligation, will be amortized as interest expense over the remaining life of the new obligations. During the year ended December 31, 2021-2023 and 2022, the Company incurred \$ 225,920 in interest expense of \$ 197,080 and \$ 295,792, and amortized \$ 139,329, 428,158 and \$ 181,259, respectively, as interest expense for debt discounts and end of term charges fee in connection with the Horizon Credit Agreement. On June 18, 2021, as a condition of entering into the SVB Loan Facility, the Company paid repaid the outstanding principal balance, an early termination fee and the end of term charges in full satisfaction of the SVB Loan Facility Horizon Credit Agreement, as amended. The following is a schedule of the amounts paid to Horizon SVB on June 18 April 21, 2021-2023: SCHEDULE OF DEBT Principal balance at June 18 April 21, 2021-2023 \$ 6,000,000 Early termination fees 150,120,000 End of term charges 275,300,000 Total payoff amount \$ 5,6,425,420,000 During the year ended December 31, 2021-2023, the Company recorded a loss of \$ 234,329,419-158 on the early termination of the SVB Loan Facility Horizon Credit Agreement, as amended, which represented the early termination fee and the end of the term fees, net of previously amortized interest expense totaling \$ 490,334,581-212 on the date of its payoff. X-References No definition available. Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrl:stringItem Type Balance Type: na Period Type: durationX-Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. References Reference 1: [http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic470-SubTopic20-NameAccountingStandardsCodification-Topic470-Section50-Paragraph1B-Subparagraph\(h\)-PublisherFASB-URIhttps://asc.fasb.org/topic&trid=2208564Reference/1943274/2147481139/470-20-50-1BReference2:](http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic470-SubTopic20-NameAccountingStandardsCodification-Topic470-Section50-Paragraph1B-Subparagraph(h)-PublisherFASB-URIhttps://asc.fasb.org/topic&trid=2208564Reference/1943274/2147481139/470-20-50-1BReference2:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph1-Subparagraph\(SX210.4-08\(c\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-599-1Reference3:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph1-Subparagraph(SX210.4-08(c))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-599-1Reference3:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph\(h\)-URIhttps://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611Reference3:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph(h)-URIhttps://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611Reference3:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference5:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference5:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference6:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference6:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference7:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1BReference7:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph\(g\)-URIhttps://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611Reference8:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic470-SubTopic20-Section50-Paragraph1B-Subparagraph(g)-URIhttps://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611Reference8:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1C-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1CReference9:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1C-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1CReference9:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1C-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1CReference10:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1C-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1CReference10:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference11:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference11:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference12:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference12:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference13:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference13:) [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference14:](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph1E-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1EReference14:) Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: durationINCOME TAXES 12 Months Ended Dec. 31, 2022-2023 Income Tax Disclosure [Abstract] INCOME TAXES 10. INCOME TAXES The income tax benefit for the years ended December 31, 2023 and 2022 and 2021 consists of the

following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 2021-Federal Current \$- - Deferred-- State and Local-- Current-- Deferred (1, 280, 385) (1, 567, 026) (1, 383, 446) Total \$ (1, 280, 385) \$ (1, 567, 026) \$ (1, 383, 446) A reconciliation of the Company's statutory tax rate to the effective rate for the years ended December 31, 2023 and 2022 and 2021 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2023 2022 2021-Federal statutory rate 21.0% 21.0% 21.0% State taxes, net of federal tax benefit 7.1% 7.8% 8.1% Permanent differences (3.1%) 2.9% 2.8% True-Up (+/-) (105.0%) (2.9%) - Change in valuation allowance and deferred rate change, net 89.0% (53.8%) (7.6%) Effective tax rate 6.1% 4.1% 6.2% The components of the Company's deferred tax asset as of December 31, 2023 and 2022 and 2021 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 2021-Net operating loss carryforwards \$ 79,677,800 310,000 \$ 64,799,915 800,000 Section 174 4,929,000- Other deferred tax assets, net 2,016,000 13,287,000 5,213,000 Subtotal 74,255,000 93,087,000 70,128,000 Valuation allowance (72,974,615) (91,519,974) (68,744,554) Total deferred tax asset \$ 1,567,280,026 385,567,446 026 The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company's ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. The Company has established a valuation reserve for its deferred income tax assets other than those related to its New Jersey NOLs. At December 31, 2021-2023, after its evaluation of its New Jersey NOLs as discussed more fully below, the Company reduced the valuation reserve and recognized \$ 1.6-3 million as a deferred income tax asset. Such tax assets are available to be recognized and benefit future periods. As of December 31, 2022-2023, the Company had federal net operating loss carryforwards of approximately \$ 330-307 million, net of net operating losses utilized in prior years of which \$ 225-218 million, if unused, will expire starting in 2023-2024 through 2037. The Federal federal NOLs net operating loss generated for the years ended after December 31, 2018 2017, 2019, 2020, and 2021 of approximately \$ 64-78 million can be carried forward indefinitely. As However, the deduction for net operating losses incurred in tax years beginning after January 1, 2018 is limited to 80% of annual taxable income. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (" CARES Act ") was enacted in response to the COVID-19 pandemic. The CARES Act provides for economic and cash liquidity stimulus through various means including payroll tax credits, payroll tax deferral, short-term changes in tax deductibility of interest expenses among other things. The Act also permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018 through 2021-2023 to be carried back to each of the five preceding tax years. The Company evaluated the various aspects of the CARES Act and determined that there was no material effect on the Financial Statements. As of December 31, 2022, the Company had state net operating loss carryforwards of approximately \$ 58-44 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2041-2042. During Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (" R & E ") activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R & E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R & E activities in the US must be amortized over a 5-year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15-year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company's income tax returns for 2019 to 2022, 2021 are still open and in subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2023, and 2022, there were no unrecognized tax benefits. The Company performed recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year. Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company's ability to utilize these carryforwards. The Company has completed an analyses-analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership. Due to the existence of full valuation allowance limitations under as defined by Section 382 of the Internal Revenue Code that would limit its ability to utilize certain net operating loss and 383 will not impact tax credit carry forwards. The Company determined that it experienced ownership changes, as defined by Section 382, in connection with certain common stock offerings in July 2011, February 2013, June 2013, June 2015, February 2017, June 2017, October 2017, August 2018, February 2020, January 2021 and November 2022. As a result, the utilization of the Company's federal effective tax net operating loss carry forwards generated rate. Further analyses will be performed prior to recognizing the benefits ownership changes are limited. As of any December 31, 2022, the Company has net operating loss carry forwards for U. S. federal and state tax purposes of approximately \$ 325 million, before excluding net operating losses that have been limited as a result of Section 382 limitations. The annual limitation due to Section 382 for or credits net operating loss carry forward utilization is approximately \$ 4.2 million per year for approximately \$ 90 million in net operating loss carry forwards existing at the ownership change occurring in July 2011, approximately \$ 1.4 million per year for approximately \$ 34 million of additional net operating losses occurring from July 2011 to the ownership change that occurred in February 2013, approximately \$ 1.5 million per year for approximately \$ 4 million of additional net operating losses occurring from February 2013 to the ownership change that occurred in June 2013, approximately \$ 1.6 million per year for approximately \$ 40 million of additional net operating losses occurring from June 2013 to the ownership change that occurred in June 2015, approximately \$ 0.3 million per year for approximately \$ 35 million of additional net operating losses occurring from June 2015 to the ownership change that occurred in February 2017, approximately \$ 0.3 million per year for approximately \$ 7 million of additional net operating losses occurring from February 2017 to the ownership change that occurred in June 2017, approximately \$ 0.8 million per year for approximately \$ 5 million of additional net operating losses occurring from June 2017 to the ownership change that occurred in October 2017, approximately \$ 1.5 million per year for approximately \$ 30 million of additional net operating losses occurring from October 2017 to the ownership change that occurred in August 2018, approximately \$ 0.8 million per year for approximately \$ 15 million of additional net operating losses occurring from August 2018 to the ownership change that occurred in February 2020 and approximately \$ 2.0 million per year for approximately \$ 40 million of additional net operating losses occurring from February 2020 to the ownership change that occurred in January 2021 and approximately \$ 28.0 million per year for approximately \$ 30 million of additional net operating losses occurring from January 2021 to the ownership change that occurred in November 2023. The utilization of these -- the financial statements net operating loss carry forwards may be further limited if the Company experiences future ownership changes as defined in Section 382 of the Internal Revenue Code. Sale of New Jersey Net Operating Losses Since 2018, the Company has annually submitted applications to sell a portion of the Company's New Jersey NOLs as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. As part of the Technology Business Tax Certificate Program, the Company sold \$ 1.6-3 million and \$ 1.5-6 million of its New Jersey NOLs in 2023 and 2022 and 2021, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1.3 million in 2023 and \$ 1.6 million in 2022 and \$ 1.4 million in 2021. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$ 10-9-3 million in net operating losses under this maximum lifetime benefit. X-ReferencesNo definition available. Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 946-SubTopic 20-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 21-13-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946 extlink & oid=121826272 & loc=d3e32857-20-50-109319Reference-----13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08 (h) (2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Section S99-Paragraph 2-Subparagraph (SAB Topic 11.C)-URI https://asc.fasb.org/extlink & oid=122134291 & loc=d3e330215-122817Reference 3: http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/1740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Section 50-Paragraph 17-Subparagraph (b)-URI

<https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482685/740-10-50-14>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SAB-TOPI-6.1.5-Q1\)-URI-https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SAB-TOPI-6.1.5-Q1)-URI-https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-21-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482685/740-10-50-21>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-270-Section-50-Paragraph-14-URI-https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482526/740-270-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-270-Section-50-Paragraph-1-URI-https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482685/740-10-50-17)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-TOPI-6.1.5-Q1\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-TOPI-6.1.5-Q1)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479360/740-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-30-Section-50-Paragraph-2-Subparagraph-\(a\)-URI-https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-30-Section-50-Paragraph-2-Subparagraph-(a)-URI-https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-S99-Paragraph-2-Subparagraph-\(SX-210-SAB-Topic-11-C-4-08\(h\)\)-Publisher-FASB-\(2\)\)-URI-https://asc.fasb.org//1943274/2147479360/740](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-S99-Paragraph-2-Subparagraph-(SX-210-SAB-Topic-11-C-4-08(h))-Publisher-FASB-(2))-URI-https://asc.fasb.org//1943274/2147479360/740) extlink & oid = 120395691 & loc = d3e23780-122690-10-S99-2Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482603/740-30-50-2)

Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dti-styles:textBlockItem Type Balance Type: na Period Type: duration STOCKHOLDERS' EQUITY 12 Months Ended Dec. 31, 2022 2023 Equity [Abstract] STOCKHOLDERS' EQUITY 11. STOCKHOLDERS' EQUITY

On March 19, 2021, the Company filed with the SEC a \$100 million shelf registration statement on Form S-3 (the "2021 Registration Statement") that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock in an amount up to \$100 million. This shelf The 2021 registration-Registration Statement was declared effective on March 30, 2021. The 2021 Registration Statement was intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. However, as of the date of these financial statements and so long as the Company's public float remains below \$75 million, it is subject to limitations with respect to the use of the 2021 Registration Statement and any other shelf registration statement that it files with the SEC pursuant to General Instruction I. B. 6 of Form S-3 (the "Baby Shelf Limitation"), which limits the amount that the Company can offer to up to one-third of its public float during any trailing 12-month period. The Company would be no longer subject to the Baby Shelf Limitation if its public float exceeds \$75 million. On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company's common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company's common stock started trading under a new CUSIP number 15117N602 although the Company's ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company's stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment were:

- To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of Common common Stock stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of Common common Stock stock;
- To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company's Common common Stock stock fell below \$1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company's Common common Stock stock is at least \$1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period. Immediately prior to the reverse stock split, the Company had 86,557,736 shares of common stock outstanding which consolidated into 5,770,516 shares of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company's overall exposure for such payouts consisting of a nominal amount. The amount of the Company's outstanding convertible preferred stock were not affected by the reverse stock split. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 6.6 million to approximately 0.4 million and outstanding warrants being reduced from approximately 2.5 million to approximately 0.2 million. At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market Offering Agreement (the "Agreement") with H. C. Wainwright & Co., LLC, as sales agent ("Wainwright"), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company's common stock having an aggregate offering price of up to \$7,500,000. During 2022 the Company sold 336,075 shares of stock for net proceeds of \$503,798. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. In 2023, the Company has sold did not sell any shares under the Agreement with Wainwright in the first nine months of 2022. From October 1, 2022 through the date of December 31, 2022, the Company sold 336,075 shares of stock for net proceeds of \$503,798. In 2023, the Company has sold 1,653,392 shares of stock for net proceeds of \$2,465,781, 438,656. Capital on Demand TM Sales Agreement On December 4, 2018, the Company entered into the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through JonesTrading shares of Common Stock having an aggregate offering price of up to \$16.0 million. During 2021, the Company has sold 0.5 million shares under the Capital on Demand Agreement, receiving approximately \$6.9 million in gross proceeds under the Capital on Demand Agreement. The Capital on Demand Agreement with JonesTrading was terminated in the first quarter of 2021. January 2021 Registered Direct Offering On January 22, 2021, the Company entered into a Securities Purchase Agreement (the "January 2021 Purchase Agreement") with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the "January 2021 Offering"), an aggregate of 1,728,395 shares of the Company's common stock at an offering price of \$20.25 per share for gross proceeds of approximately \$35 million before the deduction of the January 2021 Placement Agents (as defined below) fee and offering expenses. The closing of the January 2021 Offering occurred on January 26, 2021. In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A. G. P. Alliance Global Partners ("AGP," and together with Brookline Capital Markets, the "January 2021 Placement Agents") pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed \$82,500. March 2021 Registered Direct Offering On March 31, 2021, the Company entered into a Securities Purchase Agreement (the "March 2021 Purchase Agreement") with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the "March 2021 Offering"), an aggregate of 769,230 shares of the Company's common stock, at an offering price of \$19.50 per share for gross proceeds of approximately \$15 million before the deduction of the placement agents fee and offering expenses. The closing of the offering occurred on April 5, 2021. In connection with the March 2021 Offering, the Company entered into a placement agent agreement (the "March 2021 Placement Agent Agreement") with AGP, as lead placement agent (together with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Areadia Securities, LLC, serving as co-placement agents, the "March 2021 Placement Agents"), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed \$82,500. Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the "Preferred Stock Purchase Agreement") with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the "Preferred

Offerings”), (i) 50,000 shares of the Company’s Series A Convertible Redeemable Preferred Stock, par value \$ 0.01 per share (the “ Series A Preferred Stock ”), and (ii) 50,000 shares of the Company’s Series B Convertible Redeemable Preferred Stock, par value \$ 0.01 per share (the “ Series B Preferred Stock ” and together with the Series A Preferred Stock, the “ Preferred Stock ”), in each case at an offering price of \$ 285 per share, representing a 5 % original issue discount to the stated value of \$ 300 per share, for gross proceeds of each Preferred Offering of \$ 14.25 million, or approximately \$ 28.50 million in the aggregate for the Preferred Offerings, before the deduction of the Placement Agent’s (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 13.65 per share, into 1,098,901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 15.00 per share, into 1,000,000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. On March 3, 2022, the Company redeemed for cash at a price equal to 105 % of the \$ 300 stated value per share all of its 50,000 outstanding shares of Series A Preferred Stock and its 50,000 Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Imunon’s only class of outstanding stock is its common. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the “ Placement Agent Agreement ”) with AGP pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1,000,000 and reimburse the AGP for certain of their expenses in an amount not to exceed \$ 110,000. April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “ April 2022 Purchase Agreement ”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “ April 2022 Offering ”), an aggregate of 1,328,274 shares of the Company’s common stock at an offering price of \$ 5.27 per share for gross proceeds of \$ 7.0 million before the deduction of the April 2022 Placement Agent (as defined below) fees and offering expenses. The closing of the April 2022 Offering occurred on April 8, 2022. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the “ April 2022 Placement Agent ”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5 % of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. X-ReferencesNo definition available. Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for **shareholders' equity** comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. ReferencesReference 1: [http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://fasb-www.xbrl.org/2003/us-gaap/role/disclosureRef/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-URIhttps://asc.fasb.org/topic&trid=2208762>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(h\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(h)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph13-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph13-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481062/946](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481062/946) extlink & oid = 126973232 & loc = SL123496171-235-50-112644Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(b-d\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481062/946](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(b-d)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481062/946) extlink & oid = 126973232 & loc = SL123496171-235-50-112644Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph16-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481004/946](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph16-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481004/946) extlink & oid = 120397183 & loc = d3e187085-422770Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph\(d\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph(d)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(h\)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(h)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(e\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(e)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph\(a\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph(a)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(h\)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(h)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph14-Subparagraph\(a\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph14-Subparagraph(a)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph18-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph16-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph16-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph13-Subparagraph\(i\)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph13-Subparagraph(i)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(h\)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(h)-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-Section50-Paragraph6-16-Subparagraph\(a-b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic815-SubTopic40-Section50-Paragraph6-16-Subparagraph(a-b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13) extlink & oid = 126731327 & loc = SL126733271-114008-10-Paragraph69E-50-URIhttps://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13) extlink & oid = 124425984 & loc = d3e28555-10-50-108399Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13) extlink & oid = 123466505 & loc = SL123495355-10-50-112611Reference 18: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/extlink/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/extlink/1943274/2147481112/505-10-50-18) Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dt:types:textBlockItemType Balance Type: na Period Type: durationSTOCK-BASED COMPENSATION 12 Months Ended Dec. 31, 2022-2023 Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION 12. STOCK-BASED COMPENSATION The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “ 2018 Plan ”). The 2018 Plan, as adopted, permits the granting of 180,000 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options,

related to the Ovarian Cancer Indication of \$ 12.4 million has been modified. The Company had the option to make the payment upon achievement of the milestones as follows: a) \$ 7.0 million in cash within 10 business days of achieving the milestone; or b) \$ 12.4 million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. At December 31, 2022, the Company wrote off the earn-out milestone liability as a result of the requirements not being achieved and recognized a non-cash gain of \$ 5.4 million during 2022 as a result of the change in the fair value of the earn-out milestone liability. **The At December 31, 2021, the Company fair valued value of the earn-out milestone liability is zero at \$ 5.4 million and recognized a non-cash gain of \$ 1.6 million during 2021 as a result of the change in the fair value of the earn-out milestone liability of \$ 7.0 million at December 31, 2020-2023.** In assessing the fair value of the earnout milestone liability at December 31, 2021, the Company considered each of the settlement provisions per the Amended Asset Purchase Agreement and equally weighted the probability of a cash or cash and common stock payment. The following is a summary of the changes in the earn-out milestone liability for 2021 and 2022: SCHEDULE OF CHANGES IN EARN- OUT MILESTONE **LIABILITY Balance** **LIABILITY Balance** at January 1, 2021-2022 \$ 7, 018, 000 Non-cash loss from the adjustment for the change in fair value included in 2021 net loss (1, 622, 000) Balance at December 31, 2021-5, 396, 000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5, 396, 000) Balance at December 31, 2022 \$ -X- ReferencesNo definition available. Details Name: IMNN_DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionEarnout Milestone Liability Disclosure [Text Block] ReferencesNo definition available. Details Name: IMNN_EarnoutMilestoneLiabilityDisclosureTextBlock Namespace Prefix: IMNN_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationWARRANTS 12 Months Ended Dec. 31, 2022-2023 Warrants WARRANTS 14. WARRANTS Following is a summary of all warrant activity for the two years ended December 31, 2022-2023. SUMMARY OF WARRANT **ACTIVITY Warrants** **ACTIVITY Warrants**-Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2021-2022 256, 903 \$ 20.10 Warrants exercised during 2021 (Note 11) (81, 111) \$ 18.60 Warrants outstanding and exercisable at December 31, 2021-175, 792 \$ 20.96 Warrants expired during 2022 (7, 273) \$ 48.30 Warrants outstanding and exercisable at December 31, 2022 168, 519 \$ 19.78 **Warrants expired during 2023 (8, 459) \$ 37.29 Warrants outstanding and exercisable at December 31, 2023 160, 060 \$ 18.86** Aggregate intrinsic value of outstanding warrants at December 31, 2022-2023 \$ -0- Weighted average remaining contractual terms (years) 3-2 2 0 * Warrants to exercise 4, 059 shares of common stock at an exercise price of \$ 31.05 per share expired on January, 11, 2023. In connection with the February 2020 Registered Direct financing (see Note 11), the Company issued warrants to purchase 213, 333 shares of common stock in February 2020 of which 81, 111 of these were exercised during 2021. In connection with the Horizon Credit Agreement Amendment, the Company cancelled warrants to purchase 6, 337 shares of common stock and issued warrants to purchase 16, 501 shares of common stock in August 2020. Pursuant to a consulting agreement dated September 21, 2020, the Company issued warrants to purchase 5, 000 shares of common stock vesting immediately and having a 4-year term. The shares underlying these warrants are unregistered and have a strike price of \$ 11.85 per share. The Company fair valued these warrants at \$ 9.00 per share, recognizing \$ 45, 000 as professional fee expense.-X- ReferencesNo definition available. Details Name: IMNN_DisclosureWarrantsAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- **DefinitionDisclosure of warrants.** **Definition Warrants** [Text Block] ReferencesNo definition available. Details Name: IMNN_WarrantsTextBlock Namespace Prefix: IMNN_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationIMUNON EMPLOYEE BENEFIT PLANS 12 Months Ended Dec. 31, 2022-2023 Retirement Benefits [Abstract] IMUNON EMPLOYEE BENEFIT PLANS 15. IMUNON EMPLOYEE BENEFIT PLANS Imunon maintains a defined-contribution plan under Section 401 (k) of the Internal Revenue-Code. The plan covers substantially all employees over the age of twenty-one. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. The Company makes a matching contribution up to a maximum of 3% of an employee's annual salary. The Company's total matching contributions for the year ended December 31, 2021-2023 was and 2022 were \$ 142, 000 and \$ 117, 000 and \$ 107, 000, respectively. The Company also provided a discretionary contribution totaling \$ 172, 000 in 2021. The discretionary contribution represented 5% of each eligible participant's annual salary in 2021 and was paid out in January of the following year.-X- DefinitionThe entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-**Publisher FASB Topic 710** - Name Accounting Standards Codification- **Topic 718** **Publisher FASB** - URI https://asc.fasb.org/710/tableOfContentReference topic & trid=2228938Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-**Publisher FASB Topic 712** - Name Accounting Standards Codification- **Topic 712** **Publisher FASB** - URI https://asc.fasb.org/712/tableOfContentReference topic & trid=2197446Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-**Publisher FASB Topic 715** - Name Accounting Standards Codification- **Topic 710** **Publisher FASB** - URI https://asc.fasb.org/715/tableOfContentReference topic & trid=2127225Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-**Publisher FASB Topic 718** - Name Accounting Standards Codification- **Topic 715** **Publisher FASB** - URI https://asc.fasb.org/718/tableOfContent topic & trid=2235017-Details Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationLEASES 12 Months Ended Dec. 31, 2022-2023 Leases LEASES 16. LEASES **Lawrenceville, New Jersey Lease** In 2011 August 2023, the Company executed a renewed its Lawrenceville office lease (the "Lease") with Brandywine Operating Partnership, L.P. (Brandywine), a Delaware limited partnership, for a 24-10, 870 square foot premises located in Lawrenceville, New Jersey and relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The Lease had an initial term of 66 months month. In late 2015, Lenox Drive Office Park LLC, purchased the real estate and office building and assumed the Lease. This Lease was set to expire on April 30, 2017. In April 2017, the Company and the landlord amended the Lease effective May 1, 2017. The 1st Lease Amendment extended the term of the agreement for an additional 64 months, reduced the premises to 7, 565 square feet, reduced the monthly rent and provided four months free rent. The monthly rent ranged from approximately \$ 18, 900 in the first year to approximately \$ 20, 500 in the final year of the 1st Lease Amendment. Effective January 9, 2019, the Company amended the terms of the 1st Lease Amendment to increase the size of the premises by 2, 285 square feet to 9, 850 square feet and extended the lease term by one year to September 1, 2023. The Company had a one-time option to cancel the lease after 40 months as part of the 1st Lease Amendment, which was extended with the 2nd Lease Amendment. The option to cancel the lease expired on August 31, 2020. The monthly rent payments of under the 2nd Lease Amendment ranges from approximately \$ 25-22, 983 035 in the first year to approximately \$ 27-23, 394 088 in the final year of the lease. In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11, 500 square foot premises located in Huntsville, Alabama. In January 2018, the Company and the Huntsville landlord entered into a new 60-month lease Lease which reduced the premises to 9, 049 square feet with rent payments of approximately \$ 18, 100 per month. On June 9, 2021 and, as amended on July 7, 2021, the Company and the Huntsville landlord entered into a 22-month lease for an additional 2, 197 square foot premises with rent payments of approximately \$ 5, 500 per month. In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11, 420 square feet with monthly rent payments of approximately \$ 28, 550 to \$ 30, 903. The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, 2022-2023. SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2023-2024 \$ 238-626, 609-323 2024-2025 543, 009-2026 362, 976-2027 370, 236-2028 and thereafter Thereafter -30, 903 Subtotal future lease payments 238-1, 609-933, 447 Less imputed interest (7-308, 860-733) Total lease liabilities \$ 230-1, 749-624, 714 Weighted average remaining life 0-3, 61-5 years Weighted average discount rate 9.98% For 2023, operating lease expense was \$ 646, 633 and cash paid for operating leases included in operating cash flows was \$ 644, 593. For 2022, operating lease expense was \$ 587, 744 and cash paid for operating leases included in operating cash flows was \$ 601, 495. For 2021, operating lease expense was \$ 560, 513 and cash paid for operating leases included in operating cash flows was \$ 568, 269. Amortization expense was approximately \$ 472, 000 and \$ 535, 000 and \$ 573, 000 for the years ended December 31, 2023 and 2022 and 2021, respectively. X- ReferencesNo definition available. Details Name: IMNN_DisclosureLeasesAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-**Publisher FASB Topic 842-SubTopic 20** - Name Accounting Standards Codification- **Publisher FASB Topic 842-SubTopic 20** - URI https://asc.fasb.org/subtopic & trid=77888251/842-20/tableOfContent Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationCOMMITMENTS AND CONTINGENCIES 12 Months Ended Dec. 31, 2022-2023 Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES 17. COMMITMENTS AND CONTINGENCIES On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the "Spar Individual Defendants") in the U.S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff alleges alleged that the Company and Spar individual Defendants made false and misleading statements regarding one of the Company's drug candidates, ThermoDox®, and brings brought claims for damages under Section 10 (b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Rule 10b-5 promulgated thereunder against all Defendants defendants, and under

Section 20 (a) of the Exchange Act of 1934 against the **Spar** Individual Defendants – The Company believes that the case is without merit and intends to defend it vigorously. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted the Plaintiff plaintiff leave to file an amended complaint within 30 days. The Plaintiff plaintiff did not file an amended complaint within the 30- day deadline. In September 2023, the U. S. District Court issued and – an Order for the Company and Spar Individual Defendants therefore intend to seek dismissal Dismissal with/without prejudice of the action. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U. S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al., Case No. 3: 21- cv- 02662. The plaintiff alleges alleged breach of fiduciary duty and other claims arising out of alleged statements made by certain of the Company’ s directors and / or officers regarding ThermoDox ®. The Company believes it has meritorious defenses to these claims and intends to vigorously contest this suit. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. On March 10, 2023, the U. S. District Court for the District of New Jersey issued an order that the action is administratively terminated pending the submission, by March 17, 2023, of a joint letter advising as to how the parties wish to proceed in the matter. In August 2021, a complaint regarding a corporate books and records demand was filed against the Company in the Court of Chancery of the State of Delaware, captioned Pacheco v. Celsion Corporation, Case No. 2021– 0705. The plaintiff alleges he is entitled to inspect the Company’ s books and records concerning the OPTIMA Study and other materials. The Company believes that the scope of the demand is without merit and intends to defend it vigorously. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. In October 2021, an arbitration was commenced against the Company before the CPR Institute for Conflict Prevention & Resolution, captioned Curia New Mexico, LLC v. Celsion Corp., Case No. G– 22– 85– S. The plaintiff alleges that the Company failed to pay invoices for the manufacture of ThermoDox ®. The Company believes it has a meritorious defense to these claims and is vigorously contesting this allegation. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. X- ReferencesNo definition available. Details Name: us- gaap_ CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for commitments and contingencies. ReferencesReference 1:

oid=6457730&loc=d3e39691-107864-DefinitionContractual interest rate for funds borrowed,under the debt agreement Paragraph 6-Publisher FASB-URI https://asc. ReferencesReference 1 fasb.org//1943274/2147483326/850-10-50-6Reference 12:http:// www.xbrl.org/ 2003/ role/ disclosureRef-Publisher FASB Topic 855-SubTopic 10- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50- Paragraph 1-Subparagraph (a)-Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483326/850-extlink& oid = 123466505 & loc = SL123495323- 10-50-1Reference 112611Reference 13-2 :http:// fasb www.xbrl.org/ 2003-us- gaap/ role/ disclosureRefRef/ legacyRef- Publisher FASB Topic 855- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section 50-999- Paragraph 1- Subparagraph (b)-SX 210.5- 02.22 (a) -Publisher FASB-(11)- URI https:// asc.fasb.org/ /1943274/2147483326/850 extlink & oid = 120391452 & loc = d3e13212- 122682-10-50-Details Name: us- gaap_ RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItem Type Balance Type: na Period Type: durationSUBSEQUENT EVENTS 12 Months Ended Dec. 31, 2022-2023 Subsequent Events [Abstract] SUBSEQUENT EVENTS 20. SUBSEQUENT EVENTS

On March 6, 2024, Dr. Corinne Le Goff, Pharm. D., informed the Board of Directors of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024. Dr. Le Goff's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company is conducting a search for Dr. Le Goff's successor as Chief Executive Officer. Michael H. Tardugno, the Company's Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, has evaluated assumed day-to-day leadership of the Company until such successor is named and will continue in his role directing Company strategy subsequent events from December 31, 2022, through the date these consolidated financial statements were issued, determining all subsequent events have been disclosed. X- ReferencesNo definition available. Details Name: us- gaap_ SubsequentEventsAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

ReferencesReference 1: http:// www. xbrl. org/ 2003/ role/ disclosureRef- Publisher FASB- Topic 855- Name Accounting Standards Codification- Publisher FASB- URI https:// asc. fasb. org/ / 855/ tableOfContentReference 2: http:// www. xbrl. org/ 2003/ role/ disclosureRef- Topic 855- SubTopic 10- URI https://asc.fasb.org/ /topic & trid=2122774Reference 2: http:// www. xbrl. org/ 2003/ role/ disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 855- SubTopic 10- Section 50- Paragraph 2- Subparagraph (a)- Publisher FASB- URI https:// asc. fasb. org/ /1943274/2147483399/855 extlink & oid = 6842918 & loc = SL6314017- 165662-10-50-2 Details Name: us- gaap_ SubsequentEventsTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItem Type Balance Type: na Period Type: durationSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 12 Months Ended Dec. 31, 2022-2023 Accounting Policies [Abstract] Description of Business Description of Business On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. ("Imunon" or the "Company") reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will continue continues to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN," effective as of the opening of trading on September 21, 2022. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform is developing its non-viral DNA technologies technology across four modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and. The third modality, FixPlas®, concerns the application of Imunon's DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neopeptide cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase H-2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical proof-of-concept studies on for the development of a nucleic acid COVID-19 booster vaccine (IMNN candidate targeting SARS-CoV-2101) and a treatment for the Lassa virus (IMNN-102) in order to validate its PLACCINE platform. Imunon's platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these platforms modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions. Basis of Presentation Basis of Presentation The accompanying consolidated financial statements ("Financial Statements") of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and CLSN Laboratories, Inc. and Imunon-The Company in 2023 dissolved Celsion GmbH. All significant intercompany balances and transactions have been eliminated in consolidation. The preparation of the financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company's Financial Statements and accompanying notes. Actual results could differ materially from these estimates. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these Financial Statements have been evaluated for their possible impact on the Financial Statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the Financial Statements other than those arising in the ordinary course of business. Use of Estimates Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets and goodwill evaluation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. Revenue Recognition Revenue Recognition The Company's sole revenue stream is was related to the Hisun agreement described in Note 18, and whose contract has expired. There were no accounts receivable as of December 31, 2023 and 2022. Contract liabilities from the Hisun agreement amounted to \$0.5 million as of December 31, 2021. Contract liabilities values represent the value of cash received before the services were provided. Cash and Cash Equivalents Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance. Fair Value of Financial Instruments Fair Value of Financial Instruments The carrying values of financial investment instruments securities approximate their respective fair values. Management believes that the carrying amounts of the Company's financial investment instruments securities, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. Short-Term Investments Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification ("ASC") 320, Investments-Debt and Equity Securities. Available-for-sale securities consist of debt securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders' equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company's short-term investments consist of corporate bonds. Property and Equipment Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately \$ 248,000 and \$ 197,000 and \$ 130,000 for the years ended December 31, 2023 and 2022 and 2021, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2023 or 2022 or 2021. Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature. In-Process Research and Development, Other Intangible Assets and Goodwill In-Process Research and Development, Other Intangible Assets and Goodwill

During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. Impairment or Disposal of Long-Lived Assets Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in-process research and development. Comprehensive Income (Loss) Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and Development Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per Share of Common Share-Stock Net Loss per Share of Common Share-Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023 and 2022 and 2021, the total number of shares of common stock issued upon exercise of warrants and equity awards is was 1, 255,642 and 988,389 and 618,800, respectively. For the years ended December 31, 2023 and 2022 and 2021, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive. Income Taxes Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and / or penalties related to income tax matters in the income tax expense category. As more fully discussed in Note 10, on September 19 November 28, 2022-2023, the Company received approval from the New Jersey Economic Development Authority to sell \$ 1. 6-3 million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, 2022-2023 for the net proceeds (approximately \$ 1. 6-3 million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on October 31-November 28, 2022-2023, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On January 10-March 22, 2023-2024, the Company received approximately \$ 1. 6-3 million upon completion of the sale of the 2023 NOLs. During 2022 NOLs. During 2021, the Company received approval to sell \$ 1. 5-6 million of its New Jersey NOLs, receiving net proceeds of approximately \$ 1. 4-6 million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ 4-0. 9-4 million in net operating losses under this maximum lifetime benefit (see Note 2). Stock-Based Compensation Stock-Based Compensation In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation, which simplifies various aspects of accounting for share-based payments. The areas for simplification involve several aspects of the accounting for share-based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures in compensation cost when they occur. Recent Accounting Pronouncements Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In June 2016-December 2023, the FASB issued ASU No. 2016-2023-13-09, Improvements to Income Tax Disclosures Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies the other income tax measurement of expected credit losses on certain financial instruments. The Company adopted ASU 2016-related disclosures 13 in its first quarter of 2021 utilizing the modified retrospective transition method. Based on the composition of the Company's investment portfolio and current market conditions, the adoption of ASU 2016-13 did not have a material impact on its Financial Statements. In May 2021, the FASB issued ASU No. 2021-2023-09 04, Earnings Per Share (Topic 260), Debt Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)-Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder's accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021-2024 and allows, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or for adoption exchanges occurring on or after the effective date of the amendments a prospective basis, with a retrospective option. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted is currently evaluating the impact of the ASU 2021-04 on its the income tax disclosures within the consolidated Financial-financial Statements statements. X- Definition Disclosure of accounting policy for deposits. ReferencesNo definition available. Details Name: IMNN_DepositsPolicyTextBlock Namespace Prefix: IMNN_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of accounting policy for description of business. ReferencesNo definition available. Details Name: IMNN_DescriptionOfBusinessPolicyTextBlock Namespace Prefix: IMNN_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). ReferencesNo definition available. Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. ReferencesReference I: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 1- Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230 extlink & oid=126999549 & loc=d3e4273-108586-10-50-1 Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of accounting policy for comprehensive income. ReferencesNo definition available. Details Name: us-gaap_ComprehensiveIncomePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph\(c\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482662/260](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph(c)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482662/260) extlink & oid = 124432515 & loc = d3e3550-10-50-1092577Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482662/260> extlink & oid = 124432515 & loc = d3e3630-1092577-10-50-2Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.

ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section60-Paragraph1-SubTopic10-Topic820-Publisher-FASB-SubTopic10-Section60-Paragraph1-URIhttps://asc.fasb.org/1943274/2147482053/820> extlink & oid = 7493716 & loc = d3e21868-10-60-110260Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic825-Publisher-FASB-SubTopic10-Section50-Paragraph1-URIhttps://asc.fasb.org/1943274/2147482907/825> extlink & oid = 123594938 & loc = d3e13279-108611-10-50-1Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic360-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SABTopic360-5-CC\)-Publisher-FASB-SubTopic10-Section05-Paragraph4-URIhttps://asc.fasb.org/1943274/2147480091/360](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic360-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SABTopic360-5-CC)-Publisher-FASB-SubTopic10-Section05-Paragraph4-URIhttps://asc.fasb.org/1943274/2147480091/360) extlink & oid = 109226317 & loc = d3e202-10-S99-110218Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section05-Paragraph4-SubTopic10-Topic360-Publisher-FASB-SubTopic10-SectionS99-Paragraph2-Subparagraph\(SABTopic5-CC\)-URIhttps://asc.fasb.org/1943274/2147482338/360](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Section05-Paragraph4-SubTopic10-Topic360-Publisher-FASB-SubTopic10-SectionS99-Paragraph2-Subparagraph(SABTopic5-CC)-URIhttps://asc.fasb.org/1943274/2147482338/360) extlink & oid = 27011434 & loc = d3e125687-122742-10-05-4Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets. ReferencesNo definition available

ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic730-SubTopic20-Section50-Paragraph1-URIhttps://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380> Details Name: us-gaap_InProcessResearchAndDevelopmentPolicy Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(h\)\(1\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(h)(1))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946-10-S99-3) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-Section45-Paragraph25-URIhttps://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph\(b\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph(b)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-17) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-Section50-Paragraph20-URIhttps://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph19-URIhttps://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph15-SubTopic10-Section50-45-Paragraph1-25-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482525/740> extlink & oid = 124431353 & loc = SL116659661-10-45-227067Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-28> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-Section50-Paragraph19-URIhttps://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319> Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph\(b\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482685/740](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph(b)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482685/740) extlink & oid = 123427490 & loc = d3e32280-10-50-109318Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-1-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482765/220-10-50-1> Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph17-20-Publisher-FASB-Subparagraph\(b\)-URIhttps://asc.fasb.org/1943274/2147482685/740](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph17-20-Publisher-FASB-Subparagraph(b)-URIhttps://asc.fasb.org/1943274/2147482685/740) extlink & oid = 121826272 & loc = d3e32809-109319-10-50-20Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for investment in financial asset. ReferencesReference 1: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic944-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(3\)\(b\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483586/944](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher-FASB-Topic944-SubTopic220-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph1-Subparagraph(SX210.7-04(3)(b))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147483586/944) extlink & oid = 120400993 & loc = SL114874131-224263Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph3-Subparagraph\(a\)-SX210.6-03\(2-d\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic323-SubTopic10-Section50-S99-Paragraph3-Subparagraph(a)-SX210.6-03(2-d))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946) extlink & oid = 114001798 & loc = d3e33918-111571-10-PeriodType:instantX-S99-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph3-1B-Subparagraph\(b\)-SX210.6-03\(F\)\(1\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph3-1B-Subparagraph(b)-SX210.6-03(F)(1))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946) extlink & oid = 123466505 & loc = SL123495323-112611Reference 4: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-5-03-02.22\(fa\)\)\(2-I\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph3-1-Subparagraph(SX210.6-5-03-02.22(fa))(2-I))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479886/946) extlink & oid = 120391452 & loc = d3e13212-10-122682Details Name: us-S99-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-3Reference 5: [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Publisher-FASB-NameAccountingStandardsCodification-Topic958-SubTopic360-Section50-Paragraph1-Subparagraph\(d\)-SubTopic10-Topic360-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147482099/360](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionDetailsName:us-gaap_InvestmentPolicyTextBlock Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:durationX- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:durationX- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: <a href=) extlink & oid = 126982197 & loc = d3e99779-10-50-112916Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic944-SubTopic210-NameAccountingStandardsCodification-Topic958-SubTopic360-Section50-S99-Paragraph6-1-Subparagraph\(SX210.7-03\(a\)\(8\)\(a\)\)-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479440/944](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic944-SubTopic210-NameAccountingStandardsCodification-Topic958-SubTopic360-Section50-S99-Paragraph6-1-Subparagraph(SX210.7-03(a)(8)(a))-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147479440/944) extlink & oid = 126982197 & loc = d3e99893-210-S99-112916Reference 3: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher-FASB-NameAccountingStandardsCodification-Topic360-SubTopic10-Section50-Paragraph1-6-SubTopic360-Topic958-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480321/958> extlink & oid = 6391025 & loc = d3e2868-110229-360-50-6Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(d\)-SubTopic360-Topic958-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480321/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(d)-SubTopic360-Topic958-Publisher-FASB-URIhttps://asc.fasb.org/1943274/2147480321/958-360-50-1) Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant

Name Accounting Standards Codification- Topic 275- SubTopic 10- Section 50- Paragraph 8- **Publisher FASB Subparagraph (e)**- URI <https://asc.fasb.org/1943274/2147482861/275> extlink & oid = 99393423 & loc = d3e5967-408592-10-50-8 Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: duration INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE (Tables) 12 Months Ended Dec. 31, 2022-2023 Investments, Debt and Equity Securities [Abstract] SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS A summary of the cost, fair value and maturities of the Company's short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short-term investments U. S. Treasury securities \$ -9,796,291 \$ -9,857,087 \$ -14,786,982 \$ -14,778,705 Corporate debt securities -- 21,227,991 21,254,485 15-Total \$ 9,024,796,291 \$ 9,857,087 15-087 15-024,390 Total \$ 21,227,991 \$ 21,254,485 \$ 29,811,069 \$ 29,803,095 December 31, 2022-2023 December 31, 2021-2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months \$ 2,467,518 \$ 2,490,775 \$ 4,005,559 \$ 3,994,590 \$ 19,798,177 \$ 19,799,835 Between 3- 12 months 7,328,773 7,366,312 17,222,432 17,259,895 10-012,892 10-003,260 Total \$ 9,796,291 \$ 9,857,087 \$ 21,227,991 \$ 21,254,485 \$ 29,811,069 \$ 29,803,095 SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) The following table shows the Company's investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022 and 2021. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2022-2023 December 31, 2021-2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains \$ 9,857,087 \$ 60,796 \$ 13,278,505 \$ 43,508 \$ 8,999,580 \$ 3,499 Investments in debt securities with unrealized losses - \$ - 7,975,980 (17,014) Total \$ 9 (17,857 014) 20- 803 087 \$ 60,796 515 (11,473) Total \$ 21,254,485 \$ 26,494 \$ 29,803,095 \$ (7,974) SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023 2022 2021 Interest and dividends accrued and paid \$ 725,824 \$ 502,578 \$ 18,145 Realized losses 431,801 (49,222) Realized gains (7 losses) 431,801 (149-49,222) Investment income, net \$ 1,157,625 \$ 453,356 \$ 10,996 X- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-10-50-9) Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic320-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-10-50-3> Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic320-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-10-50-3> Reference 4: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph2-1B-Subparagraph\(e-b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-extlink&oid=1234466505&loc=SL123495323-10-50-2](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-Section50-Paragraph2-1B-Subparagraph(e-b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481800/320-extlink&oid=1234466505&loc=SL123495323-10-50-2) Reference 5: [http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section50-999-Paragraph2-1-Subparagraph\(SX210.5-02.22\(a\)-PublisherFASB\(1\)\)-URIhttps://asc.fasb.org/1943274/2147481800/320-extlink&oid=120391452&loc=d3e13212-122682-10-50-2](http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic320-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-Section50-999-Paragraph2-1-Subparagraph(SX210.5-02.22(a)-PublisherFASB(1))-URIhttps://asc.fasb.org/1943274/2147481800/320-extlink&oid=120391452&loc=d3e13212-122682-10-50-2) Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: duration X- Definition Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments. References Reference 1: [http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-04(2))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586/944-220-S99-1) Reference 2: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-9\)-URIhttps://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph(SX210.5-03-9)-URIhttps://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227) Reference 2: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph2-Subparagraph\(SX210.7-04-03-2-8\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=120400993&loc=SL114874131-10-S99-224263](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic944-SubTopic220-SectionS99-Paragraph2-Subparagraph(SX210.7-04-03-2-8)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=120400993&loc=SL114874131-10-S99-224263) Reference 3: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-9\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-9)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 4: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-7\(a\)-\(b\)\)-URIhttps://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph(SX210.5-03-7(a)-(b))-URIhttps://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227) Reference 4: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-8-7\(a\),\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=126953954&loc=SL114868664-224227-10-S99-2](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic220-SubTopic10-SectionS99-Paragraph2-Subparagraph(SX210.5-03-8-7(a),(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-extlink&oid=126953954&loc=SL114868664-224227-10-S99-2) Details Name: us-gaap_InvestmentIncomeTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: duration X- References No definition available. Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X- Definition For all Definition Tabular disclosure of unrealized gains and losses on investments in an unrealized loss position, including those for which other than temporary impairments have not been recognized in earnings (including investments for which a portion of an other than temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value). References No definition available. References Reference 1: <http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic320-SubTopic10-Section50-Paragraph6-URIhttps://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563> Details Name: us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock ----- gaap_UnrealizedGainLossOnInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: duration RESTRICTED CASH (Tables) 12 Months Ended Dec. 31, 2022-2023 Receivables [Abstract] SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2022-2023 December 31, 2021-2022 Cash and cash equivalents \$ 5,838,566 \$ 11,492,841 \$ 19,586,272 Money market investments, restricted - 6,000,000 6,000,000 Total \$ 5,838,566 \$ 17,492,841 \$ 25,586,272 X- References No definition available. Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X- Definition Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. References Reference 1: [http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-03(a)(2))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/944-210-S99-1) Reference 2: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic942-SubTopic210-SectionS99-Paragraph1-Subparagraph\(SX210.9-03\(1\)\(a\)\)-URIhttps://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-Topic942-SubTopic210-SectionS99-Paragraph1-Subparagraph(SX210.9-03(1)(a))-URIhttps://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878) Reference 2: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-SubTopic10-Section50-999-Paragraph8-1-Subparagraph\(SX210.9-03\(1\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479853/942-extlink&oid=126999549&loc=SL98516268-210-S99-408586](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-SubTopic10-Section50-999-Paragraph8-1-Subparagraph(SX210.9-03(1)(a))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479853/942-extlink&oid=126999549&loc=SL98516268-210-S99-408586) Reference 3: [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-999-Paragraph8-SubTopic10-Topic944-230-PublisherFASBSubTopic210-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(2\)\)-URIhttps://asc.fasb.org/1943274/2147482913/230-extlink&oid=126734703&loc=d3e572229-122910-10-50-8](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-999-Paragraph8-SubTopic10-Topic944-230-PublisherFASBSubTopic210-SectionS99-Paragraph1-Subparagraph(SX210.7-03(a)(2))-URIhttps://asc.fasb.org/1943274/2147482913/230-extlink&oid=126734703&loc=d3e572229-122910-10-50-8) Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: duration FAIR VALUES OF FINANCIAL INSTRUMENTS (Tables) 12 Months Ended Dec. 31, 2022-2023 Fair Values Of Financial Instruments SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Assets and liabilities measured at fair value are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets / Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2023 Corporate debt securities, available for sale \$ 9,857,087 \$ 9,857,087 \$ - - Recurring items as of December 31, 2022 Corporate debt securities and U. S. treasury obligations, available for sale \$ 21,254,485 \$ - \$ - \$ 21,254,485 Non-recurring items as of December 31, 2022 In-process R & D (Note 6) \$ - \$ - \$ - \$ - Liabilities: Recurring items as of December 31, 2021 Corporate debt

securities and U. S. treasury obligations, available for sale \$ 29, 803, 095 \$ — \$ 29, 803, 095 Non-recurring items as of December 31, 2021 In-process R & D (Note 6) \$ 13, 366, 234 \$ — \$ 13, 366, 234 Liabilities: Recurring items as of December 31, 2022 Earn-out milestone liability (Note 13) \$ — \$ — \$ — Recurring items as of December 31, 2021 Earn-out milestone liability (Note 13) \$ 5, 396, 000 \$ — \$ 5, 396, 000 X- ReferencesNo definition available. Details Name: IMNN_DisclosureFairValuesOfFinancialInstrumentsAbstract Namespace Prefix: IMNN_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-820-SubTopic-10> Name Accounting Standards Codification-Section 50- Paragraph 2- Subparagraph (a)- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-\(a-b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(a-b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482106/820-10-50-2>extlink & oid=126976982 & loc=d3e19207-110258Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-\(a-b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(a-b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482106/820-10-50-2>extlink & oid=126976982 & loc=d3e19207-110258-10-50-2 Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationINTANGIBLE ASSETS (Tables) 12 Months Ended Dec. 31, 2022-2023 Goodwill and Intangible Assets Disclosure [Abstract] SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the two years year ended December 31, 2022: SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR & D Goodwill Covenant Not to Compete Balance at January 1, 2021-2022, net \$ 13, 366, 234 Balance \$ 1, 976, 401 \$ 113- 13, 366, 660 Amortization --(113- 234, 660) Impairment charge --(1-13, 976, 366, 401-234) --Balance at December 31, 2021, net-13, 366, 234--Balance 13, 366, 234--Impairment charge (13, 366, 234)--Balance at December 31, 2022, net \$- \$- \$- Balance \$- \$- X- DefinitionTabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination. ReferencesNo definition available. Details Name: us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationPROPERTY AND EQUIPMENT (Tables) 12 Months Ended Dec. 31, 2022-2023 Property, Plant and Equipment [Abstract] SUMMARY OF PROPERTY AND EQUIPMENT Property and equipment at December 31, 2023 and 2022 and 2021 consist of the following: SUMMARY OF PROPERTY AND EQUIPMENT 2023 2022 2021-December 31, 2023 2022 2021-Machinery and equipment (5- 7 year life) \$ 2, 055, 192 \$ 2, 468, 388 Machinery and equipment (5- 7 year life) \$ 3-2, 106-055, 069-192 \$ 2, 468, 388 Furniture and fixtures (3- 5 year life) 191, 932 350, 481 383, 477-Leasehold improvements (5- 7 year life) 607, 054 373, 194 343-203-Property and equipment gross 2, 854, 178 3, 192, 063 3, 832, 749-Less accumulated depreciation and amortization (2, 102, 272) (2, 643, 762) (3, 355, 738) Total \$ 751, 906 \$ 548, 301 \$ 477, 011 X- ReferencesNo definition available. Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-SubTopic-10-Topic-360-Publisher-FASB-SubTopic-10-Section-50-Paragraph-1-URI> <https://asc.fasb.org/1943274/2147482099/360-10-360-10-50-1>extlink & oid=6391035 & loc=d3e2868-110229-10-50-1 Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationOTHER ACCRUED LIABILITIES (Tables) 12 Months Ended Dec. 31, 2022-2023 Payables and Accruals [Abstract] SCHEDULE OF OTHER ACCRUED LIABILITIES Other accrued liabilities at December 31, 2023 and 2022 and 2021 include the following: SCHEDULE OF OTHER ACCRUED LIABILITIES 2023 2022 2021-December 31, 2023 2022 2021-Amounts due to contract research organizations and other contractual agreements \$ 1, 442, 659 \$ 2, 196, 711 \$ 1, 401, 356-Accrued payroll and related benefits 1, 693, 383 2, 139, 927 1, 636, 727-Accrued interest 37, 583 16, 792-Accrued professional fees 234, 479 215, 402 87, 250-Other 20, 000 205, 313 31, 412-Total \$ 3, 390, 521 \$ 4, 794, 936 \$ 3, 173, 537 X- ReferencesNo definition available. Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of accrued liabilities. ReferencesNo definition available. Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationNOTES PAYABLE (Tables) 12 Months Ended Dec. 31, 2022-2023 Debt Disclosure [Abstract] SCHEDULE OF FUTURE PRINCIPAL PAYMENTS, NET OF UNAMORTIZED DEBT DISCOUNTS-On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of future principal payments, net of unamortized debt discounts and amortized end-of-term fee, due on the SVB Loan Facility: SCHEDULE OF FUTURE PRINCIPAL PAYMENTS, NET OF UNAMORTIZED DEBT DISCOUNTS As of December 31, 2023 \$ 1, 500, 000 2024 \$ 3, 000, 000 2025 and thereafter 1, 500, 000 Subtotal of future principal payments 6, 000, 000 Amortized end-of-term fee, net (35, 720) Total \$ 5, 964, 280 SCHEDULE OF DEBT On June 18, 2021, as a condition of entering into the SVB Loan Facility, the Company paid the outstanding principal balance, an early termination fee and the end of term charges in full satisfaction of the Horizon Credit Agreement, as amended. The following is a schedule of the amounts paid to Horizon SVB on June 18-April 21, 2021-2023: SCHEDULE OF DEBT Principal balance at June 18-April 21, 2021-2023 \$ 5-6, 000, 000 Early termination fees 150-120, 000 End of term charges 275-300, 000 Total payoff amount \$ 5-6, 425-420, 000 X- ReferencesNo definition available. Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of information pertaining to short-term and long-term debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. ReferencesNo definition available. Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of maturity and..... Balance Type: na Period Type: durationINCOME TAXES (Tables) 12 Months Ended Dec. 31, 2022-2023 Income Tax Disclosure [Abstract] SCHEDULE OF INCOME TAX PROVISION (BENEFIT) The income tax benefit for the years ended December 31, 2023 and 2022 and 2021 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2023 2022 2021-Federal Current \$- \$- Deferred-- State and Local-- Current-- Deferred (1, 280, 385) (1, 567, 026) (1, 383, 446) Total \$ (1, 280, 385) \$ (1, 567, 026) (1, 383, 446) SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION A reconciliation of the Company's statutory tax rate to the effective rate for the years ended December 31, 2023 and 2022 and 2021 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2023 2022 2021-Federal statutory rate 21. 0 % 21. 0 % State taxes, net of federal tax benefit 7. 1 7. 8-1 Permanent differences (3. 1) 29. 8 True-Up (15-105, 0) - Other (2. 9) - Change in valuation allowance and deferred rate change, net 89. 0 (53. 8) (7. 6) Effective tax rate 6. 1 % 4. 1 6 % 6. 2 % SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES The components of the Company's deferred tax asset as of December 31, 2023 and 2022 and 2021 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022 2021-December 31, 2023 2022 2021-Net operating loss carryforwards \$ 79-67, 800 310, 000 \$ 64-79, 915-800, 000 Section 174 4, 929, 000- Other deferred tax assets, net 2, 016, 000 13, 287, 000 5, 213, 000 Subtotal 74, 255, 000 93, 087, 000 70, 128, 000 Valuation allowance (72, 974, 615) (91, 519, 974) (68, 744, 554) Total deferred tax asset \$ 1, 567, 280, 026 385 \$ 1, 383, 567, 446-026 X- ReferencesNo definition available. Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-740-SubTopic-10-Section-50-Paragraph-9-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482685/740-10-740-10-50-9>extlink & oid=121826272 & loc=d3e32639-109319-10-50-9 Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Paragraph-2-Topic-740-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482685/740-10-740-10-50-9>extlink

& oid=121826272 & loc=d3e32537-109319-10-50-2 Details Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic 740-SubTopic 10-Name Accounting Standards Codification-Paragraph 12-Topic 740-SubTopic 10-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740 extlink & oid=121826272 & loc=d3e32687-109319-10-50-12 Details Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationSTOCK- BASED COMPENSATION (Tables) 12 Months Ended Dec. 31, 2022-2023 Share- Based Payment Arrangement [Abstract] SUMMARY OF STOCK OPTIONS A summary of stock option awards as of December 31, 2022-2023 and changes during the two-year period ended December 31, 2022-2023 is presented below: SUMMARY OF STOCK OPTIONS Stock Options Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2021-2022 308, 313 \$ 41.55 Options granted 148, 016 \$ 32.09 Options exercised (500) \$ 9.45 Options canceled or expired (14, 404) \$ 38.23 Outstanding at December 31, 2021-2022 441, 425 \$ 38.50 Options granted 716, 156 \$ 2.72 Options canceled or expired (397, 361) \$ 39.06 Outstanding at December 31, 2022 760, 220 \$ 4.55 Options granted 432, 500 \$ 1.23 Options canceled or expired (129, 238) \$ 9.25-37 Outstanding at December 31, 2023 1, 063, 482 \$ 2.61 8.8 \$ - Exercisable at December 31, 2022-2023 201-453, 935-766 \$ 3.64 8.5 978-9 \$ - SUMMARY OF NON- VESTED RESTRICTED STOCK AWARDS A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2022-2023 and changes during the two-year period ended December 31, 2022-2023, is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS Restricted AWARDS Restricted Stock Number Outstanding Weighted Average Grant Date Fair Value Non-vested stock awards outstanding at January 1, 2021-2022 83-1, 481 \$ 12.36 Granted 69, 650 \$ 1.92 Vested and issued (1, 381) \$ 12.04 Forfeited (100) \$ 9.45 Granted 1, 464 \$ 13.48 Forfeited (66) \$ 33.30 Non-vested stock awards outstanding at December 31, 2021-2022 1, 481 \$ 12.36 Granted 69, 650 \$ 1.92 Granted 22, 100 \$ 0.92 Vested and issued (59, 450) \$ 1, 381, 91 Forfeited (200) \$ 12-4 60 04 Forfeited (100) \$ 9.45 Non-vested stock awards outstanding at December 31, 2022 2023 69-32, 650-100 \$ 1.92-23 SUMMARY OF STOCK OPTIONS OUTSTANDING A summary of stock options outstanding at December 31, 2022-2023 by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to \$ 1.95 689, 113 9.1 \$ 1.74 315, 867 8.8 \$ 1.71 1.96 to \$ 10.00 709-347, 952-9-975 8, 441 2.2-78-166, 301-9-33 \$ 3.27-113, 936 8.2 \$ 10-4.63 01 to \$ 25.00-10, 500 8.08 \$ 18.42-5, 597 7.82 \$ 18.54 Above \$ 25 10, 01 26, 39-394, 768-6.67 3 \$ 32-23, 43-30-69 23, 037-963 6.52-1 \$ 33-24, 62-760-29 1, 063 220-201, 935-482 453, 766 SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon's stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, 2023 2021-Risk-free interest rate 3.39% to 4.81% 1.74% to 3.97% 1.54% to 1.74%-Expected volatility 100.0% to 113.9-6% 106-100, 8-0% to 113.2-9% Expected life (in years) 7.5 to 10.0 7.5 to 10.0 Expected dividend yield 0.0% to 0.0% X-ReferencesNo definition available. Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718 extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (d-e) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718 extlink & oid=128089324 & loc=d3e5070-113901Reference 10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-SubTopic 10-Topic 718-Publisher FASB SubTopic 10-Section 50-Paragraph 2-Subparagraph (e)-URI https://asc.fasb.org/1943274/2147480429/718 extlink & oid=128089324 & loc=d3e5070-113901Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-SubTopic 10-Topic 718-Publisher FASB SubTopic 10-Section 50-Paragraph 2-Subparagraph (e) (1)-URI https://asc.fasb.org/1943274/2147480429/718 extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate (s), and (e) discount for post-vesting restrictions. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Topic 718-SubTopic 10-Subparagraph (f) (2)-Name Accounting Standards Codification-Paragraph 2-Topic 718-SubTopic 10-Section 50-Publisher FASB Paragraph 2-Subparagraph (f) (2)-URI https://asc.fasb.org/1943274/2147480429/718 extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. ReferencesNo definition available. Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationEARN- OUT MILESTONE LIABILITY (Tables) 12 Months Ended Dec. 31, 2022-2023 Earn-out Milestone Liability SCHEDULE OF CHANGES IN EARN- OUT MILESTONE LIABILITY The following is a summary of the changes in the earn-out milestone liability for 2021 and 2022: SCHEDULE OF CHANGES IN EARN- OUT MILESTONE LIABILITY Balance at January 1, 2021-2022 \$-7, 018, 000 Non-cash loss from the adjustment for the change in fair value included in 2021 net loss (1, 622, 000) Balance at December 31, 2021-5, 396, 000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5, 396, 000) Balance at December 31, 2022 \$-X-ReferencesNo definition available. Details Name: IMNN_DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Schedule Of Changes In Earn Out Milestone Liabilities Table [TextBlock] ReferencesNo definition available. Details Name: IMNN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock Namespace Prefix: IMNN_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationWARRANTS (Tables) 12 Months Ended Dec. 31, 2022-2023 Warrants SUMMARY OF WARRANT ACTIVITY Following is a summary of all warrant activity for the two years ended December 31, 2022-2023: SUMMARY OF WARRANT ACTIVITY Warrants Activity Warrants-Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2021-2022 256, 903 \$ 20.10 Warrants exercised during 2021 (Note 11) (81, 111) \$ 18.60 Warrants outstanding and exercisable at December 31, 2021-175, 792 \$ 20.96 Warrants expired during 2022 (7, 273) \$ 48.30 Warrants outstanding and exercisable at December 31, 2022 168, 519 \$ 19.78 Warrants expired during 2023 (8, 459) \$ 37.29 Warrants outstanding and exercisable at December 31, 2023 160, 060 \$ 18.86 Aggregate intrinsic value of outstanding warrants at December 31, 2022-2023 \$ -0- Weighted average remaining contractual terms (years) 3-2, 2 0 * Warrants to exercise 4, 059 shares of common stock at an exercise price of \$ 31.05 per share expired on January, 11, 2023-X-ReferencesNo definition available. Details Name: IMNN_DisclosureWarrantsAbstract Namespace Prefix: IMNN_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 1-

Subparagraph (a)- **Publisher FASB-**URI <https://asc.fasb.org/extentlink&oid=128089324&loc=d3e5047-113901>Reference 2: <http://1943274/2147480429> fasb.org/ us-718-10 gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 50- Section S99- Paragraph 1-** URI <https://asc.fasb.org/extentlink&oid=6784392&loc=d3e188667-122775> Details Name: us- gaap_ ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationLEASES (Tables) 12 Months Ended Dec. 31, 2022-2023 Leases SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, 2022-2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2023-2024 \$ 238-626, 609 323 2024-2025 543, 009 2026 362, 976 2027 370, 236 2028 and thereafter Thereafter -30, 903 Subtotal future lease payments 238-1, 609-933, 447 Less imputed interest (7-308, 860-733) Total lease liabilities \$ 230-1, 749-624, 714 Weighted average remaining life 0-3, 61-5 years Weighted average discount rate 9.98 % X-ReferencesNo definition available. Details Name: IMNN_DisclosureLeasesAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-> **Publisher FASB Topic 842- SubTopic 20 - Name Accounting Standards Codification- Topic 842- SubTopic 20- Section 50- Paragraph 6-** **Publisher FASB-** URI <https://asc.fasb.org/1943274/2147478964/842> extentlink & oid = 128292326 & loc = SL77918701- 209980-20-50-6 Details Name: us- gaap_ LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us- gaap_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)- USD (\$) 12 Months EndedDec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Mar. 22, 2024 Nov. 28, 2023 Jan. 10, 2023 Sep. 19, 2022 Jan. 31, 2021 Feb. 28, 2020 Aug. 31, 2018 Oct. 31, 2017 Jun. 30, 2017 Feb. 28, 2017 Jun. 30, 2015 Jun. 30, 2013 Feb. 28, 2013 Jul. 31, 2011Property 2022Property. Plant and Equipment [Line Items] Accounts receivable \$ 0 \$ 0 Depreciation expense 248, 000 197, 000 \$ 130, 000 Impairment of property or equipment \$ 0 \$ 0 Number of shares of common stock issuable upon exercise of warrants and equity awards 1, 255, 642 988, 389 NEW 618, 800 Net proceeds from sale of net operating losses \$ 1, 600, 000 \$ 1, 400, 000 \$ 28, 000, 000 \$ 2, 000, 000 \$ 1, 500, 000 \$ 800, 000 \$ 300, 000 \$ 300, 000 \$ 1, 600, 000 \$ 1, 500, 000 \$ 1, 400, 000 \$ 4, 200, 000NEW JERSEY Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses 1, 600, 000 1, 500, 000 \$ 1, 400, 600. 000 Tax 000 Tax-benefits of EDA \$ 1, 500-600. 000 NEW JERSEY | Minimum New Jersey Division of Taxation [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses 15, 000, 000 NEW JERSEY | Maximum [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses 20, 000, 000 Direct financing lease, selling loss 1, 900, 000 NEW JERSEY | New Jersey Division of Taxation [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 1, 600-300. 000 \$ 1, 600, 000 \$ 1, 300, 000 NEW JERSEY | New Jersey Division of Taxation [Member] | Subsequent Event [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 1, 600-300. 000 Minimum Hisun Agreement [Member] Property, Plant and Equipment [Line Items] Contract liabilities Property plant and equipment useful life 3 years Minimum [Member] | NEW JERSEY Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 500-15, 000, 000 Maximum [Member] Property, Plant and Equipment [Line Items] Property plant and equipment useful life 7 years Maximum [Member] | NEW JERSEY Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses 20, 000, 000 Direct financing lease, selling loss \$ 400. 000 X- DefinitionRepresents the total number of Shares of common stock issuable upon exercise of warrants and equity awards. ReferencesNo definition available. Details Name: IMNN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards Namespace Prefix: IMNN_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionTax benefits of EDA ReferencesNo definition available. Details Name: IMNN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-> **Publisher FASB Topic 946- SubTopic 310 - Name Accounting Standards Codification- Topic 954- SubTopic 310- Section 45- Paragraph 1- Subparagraph (d)- Publisher FASB-** URI <https://asc.fasb.org/1943274/2147480833/946> extentlink & oid = 126942793 & loc = d3e3073- 310-45-115593Reference----- 1Reference 2: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-> **Publisher FASB Topic 944- SubTopic 210 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 03 (a) (5))- Publisher FASB-** URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-> Topic 944-946 - SubTopic 210 - Section S99- Paragraph 1- Subparagraph (d)- Publisher FASB- Name Accounting Standards Codification- Topic 606- SubTopic 10- Section 45- S99- Paragraph 1- Subparagraph (SX 210. 6- 04 (5) (b))- **Publisher FASB-** URI <https://asc.fasb.org/1943274/2147479617/946> extentlink & oid = 126919976 & loc = SL49130531- 203044Reference 2-210- S99- 1Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-> **Publisher FASB Topic 954- SubTopic 310 - Name Accounting Standards Codification- Topic 606- SubTopic 10- Section 50-45 - Paragraph 8-1 - Publisher FASB Subparagraph (a)-** URI <https://asc.fasb.org/1943274/2147481058/954> extentlink & oid = 126920106 & loc = SL49130549- 203045Reference 3-310- 45- 1 Details Name: us- gaap_ AccountsReceivableNet Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionThe current period expense charged against earnings on long- lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. ReferencesReference 1: <http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-> **Publisher FASB- Name Accounting Standards Codification- Topic 606- SubTopic 10- Section 45- Paragraph 2-28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB-** URI <https://asc.fasb.org/1943274/2147482740/230> extentlink & oid = 126919976 & loc = SL49130532- 203044 Details Name 10- 45- 28Reference 2: <http://fasb.org/us-gaap-ContractWithCustomerLiability> Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non- production related depreciation. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-> **Publisher FASB- Name Accounting Standards Codification- Topic 360- SubTopic 10- Section 50- Paragraph 1- Subparagraph (a)-** **Publisher FASB-** URI <https://asc.fasb.org/extentlink&oid=6391035&loc=d3e2868-110229>Reference 2: <http://1943274/2147482099> fasb.org- us-360- gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 230- SubTopic 10- 50 Section 45- 1 Paragraph 28- Subparagraph (b)-** URI <https://asc.fasb.org/extentlink&oid=126954810&loc=d3e3602-108585> Details Name: us- gaap_ Depreciation- gaap_ DepreciationAndAmortization Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of loss recognized at commencement from direct financing lease. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-> **Publisher FASB Topic 270- SubTopic 10 - Name Accounting Standards Codification- Topic 270- SubTopic 10- Section 50- Paragraph 6A- Publisher FASB-** URI <https://asc.fasb.org/1943274/2147482964/270> extentlink & oid = 126900988 & loc = SL77927221- 10- 50- 108306Reference----- 6AReference 2: <http://www.xbrl.org/2003/role/disclosureRef-> **Publisher FASB Topic 842- SubTopic 30 - Name Accounting Standards Codification- Topic 842- SubTopic 30- Section 50- Paragraph 5- Subparagraph (1)-** **Publisher FASB-** URI <https://asc.fasb.org/1943274/2147479773/842> extentlink & oid = 124258985 & loc = SL77919372- 209981-30-50-5 Details Name: us- gaap_ DirectFinancingLeaseSellingLoss Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe aggregate amount of write- downs for impairments recognized during the period for long- lived assets held for abandonment, exchange or sale. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-> **Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB SubTopic 10- Section 45- Paragraph 28- Subparagraph (b)-** URI <https://asc.fasb.org/1943274/2147482740/230> extentlink & oid = 126954810 & loc = d3e3602- 10- 45- 108585Reference --- 28Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-> **Publisher FASB Topic 360- SubTopic 10 - Name Accounting Standards Codification- Topic 360- SubTopic 10- Section 45- Paragraph 15- Publisher FASB-** URI <https://asc.fasb.org/1943274/2147482130/360> extentlink & oid = 126905981 & loc = d3e2611- 110228-10-45-15 Details Name: us- gaap_ ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-> **Publisher FASB- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 3- Subparagraph (a)-** **Publisher FASB-** URI <https://asc.fasb.org/1943274/2147482685/740> extentlink & oid = 121826272 & loc = d3e32559- 109319-10-50-3 Details Name: us- gaap_ OperatingLossCarryforwards Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us- gaap_ PropertyPlantAndEquipmentLineItems Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in' PnYnMnDTnHnMnS' format, for

example, 'PIY5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. ReferencesNo definition available. Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: instantX-Details Name: srt_StatementGeographicalAxis = srt_NJ Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeTaxAuthorityNameAxis = us-gaap_NewJerseyDivisionOfTaxationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeTaxAuthorityNameAxis = us-gaap_NewJerseyDivisionOfTaxationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_TypeOfArrangementAxis = IMNN_HisunAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: FINANCIAL CONDITION AND LIQUIDITY GOING CONCERN UNCERTAINTY (Details Narrative)- USD (\$) +Months Ended-12 Months EndedAug-EndedDec 28-31 2020-2023 Jun-30, 2018-Dec 31, 2022Organization 2022-Dec-31, Consolidation 2021-Jun-30, 2021-Jan-31, 2021-Feb-28, 2020-Aug-31, 2018-Oct-31, 2017-Jun-30, 2017-Feb-28, 2017-Jun-30, 2015-Jun-30, 2013-Feb-28, 2013-Jul-31, 2011Collaborative Arrangement and Arrangement Other than Collaborative Presentation of Financial Statements [Abstract Line Items] Net loss \$ 19,514,977 \$ 35,898,234Fund operation 19,022,148 23,096,Cumulated net losses 388,182,802 \$ 368,667,825Cash 825 \$ 332,769,591 Cash and cash equivalents, short-term investments 22-15,800-700,000 Proceeds from sale of net operating losses 1,600,000 Restricted cash 6,000,000-0 Net proceeds from sale of net operating losses \$ 1,600,000 1,400,000 \$ 28,000,000-0 \$ 2,000,000-0 \$ 1,500,000-0 \$ 800,000-0 \$ 300,000-0 \$ 300,000-0 \$ 1,600,000-0 \$ 1,500,000-0 \$ 1,400,000-0 \$ 4,200,000Horizon Credit Agreement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument related end term charges \$ 200,000 Horizon Credit Agreement [Member] Horizon Technology Finance Corporation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Proceeds from contributed capital \$ 10,000,000 Debt instrument, face amount 10,000,000 Line of credit facility, maximum borrowing capacity \$ 10,000,000 SVB Loan Facility [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument, description Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus 7.625%) for the first 24 months through July 2020, followed by a 21-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity date on April 1, 2023- SVB Loan Facility [Member] Silicon Valley Bank [Member] Prime Rate [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument, interest rate, stated percentage 7.75% SVB Loan Facility [Member] Horizon Technology Finance Corporation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Restricted cash \$ 6,000,000 Repayment of outstanding indebtedness amount \$ 6,000,000 Amendment to Horizon Credit Agreement [Member] Horizon Technology Finance Corporation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Repayments of notes payable 5,000,000 Debt instrument, face amount 5,000,000-5,000,000 Debt instrument related end term charges \$ 200,000 NEW JERSEY Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net proceeds from sale of net operating losses \$ 1,600,000 1,500,000 \$ 1,400,000 NEW JERSEY Minimum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net proceeds from sale of net operating losses 15,000,000 NEW JERSEY Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net proceeds from sale of net operating losses 20,000,000 Operating costs and expenses \$ 1,900,000 X-DefinitionDebt instrument related end term charges. ReferencesNo definition available. Details Name: IMNN_PaymentOfDebtEndTermCharges Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionProceeds From Sale Of Net Operating Losses. ReferencesNo definition available. Details Name: IMNN_ProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionRepayment of outstanding indebtedness amount. ReferencesNo definition available. Details Name: IMNN_RepaymentOfOutstandingIndebtednessAmount Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(9))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments fasb-Period Type: instantX-DefinitionContractual interest rate for funds borrowed, under the debt agreement. ReferencesReference 1: [http://www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph1B-Subparagraph\(bSX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-extlink&oid=123466505&loc=SL123495323-10-S99-1Reference-112611Reference-8-2:https://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(22\)\(30\)\(a\)\(3I\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic470-SubTopic20-SectionS99-50-Paragraph1B-Subparagraph(bSX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-extlink&oid=123466505&loc=SL123495323-10-S99-1Reference-112611Reference-8-2:https://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(22)(30)(a)(3I))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_RetainedEarningsAccumulatedDeficit gaap_DebtInstrumentInterestRateScheduledPercentage Namespace Prefix: us-gaap Data Type: xbrli:dtr-types: monetaryItemType PercentItemType Balance Type: na credit Period Type: instantX-SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT-TERM INVESTMENTS (Details Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_CollaborativeArrangementsAndNoneCollaborativeArrangementTransactionsLineItems gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionIdentification Definition Amount of the lender and information about a contractual promise investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking fund requirements, voting rights, basis for conversion if convertible and current remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. ReferencesReference 1:

gaap—Data Type: na dtr—types: percentItem Type-Balance Type: na-Period Type: instantX-X- DefinitionMaximum borrowing capacity under the credit facility..... & loc = d3e13212-122682 Details Name: us-gaap-LineOfCreditFacilityMaximumBorrowingCapacity gaap FinancialInstrumentAxis = us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: us-gaap—Data Type: na xbrli:monetaryItem Type-Balance Type: credit-Period Type: instantX

SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) (Details) - DefinitionGenerally recurring costs associated-USD (\$) Dec. 31, 2023 Dec. 31, 2022Investments, Debt and Equity Securities [Abstract] Investments with normal operations except unrealized gains, Fair Value \$ 9, 857, 087 \$ 13, 278, 505Investments with unrealized gains, Unrealized Holding Gains (Losses) 60, 796 43, 508Investments with unrealized losses, Fair Value 7, 975, 980Investments with unrealized Losses, Unrealized Holding Gains (Losses) (17, 014) Total, Fair Value 9, 857, 087 21, 254, 485Total, Unrealized Holding Gains (Losses) \$ 60, 796 \$ 26, 494X- DefinitionAvailable for the portion of these expenses which can be clearly related to production and included in cost of sales- sale securities unrealized gains fair value or services- Excludes Selling, General and Administrative Expense- ReferencesNo definition available. Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedGainsFairValue us-gaap-OperatingCostsAndExpenses-Namespace Prefix: IMNN us-gaap—Data Type: xbrli:monetaryItem Type-Balance Type: credit definition available. Details Name:IMNN_EndOfTermChargePercentage-Namespace Prefix:IMNN_Data Type:dtr-types:percentItem Type-Balance Type:na-Period Type: durationX-instantX- DefinitionEnd of term fees-DefinitionAvailable for sale securities unrealized gains less than twelve months. ReferencesNo definition available. Details Name: IMNN_EndOfTermFees

IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths Namespace Prefix:IMNN Data Type:xbrli:monetaryItem Type Balance Type: debit-credit-Period Type: durationX-instantX- DefinitionFinal DefinitionAvailable Payment-Percentage for sale securities unrealized gains (losses) less than twelve months. ReferencesNo definition available. Details Name: IMNN_FinalPaymentPercentage

IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths Namespace Prefix:IMNN Data Type: xbrli dtr—types: percentItem Type-Balance Type: na-credit-Period Type: instantX- DefinitionDebt instrument related end term charges-DefinitionAvailable for sale securities unrealized losses less than twelve months. ReferencesNo definition available. Details Name: IMNN_PaymentOfDebtEndTermCharges

IMNN_AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths Namespace Prefix:IMNN Data Type:xbrli :monetaryItem Type Balance Type: debit-Period Type: durationX-instantX- DefinitionAmount of operating DefinitionAvailable for sale securities unrealized loss-losses carry forward, before tax effects, fair value. ReferencesNo definition available to reduce future taxable income under enacted tax laws- ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 3-Subparagraph (a)-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319-Details Name:

IMNN_AvailableForSaleSecuritiesUnrealizedLossFairValue us-gaap-OperatingLossCarryforwards-Namespace Prefix: IMNN us-gaap—Data Type: xbrli: monetaryItem Type Balance Type: debit-Period Type: instantX- DefinitionThe cash inflow associated with the amount.....: credit-Period Type: durationX- DefinitionAmount of cash restricted as to withdrawal or.....- DefinitionThe current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 320-SubTopic 10-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 50 45-Paragraph 4B-2-Publisher FASB Subparagraph (b)-URI https://asc.fasb.org/1943274/2147481830/320 extlink&oid=123466505&loc=SL123495323-10-45-112611Reference 2: http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef ref/legacyRef-Publisher-FASB-Topic 320-SubTopic 30-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99 45-Paragraph 1-Publisher FASB Subparagraph (SX 210.5-02.22 (a)-(1))-URI https://asc.fasb.org/1943274/2147479130/326 extlink&oid=120391452&loc=d3e13212-122682-30-45-1 Details Name:us-gaap-DebtInstrumentInterestRateStatedPercentage-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItem Type Balance Type:debit-Period Type:instantX-ReferencesNo definition available. Details Name: IMNN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent-us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: IMNN-us-gaap_Data Type: xbrli: monetaryItem Type-stringItem Type Balance Type: debit na-Period Type: instantX-durationSUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS (Details) - USD (\$) 12 Months EndedDec. 31, 2023 Dec. 31, 2022Investments, Debt and Equity Securities [Abstract] Interest and dividends accrued and paid \$ 725, 824 \$ 502, 578Realized gains (losses) 431, 801 (49, 222) Investment income, net \$ 1, 157, 625 \$ 453, 356X- DefinitionAmortized---- DefinitionAmount east of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated..... date and allocated without single maturity date. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic 320-SubTopic 10-Name Accounting Standards Codification-Topic 942-SubTopic 320-Section 50-Paragraph 3A-9-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320 extlink&oid=126980459&loc=SL120269850-112803Reference 2-10-50-9 Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: credit-Period Type: durationX- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. ReferencesReference 1: http://www.fasb xbrl-org/2009-us-gaap/role/commonPracticeRef ref/legacyRef-Publisher-FASB-Topic 220-SubTopic 10-Name Accounting Standards Codification-Topic 320-SubTopic 10-Section 50 S99 -Paragraph 2-Subparagraph (d)SX 210.5-03.7(a), (b))-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220 extlink&oid=126970911&loc=d3e27161-111563Reference 3-10-S99-2 Details Name: us-gaap_InvestmentIncomeInterestAndDividend Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: credit-Period Type: durationX- DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. ReferencesReference 1: http://www.fasb xbrl-org/2009-us-gaap/role/commonPracticeRef ref/legacyRef-Publisher-FASB-Topic 220-SubTopic 10-Name Accounting Standards Codification-Topic 320-SubTopic 10-Section 50 S99 -Paragraph 3-2-Subparagraph (SX 210.5-03.8)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220 extlink&oid=126970911&loc=d3e27198-111563-Details Name:10-S99-2Reference 2: http://fasb.org/us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate-Namespace Prefix: us-gaap-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit-Period Type: instantX-DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef ref/legacyRef-Publisher-FASB-Topic 220-SubTopic 10-Name Accounting Standards Codification-Topic 326-SubTopic 30-Section 45 S99 -Paragraph 1-2-Subparagraph (SX 210.5-03.7(a),(b))-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220 extlink&oid=124258926&loc=SL82898722-210454Reference 10-S99-2 Details Name:us-gaap_InvestmentIncomeNet Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItem Type Balance Type:credit-Period Type: durationX-ReferencesNo definition available. Details Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_Data Type:xbrli:stringItem Type Balance Type:na-Period Type:durationINVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE (Details Narrative)- USD (\$) Dec.31, 2022-2023 Dec.31, 2021Investments-2022Investments -Debt and Equity Securities [Abstract] Investment in debt securities- available for sale,at fair value \$ 9,857,087 \$ 21,254, 485 \$ 29,803,095SCHEDULE 485SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details)- USD (\$) Dec.31, 2022-2023 Dec.31, 2021Receivables-2022Receivables [Abstract] Cash and cash equivalents \$ 5,838,566 \$ 11,492, 841Money 841 \$ 19,586,272Money market investments,restricted 6,000, 000 6,000, 000Total \$ 5,838,566 \$ 17,492, 841-841X \$ 25,586,272X- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions.Includes other kinds of accounts that have the general characteristics of demand deposits.Also includes short-term,highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB- http://fasb-www xbrl.org/2003 us-gaap/role/disclosureRef ref/legacyRef-Publisher-FASB-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 320-210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-1-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/210 extlink&oid=124260329&loc=d3e26626-111562-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit-Period Type: instantX as-Period Type: instantX- DefinitionContractual interest rate or for included in marketable (funds borrowed, under the debt, equity, or other) securities whose use is restricted in whole or in part,generally by contractual agreements- agreement or regulatory requirements.For use in an unclassified balance sheet. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB Topic 954-SubTopic 210-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 45-50-Paragraph 4-1B-

Publisher FASB Subparagraph (b) - URI https://asc.fasb.org/1943274/2147480632/954-extlink & oid = 123466505 & loc = SL123495323-112611Reference 210-45-4Reference 2: http://fasb.www.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Publisher FASB Topic 954-SubTopic 210-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section 50 S99-Paragraph 2-1-Publisher FASB Subparagraph (SX 210.5-02.22 (a) (1)) - URI https://asc.fasb.org/1943274/2147480602/954-extlink & oid = 120391452 & loc = d3e13212-122682 210-50-2-Details Name:us-gaap-RestrictedInvestments gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap Data Type: xbrli:dttr-types:monetaryItemType percentItem Type Balance Type: na debit Period Type- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available-Details Name:us-gaap-MarketableSecuritiesLineItems Namespace Prefix:us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition Amount of investments including trading securities, available for sale securities, held to maturity securities, and short-term investments classified as other and current. ReferencesReference 1: http://fasb.www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher FASB Topic 235-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-4-03-08 (16 f)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-extlink & oid = 126897435 & loc = d3e534808-122878-10-S99-1-Details Name:us-gaap-DebtInstrumentCarryingAmount gaap_LineOfCreditFacilityLineItems Namespace Prefix:us-gaap Data Type: xbrli:monetaryItemType-stringItem Type Balance Type: credit na Period Type: instantX-durationX-Definition Amount Definition Investments which are not defined as or included in marketable (debt) equity after accumulated amortization, of debt issuance costs or other securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in Includes, but is not limited to, legal, accounting, underwriting, printing, and an registration costs unclassified balance sheet. ReferencesReference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Publisher FASB-Topic 942-954-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-03 (4))-URI https://asc.fasb.org/extlink & oid = 126897435 & loc = d3e534808-122878Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147480632/954-210-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-954-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-03 (5))-URI https://asc.fasb.org/extlink & oid = 126897435 & loc = d3e534808-122878Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher FASB-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-50-Paragraph 1-2-Publisher FASB Subparagraph (SX 210.5-02 (8))-URI https://asc.fasb.org/extlink & oid = 120391452 & loc = d3e13212-122682Reference 4: http://1943274/2147480602 fasb.org/us-954-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 944-SubTopic 210-50 Section S99-2 Paragraph 1-Subparagraph (SX 210.7-03 (a) (1) (g))-URI https://asc.fasb.org/extlink & oid = 126734703 & loc = d3e572229-122910-Details Name: us-gaap_ShortTermInvestments gaap_RestrictedInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Details Name: us-gaap_FinancialInstrumentAxis gaap_CreditFacilityAxis = IMNN_SiliconValleyBankMember us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details Name: us-gaap_FinancialInstrumentAxis = us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) (Details) - USD (\$) Dec. 31, 2022 2023 Dec. 31, 2022 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2021 Investments ----- Investment in debt securities- available for sale , at fair value \$ 9, 857, 087 \$ 21, 254, 485 Corporate Debt and Equity Securities [Abstract Member] Investments with unrealized gains, Fair Value \$ 13- 278, 505 \$ 8- 999, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 580 Investments ----- Investment with unrealized gains in debt securities- available for sale , at fair value 21 Unrealized Holding Gains (Losses) 43- 254 508 3- 485 Fair Value 499 Investments with unrealized losses- Recurring [Member] Fair Value 7- Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn-out milestone liability 975, 980 20- 803, 515 Investments with unrealized losses, Unrealized Holding Gains (Losses) (17, 014) (11, 473) Total, Fair Value 21- 254 Recurring [Member] | Fair Value, Inputs 485 29- 803 Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn 095 Total, Unrealized Holding Gains (Losses) \$ 26, 494 \$ (7, 974) X- Definition Available 000 Fair-out milestone liability Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn-out milestone liability Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn-out milestone liability Fair 5, 396, 000 Fair Value, Recurring [Member] | Corporate Debt Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale , at securities unrealized gains fair value -ReferencesNo definition 9, 857, 087 21, 254, 485 Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available -Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedGainsFairValue Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Available for sale , at fair value 9, 857, 087 21, 254, 485 Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- unrealized gains less than twelve months-ReferencesNo definition available -Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Available for sale , at fair value Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- unrealized gains (losses) less than twelve months-ReferencesNo definition available -Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Available for sale , at fair value Fair Value, Nonrecurring [Member] | Inprocess R & D [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- unrealized losses less than twelve months-ReferencesNo definition available -Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Available for sale , at securities unrealized losses fair value -ReferencesNo definition Fair Value, Nonrecurring [Member] | Inprocess R & D [Member] | Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available -Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedLossFairValue Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: for sale, at fair value Fair Value, Nonrecurring [Member] | Inprocess R & D [Member] | Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value Fair Value, Nonrecurring [Member] | Inprocess R & D [Member] | Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value X- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Section 45-Paragraph 1-URI https://asc.fasb.org/extlink & oid = 124258926 & loc = SL82898722-210454Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 320-SubTopic 10-Section 45-Paragraph 2-1-Publisher FASB - URI https://asc.fasb.org/1943274/2147479130/326-extlink & oid = 124260329 & loc = d3e26626-11562-30-45-1-Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount of liability recognized arising from contingent consideration in a business combination ReferencesNo definition available-Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationSUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS (Details) -USD (\$) 12 Months Ended Dec. 31-, expected to be settled beyond one year or the normal 2022-Dec. 31, 2021 Investments, Debt and Equity Securities [Abstract] Interest and dividends accrued and paid \$ 502, 578 \$ 18, 145 Realized losses (49, 222) (7, 149) Investment income, net \$ 453, 356 \$ 10, 996 X- Definition Investment income loss non-operating cycle, if longer -ReferencesNo definition available-Details Name: IMNN_InvestmentIncomeLossNonoperating Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). ReferencesReference 1: http://www.fasb.xbrl.org/2009-us-gaap/role/ref/legacyRef commonPracticeRef-Publisher FASB-Name

Accounting Standards Codification- Topic 320-805 - SubTopic 10-30 - Section 50-25 - Paragraph 9-6 - Publisher FASB Subparagraph (a)- URI https://asc.fasb.org/1943274/2147479668/805 extlink & oid=126970911 & loc=d3e27357-11563-Details Name: 30-25-6Reference 2: http://fasb.org/us-gaap-DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 35- Paragraph 1- Subparagraph b- SubTopic 30- Topic 220-805 - Publisher FASB SubTopic 10- Section 599- Paragraph 2- Subparagraph (SX 210-5-03-7(a),(b))- URI https://asc.fasb.org/1943274/2147479613/805 extlink & oid=126953954 & loc=SL114868664-224227-30-35-1-Details Name: us-gaap-InvestmentIncomeInterestAndDividend gaap_BusinessCombinationContingentLiabilityNoncurrent Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- ReferencesNo definition available. Balance Type: debit Period Type: instantX- DefinitionAmount of cash and cash equivalents..... \$ 4, 500, 000 X- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits-ReferencesReference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Publisher FASB- Topic 820- SubTopic 10 - Name Accounting Standards Codification- Topic 210- SubTopic 10- Section 599-50- Paragraph 1-2- Subparagraph (a) SX 210-5-02(-)- Publisher FASB - URI https://asc.fasb.org/1943274/2147482106/820 extlink & oid=120391452 & loc=d3e13212-10-50-122682Reference----- 2Reference 2: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Publisher FASB- Topic 820- SubTopic 10 - Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 8-2- Subparagraph (b)- Publisher FASB - URI https://asc.fasb.org/1943274/2147482106/820 extlink & oid=126999549 & loc=SL98516268-108586Reference-10-50-2Reference 3: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Publisher FASB- Topic 820- SubTopic 10 - Name Accounting Standards Codification- Topic 942- SubTopic 210- Section 599-50- Paragraph 1-3- Publisher FASB Subparagraph (SX 210-9-03(-)(a))- URI https://asc.fasb.org/extlink & oid/1943274/2147482106/820-10-50-3-Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Details Name: us-gaap_FinancialInstrumentAxis = 126897435 & loc=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis = gaap_TypeOfArrangementAxis = IMNN_FirstLeaseAmendmentMember us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis = gaap_AwardTypeAxis = IMNN_FirstYearMember us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis = gaap_AwardTypeAxis = IMNN_FinalYearMember us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FairValueByMeasurementFrequencyAxis = gaap_TypeOfArrangementAxis = IMNN_SecondLeaseAmendmentMember us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FinancialInstrumentAxis = gaap_TypeOfArrangementAxis = IMNN_InProcessRandMMember IMNN_EGENAssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_SCHEDULE OF X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_OperatingLeasesMember: http://www.xbrl.org/2009-2003/role/commonPracticeRef disclosureRef- Publisher FASB- Topic 926- SubTopic 20 - Name Accounting Standards Codification- Topic 944- SubTopic 210- Section 599-50- Paragraph 1-5- Publisher FASB Subparagraph (SX 210-7-03(a)(2))- URI https://asc.fasb.org/1943274/2147483154/926 extlink & oid=126734703 & loc=d3e572229-122910-Details Name: 20-50-5Reference 2: http://fasb.org/us-gaap-RestrictedCash Namespace Prefix: us-gaap- gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionInvestments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet. ReferencesReference 1: http://www.xbrl.org/2003- role / disclosureRef ref / legacyRef - Publisher FASB- Topic 350- SubTopic 30 - Name Accounting Standards Codification- Topic 954- SubTopic 210- Section 45-50- Paragraph 4-2- Subparagraph (a) (1)- Publisher FASB - URI https://asc.fasb.org/1943274/2147482665/350 extlink & oid=120413173 & loc=SL6242262-115580Reference-30-50-2-Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionFor the asset that is reclassified back to held and used from held- for- sale, the amount of impairment charge that is recognized on the reclassification date. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 954-360- SubTopic 210-10- Section 50-45- Paragraph 2-7- Publisher FASB - URI https://asc.fasb.org/1943274/2147482130/360 extlink & oid=127002003 & loc=SL6242269-115581-Details Name: 10-45-7Reference 2: http://fasb.org/us-gaap-RestrictedInvestments Namespace Prefix: us-gaap- gaap-Data Type: xbrli:monetaryItemType Balance..... www.xbrl.org/2003/role/ref/legacyRef disclosureRef- Publisher FASB - Name Accounting Standards Codification- Topic 326-360- SubTopic 30-10- Section 45-35- Paragraph 1-44- Publisher FASB - URI https://asc.fasb.org/extlink & oid=124258926 & loc=SL82898722-210454Reference 2: http://1943274/2147482190 fasb.org/us-360- gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 320- SubTopic 10-35 Section 45-44 Paragraph 2- URI https://asc.fasb.org/extlink & oid=124260329 & loc=d3e26626-11562-Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent gaap_ImpairmentChargeOnReclassifiedAssets Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- instantX- DefinitionAmount of liability recognized arising..... Type: credit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems gaap_ImpairmentEffectsOnEarningsPerShareLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Details Name: us-gaap_FinancialInstrumentAxis = gaap_FairValueByAssetClassAxis = IMNN_IPRAndDMember us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- INTANGIBLE ASSETS (Details Narrative Name: us-gaap_FairValueByMeasurementFrequencyAxis = us..... FAIR VALUE OF ASSETS ACQUIRED (Details) - In Process Research and Development [Member] - USD (\$) \$ in Millions 3 Months Ended 12 Months Ended Dec. 31, 2022 Dec. 31, 2021Noneompete Agreements 2023 Dec. 31, 2022EGEN Inc [Member] | IPR & D Drug Technology Platforms [Member] Finitive- Lived Intangible Assets [Line Items] Balance- Estimated acquisition price \$ 24. 2 | 13, 660Amortization (113, 660) Impairment charge- Balance- IPR And- & D Drug Technology Platforms [Member] Finitive- Lived Intangible Assets [Line Items] Asset impairment charges \$ 13. 4 Non- cash charge \$ 13. 4 X- DefinitionNon- cash charge. ReferencesNo definition available. Details Name: IMNN_NoncashCharge Namespace Prefix: IMNN-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- 13, 366, 234-13, 366, 234Amortization Impairment charge (13, 366, 234) Balance-13, 366, 234Goodwill [Member] Finitive- Lived Intangible DefinitionAmount of write- down of Assets assets [Line Items] Balance-1- recognized in the income statement. Includes, but is not limited 976, 101Amortization Impairment charge (1, 976, 101) Balance X- DefinitionThe aggregate expense charged against earnings to allocate the cost of, losses from tangible assets, intangible assets (nonphysical assets not used in production) in a systematic and goodwill rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 28- Subparagraph (b)- SubTopic 10- Topic 230- Publisher FASB SubTopic 10- Section 45- Paragraph 28- Subparagraph (b)- URI https://asc.fasb.org/1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3602-10-45-108585Reference----- 28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 350-360- SubTopic 30-10- Section 50-45- Paragraph 2-4- Publisher FASB Subparagraph (a) (2)- URI https://asc.fasb.org/1943274/2147482130/360 extlink & oid=66006027 & loc=d3e16323-109275Reference-3-10-45-4-Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionPurchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition. ReferencesReference 1: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 15- Paragraph 3- SubTopic 10- Topic 350-805 - Publisher FASB SubTopic 30- Section 45- Paragraph 2- URI https://asc.fasb.org/extlink & oid=6388964 & loc=d3e16225-109274-1943274/2147479455/805-10-15-3-Details Name: us-gaap_AmortizationOfIntangibleAssets gaap_BusinessCombinationPriceOfAcquisitionExpected Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit-credit Period

Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap-FiniteLivedIntangibleAssetsLineItems

Namespaces Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic926-SubTopic20> - Name Accounting Standards Codification-Topic926-SubTopic20-Section50-Paragraph5- Publisher FASB- URI <https://asc.fasb.org/extlink&oid=1943274/2147483154/926-20-50-5> Details Name: us-gaap-FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Details Name: us-gaap-BusinessAcquisitionAxis = 120154696 & loc=IMNN_EGENIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: dei_LegalEntityAxis = d3e54445

IMNN_IPRAndDDrugTechnologyPlatformsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- 107959Reference- Details Name: us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap-InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap-BusinessAcquisitionAxis = IMNN_IPRAndDDrugTechnologyPlatformsMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF PROPERTY AND EQUIPMENT (Details)- USD (\$) Dec. 31, 2023 Dec. 31, 2022Property, Plant and Equipment [Line Items] Property and equipment gross \$ 2, 854, 178 \$ 3, 192, 063Less accumulated depreciation and amortization (2, 102, 272) (2, 643, 762) Total 751, 906 548, 301Machinery and Equipment [Member] Property, Plant and Equipment [Line Items] Property and equipment gross 191, 932 350, 481Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property and equipment gross \$ 607, 054 \$ 373, 194X- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic210> - Name Accounting Standards Codification-Topic350-SubTopic30-Section50-S99- Paragraph 2-1- Subparagraph (SX 210. 7-03 (a) (+8) (b))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147479440/944> extlink & oid = 66006027 & loc = d3e16323- 210-109275-Details Name: us- S99

gaap-FiniteLivedIntangibleAssetsNet Namespace Prefix: us- IReference 2 gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionFor the asset that is reclassified back to held and used from held-for sale, the amount of impairment charge that is recognized on the reclassification date.

ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic210-SubTopic10> - Name Accounting Standards Codification-Topic360-SubTopic10-Section35-S99- Paragraph 44-1- Subparagraph (SX 210. 5-02 (14))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 29624951 & loc = d3e1756- 10- S99-110224Reference----- IReference 2-3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic360-SubTopic10-Section45-50-Paragraph7-1-Subparagraph\(c\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic360-SubTopic10-Section45-50-Paragraph7-1-Subparagraph(c)-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482099/360> extlink & oid = 126905981 & loc = d3e2459-110228-10-50-1-Details Name: us-gaap-ImpairmentChargeOnReclassifiedAssets gaap-AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit credit Period Type: durationX-instantX- DefinitionAmount before accumulated depreciation Details Name: us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap-NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap-FairValueByAssetClassAxis = IMNN_IPRAndDMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap-FairValueByAssetClassAxis = us-gaap-GoodwillMember Namespace Prefix: Data Type: na Balance Type: Period Type: INTANGIBLE ASSETS (Details Narrative)- USD (\$) 3 Months Ended 12 Months EndedDec. 31- depletion 2022 Dec. 31, 2021 Dec. 31, 2022 Dec. 31, 2021Finite-Lived Intangible Assets [Line Items] Goodwill acquired \$ 2, 000, 000. 0 IPR and amortization of physical D-Drug Technology Platforms [Member] In Process Research and Development [Member] Finite-Lived Intangible Assets [Line Items] Asset impairment charges \$ 0 EGEN Inc [Member] Goodwill [Member] Finite-Lived Intangible Assets [Line Items] Asset impairment charges 2, 000, 000. 0 Non-cash charge \$ 2, 000, 000. 0 EGEN Inc [Member] Purchase Agreement [Member] Finite-Lived Intangible Assets [Line Items] Finite-lived intangible assets used acquired \$ 1, 600, 000 Finite-lived intangible asset, useful life 7 years Amortization \$ 112, 660 EGEN Inc [Member] IPR and D-Drug Technology Platforms [Member] In Process Research and Development [Member] Finite-Lived Intangible Assets [Line Items] Estimated acquisition price \$ 24, 200, 000 IPR and D-Drug Technology Platforms [Member] In Process Research and Development [Member] Finite-Lived Intangible Assets [Line Items] Asset impairment charges \$ 13, 400, 000 Non-cash charge \$ 13, 400, 000 X- DefinitionNon-cash charge. ReferencesNo definition available. Details Name: IMNN-NoncashCharge Namespace Prefix: IMNN-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe aggregate amount of recurring noncash expense charge against earnings in the period normal conduct of business and not intended for resale. Examples include, but are not limited to allocate the cost of assets over their estimated remaining economic lives, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic944-SubTopic210> - Name Accounting Standards Codification-Topic350-SubTopic30-Section50-S99- Paragraph 2-1- Subparagraph (SX 210. 7-03 (a) (2-8))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147479440/944> extlink & oid = 66006027 & loc = d3e16323- 210- S99-109275Reference----- IReference 2: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic210-SubTopic10> - Name Accounting Standards Codification-Topic230-SubTopic10-Section45-S99- Paragraph 28-1- Subparagraph (b SX 210. 5-02 (13))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566/210> extlink & oid = 126954810 & loc = d3e3602- 108585-Details Name 10- S99-1Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic360-SubTopic10](http://fasb.org/us-gaap-AdjustmentForAmortizationNamespacePrefix:us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic360-SubTopic10) - Name Accounting Standards Codification-Topic230-SubTopic10-Section45-50- Paragraph 28-1- Subparagraph (b) - Publisher FASB- URI <https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585> Reference 2: <http://1943274/2147482099> fasb.org / us-gaap / role / ref / legacyRef - Publisher FASB - Name Accounting Standards Codification - Topic 360 - SubTopic 10 - Section 45 - 50 - Paragraph 4 - URI <https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228> Details Name: us-gaap-AssetImpairmentCharges gaap-PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX durationX- DefinitionPurchase price of expected business..... Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap-FiniteLivedIntangibleAssetsLineItems gaap-PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount after accumulated depreciation, depletion and amortization of increase-physical assets used in the normal conduct of business to produce goods assets, excluding financial assets, lacking physical substance with a definite life, from an-and acquisition services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic350-SubTopic20-Section50-Paragraph1-Subparagraph\(a\)\(1\)-SubTopic10-Topic360-PublisherFASB-URI](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic350-SubTopic20-Section50-Paragraph1-Subparagraph(a)(1)-SubTopic10-Topic360-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482099/360> extlink & oid = 66006027 & loc = d3e16265- 10-109275-Details Name: us- 50 gaap-FinitelivedIntangibleAssetsAcquired+ Namespace Prefix: us- IReference 2 gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-PublisherFASB-Topic852-SubTopic10> - Name Accounting Standards Codification-Topic350-SubTopic20-Section55- Paragraph 24-10- Publisher FASB- URI <https://asc.fasb.org/1943274/2147481372/852> extlink & oid = 122137925 & loc = d3e14258- 10-55-109268Reference----- IReference 2-3: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic944-SubTopic210> - Name Accounting Standards Codification-Section S99- Paragraph 1- Subparagraph (SX 210. 7-03 (a) (8))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic350-942-SubTopic20-360-NameAccountingStandardsCodification-Section50-Paragraph1-1-PublisherFASB-Subparagraph\(b\)-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic350-942-SubTopic20-360-NameAccountingStandardsCodification-Section50-Paragraph1-1-PublisherFASB-Subparagraph(b)-URI) <https://asc.fasb.org/1943274/2147480842/942> extlink & oid = 121556970 & loc = d3e13816- 109267-360-50-1-Details Name: us-gaap-GoodwillAcquiredDuringPeriod gaap-PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-instantX- Details Name: dei_LegalEntityAxis = us-gaap-PropertyPlantAndEquipmentByTypeAxis = IMNN_IPRAndDDrugTechnologyPlatformsMember us-gaap-MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-InProcessResearchAndDevelopmentMember gaap-FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis gaap-BusinessAcquisitionAxis = IMNN_EGENIncMember Namespace Prefix: Data Type: na Balance Type:

Period Type: X-Details Name: us-gaap-FairValueByAssetClassAxis = us-gaap-LeaseholdImprovementsMember gaap-GoodwillMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-TypeOfArrangementAxis = IMNN-PurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-BusinessAcquisitionAxis = IMNN-IPRandDDrugTechnologyPlatformsMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF PROPERTY AND EQUIPMENT (Details) (Parenthetical) 12 Months Ended Dec. 31, 2022

2023 Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 3 years Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years Machinery and Equipment [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Machinery and Equipment [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years Furniture and Fixtures [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 3 years Furniture and Fixtures [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Leasehold Improvements [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Leasehold Improvements [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years X-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap-PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. References No definition available. Details Name: us-gaap-PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap-Data Type: xbrli:durationItemType Balance Type: na Period Type: instantX durationX-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt-RangeAxis = srt-MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt-RangeAxis = srt-MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY SCHEDULE OF PROPERTY AND EQUIPMENT OTHER ACCRUED LIABILITIES (Details)-USD (\$) Dec. 31, 2022-2023 Dec. 31, 2021 Property 2022 Payables and Accruals [Abstract] Amounts due to contract research organizations and other contractual agreements \$ 1 Plant cycle if longer non-option equity instruments exercised by participants. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 210-718-SubTopic 10-Section 999-50-Paragraph 4-2-Subparagraph (c) SX 210-5-02-20 -Publisher FASB (I) (iv) (2)-URI https://asc.fasb.org/1943274/2147480566/210-extlink & oid = 128089324 & loc = d3e5070-11390140-S99-1-Details Name: us-gaap-AccruedLiabilitiesCurrent

gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType sharesItemType Balance Type: credit na Period Type: instantX durationX-Definition Carrying value as of the balance sheet end - an Equipment 210 Period Type: instantX -10-S99-1Reference 2-Definition Contractual interest rate for funds borrowed, under the debt agreement. References Reference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher FASB-Topic 944-SubTopic 210-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 999-50-Paragraph 1-1B-Subparagraph (b) SX 210-7-03(a)-(16)(a)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-extlink & oid = 123466505 & loc = SL123495323-210-S99-1Reference 112611Reference 3-2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Topic 942-SubTopic 210-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section 999-Paragraph 1-Subparagraph (SX 210-9-5-03-02.22 (46)(I))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-extlink & oid = 120391452 & loc = d3e13212-122682-210-S99-1-Details Name: us-gaap-LineOfCredit gaap-DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap-Data Type: xbrli:dtr-types:monetaryItemType percentItemType Balance Type: credit na [Line Items] Interest expense debt Property and equipment gross \$ 3-197,080 192,063 \$ 3-5,832-028,618 Silicon Valley Bank 749 Less accumulated depreciation and amortization (2,643,762) (3,355,738) Total 548,301 477,011 Machinery and Equipment [Member] Line of Credit Facility Property, Plant and Equipment [Line Items] Property and equipment gross 2 Gain (loss) on contract termination 329,158 Silicon Valley Bank 468,388 3,106,069 Furniture and Fixtures [Member] Line of Credit Facility Property, Plant and Equipment [Line Items] Property and equipment gross 350,481 383,477 Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property and equipment gross of credit facility, maximum borrowing capacity \$ 373-10,494,000,000 Proceeds from lines of credit 6,000,000 Loan amount withdrawn \$ 343-10,203X-000,000 Proceeds from Repayments of lines of credit 6 \$ 5,000,000 Restricted cash \$ 6,000,000.0 Debt instrument, interest rate 7.75 % Final payment percentage 3.00 % Long term Line line of credit \$ 10,000,000 Debt instrument, description Payments under the loan agreement are were interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. Financing fees and expenses \$ 243,370 End of term charge percentage 3.00 % Interest expense debt \$ 300,000 334,212 Interest expense debt \$ 197,080 295,792 106,709 Amortization 792 Amortization of debt issuance costs \$ 329,158 \$ 181,259 259X \$ 97,831 X-Definition Warrants cancelled Definition End of term charge percentage. References No definition available. Details Name: IMNN-ClassOfWarrantOrRight WarrantsOrRightsCancelled IMNN-EndOfTermChargePercentage Namespace Prefix: IMNN-Data Type: xbrli:dtr-types:sharesItemType percentItemType Balance Type: na Period Type: instantX durationX-Definition End Definition Final Payment of term charge percentage Percentage. References No definition available. Details Name: IMNN-EndOfTermChargePercentage IMNN-FinalPaymentPercentage Namespace Prefix: IMNN-Data Type: dtr-types:percentItemType Balance Type: na Period Type: instantX-Definition Amount of accumulated depreciation, depletion and amortization expense attributable for physical assets used in the normal conduct of business to produce goods debt discount (premium) and services debt issuance costs. References Reference 1: http://fasb-www.xbrl.org/2003-us-gaap/exampleRef-ref/legacyRef-Publisher FASB-Topic 470-SubTopic 20-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-55-Paragraph 1-69E-Publisher FASB Subparagraph (c)-URI https://asc.fasb.org/1943274/2147481568/470-extlink & oid = 6391035 & loc = d3e2868-110229Reference 20-55-69EReference 2: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher FASB-Topic 470-SubTopic 20-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section 999-55-Paragraph 1-69F-Publisher FASB Subparagraph (SX 210-5-02(14))-URI https://asc.fasb.org/1943274/2147481568/470-extlink & oid = 120391452 & loc = d3e13212-20-122682-Details Name: us-55

gaap-AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentNamespace Prefix: us-69FReference 3 gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB-Topic 470-SubTopic 20-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section 999-50-Paragraph 1-1E-Subparagraph (b) SX 210-5-02(13)-(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-extlink & oid = 120391452 & loc = d3e13212-20-50-122682Reference 1FReference 2-4: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Publisher FASB-Topic 230-SubTopic 10-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-45-Paragraph 1-28-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-extlink & oid = 6391035 & loc = d3e2868-110229Reference 10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-3

Details Name: us-gaap-PropertyPlantAndEquipmentGross gaap-AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit #210 Period Type: instantX -10-S99-1Reference 2-Definition Contractual interest rate for funds borrowed, under the debt agreement. References Reference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Publisher FASB-Topic 944-SubTopic 210-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 999-50-Paragraph 1-1B-Subparagraph (b) SX 210-7-03(a)-(16)(a)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-extlink & oid = 123466505 & loc = SL123495323-210-S99-1Reference 112611Reference 3-2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Topic 942-SubTopic 210-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section 999-Paragraph 1-Subparagraph (SX 210-9-5-03-02.22 (46)(I))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-extlink & oid = 120391452 & loc = d3e13212-122682-210-S99-1-Details Name: us-gaap-LineOfCredit gaap-DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap-Data Type: xbrli:dtr-types:monetaryItemType percentItemType Balance Type: na Period Type: instantX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-

gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-S99-Paragraph-1-Subparagraph-(SX-210.4-08(f))-Publisher-FASB-URI-https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229)Reference 2: [1943274/2147480678.fasb.org/us-235-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678](http://1943274/2147480678.fasb.org/us-235-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-10-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(2))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678) Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02.19\(b\),22\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02.19(b),22(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-extlink&oid=120391452&loc=d3e13212-122682-10-S99-1) Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of borrowing capacity currently available..... Type: credit Period Type: durationX- DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. ReferencesReference 1: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-S99-Paragraph-14-1-Subparagraph-\(b-SX-210.4-08\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126954810&loc=d3e3255-10-S99-108585Reference-----1Reference-2: http://www.fasb.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-230-SubTopic-10-Section-S99-45-Paragraph-14-1-Subparagraph-\(b-SX-210.4-08\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-extlink&oid=120395691&loc=d3e23780-122690-10-45-14](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-S99-Paragraph-14-1-Subparagraph-(b-SX-210.4-08(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126954810&loc=d3e3255-10-S99-108585Reference-----1Reference-2: http://www.fasb.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-230-SubTopic-10-Section-S99-45-Paragraph-14-1-Subparagraph-(b-SX-210.4-08(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-extlink&oid=120395691&loc=d3e23780-122690-10-45-14) Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash inflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. ReferencesReference 1: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-S99-Paragraph-15-1-Subparagraph-\(b-SX-210.4-08\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126954810&loc=d3e3291-10-S99-108585Reference-----1Reference-2: http://www.fasb.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-230-SubTopic-10-Section-S99-45-Paragraph-15-1-Subparagraph-\(b-SX-210.4-08\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-extlink&oid=120395691&loc=d3e23780-122690-10-45-15](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-S99-Paragraph-15-1-Subparagraph-(b-SX-210.4-08(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=126954810&loc=d3e3291-10-S99-108585Reference-----1Reference-2: http://www.fasb.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-235-230-SubTopic-10-Section-S99-45-Paragraph-15-1-Subparagraph-(b-SX-210.4-08(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-extlink&oid=120395691&loc=d3e23780-122690-10-45-15) Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(1\)\)-URI-https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Section-50-Paragraph-8-URI-https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference-4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-942-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-03\(1\)\(a\)\)-URI-https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878Reference-4: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-9\)-03\(1\)\(a\)\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-extlink&oid=126734703&loc=d3e572229-122910-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(2))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(1))-URI-https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Section-50-Paragraph-8-URI-https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference-4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-942-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-03(1)(a))-URI-https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878Reference-4: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-944-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-9)-03(1)(a)(2))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-extlink&oid=126734703&loc=d3e572229-122910-210-S99-1) Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionFair value portion of warrants not settleable in cash classified as equity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-\(a\)-URI-https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Topic-820-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(a)-URI-https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258) Details Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Details Name: us-gaap_DebtInstrumentAxis = IMNN_InitialHorizonCreditAgreementAmendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: dei_LegalEntityAxis = IMNN_HorizonTechnologyFinanceCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_SiliconValleyBankMember IMNN_HorizonCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_AmendmentToHorizonCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_StatementOfEquityComponentsAxis = us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_InitialHorizonCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_LineOfCreditFacilityAxis = IMNN_SiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)- USD (\$) 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021Income-2022Income Tax Disclosure [Abstract] Current Deferred State and Local Current Deferred (1, 280, 385) (1, 567, 026) (1, 383, 446) Total \$ (1, 280, 385) \$ (1, 567, 026) \$ (1, 383, 446) X- DefinitionAmount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference-----1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Subparagraph-\(a\)-SubTopic-10-Section-S99-Paragraph-9-Subparagraph-\(a\)-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-6.I.7\)-URI-https://asc.fasb.org/1943274/2147482685/740-extlink&oid=122134291&loc=d3e330036-122817Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-740-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-6.I.7\)-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=121826272&loc=d3e32639-109319-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Topic-235-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference-----1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Subparagraph-(a)-SubTopic-10-Section-S99-Paragraph-9-Subparagraph-(a)-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-6.I.7)-URI-https://asc.fasb.org/1943274/2147482685/740-extlink&oid=122134291&loc=d3e330036-122817Reference-3: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-740-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-6.I.7)-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=121826272&loc=d3e32639-109319-10-S99-1) Details Name: us-gaap_CurrentFederalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\(1\)\(Note-1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Publisher-FASB-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h)(1)(Note-1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1:

Publisher FASB- URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 740- SubTopic 10 -Section S99- Paragraph 1- Subparagraph (SAB Topic 6.1.7)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Publisher FASB- Name Accounting Standards Codification- Topic 235- SubTopic 10- Section S99-50- Paragraph 1-9- Subparagraph (b SX 210.4-08(h) - Publisher FASB (1)(Note 1))- URI https://asc.fasb.org//1943274/2147482685/740 extlink&oid=120395691&loc=d3e23780-10-50-122690Reference----- 9Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef- Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 6.1.7 740- SubTopic 10- Section 50- Paragraph 9- Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org//1943274/2147479360/740 extlink&oid=121826272&loc=d3e32639-109319-10-S99-1 Details Name: us- gaap_DeferredFederalIncomeTaxExpenseBenefit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non- US (United States of America) jurisdiction. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 10- Publisher FASB- URI https://asc.fasb.org//1943274/2147482685/740 extlink&oid=121826272&loc=d3e32672-109319-10-50-10** Details Name: us- gaap_DeferredFederalStateAndLocalTaxExpenseBenefit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non- US (United States of America) jurisdiction. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Topic 235- SubTopic 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.4-08(h) (1) (Note 1))- Publisher FASB- URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 740- SubTopic 10 -Section 50- Paragraph 9- Subparagraph (b)- URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 9- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org//1943274/2147482685/740-10-50-9Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 740- SubTopic 10 -Section S99- Paragraph 1- Subparagraph (SAB Topic 6.1.7)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef- Publisher FASB- Name Accounting Standards Codification- Topic 235- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210 SAB Topic 6.1.7 4-08(h) - Publisher FASB (1)(Note 1))- URI https://asc.fasb.org//1943274/2147479360/740 extlink&oid=120395691&loc=d3e23780-10-50-122690-1** Details Name: us- gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 250- SubTopic 10 - Name Accounting Standards Codification- Topic 740- SubTopic 10- Section S99-50- Paragraph 1-8- Publisher FASB Subparagraph (SAB TOPIC 6.1.7)- URI https://asc.fasb.org//1943274/2147483443/250 extlink&oid=122134291&loc=d3e330036-10-50-122817Reference----- 8Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 250- SubTopic 10 - Name Accounting Standards Codification- Section 50- Paragraph 9- Publisher FASB- URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 740- SubTopic 10 - Section 50- Paragraph 10- URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 280- SubTopic 10- Section 50- Paragraph 22-10- Publisher FASB Subparagraph (h)- URI https://asc.fasb.org//1943274/2147482685/740 extlink&oid=126901519&loc=d3e8736-10-50-108599Reference----- 10Reference 4: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Topic 235- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210 SAB TOPIC 6.1.7 4-08(h) - Publisher FASB - URI https://asc.fasb.org//1943274/2147479360/740 extlink&oid=120395691&loc=d3e23780-10-S99-122690Reference----- 1Reference 5: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 280- SubTopic 10 - Name Accounting Standards Codification- Topic 250- SubTopic 10- Section 50- Paragraph 9-22- Subparagraph (h)- Publisher FASB - URI https://asc.fasb.org//1943274/2147482810/280 extlink&oid=124431687&loc=d3e22663-107794Reference-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 944- SubTopic 220 - Name Accounting Standards Codification- Topic 740- SubTopic 20- Section 45 S99- Paragraph 2-1- Subparagraph (a SX 210.7-04(9) - Publisher FASB - URI https://asc.fasb.org//1943274/2147483586/944 extlink&oid=123586238&loc=d3e38679-220-S99-109324Reference----- 1Reference 7: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 2- Subparagraph (a)- SubTopic 20- Topic 944-740 - Publisher FASB SubTopic 220- Section S99- Paragraph 1- Subparagraph (SX 210.7-04(9))- URI https://asc.fasb.org//1943274/2147482659/740 extlink&oid=120400993&loc=SL114874131-20-45-224263Reference----- 2Reference 8: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.4-08(h) - Publisher FASB SubTopic 10- Section 50- Paragraph 8- URI https://asc.fasb.org//1943274/2147480678/235 extlink&oid=124431687&loc=d3e22658-107794-10-S99-1** Details Name: us- gaap_IncomeTaxExpenseBenefit Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionSCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021 Income 2022 Income Tax Disclosure [Abstract] Federal statutory rate 21.00 % 21.00 % State taxes, net of federal tax benefit 7.10 % 7.80 % 10 % Permanent differences (3.10 %) 29.80 % True-Up (+5105.00 %) Other (2.90 %) Change in valuation allowance and deferred rate change, net 89.00 % (53.80 %) (7.60 %) Effective tax rate 6.10 % 4.10 60 % 6.20 % X- DefinitionEffective income tax rate reconciliation permanent differences. ReferencesNo definition available. Details Name: IMNN_EffectiveIncomeTaxRateReconciliationPermanentDifferences Namespace Prefix: IMNN_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionEffective income tax rate reconciliation time up. ReferencesNo definition available. Details Name: IMNN_EffectiveIncomeTaxRateReconciliationTimeUp Namespace Prefix: IMNN_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 12- Publisher FASB- URI https://asc.fasb.org//1943274/2147482685/740 extlink&oid=121826272&loc=d3e32687-109319-10-50-12** Details Name: us- gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 235- SubTopic 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.4-08(h) (2))- Publisher FASB- URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 740- SubTopic 10 -Section S99- Paragraph 1- Subparagraph (SAB Topic 6.1. Fact. 4)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Name Accounting Standards Codification- Topic 235- SubTopic 10- Section S99-50- Paragraph 1-12- Publisher FASB Subparagraph (SX 210.4-08(h) (2))- URI https://asc.fasb.org//1943274/2147482685/740 extlink&oid=120395691&loc=d3e23780-10-50-122690Reference----- 12Reference 3: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 740 6.1. Fact. 4)- Publisher FASB SubTopic 10- Section 50- Paragraph 12- URI https://asc.fasb.org//1943274/2147479360/740 extlink&oid=121826272&loc=d3e32687-109319-10-S99-1** Details Name: us- gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Topic 740- SubTopic 10 - Name Accounting Standards Codification- Section 50- Paragraph 12- Publisher FASB- URI https://asc.fasb.org//1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 740- SubTopic 10 -Section S99- Paragraph 1- Subparagraph (SAB Topic 6.1. Fact. 4)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef- **Publisher FASB- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 740 6.1. Fact. 4)- Publisher FASB SubTopic 10- Section 50- Paragraph 12- URI https://asc.fasb.org//1943274/2147479360/740 extlink&oid=121826272&loc=d3e32687-109319-10-S99-1** Details Name: us- gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType**********

Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Section 50- Paragraph 12- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-Section50-Paragraph12-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB- Name Accounting Standards Codification- Topic 740-SubTopic 10-Section 50- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 4)- **Publisher FASB- URI https://asc.fasb.org/1943274/2147479360/740-extlink&oid=122134291&loc=d3e330036-122817-10-50-1** Details Name: us- gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Section 50- Paragraph 12- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic 10-Section 50- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 4)- URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB- Name Accounting Standards Codification- **Section 50- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 4)- **Publisher FASB SubTopic 10- Section 50- Paragraph 12- URI https://asc.fasb.org/1943274/2147479360/740 extlink&oid=121826272&loc=d3e32687-109319-10-50-1**** Details Name: us- gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationSCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)- USD (\$) Dec. 31, 2022-2023 Dec. 31, 2021Income-2022Income Tax Disclosure [Abstract] Net operating loss carryforwards \$ 79-67, 800-310, 000 \$ 64-79, 915-800, 000Section 174 4, 929, 000 000Other- Other deferred tax assets, net 2, 016, 000 13, 287, 000Subtotal 74, 255, 000 5, 213, 000Subtotal 93, 087, 000 70, 128, 000Valuation allowance (72, 974, 615) (91, 519, 974) (68, 744, 554) Total deferred tax asset \$ 1, 567-280, 026-385 \$ 1, 383-567, 446X- DefinitionDeferred tax assets legal act. ReferencesNo definition available. Details Name: IMNN_DeferredTaxAssetsLegalAct Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Topic 740- SubTopic 10- Section 50- Paragraph 2- Subparagraph (b)- **Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740 extlink&oid=121826272&loc=d3e32537-109319-10-50-2**** Details Name: us- gaap_DeferredTaxAssetsGross Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Topic 740- SubTopic 10- Section 50- Paragraph 2- **Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740 extlink&oid=121826272&loc=d3e32537-109319-10-50-2**** Details Name: us- gaap_DeferredTaxAssetsNet Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. ReferencesReference 1: <http://www.fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Topic 740- SubTopic 10- Section 50- Paragraph 8-6- **Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740 extlink&oid=121826272&loc=d3e32632-109319Reference 10-50-6Reference 2: http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-PublisherFASB- Name Accounting Standards Codification- Topic 740- SubTopic 10- Section 50- Paragraph 8- **Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740 extlink&oid=121826272&loc=d3e32632-109319-10-50-8**** Details Name: us- gaap_DeferredTaxAssetsOther Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic740-SubTopic10> - Name Accounting Standards Codification- **Topic 740- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c)- **Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740 extlink&oid=121826272&loc=d3e32537-109319-10-50-2**** Details Name: us- gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- ReferencesNo definition available. Details Name: us- gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationINCOME TAXES (Details Narrative)- USD (\$) 1-Months Ended-12 Months EndedJan EndedDec 31, 2021-2023 Jan. 31, 2021-Aug. 31, 2018 Aug. 31, 2018 Oct. 31, 2017 Jun. 30, 2017 Feb. 28, 2017 Jun. 30, 2015 Jun. 30, 2013 Feb. 28, 2013 Jul. 31, 2011-Dec. 31, 2022 Dec. 31, 2021 Feb Nov. 28, 2023 Jan. 31, 2022 Dec. 31, 2020Operating 2018Operating Loss Carryforwards [Line Items] Proceeds from sale of losses [custom: ProceedsFromSaleOfNetOperatingLosses] \$ 1, 600-300, 000 Net Deferred Tax Assets, operating Operating losses-Loss Carryforwards \$ 28-67, 310 000; 000-0 \$ 28, 000-000-0 \$ 1, 500, 000 \$ 1-79, 500 800, 000 [custom: NetOperatingLossesExpirationDescription] \$ 800, 000 \$ 300, 000 \$ 300, 000 \$ 1, 600, 000 \$ 1, 500, 000 \$ 1, 400, 000 \$ 4, 200, 000 1, 600, 000 \$ 1, 400, 000 \$ 2, 000, 000 0Net operating losses expiration, description the deduction for net operating losses incurred in tax years beginning after January 1, 2018 is limited to 80 % of annual taxable income. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (" CARES Act ") was enacted in response to the COVID- 19 pandemic. The CARES Act provides for economic and cash liquidity stimulus through various means including payroll tax credits, payroll tax deferral, short- term changes in tax deductibility of interest expenses among other things. The Act also permits NOL carryovers and carrybacks to offset 100 % of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80 % of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018 through 2021 to be carried back to each of the five preceding tax years. The Company evaluated the various aspects of the Cares Act and determined that there was no material effect on the Financial Statements. Net operating losses expiration, description expire starting in 2029 through 2041-2042 Income tax examination, description Expenses incurred in connection with R & E activities in the US must be amortized over a 5- year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15- year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company's income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years Operating Income (loss-Loss) carry forwards, limitation on use \$ (21, 30-030, 000-000 \$ 40 430 -000, 000 \$ 30, 000-000 \$ 15, 000, 000 \$ 5, 000, 000 \$ 7, 000, 000 \$ 35, 000, 000 \$ 40, 000, 000 \$ 4, 000, 000 \$ 34, 000, 000 \$ 90, 000, 000 Operating income (loss-) (24, 921, 565) \$ (21, 007, 190) Domestic Tax Authority [Member] Operating Loss Carryforwards [Line Items] Net operating-Operating losses 330-Loss Carryforwards 307, 000, 000 Net operating losses, unused 225-218, 000, 000 Federal Income Tax [Member] | No Expiration [Member] Operating Loss Carryforwards [Line Items] Net operating-Operating losses 64-Loss Carryforwards \$ 78, 000, 000 State-000State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Deferred Tax Assets Net operating losses-58, 000, 000 U. S. Federal and State [Member] Operating Loss Carryforwards 44 [Line Items] Net operating losses 325, 000, 000 New Jersey [Member] Operating Loss Carryforwards [Line Items] Proceeds from sale of losses [custom: ProceedsFromSaleOfNetOperatingLosses] 1, 300 600, 000 Tax benefits of EDA 1, 600, 000 1, 500, 000 Net proceeds from sale of net operating losses \$ 1, 600 300, 000 1, 400 600, 000 New Jersey [Member] | Maximum [Member] Operating Loss Carryforwards [Line Items] Operating income Income (loss-Loss) \$ 300 1, 900, 000 New Jersey [Member] | State and Local Jurisdiction [Member] | Minimum [Member] Operating Loss Carryforwards [Line Items] Net proceeds from sale of net operating losses 15, 000, 000 New Jersey [Member] | State and Local Jurisdiction [Member] | Maximum [Member] Operating Loss******

Carryforwards [Line Items] Net proceeds from sale of net operating losses **20,000,000 NEW JERSEY Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 1,600,000 NEW JERSEY | Minimum [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards 15,000,000 NEW JERSEY | Maximum [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 20,000,000 NEW JERSEY | New Jersey Division of Taxation [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 1,300,000 \$ 1,600,000 \$ 1,300,000 X** - DefinitionNet operating losses carryforward limits, description. ReferencesNo definition available. Details Name: IMNN_NetOperatingLossesCarryforwardLimitsDescription Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX - DefinitionNet operating losses expiration, description. ReferencesNo definition available. Details Name: IMNN_NetOperatingLossesExpirationDescription Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionNet operating losses, unused. ReferencesNo definition available. Details Name: IMNN_NetOperatingLossesUnused Namespace Prefix: IMNN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionNet proceeds from sale of net operating losses ReferencesNo definition available. Details Name: IMNN_ProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionOperating loss carry forwards, limitation on use ReferencesNo definition available. Details Name: IMNN_OperatingLossCarryForwardsLimitationOnUse Namespace Prefix: IMNN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionProceeds From Sale Of Net Operating Losses. ReferencesNo definition available. Details Name: IMNN_ProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionTax benefits DefinitionAmount before allocation of EDA valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-ReferencesNo-6Referencedefinitionavailable2:http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-8> Details Name: IMNN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization-us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: IMNN-us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit 50 Period Type:instantX - Paragraph 2-Subparagraph (a) (2)- URI https://asc-DefinitionA brief description of status of the tax examination,significant findings to date, and the entity's position with respect to the findings. ReferencesReference 1: <http://www.fasb.org/extlink&oid=66006027&loc=d3e16323-109275> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-740-SubTopic10-Section45-50-Paragraph15-Subparagraph\(b-d\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-extlink&oid=126954810&loc=d3e3602-108585-10-50-15](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic230-740-SubTopic10-Section45-50-Paragraph15-Subparagraph(b-d)(2)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-extlink&oid=126954810&loc=d3e3602-108585-10-50-15) Details Name:us-gaap_AdjustmentForAmortization-gaap_IncomeTaxExaminationDescription Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType stringItemType Balance Type: na debit Period Type:Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22Reference2:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph31-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599Reference2:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30Reference3:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph\(b\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599Reference3:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32Reference4:http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph\(c\)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference4:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-31Reference5:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-extlink&oid=126901519&loc=d3e8736-108599-10-50-32](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-PublisherFASB-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22Reference2:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph31-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599Reference2:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30Reference3:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph30-Subparagraph(b)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599Reference3:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32Reference4:http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(c)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference4:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-31Reference5:http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-Section50-Paragraph32-Subparagraph(f)-URIhttps://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599Reference5:http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic280-SubTopic10-Section50-Paragraph22-32-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-extlink&oid=126901519&loc=d3e8736-108599-10-50-32) Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph3-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-extlink&oid=121826272&loc=d3e32559-109319-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph3-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-extlink&oid=121826272&loc=d3e32559-109319-10-50-3) Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_OperatingLossCarryforwardsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Details Name: us-gaap_IncomeTaxAuthorityAxis = us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeTaxAuthorityAxis = IMNN_FederalIncomeTaxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_StatementScenarioAxis = IMNN_NoExpirationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeTaxAuthorityAxis = us-gaap_StateAndLocalJurisdictionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeTaxAuthorityAxis = IMNN_USFederalAndStateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_StatementGeographicalAxis = IMNN_NJMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: X- Details Name: srt_StatementGeographicalAxis = srt_NJ Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeTaxAuthorityAxis = us-gaap_NewJerseyDivisionOfTaxationMember Namespace Prefix: Data Type: na Balance Type: Period Type: STOCKHOLDERS' EQUITY (Details Narrative)- USD (\$) 1Months Ended3Months Ended12Months EndedMay 25, 2022 Apr. 06, 2022 Jan. 10, 2022 Mar. 31, 2021 Mar. 19, 2021 Jan. 22, 2021 Dec. 04, 2018 Jan. 31, 2021 Dec. 31, 2022 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021-Mar. 03, 2022 Feb. 28, 2021-2022 Feb. Jan. 28 13, 2022Class of Stock 2020Accumulated Other Comprehensive Income (Loss) [Line Items] Shelf registration statement amount **Stock issued during period, value, new issues \$ 100,200,000 781,000 438 \$ 6,722,654** Reverse stock split, description On February 28, 2022, the Company effected a 15- for- 1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15- for- 1 reverse stock split. In addition, at the market open on March 1, 2022, the Company's common stock started trading under a new CUSIP number 15117N602 although the Company's ticker symbol, CLSN, remained unchanged. Stockholders equity note changes in capital structure description To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$ 1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company's **Common common Stock stock** fell below \$ 1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company's **Common common Stock stock** is at least \$ 1.00 per share for a minimum of ten consecutive business days during the 180- day compliance period. **Common stock, shares outstanding 9,399,789 7,436,197 86,557,736** Reverse stock split **common stock outstanding-5,770,516 Common stock, shares outstanding-7,436,197 7,436,197 5,770,516** Warrants issued 4,059 4,059 213,333 **Stock issued during period, value, new issues \$ 6,722,654 \$ 52,688,946** Proceeds from issuance of common stock \$ 6,722,667 \$ 52,688,946 **Share price \$ 285-Preferred stock, shares issued Preferred stock, stated value \$ 300 \$ 0.01 \$ 0.01 \$ 300** Original Issue Discount Rate 500-00 % Proceeds from issuance of preferred stock \$ **14 28,250 500** .000 Preferred stock, shares outstanding Proceeds from issuance under placement \$ 1,000,000 **Proceeds from issuance of common stock \$ 2,781,438 \$ 6,722,654** Series A Convertible Redeemable Preferred Stock [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock, shares issued 50,000 Preferred stock, stated value \$ 0.01** Share price \$ 300 **Original** Preferred stock, shares issued- **issue 50, discount rate 5,000- 00 %** Preferred stock, stated value \$ 0.01 Proceeds from issuance of preferred stock \$ 28,500,000-Preferred stock, conversion price \$ 13.65 Conversion of stock, shares issued 1,098,901 Preferred stock, shares outstanding 50,000 Series B Convertible Redeemable Preferred Stock [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss) [Line**

Items | Share price \$ 300 Preferred stock, shares issued 50,000 Preferred stock, stated value \$ 0.01 **Share price \$ 285 \$ 300 Proceeds from issuance of preferred stock \$ 14,250,000** Preferred stock, conversion price \$ 15.00 **Conversion 00 Conversion** of stock, shares issued 1,000,000 Preferred **000 Preferred** stock, shares outstanding 50,000 Market Offering Agreement [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss)** [Line Items] Stock issued during period, value, new issues \$ 7,500,000 Number of shares sold **1,904,142** 336,075 Proceeds from sale of stock \$ **2,781,438 \$** 503,798 Market Offering Agreement [Member] Forecast [Member] **Accumulated Other Comprehensive Income (Loss)** [Line Items] Number of shares sold 1,653,392 Proceeds from sale of stock \$ 2,465,656 Capital on Demand TM Sales Agreement [Member] **Accumulated Other Comprehensive Income (Loss)** [Line Items] Less than 12 months, unrealized gains, fair value \$ 16,000,000.0 Capital on Demand Agreement [Member] **Accumulated Other Comprehensive Income (Loss)** [Line Items] Stock issued, shares 500,000 Proceeds from issuance of common stock \$ 6,900,000 Securities Purchase Agreement [Member] | January 2021 Registered Direct Offering [Member] **Accumulated Other Comprehensive Income (Loss)** [Line Items] Stock issued, shares 1,728,395 Proceeds from issuance of common stock \$ 35,000,000 Share price \$ 20.25 Placement agent fee description In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners ("AGP," and together with Brookline Capital Markets, the "January 2021 Placement Agents") pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed \$ 82,500. Securities Purchase Agreement [Member] | March 2021 Registered Direct Offering [Member] **Accumulated Other Comprehensive Income (Loss)** [Line Items] Stock issued, shares 769,230 Proceeds from issuance of common stock \$ 15,000,000 Share price \$ 19.50 Placement agent fee description Placement Agent Agreement") with AGP, as lead placement agent (together with Jones Trading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, serving as co-placement agents, the "March 2021 Placement Agents"), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed \$ 82,500. Securities Purchase Agreement [Member] | April 2022 Registered Direct Offering [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss)** [Line Items] **Share price \$ 5.27** Stock issued, shares 1,328,274 Proceeds from issuance of common stock \$ 7,000,000.0 **Share price \$ 5.27** Placement agent fee description In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the "April 2022 Placement Agent") pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. Maximum [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss)** [Line Items] Common stock, shares outstanding 6,600,000 **6,600,000** Warrants issued 2,500,000 2,500,000 Proceeds from issuance under placement \$ 110,000 Minimum [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss)** [Line Items] Common stock, shares outstanding 400,000 **400,000** Warrants issued 200,000 **2021 Registration Statement** 200,000 81,111 Common Stock [Member] **Class of Stock Accumulated Other Comprehensive Income (Loss)** [Line Items] **Reverse stock split common stock outstanding 86,557,736** Stock issued during period, value, new issues \$ **16,100,644,000,000 Public float 75,000,000 2021 Registration Statement** [Member] | **Baby Shelf Limitation** [Member] **Class of Stock** [Line Items] **Public float** \$ **29,755-75** Stock issued, 000 shares 1,000 664,349 2,975,503 X- Definition Aggregate offering price **Definition Original issue discount rate**. References No definition available. Details Name: IMNN_AggregateOfferingPrices-**IMNN_OriginalIssueDiscountRate** Namespace Prefix: IMNN_ Data Type: xbrli-dtr-types: monetaryItemType **percentItem** Type Balance Type: credit na Period Type: durationX **instantX** - Definition Original issue discount rate **Definition Placement agent fee description**. References No definition available. Details Name: IMNN_OriginalIssueDiscountRate-**IMNN_PlacementAgentFeeDescription** Namespace Prefix: IMNN_ Data Type: xbrli-dtr-types: percentItemType **stringItem** Type Balance Type: na Period Type: instantX **durationX** - Definition Placement agent fee description **Definition Amount of public float**. References No definition available. Details Name: **IMNN_PublicFloat** IMNN_PlacementAgentFeeDescription Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX - Definition Shelf Registration statement amount. References No definition available. Details Name: IMNN_ShelfRegistrationStatementAmount Namespace Prefix: IMNN_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. **References Reference 1**: http://www.xbrl.org/2003/role/disclosureRef **exampleRef** - Publisher FASB **Topic 505-SubTopic 10** - Name Accounting Standards Codification- **Topic 470-SubTopic 20-Section 50-Paragraph 18-13** - Subparagraph (b-d) - Publisher FASB - URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid = 123466505 & loc = SL123495323-10-50-112611 **Reference 13 Reference 2**: http://fasb-www.xbrl.org/2003-us-gaap/role/recommendedDisclosureRef ref/legacyRef- Publisher FASB **Topic 272-SubTopic 10** - Name Accounting Standards Codification- **Topic 210-SubTopic 10-Section 999-45** - Paragraph 1-3 - Publisher FASB Subparagraph (SX 210.5-02.22(a)-(1))- URI https://asc.fasb.org//1943274/2147483014/272-10-45- **References No** - **3 Reference definition available 3**: http://www.Codification- **Period Type: instantX** - **Definition Contractual interest rate for funds borrowed under the debt agreement** Section 50- Paragraph 14- Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 **Reference 10**: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB Topic 505-SubTopic 10** - Name Accounting Standards Codification- **Topic 470-SubTopic 20-Section 50-Paragraph 18-1B** - Subparagraph (e-b) - Publisher FASB - URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid = 123466505 & loc = SL123495323-10-50-18 **Reference 11 Reference 11** **2**: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 210-SubTopic 10-Name Accounting Standards Codification- Section 999- Paragraph 1- Subparagraph (SX 210.5-02.22(27-a)) (b-1)** - Publisher FASB - URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 120391452 & loc = d3e13212-10-122682 **Details Name: us- S99 gaap_DebtInstrumentInterestRateStatedPercentage** Namespace Prefix: us- Data Type: http-dtr-types: //www-percentItem Type **Balance Type: na** Details Name: us- gaap_AccumulatedOtherComprehensiveIncomeLossLineItems **gaap_ClassOfStockLineItems** Namespace Prefix: us- gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX - Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. **References Reference 1**: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 505-SubTopic 10** - Name Accounting Standards Codification- **Topic 505-SubTopic 10-Section 50-Paragraph 3- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid = 126973232 & loc = d3e21475-112644-10-50-3** Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us- gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX - Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. **References Reference 1**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB-Name Accounting Standards Codification- Section 50- Paragraph 2-SubTopic 10-Topic 505- Publisher FASB SubTopic 10-Section 50-Paragraph 2- URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid = 126973232 & loc = d3e21463-10-50-112644** **Reference 2**: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef ref/legacyRef- **Publisher FASB-Topic 946-SubTopic 210** - Name Accounting Standards Codification- **Section 999- Paragraph 2- Subparagraph (SX 210.6-05(4))- Publisher FASB- URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2** **Reference 3**: http://www.xbrl.org/2003/role/commonPracticeRef- **Topic 946-SubTopic 220-Name Accounting Standards Codification- Section 999- Paragraph 3- Subparagraph (SX 210.6-09(4)(b))- Publisher FASB- URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3** **Reference 4**: http://www.xbrl.org/2003/role/disclosureRef- **Topic 946-SubTopic 210-Name Accounting Standards Codification- Section 999- Paragraph 1- Subparagraph (SX 210.6-04(16)(a))- Publisher FASB- URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1** **Reference 5**: http://www.xbrl.org/2009/role/commonPracticeRef- **Topic 946-SubTopic 220-Name Accounting Standards Codification- Section 999- Paragraph 3- Subparagraph (SX 210.6-09(7))- Publisher FASB- URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3** **Reference 6**: http://fasb.org/us-gaap/role/ref/legacyRef- **Topic 210-SubTopic 10-Name Accounting Standards Codification- Section 999- Paragraph 1- Subparagraph (SX 210.5-02(29))- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 120391452 & loc = d3e13212-122682-10-S99-1** Details Name: us- gaap_CommonStockSharesOutstanding Namespace Prefix: us- gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX - Definition Number of shares issued for each share of convertible preferred stock that is converted. **References Reference 1**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB-Name Accounting Standards Codification- Section 999- Paragraph 1-Subparagraph (SX 210.5-02(27))- SubTopic 10-Topic 210- Publisher FASB SubTopic 10-Section 999- Paragraph 1- Subparagraph (SX 210.5-02(27))- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = 120391452 & loc = d3e13212-10-S99-122682** **Reference 2**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB-Topic 210-SubTopic 10** - Name Accounting Standards Codification- **Topic 210-SubTopic 10-Section 999- Paragraph 1- Subparagraph (SX 210.5-02(28))- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid = d3e13212-10-S99-122682** **Reference 3**: http://fasb.org/us-gaap/role/ref/legacyRef- **Publisher FASB- Name Accounting Standards Codification- Topic 505-SubTopic 10-Section 50- Paragraph 3- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid = 126973232 & loc = d3e21475-112644** **Reference 10-50-3** **Reference 4**: http://www-fasb.xbrl.org/2003-us-gaap/role/disclosureRef ref/legacyRef -

Publisher FASB Topic 505- SubTopic 10 - Name Accounting Standards Codification- **Section 50- Paragraph 6- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505-10-50-6**Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505- SubTopic 10 -Section 50- Paragraph 16- Subparagraph \(c\)- URI https://asc.fasb.org/extlink & oid=126973232 & loc=SL123496180-112644](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-Section50-Paragraph16-Subparagraph(c)-URIhttps://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 505- SubTopic 10-Section 50- Paragraph 6-16- Subparagraph \(b-c\) - Publisher FASB - URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid=126973232 & loc=d3e21506-112644](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-Paragraph6-16-Subparagraph(b-c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481112/505extlink&oid=126973232&loc=d3e21506-11264410-50-16) 10-50-16 Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- DefinitionPer share conversion price of preferred stock. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- Topic 505- SubTopic 10 -Section 50- Paragraph 13- Subparagraph \(c\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid=126973232 & loc=SL123496158-112644](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50-Paragraph13-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481112/505extlink&oid=126973232&loc=SL123496158-11264410-50-13) 10-50-13 Details Name: us-gaap_PREFERREDStockConvertibleConversionPrice Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 505- SubTopic 10 -Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph \(a\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10 -Section S99- Paragraph 1- Subparagraph \(SX 210. 5-02 \(28\)\)- URI https://asc.fasb.org/extlink & oid=120391452 & loc=d3e13212-122682](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02(28))-URIhttps://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid=126973232 & loc=SL123496158-112644](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50S99-Paragraph13-1-Subparagraph(a-SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480566/210extlink&oid=126973232&loc=SL123496158-11264410-S99-1) 10-S99-1 Details Name: us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. ReferencesReference 1: [http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 505- SubTopic 10 -Name Accounting Standards Codification- Section 50- Paragraph 13- Subparagraph \(a\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481112/505-10-50-13](http://fasb-www.xbrl.org/2003us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10 -Section S99- Paragraph 1- Subparagraph \(SX 210. 5-02 \(28\)\)- URI https://asc.fasb.org/extlink & oid=120391452 & loc=d3e13212-122682](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-URIhttps://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid=126973232 & loc=SL123496158-112644](http://www.xbrl.org/2003/role/disclosureRef-PublisherFASB-NameAccountingStandardsCodification-Topic505-SubTopic10-Section50S99-Paragraph13-1-Subparagraph(a-SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480566/210extlink&oid=126973232&loc=SL123496158-11264410-S99-1) 10-S99-1 Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. ReferencesReference 1: [http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 946- SubTopic 210 -Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph \(SX 210. 6-05 \(4\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2](http://fasb-www.xbrl.org/2003us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.6-05(4))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479617/946-210-S99-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph \(SX 210. 6-09 \(4\) \(b\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(4)(b))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 6-04 \(16\) \(a\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-04(16)(a))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph \(SX 210. 6-09 \(7\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(7))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 5-02 \(28\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid=120391452 & loc=d3e13212-122682](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480566/210extlink&oid=120391452&loc=d3e13212-12268210-S99-1) 10-S99-1 Details Name: us-gaap_PREFERREDStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- DefinitionThe cash inflow from the additional capital contribution to the entity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 14- Subparagraph \(a\)- SubTopic 10- Topic 230- Publisher FASB- SubTopic 10- Section 45- Paragraph 14- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3255-108585](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URIhttps://asc.fasb.org//1943274/2147482740/230extlink&oid=126954810&loc=d3e3255-10858510-45-14) 10-45-14 Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 14- Subparagraph \(a\)- SubTopic 10- Topic 230- Publisher FASB- SubTopic 10- Section 45- Paragraph 14- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3255-108585](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URIhttps://asc.fasb.org//1943274/2147482740/230extlink&oid=126954810&loc=d3e3255-10858510-45-14) 10-45-14 Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 45- Paragraph 14- Subparagraph \(a\)- SubTopic 10- Topic 230- Publisher FASB- SubTopic 10- Section 45- Paragraph 14- Subparagraph \(a\)- URI https://asc.fasb.org//1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3255-108585](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-SubTopic10-Section45-Paragraph14-Subparagraph(a)-URIhttps://asc.fasb.org//1943274/2147482740/230extlink&oid=126954810&loc=d3e3255-10858510-45-14) 10-45-14 Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. ReferencesNo definition available. Details Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. ReferencesNo definition available. Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- DefinitionPrice of a single share of a number of saleable stocks of a company. ReferencesNo definition available. Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX- DefinitionNumber of new stock issued during the period. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 210505- Publisher FASB- SubTopic 10- Section S99- Paragraph 1- Subparagraph \(SX 210. 5-02 \(29\)\)- URI https://asc.fasb.org//1943274/2147481112/505 extlink & oid=120391452 & loc=d3e13212-10-50-122682](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic210505-PublisherFASB-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-URIhttps://asc.fasb.org//1943274/2147481112/505extlink&oid=120391452&loc=d3e13212-10-50-122682)Reference 2: [http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 946- SubTopic 10- Section 50- Paragraph 2- Subparagraph \(a\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147481004/946 extlink & oid=126973232 & loc=d3e21463-505-50-112644](http://fasb-www.xbrl.org/2003us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic10-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481004/946extlink&oid=126973232&loc=d3e21463-505-50-112644)Reference 3: [http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 13-1- Subparagraph \(a-SX 210. 6-04 \(16\) \(a\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147483575/946 extlink & oid=120391452 & loc=d3e187085-122770](http://fasb-www.xbrl.org/2003us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic220-NameAccountingStandardsCodification-Topic505-SubTopic10-SectionS99-Paragraph13-1-Subparagraph(a-SX210.6-04(16)(a))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946extlink&oid=120391452&loc=d3e187085-122770)Reference 4: [http://fasb-www.xbrl.org/2003 us-gaap/role/disclosureRef-ref/legacyRef- Publisher FASB- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 3- Subparagraph \(SX 210. 6-03 \(i\) \(1\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://fasb-www.xbrl.org/2003us-gaap/role/disclosureRef-ref/legacyRef-PublisherFASB-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(i)(1))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 5-02 \(28\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid=120391452 & loc=d3e13212-122682](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480566/210extlink&oid=120391452&loc=d3e13212-122682) lives-ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef- Publisher FASB- Topic 505- SubTopic 10- Section S99- Paragraph 2-1- Subparagraph \(b-SX 210. 5-02 \(29\)\)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480566/210 extlink & oid=126954810 & loc=d3e3602-108585](http://fasb.org/us-gaap/role/ref/legacyRef-PublisherFASB-Topic505-SubTopic10-SectionS99-Paragraph2-1-Subparagraph(b-SX210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480566/210extlink&oid=126954810&loc=d3e3602-108585) Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap-1 Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us- DefinitionThe aggregate amount of recurring noncash expense charged against earnings-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:durationX- DefinitionReduction in the number of shares during the period as

a result to allocate the cost of a reverse stock split assets over their estimated remaining economic lives. ReferencesReference 1: http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 350- SubTopic 30- Section 50- Paragraph 2- Subparagraph (a) (2) SubTopic 10- Topic 505- Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147481112 / 505 extlink & oid = 66006027 & loc = d3e16323- 109275Reference 10- 50- 2 Details Name: http:// fasb.org / us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 946- SubTopic 830- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section 50- 55- Paragraph 2- 11- Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480167 / 946 extlink & oid = 126973232 & loc = d3e21463- 830- 55- 112644Reference 11Reference 3: http:// fasb- www. xbrl. org / 2003 us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 946- SubTopic 205- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- 45- Paragraph 1- 4- Subparagraph (a) SX 210- 5- 02 (29) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480767 / 946 extlink & oid = 120391452 & loc = d3e13212- 122682Reference 205- 45- 4Reference 4: http:// fasb- www. xbrl. org / 2003 us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 946- SubTopic 505- Name Accounting Standards Codification- legacyRef Section 50- Paragraph 2- Subparagraph (a) - Publisher FASB - Name Accounting Standards Codification- Topic 805- SubTopic 30- Section 25- Paragraph 5- URI https:// asc.fasb.org / / 1943274 / 2147481004 / 946 extlink & oid = 6911189 & loc = d3e6405- 505- 50- 128476Reference 2Reference 3- 5: http:// www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 946- SubTopic 220- Name Accounting Standards Codification- Topic 805- SubTopic 30- Section 50- S99- Paragraph 1- 3- Subparagraph (SX 210.6- 09 (4) (b) (3) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147483575 / 946 extlink & oid = 126975305 & loc = d3e6927- 128479Reference 4 220- S99- 3Reference 6 : http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28)) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480566 / 210 extlink & oid = 120391452 & loc = d3e13212- 122682 lives- ReferencesReference 1- 10- S99- 1Reference 7 : http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Topic 505- SubTopic 10- Name Accounting Standards Codification- Topic 350- SubTopic 30- Section 50- S99- Paragraph 2- 1- Subparagraph (a) SX 210.3- 04 (2) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480008 / 505 extlink & oid = 66006027 & loc = d3e16323- 10- S99- 109275Reference 1Reference 2- 8 : http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- S99- Paragraph 28 1- Subparagraph (b) SX 210.5- 02 (29) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480566 / 210 extlink & oid = 126954810 & loc = d3e3602- 10 108585 Details Name: us- S99 gaap- AdjustmentForAmortization Namespace Prefix: us- gaap- 1 Details Name: us- gaap_ StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionDescription of the total capital structure change due to a stock dividend, stock split and reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statement or the effective date of registration statement. ReferencesReference 1: http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Topic 505- SubTopic 10- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section S99- Paragraph 4- Subparagraph (SAB Topic 4. C) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480008 / 505 extlink & oid = 120397183 & loc = d3e187143- 122770- 10- S99- 4 Details Name: us- gaap_ StockholdersEquityNoteChangesInCapitalStructureRetroactiveImpact Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. ReferencesReference 1: http:// fasb.org / us- gaap / role / ref / legacyRef- Publisher FASB- Topic 505- SubTopic 10- Name Accounting Standards Codification- Topic 505- SubTopic 10- Section S99- Paragraph 4- Subparagraph (SAB Topic 4. C) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480008 / 505 extlink & oid = 120397183 & loc = d3e187143- 122770- 10- S99- 4 Details Name: us- gaap_ StockholdersEquityReverseStockSplit Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Details Name: us- gaap_ StatementClassOfStockAxis = IMNN_ SeriesAConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ StatementClassOfStockAxis = IMNN_ SeriesBConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ TypeOfArrangementAxis = IMNN_ CapitalOnDemandTMSAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ TypeOfArrangementAxis = IMNN_ CapitalOnDemandAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ TypeOfArrangementAxis = IMNN_ SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ SubsidiarySaleOfStockAxis = IMNN_ JanuaryRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ SubsidiarySaleOfStockAxis = IMNN_ MarchRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ SubsidiarySaleOfStockAxis = IMNN_ AprilRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_ RangeAxis = srt_ MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us- gaap_ StatementEquityComponentsAxis gaap_ AwardTypeAxis = us- IMNN_ TwentyTwentyOneRegistrationStatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- gaap_ CommonStockMember Details Name: dei_ LegalEntityAxis = IMNN_ BabyShellLimitationMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF STOCK OPTIONS (Details)- USD (\$ 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021Share 2022Share - Based Compensation Arrangement by Share- Based Payment Award [Line Items] Number Outstanding, Outstanding, Ending balance 760- 1, 220- 063, 482 Number Outstanding, Exercisable, Ending balance 201- 453, 935- 766 Share- Based Payment Arrangement, Option [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Number Outstanding, Outstanding, Beginning balance 760, 220- 441, 425Weighted 425- 308, 313Weighted Average Exercise Price, Outstanding, Beginning balance \$ 4. 55 \$ 38. 50 \$ 41. 55Number 50Number Outstanding, Options granted 432, 500 716, 456- 148, 016Weighted- 156Weighted Average Exercise Price, Options granted \$ 1. 23 \$ 2. 72 \$ 32. 09Number 72Number Outstanding, Options exercised (500) Weighted Average Exercise Price, Options exercised \$ 9. 45Number Outstanding, Options canceled or expired (129, 238) (397, 361) (14, 404) Weighted Average Exercise Price, Options canceled or expired \$ 9. 37 \$ 39. 06 \$ 38. 23Number 06Number Outstanding, Outstanding, Ending balance 1, 063, 482 760, 220- 441, 425Weighted- 220Weighted Average Exercise Price, Outstanding, Ending balance \$ 2. 61 \$ 4. 55 \$ 38. 50Weighted 55Weighted Average Remaining Contractual Term (years), Outstanding, Ending balance 8 years 9 years 3- months 18 days Aggregate Intrinsic Value, Outstanding, Ending balance Number Outstanding, Exercisable, Ending balance 201- 453, 935- 766 Weighted Average Exercise Price, Exercisable, Ending balance \$ 8- 3, 07- 64 Weighted Average Remaining Contractual Term (years), Exercisable, Ending balance 8 years 10- 6 months 24 days Aggregate Intrinsic Value, Exercisable, Ending balance X- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Period Type: instantX- DefinitionContractual interest rate for funds borrowed under the debt agreement. ReferencesReference 1: http:// www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50- 35- Paragraph 1B- 1D- Publisher FASB Subparagraph (b)- URI https:// asc.fasb.org / / 1943274 / 2147480483 / 718 extlink & oid = 123466505 & loc = SL123495323- 10- 35- 112611Reference 1DReference 2: http:// fasb- www.xbrl. org / 2003 us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 210- Section 35- SubTopic Paragraph 3- Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480483 / 718- 10- 35 Section S99- Paragraph ReferencesNo- 3Reference definition available 3: http:// www. // asc- DefinitionContractual interest rate for funds borrowed under the debt agreement. ReferencesReference 1 fasb.org // 1943274 / 2147480429 / 718- 10- 50- 2Reference 5- http:// www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50- Paragraph 2- 1B- Subparagraph (a) (b) (3) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480429 / 718 extlink & oid = 123466505 & loc = SL123495323- 10- 50- 2Reference 112611Reference 6- 2 : http:// fasb- www.xbrl. org / 2003 us- gaap / role / disclosureRef / legacyRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section 50- S99- Paragraph 2- 1- Subparagraph (e) SX 210.5- 02.22 (a) (1) (i) - Publisher FASB- URI https:// asc.fasb.org / / 1943274 / 2147480429 / 718 extlink & oid = 120391452 & loc = d3e13212- 122682 10- 50- Details Name: us- gaap_ ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. ReferencesReference 1: http:// www.xbrl.org / 2003 / role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10-

Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iii)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- DefinitionThe weighted- average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iii)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iv)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average price of options that were either forfeited or expired. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iv)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionNet number of share options (or share units) granted during the period. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iv) (01)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instantX- DefinitionNumber of options outstanding, including both vested and non-vested options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Section 50- Paragraph 2- Subparagraph (c) (1) (i)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718-10-50-2~~ **Reference 2: http://www.xbrl.org/2003/role/disclosureRef-** ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (ii)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~extlink & oid=128089324 & loc=d3e5070-113901~~ **Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-** Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (i)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Section 50- Paragraph 2- Subparagraph (c) (1) (i)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718-10-50-2~~ **Reference 2: http://www.xbrl.org/2003/role/disclosureRef-** ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (ii)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~extlink & oid=128089324 & loc=d3e5070-113901~~ **Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Publisher FASB-** Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (i)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- ~~DefinitionWeighted average price at which option..... Type: na Period Type: durationX-~~ DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (iv) (01)-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instantX- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB-~~ Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2-~~ **Publisher FASB-** URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB-Topic 718- SubTopic 10- Subparagraph (e) (1)-~~ Name Accounting Standards Codification- ~~Paragraph 2- Topic 718- SubTopic 10- Section 50-~~ **Publisher FASB** ~~Paragraph 2- Subparagraph (e) (1)-~~ URI https://asc.fasb.org/~~/1943274/2147480429/718~~ **extlink & oid=128089324 & loc=d3e5070-113901-10-50-2** Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type:..... gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS (Details)- \$ / shares 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021-Share 2022Share -Based Payment Arrangement [Abstract] Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance **69,650** 1, 481Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance \$ **1.92** \$ **12.36** \$ **9.45**Number **36**Number **36**Number Outstanding, Non-vested stock awards, Granted **22,100** 69,650 1, 464Weighted- **650**Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted \$ **1-0.92** \$ **13-1.48**Number **92**Number Outstanding, Non-vested stock awards, ~~Forfeited~~ **Vested and issued** (**100** **59,450**) (**66-1,381**) Weighted Average Grant Date Fair Value, Non-vested stock awards, ~~Forfeited~~ **Vested and issued** \$ **9-1.45** \$ **91-23-12.30**Number- **04**Number Outstanding, Non-vested stock awards, ~~Forfeited~~ **Vested and issued** (**1,381** **200**) (**100**) Weighted Average Grant Date Fair Value, Non-vested stock awards, ~~Forfeited~~ **Vested and issued** \$ **4-4.04** \$ **60-9.45**Number **45**Number Outstanding, Non-vested stock awards, Outstanding, Ending balance **32,100** 69,650Weighted **650** 1, 481Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Ending balance \$ **1.92** \$ **23-1.36** \$ **9-2X** - ReferencesNo definition available. Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB-Topic 718- SubTopic 10-~~ Name Accounting Standards Codification-

Topic 718-SubTopic 10-Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (03)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (03)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (01)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (01)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Section 50- Paragraph 2- Subparagraph (c) (2) (i)- Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2**Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (ii)-URI https://asc.fasb.org/extlink & oid=128089324 & loc=d3e5070-113901Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (i)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition Per share or unit weighted- average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Section 50- Paragraph 2- Subparagraph (c) (2) (i)- Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2**Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (ii)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: instantX- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (02)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX- Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (2) (iii) (02)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationSUMMARY OF STOCK OPTIONS OUTSTANDING (Details) 12 Months Ended Dec. 31, 2022-2023 \$ / shares sharesShare- Based Payment Arrangement, Option, Exercise Price Range [Line Items] Options Outstanding, Number | shares 760-1, 063, 220Options-- 482Options Exercisable, Number | shares 201-453, 935Exercise 766Exercise Price One [Member] Share- Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, Upper \$ 10-1, 00Options-95Options Outstanding, Number | shares 709-689, 952Options-113Options Outstanding, Weighted Average Remaining Contractual Term (in years) 9 years 4-1 months- month 28-6 daysOptions Outstanding, Weighted Average Exercise Price \$ 2-1, 78Options-74Options Exercisable, Number | shares 166-315, 301Options-867Options Exercisable, Weighted Average Remaining Contractual Term (in years) 8 years 9 months 29-18 daysOptions Exercisable, Weighted Average Exercise Price \$ 3-1, 11Exercise 71Exercise Price Two [Member] Share- Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, Upper \$ 25-10, 00Options Outstanding, Number | shares 10-347, 500Options-- 975Options Outstanding, Weighted Average Remaining Contractual Term (in years) 8 years 29-4 months 24 daysOptions Outstanding, Weighted Average Exercise Price \$ 18-3, 42Options-- 27Options Exercisable, Number | shares 5-113, 597Options-- 936Options Exercisable, Weighted Average Remaining Contractual Term (in years) 7-8 years 9-2 months 25-12 daysOptions Exercisable, Weighted Average Exercise Price \$ 18-4, 54Share-63Share- Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 10-1, 01Exercise 96Exercise Price Three [Member] Share- Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, Upper \$ 25-10, 01Options Outstanding, Number | shares 39-26, 768Options-394Options Outstanding, Weighted Average Remaining Contractual Term (in years) 6 years 8-3 months 1-18 dayOptions daysOptions Outstanding, Weighted Average Exercise Price \$ 32-23, 43Options-69Options Exercisable, Number | shares 30-23, 037Options-- 963Options Exercisable, Weighted Average Remaining Contractual Term (in years) 6 years 1 month 6 months 7 daysOptions Exercisable, Weighted Average Exercise Price \$ 33-24, 62X-29X- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (1) (iii)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition The weighted- average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (1) (iii)- **Publisher FASB-**URI https://asc.fasb.org/**/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: instantX- Definition Number of options outstanding, including both vested and non-vested options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-Topic 718-SubTopic 10-** Name Accounting Standards Codification- **Section 50- Paragraph 2- Subparagraph (c) (1) (i)- Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2**Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Topic 718-SubTopic 10-** Section 50- Paragraph 2- Subparagraph (c) (1) (ii)-URI https://asc.fasb.org/extlink & oid=128089324 & loc=d3e5070-113901Reference 2: http://www.xbrl.org/2003/role/disclosureRef- **Publisher FASB-**

Name Accounting Standards Codification- ~~Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (i) (ii) - Publisher FASB~~ - URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB- Topic 718- SubTopic 10 - Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (c) (1) (i)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718- 10- 50- 2Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 718- SubTopic 10 -Section 50- Paragraph 2- Subparagraph (c) (1) (ii)- URI https://asc.fasb.org/extlink & oid = 128089324 & loc = d3e5070- 113901Reference 2: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (c) (1) (ii) - Publisher FASB~~ - URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (g) - Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2~~ Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (g) - Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2~~ Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2~~ Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- ~~Publisher FASB- Topic 718- SubTopic 10- Subparagraph (e) (1) - Name Accounting Standards Codification- Paragraph 2 Topic 718- SubTopic 10- Section 50- Publisher FASB Paragraph 2- Subparagraph (e) (1)- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2~~ Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = IMNN_ExercisePriceOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = IMNN_ExercisePriceTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis = IMNN_ExercisePriceThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED (Details) 12 Months Ended Dec. 31, 2022 2023 Dec. 31, 2021 Share 2022 Share - Based Compensation Arrangement by Share- Based Payment Award [Line Items] Risk- free interest rate, minimum 1.31 74.39 % 1.54 74 % Risk- free interest rate, maximum 4.81 % 3.97 % 1.74 % Expected volatility, minimum 100.00 % 106 100 80 00 % Expected volatility, maximum 113.90 60 % 113.20 90 % Expected dividend yield 0.00 % 0.00 % Minimum [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Expected life (in years) 7 years 6 months 7 years 6 months Maximum [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Expected life (in years) 10 years 10 years X- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB- Topic 718- SubTopic 10 - Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (f) (2) (iii) - Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2~~ Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionThe maximum risk- free interest rate assumption that is used in valuing an option on its own shares. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionThe minimum risk- free interest rate assumption that is used in valuing an option on its own shares. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_Data Type: dtr- types: percentItem Type Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ~~Period Type: instantX- DefinitionContractual interest rate for funds borrowed, under the debt agreement.~~ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB- Topic 718- SubTopic 10 - Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50 35- Paragraph 1B 1D - Publisher FASB Subparagraph (b)- URI https://asc.fasb.org//1943274/2147480483/718 extlink & oid = 123466505 & loc = SL123495323- 10- 35- 112611Reference 1DReference 2: http://fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- ~~Publisher FASB- Topic 718- SubTopic 10 - Name Accounting Standards Codification- Topic 210 Section 35 - SubTopic Paragraph 3- Publisher FASB- URI https://asc.fasb.org//1943274/2147480483/718- 10- 35 Section S99- Paragraph~~ ReferencesNo --- 3Reference definition available 3: http://www.//ase-DefinitionContractual interest rate for funds borrowed, under the debt agreement. ReferencesReference 1 fasb.org//1943274/2147480429/718- 10- 50- 2Reference 5- http://www.xbrl.org/2003/role/disclosureRef- ~~Publisher FASB Topic 718- SubTopic 10 - Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50- Paragraph 2 1B - Subparagraph (a-b) (3)- Publisher FASB- URI https://asc.fasb.org//1943274/2147480429/718 extlink & oid = 123466505 & loc = SL123495323- 10- 50- 2Reference 112611Reference 6- 2: http://fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- ~~Publisher FASB Topic 718- SubTopic 10 - Name Accounting Standards Codification- Topic~~~~~~~~

210-SubTopic 10- Section 50-S99- Paragraph 2-1- Subparagraph (e-SX 210.5- 02.22 (a) (1) (i) -Publisher FASB- URI https:// asc.fasb.org /#1943274/2147480429 /718 extlink & oid = 120391452 & loc = d3e13212- 122682 10-50-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionExpected term of award under share- based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. ReferencesReference 1: http:// www. xbrl. org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (f) (2) (i) -Publisher FASB- URI https:// asc. fasb. org /#1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm Namespace Prefix: us-gaap_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: STOCK- BASED COMPENSATION (Details Narrative)- USD (\$) \$ / shares in Units, \$ in Millions 12 Months EndedDec. 31, 2023 Dec. 31, 2022 Dec-Jun 31-14, 2021-2023 Jun. 10, 2021 Jun. 15, 2020 May 14, 2019 May 15, 2018Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Unrecognized compensation cost \$ 0. 74 Cost recognized over a weighted- average period 2 years-1 year 9 month months 6-18 days Equity Stock Awards [Member] | Granted Under 2018 Plan and 2007 Plan [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Common stock, reserved for future issuance 556-768 149-731 Inducement Awards [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Common stock, reserved for future issuance 263-294, 751 Stock Options and Restricted Stock Awards [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share based compensation \$ 0. 8 \$ 2. 7 \$ 3-8 Stock Options and Restricted Stock Awards [Member] | Research and Development Expense [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share based compensation 0. 20 9 1-4 Stock Options and Restricted Stock Awards [Member] | General and Administrative Expense [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share based compensation \$ 0. 6 \$ 1. 8 \$ 2-4 2018 Stock Incentive Plan [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share- based payment award, shares authorized 180, 000 Shares available for issuance 1,206,342 Compensation Arrangement by Share- Based Payment Award [Line Items] Stock options, strike price description Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100 % of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10 % of the outstanding stock of Imunon must be at least 110 % of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. 000 Common --- Common stock, reserved for future issuance 945-1, 975, 073 2018 Stock Incentive Plan [Member] | Minimum [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share Shares based payment award available for issuance 1, shares granted 030, 000 513, 333 166, 667 80, 000 2018 Stock Incentive Plan [Member] | Maximum [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Share Shares based payment award available for issuance 1, shares granted 970, 000 940, 000 426, 667 260, 000 2007 Stock Incentive Plan [Member] employees may receive incentive stock options. Inducement Option Grants [Member] | Five New Employees [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Exercise price per share \$ 1. 76-59 Inducement Option Grants [Member] | Five New Employees [Member] | Restricted Stock [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Restricted stock 69-91, 250-350 Inducement Option Grants [Member] | Five New Employees [Member] | Common Stock [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Restricted stock 204-294, 751 501-2018 Plan [Member] Share- Based Compensation Arrangement by Share- Based Payment Award [Line Items] Common stock, reserved for future issuance 388, 954 X- Definition Stock options, strike price description. ReferencesNo definition available. Details Name: IMNN_StockOptionsStrikePriceDescription Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of expense for award under share- based payment arrangement. Excludes amount capitalized. ReferencesReference 1: http:// www. xbrl. org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SAB Topic 14. F)- Publisher FASB- URI https:// asc. fasb. org //1943274 /2147479830 /718- 10- S99- 1Reference 2: http:// www. xbrl. org /2003 /role / disclosureRef- Topic 718- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (h) (1) (i)- Publisher FASB- URI https:// asc. fasb. org //1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAggregate number of common shares reserved for future issuance. ReferencesReference 1: http:// fasb. org /us-gaap /role /ref /legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02. 29)- Publisher FASB- URI https:// asc. fasb. org /#1943274 /2147480566 /210 extlink & oid =120391452 & loc =d3e13212- 122682 10- S99- 1Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionAmount of cost not yet recognized for nonvested award under share- based payment arrangement. ReferencesReference 1: http:// www. xbrl. org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (i)- Publisher FASB- URI https:// asc. fasb. org //1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionWeighted- average period over which cost not yet recognized is expected to be recognized for award under share- based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. ReferencesReference 1: http:// www. xbrl. org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (i)- Publisher FASB- URI https:// asc. fasb. org //1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognitionI Namespace Prefix: us-gaap_ Data Type: xbrli: durationItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Period Type: instantX- DefinitionContractual interest rate for funds borrowed, under the debt agreement. ReferencesReference 1: http:// www. xbrl. org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50-35- Paragraph 1B-1D- Publisher FASB Subparagraph (b)- URI https:// asc.fasb.org //1943274 /2147480483 /718 extlink & oid =123466505 & loc =SL123495323- 10-35- 112611Reference 1DReference 2: http:// fasb www.xbrl.org /2003 us-gaap /role / disclosureRef /ref /legacyRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 210 Section 35- SubTopic Paragraph 3- Publisher FASB- URI https:// asc.fasb.org //1943274 /2147480483 /718- 10- 35 Section S99- Paragraph ReferencesNo --- 3Reference definition available 3: http:// www. //asc-DefinitionContractual interest rate for funds borrowed, under the debt agreement . ReferencesReference 1 fasb.org //1943274 /2147480429 /718- 10- 50- 2Reference 5-: http:// www.xbrl.org /2003 /role / disclosureRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 470- SubTopic 20- Section 50- Paragraph 2-1B- Subparagraph (a-b) (3)- Publisher FASB- URI https:// asc.fasb.org /#1943274 /2147480429 /718 extlink & oid = 123466505 & loc = SL123495323- 10-50- 2Reference 112611Reference 6-2: http:// fasb www.xbrl.org /2003 us-gaap /role / disclosureRef /ref /legacyRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 210- SubTopic 10- Section 50-S99- Paragraph 2-1- Subparagraph (e-SX 210.5- 02.22 (a) (1) (i) -Publisher FASB- URI https:// asc.fasb.org /#1943274/2147480429 /718 extlink & oid = 120391452 & loc = d3e13212- 122682 10-50-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionNumber of shares authorized for issuance under share- based payment arrangement. ReferencesReference 1: http:// www. xbrl. org /2003 /role / exampleRef- Publisher FASB- Topic 718- SubTopic 10- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph (a) (3)- Publisher FASB- URI https:// asc. fasb. org //1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity- based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. ReferencesReference 1: http:// fasb. org /us-gaap /role /ref /legacyRef- Publisher FASB- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 2- Publisher FASB- URI https:// asc. fasb. org /#1943274 /2147480429 /718 extlink & oid =128089324 & loc =d3e5070- 113901-10-50-2 Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-718-SubTopic-10>. Name Accounting Standards Codification- **Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718** extlink & oid=128089324 & loc=d3e5070-113901-10-50-2 Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB SubTopic 10-Section 50-Paragraph 2](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-SubTopic-10-Section-50-Paragraph-2) - URI https://asc.fasb.org/1943274/2147481112/505 extlink & oid=126973232 & loc=d3e21463-112644-10-50-2 Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- Details Name: us-gaap_AwardTypeAxis = IMNN_EquityStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_StatementScenarioAxis = IMNN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_AwardTypeAxis = IMNN_InducementAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_AwardTypeAxis = IMNN_EmployeeStockOptionAndRestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_PlanNameAxis = IMNN_TwoThousandAndEighteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_PlanNameAxis = IMNN_TwoThousandSevenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_PlanNameAxis = IMNN_InducementOptionGrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_TitleOfIndividualAxis = IMNN_FiveNewEmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_AwardTypeAxis = us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_PlanNameAxis = IMNN_TwoThousandAndEighteenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY (Details) - USD (\$) 12 Months Ended Dec. 31, 2022 Dec. 31, 2021 Earn USD (\$) Earn -out Milestone Liability Earn-out liabilities, beginning balance \$ 5,396,000 \$ 7,018,000 Non-cash gain loss from the adjustment for the change in fair value (5,396,000) (4,622,000) Earn-out liabilities, ending balance X \$ 5,396,000X - References No definition available. Details Name: IMNN_DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- Definition Earn-out liabilities, beginning balance. References No definition available. Details Name: IMNN_EarnoutMilestoneLiability Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- Definition The amount of gain (loss) from the change in the fair value of earn-out milestone liability. References No definition available. Details Name: IMNN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationEARN-OUT MILESTONE LIABILITY (Details Narrative)- USD (\$) in Millions 12 Months Ended Jun. 20, 2014 Dec. 31, 2022 Dec. 31, 2021 Dec. 31, 2020 Mar. 28, 2019 EGWC, Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout payment options description each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). Non-cash charge on earnout milestone liability \$ 5.4 \$ 1.6 Amended Asset Purchase Agreement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 13.9 \$ 12.4 Amended Asset Purchase Agreement [Member] Within One Year of Achieving Milestone [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 30.4 Amended Asset Purchase Agreement [Member] 10 Business Days of Achieving Milestone [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 7.0X 0 Fair Value Earnout Milestone Liability [Member] EGWC, Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Business combination, consideration transferred, liabilities incurred \$ 5.4 \$ 7.0X - Definition Earnout milestone liability. References No definition available. Details Name: IMNN_EarnoutMilestoneLiability1 Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- Definition Earn-out payment options, description. References No definition available. Details Name: IMNN_EarnoutPaymentOptionsDescription Namespace Prefix: IMNN_ Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- Definition Non-cash charge on earnout milestone liability. References No definition available. Details Name: IMNN_NoncashChargeOnEarnoutMilestoneLiability Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX- Definition Amount of..... xbrli: monetaryItem Type Balance Type: credit Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479402/808-10-50-1) Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap_BusinessAcquisitionAxis = IMNN_EGWCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_AmendedAssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RelatedPartyTransactionAxis = IMNN_AchievingMilestoneWithInOneYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RelatedPartyTransactionAxis = IMNN_CertainBusinessDaysOfAchievingMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_FairValueEarnoutMilestoneLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF WARRANT ACTIVITY (Details)- USD (\$) 12 Months Ended Dec. 31, 2022 2023 Dec. 31, 2021 Warrants 2022 Warrants Number of Warrants Issued, Warrants outstanding, Beginning balance 168,519 175,792 [1] 256,903 Weighted 792 Weighted Average Exercise Price, Warrants outstanding, Beginning balance \$ 20.19 96.78 \$ 20.40 Number 96 Number of Warrants Issued, Warrants warrants exercised expired (818) (41459) (7,273) Weighted Average Exercise Price, Warrants exercised expired \$ 48.37 29 \$ 48.60 Number 30 Number of Warrants Issued, warrants outstanding expired (7,273) Ending balance 160,060 168,519 Weighted 519 Weighted Average Exercise Price, Warrants expired \$ 48.30 Number of Warrants Issued, Warrants outstanding, Ending balance [1] 168,519 175,792 Weighted Average Exercise Price, Warrants ending balance \$ 18.86 \$ 19.78 \$ 20.96 Aggregate 78 Aggregate intrinsic value of outstanding warrants \$ 0 Weighted average remaining contractual terms (years) 2 [1] 3 years 2 months 12 days [1] Warrants to exercise 4,059 shares of common stock at an exercise price of \$ 31.05 per share expired on January, 11, 2023 -X- References No definition available. Details Name: IMNN_DisclosureWarrantsAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- Definition Share based compensation arrangement by share based payment award non-option equity instruments exercised in period weighted average exercise price. References No definition available. Details Name: IMNN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExerciseInPeriodWeightedAverageExercisePrice Namespace Prefix: IMNN_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: durationX- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. References No definition available. Details Name: IMNN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice Namespace Prefix: IMNN_ Data Type: dtr-types: perShareItem Type Balance Type: na Period Type: instantX- Definition Share based compensation arrangement by share based payment award non options outstanding intrinsic value. References No definition available. Details Name: IMNN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX- Definition Weighted average remaining contractual term for non-option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: IMNN_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: IMNN_ Data Type: xbrli: durationItem Type Balance Type: na Period Type: durationX- Definition Number of non-option equity instruments exercised by..... Period Type: durationX- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section 50-Paragraph 2](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-2)

Subparagraph (c) (1) (iv) (4)- SubTopic 10- Topic 718- Publisher FASB SubTopic 10- Section 50- Paragraph 2- Subparagraph (e) (1) (iv) (4)- URI <https://asc.fasb.org//1943274/2147480429/718> extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2 Details Name: us- gaap_ ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section 50- Paragraph 2- Subparagraph \(c\) \(1\) \(i\)- SubTopic 10- Topic 718- Publisher FASB SubTopic 10- Section 50- Paragraph 2- Subparagraph \(c\) \(1\) \(ii\)-](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)-(1)-(ii)-) URI <https://asc.fasb.org//1943274/2147480429/718> extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section 50- Paragraph 2- Subparagraph \(c\) \(1\) \(ii\)- SubTopic 10- Topic 718- Publisher FASB SubTopic 10- Section 50- Paragraph 2- Subparagraph \(e\) \(1\) \(i\)-](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher-FASB-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)-(1)-(ii)-SubTopic-10-Topic-718-Publisher-FASB-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(e)-(1)-(i)-) URI <https://asc.fasb.org//1943274/2147480429/718> extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2 Details Name: us- gaap_ ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us- gaap_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 718- SubTopic 10- Section 50- Paragraph 2- Subparagraph \(c\) \(1\) \(iv\) \(4\)-](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-718-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(c)-(1)-(iv)-(4)-) **Publisher FASB-** URI <https://asc.fasb.org//1943274/2147480429/718> extlink & oid = 128089324 & loc = d3e5070- 113901-10- 50- 2 Details Name: us- gaap_ ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationIMUNON durationSUMMARY OF WARRANT ACTIVITY (Details)..... Balance Type: Period Type: IMUNON EMPLOYEE BENEFIT PLANS (Details Narrative)- USD (\$) 12 Months Ended Dec. 31, 2022-2023 Dec. 31, 2021Retirement 2022Retirement Benefits [Abstract] Maximum annual contributions per employee, percent 3.00 % Matching contributions of employee \$ 147-142 , 000 \$ 107-117, 000X 000Discretionary contribution \$ 172,000Discretionary contribution, rate 5.00 % X- Definition Amount of discretionary contributions made by an employer as a percentage of each participants annual salary to a defined contribution plan. ReferencesNo definition available. Details Name: IMNN- DefinedContributionPlanEmployerDiscretionaryContributionPercent Namespace Prefix: IMNN- Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap_ CompensationAndRetirementDisclosureAbstract Namespace Prefix: us- gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Amount of discretionary contributions made by an employer to a defined contribution plan. ReferencesNo definition available. Details Name: us- gaap_ DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- Definition Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. ReferencesNo definition available. Details Name: us- gaap_ DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us- gaap_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- Definition Maximum amount the employee may contribute to a defined contribution plan. ReferencesNo definition available. Details Name: us- gaap_ DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationsSCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES (Details) Dec. 31, 2022-2023 USD (\$) Leases \$ 238-626, 6092024-323543, 009362, 976370, 2362028 and thereafter- Thereafter 30, Subtotal 903Subtotal future lease payments 238-1, 609Less 933, 447Less imputed interest (7-308, 866-733) Total lease liabilities \$ 230-1, 624, 749Operating- 714Operating lease, weighted average remaining lease term 7 months 9 days Operating 3 years 6 months Operating lease, weighted average discount rate, percent 9.98 % X- ReferencesNo definition available. Details Name: IMNN_ DisclosureLeasesAbstract Namespace Prefix: IMNN_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Operating Definition Lessee operating lease liability payments due year five and after year five one and there after. ReferencesNo definition available. Details Name: IMNN_ LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOneAndThereAfter----- IMNN_ LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAfterYearFour Namespace Prefix: IMNN_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of lessee' s undiscounted obligation for lease payment for operating lease. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 842- SubTopic 20- Section 50- Paragraph 6- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-842-SubTopic-20-Section-50-Paragraph-6-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147478964/842> extlink & oid = 128292326 & loc = SL77918701- 209980-20- 50- 6 Details Name: us- gaap_ LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of lessee' s undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 842- SubTopic 20- Section 50- Paragraph 6- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-842-SubTopic-20-Section-50-Paragraph-6-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147478964/842> extlink & oid = 128292326 & loc = SL77918701- 209980-20- 50- 6 Details Name: us- gaap_ LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths non- option equity instruments exercised by participants and annual periods when interim periods are reported from current statement of financial position date (rolling approach). ReferencesReference 1: [http://www.xbrl.org/2003-us- gaap/role/disclosureRef-ref/legacyRef-Publisher FASB Topic 842- SubTopic 20- Name Accounting Standards Codification- Topic 718- SubTopic 10- Section 50- Paragraph 6- 2- Publisher FASB Subparagraph \(c\) \(1\) \(iv\) \(2\)-](http://www.xbrl.org/2003/us-gaap/role/disclosureRef-ref/legacyRef-Publisher-FASB-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-6-2-Publisher-FASB-Subparagraph-(c)-(1)-(iv)-(2)-) URI <https://asc.fasb.org//1943274/2147478964/842> extlink & oid = 128089324 & loc = d3e5070- 113901-20- 50- 6 Details Name: us- gaap_ LesseeOperatingLeaseLiabilityPaymentsDueYearFour gaap_ ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType sharesItemType Balance Type: credit na Period Type: instantX- durationX- Definition Amount Definition Number of lessee' s undiscounted- Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of lessee' s undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 842- SubTopic 20- Name Accounting Standards Codification- Topic 842- SubTopic 20- Section 50- Paragraph 6- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-50-Paragraph-6-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147478964/842> extlink & oid = 128292326 & loc = SL77918701- 209980-20- 50- 6 Details Name: us- gaap_ LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Present value of lessee' s discounted obligation for lease payments from operating lease. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic 842- SubTopic 20- Name Accounting Standards Codification- Topic 842- SubTopic 20- Section 45- Paragraph 1- Subparagraph \(b\)- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Publisher-FASB-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Topic-842-SubTopic-20-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479041/842> extlink & oid = 123391704 & loc = SL77918627- 209977-20- 45- 1 Details Name: us- gaap_ OperatingLeaseLiability Namespace Prefix: us- gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Weighted average discount rate for operating lease calculated at point in time. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic 842- SubTopic 20- Name Accounting Standards Codification- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Publisher-FASB-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 50- Paragraph 4- Subparagraph \(g\) \(4\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-50-Paragraph-4-Subparagraph-(g)-(4)-) URI <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) <https://asc.fasb.org//1943274/2147479589/842-20-55-53> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842- SubTopic 20- Section 55- Paragraph 53- Publisher FASB- URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Section-55-Paragraph-53-Publisher-FASB-URI) [https://asc.fasb.org//1](https://asc.fasb.org//1943274/2147479589/842-20-55-53)

executed a lease (the "Lease") with Brandywine Operating Partnership, L. P. (Brandywine), a Delaware limited partnership, for a 10, 870 square foot premises located in Lawrenceville, New Jersey and relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The Lease had an initial term of 66 months. In late 2015, Lenox Drive Office Park LLC, purchased the real estate and office building and assumed the Lease. Area of land | ft² 10, 870 10, 870 Lease term 66 months 66 months Lease expiration date Apr. 30, 2017 Operating lease, term 24 months 60 months Operating lease, cost \$ 646, 633 \$ 587, 744 Operating lease, payments 644, 593 601, 495 Amortization expense \$ 601 472, 495 000 \$ 568 535, 269 Huntsville [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Lease 000 Lease Agreement term 60 months Huntsville [Member] Subsequent Event [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Area of land | ft² 9, 850 11, 420 Lease Agreement term 60 months Payments for rent \$ 28, 550 Huntsville Alabama [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Area of land | ft² 2, 197 Lease term 22 months 1st Lease Amendment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Lease operating, description increase the size of the premises by 2, 285 square feet to 9, 850 square feet and extended the lease term by one year to September 1, 2023. 1st Lease Amendment [Member] | Minimum First Year [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments for rent 18, 900 1st Lease Amendment [Member] Final Year [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments for rent 20, 500 2nd Lease Amendment [Member] First Year [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments for rent 25, 035 2nd Lease Amendment [Member] Final Year [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments for rent \$ 27 22, 088 EGEN Asset Purchase 983 \$ 28, 550 Lease Agreement [Member] | Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Lease operating, description In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11, 500 square foot premises located in Huntsville Alabama. Area of land | ft² 9, 049 Payments --- Payments for rent \$ 5 23, 500 394 \$ 18 30, 903 100 Operating Leases [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Operating lease, cost \$ 587, 744 560, 513 Operating lease, payments 601, 495 568, 269 Amortization expense \$ 535, 000 \$ 573, 000 X Definition The aggregate amount of recurring noncash..... Type: debit Period Type: durationX - Definition Area of land held. References No definition available. Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_Data Type: dtr-types: arealtemType Balance Type: na Period Type: instantX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Date which lease or group of leases is set to expire, in YYYY-MM-DD format. References No definition available. Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_Data Type: xbrli:dateTimeType Balance Type: na Period Type: durationX- Definition Description of lessee's operating lease. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB-Topic 842-SubTopic 10-Name Accounting Standards Codification-Topic 842-SubTopic 20-Section 50-Paragraph 3-1-Subparagraph (a-d)-(1)-(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808 extlink & oid=128292326 & loc=SL77918673-209980-10-50-1 Details Name: us-gaap_LesseeOperatingLeaseDescription-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Term of lessee's operating lease, in PnYnMnDtnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher FASB-Topic 842-SubTopic 20-Name Accounting Standards Codification-Topic 842-SubTopic 20-Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842 extlink & oid=128292326 & loc=SL77918673-209980-20-50-3 Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instantX- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. References Reference 1: http://www.xbrl.org/2003/role/exampleRef-Publisher FASB-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Section 55-Paragraph 53-URI https://asc.fasb.org/extlink & oid=123414884 & loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB-Name Accounting Standards Codification-Topic 842-SubTopic 20-Section 50-Paragraph 4-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842 extlink & oid=128292326 & loc=SL77918686-209980-20-50-4 Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Section 45-Paragraph 5-Subparagraph (c)-URI https://asc.fasb.org/extlink & oid=123391704 & loc=SL77918643-209977 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Publisher FASB-Name Accounting Standards Codification-Topic 842-SubTopic 20-Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842 extlink & oid=128292326 & loc=SL77918686-209980-20-50-4 Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-instantX- Definition Amount of expense charged against earnings to allocate Definition Contractual interest rate for funds borrowed, under the debt agreement cost of tangible and intangible assets over their remaining economic lives, classified as other. References Reference 1: http://fasb-www.xbrl.org/2003 us-gaap/role/ref/legacyRef-disclosureRef-Publisher FASB-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 45-50-Paragraph 28-1B-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230 extlink & oid=123466505 & loc=SL123495323-10-45-28 Reference 112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 360-210-SubTopic 10-Section 50-S99-Paragraph 1-Subparagraph (SX 210.5-02.22(a)-Publisher FASB-(1))-URI https://asc.fasb.org/1943274/2147482099/360 extlink & oid=120391452 & loc=d3e13212-122682 Details Name 10-50-1 Reference 3: http://fasb.org/us-gaap/DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap/role/ref/legacyRef-Topic gaap_Data Type:dtr-types:percentItemType Balance Type:na Period Type: durationX- Definition Cash payments to lessor's for use of assets under operating leases. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (g)-SubTopic 10-Topic 230-Publisher FASB SubTopic 10-Section 45-Paragraph 25-Subparagraph (g)-URI https://asc.fasb.org/1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3536-108585-10-45-25 Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Details Name: srt_StatementGeographicalAxis us-gaap_TypeOfArrangementAxis = IMNN_HuntsvilleMember-IMNN_LeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_RangeAxis us-gaap_SubsequentEventTypeAxis = srt_MinimumMember us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt_StatementGeographicalAxis srt_RangeAxis = srt_MaximumMember IMNN_HuntsvilleAlabamaMember Namespace Prefix: Data Type:..... Name: us-gaap_TypeOfArrangementAxis = IMNN_OperatingLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS (Details Narrative)-Hisun [Member] \$ in Millions Jan. 18, 2013 USD (\$) Accounts, Notes, Loans and Financing Receivable [Line Items] Proceeds from license fees received \$ 5. 0 Deferred revenue \$ 5. 0 Deferred revenue amortization period 10 yearsX- Definition The amortization period for deferred revenue. References No definition available. Details Name: IMNN_DeferredRevenueAmortizationPeriod Namespace Prefix: IMNN_Data Type: xbrli:durationItemType Balance Type: na Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Publisher FASB-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(26)(c))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210 extlink & oid=120391452 & loc=d3e13212-122682-10-S99-1 Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Definition Cash received from licensees for license fees during the current period. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230 extlink & oid=126954810 & loc=d3e3536-108585-10-45-25 Details Name: us-gaap_ProceedsFromLicenseFeesReceived Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis = IMNN_HisunMember Namespace Prefix: Data Type: na Balance Type: Period Type: RELATED PARTY TRANSACTION (Details Narrative) -Nov. 16, 2022 USD (\$) Convertible Note Purchase Agreement [Member] - [Transomic Technologies, Inc.] [Member] Nov. 16, 2022 USD (\$) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Convertable and warrants \$ 375,000X.000Interest rate 5.00% X- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available-ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1) Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 942-210-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 942-210-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(16\)\)-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(16))-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(16)(a)(2))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 946-942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(13\)\)-URI https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 946-942-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(13))-URI https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-9-02-03\(22-16\)\)-Publisher FASB-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682](http://fasb.org/us-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-9-02-03(22-16))-Publisher FASB-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682)Reference 4: [http://1943274/2147479853.fasb.org/us-942-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 944-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\)-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910](http://1943274/2147479853.fasb.org/us-942-gaap/role/ref/legacyRef-Publisher FASB-Name Accounting Standards Codification-Topic 944-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(16)(a))-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910)Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionContractual interest..... types: percentItemType Balance Type: na Period Type: instantX- Details Name: us-gaap_TypeOfArrangementAxis = IMNN_ConvertibleNotePurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: dei_LegalEntityAxis = IMNN_TransomicTechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: